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Summary 
Death Receptor 3 (DR3) is a death domain containing member of the TNF 
Receptor Superfamily (TNFRSF), refereeing a range of cellular responses from 
differentiation and proliferation to cell death, depending upon the context of 
receptor activation. DR3 has been reported to have a role in many 
inflammatory diseases, including inflammatory arthritis and inflammatory 
bowel disease. The aim of this study was to determine the contribution of DR3 
in a mouse model of acute and chronic allergic lung inflammation.  
 
Mice genetically deficient in the DR3 gene (DR3ko) were resistant to cellular 
accumulation within the lungs and bronchoalveolar lavage following acute 
lung inflammation, induced by priming with ovalbumin (OVA) and the 
adjuvant aluminium hydroxide (Alum) prior to 2 OVA aerosol exposures. To 
discern the role of DR3 in a more physiologically relevant chronic model of 
allergic lung inflammation, mice underwent repeated inhalation challenges 
with OVA subsequent to priming with OVA and Alum. Whilst cellular 
accumulation did not differ, DR3ko mice displayed reduced immuno-
histopathology, and goblet cell hyperplasia, hallmarks of the asthmatic 
phenotype. Intriguingly, DR3ko mice exhibited reduced accumulation of 
various cell types into the spleen in both models. Early priming events were 
therefore investigated, prior to aerosolised antigenic challenge to decipher the 
effects of DR3. One sensitisation injection was sufficient to induce decreased 
DR3ko splenocyte accumulation, though T and B cell responses were observed 
to be comparable between DR3ko and DR3wt controls.  DR3ko mice had 
depleted CXCL10 levels, suggesting cellular recruitment in response to 
inflammation is DR3 dependent. 
 
The underlying DR3 dependent mechanisms concerning the DR3ko splenic 
defects are under further investigation and may have impact on the use of the 
DR3/TL1A pathway as a therapeutic target, either as an anti-inflammatory or 
as a booster of the immune response to pathogens.   
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1.1 The Tumour Necrosis Factor Superfamily (TNFSF)  
 
1.1.1 History  
The term TNF superfamily (TNFSF) was first coined following the discovery of TNF 
and lymphotoxin in 1975 and 1968 respectively (Granger and Kolb 1968; Carswell, Old 
et al. 1975). The proteins were found to be released by macrophages and lymphocytes 
and both were observed to cause tumour necrosis and regression, hence the title, tumour 
necrosis factor (TNF). TNF was first isolated in 1984, whereby its sequence and 
structure were determined and compared to that of lymphotoxin (Aggarwal, Eessalu et 
al. 1985). The two were found to bind to the same cell surface receptors as well as 
display 50% amino acid sequence homology (Aggarwal, Eessalu et al. 1985).  To date 
the TNF superfamily consists of 19 members that bind to 29 receptors (Croft 2009). The 
TNF superfamily is now known to be involved in a number of cellular events and 
signalling pathways, which ultimately orchestrate the adaptive immune response and 
influence immune tissue development, homeostasis and organisation (Ware 2008).  
 
 
1.1.2 Structure and binding of TNFSF members and their receptors 
A recognised hallmark of any TNF receptor superfamily member is its cysteine rich 
domain (CRD), which lies within the extracellular region. Most receptors have between 
1 and 4 CRDs, which typically comprise 6-8 cysteine residues, 3 pairs of which form 
disulphide bonds. These disulphide bonds act as a scaffold for the adaptation of an 
elongated receptor structure and receptor signalling (Locksley, Killeen et al. 2001; 
MacEwan and MacEwan 2002; Bossen, Ingold et al. 2006).   
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Of the 29 receptors identified, all but two are type I transmembrane proteins. 
Osteoprotegerin (OPG) and Decoy Receptor 3 (DcR3) lack a hydrophobic 
transmembrane region, thus forming soluble secreted proteins (Bossen, Ingold et al. 
2006). Additionally, 8 of the 29 receptors display further homology within a 
cytoplasmic region known as the death domain (DD). This ~80 amino acid sequence 
contains 6 conserved alpha helices and its presence determines if a receptor is able to 
induce programmed cell death, these being known as death receptors (Locksley, Killeen 
et al. 2001; MacEwan and MacEwan 2002; Aggarwal 2003).  
 
The 19 TNFSF members are type II transmembrane proteins, which can either be 
membrane bound, or cleaved and released into their soluble mature form (Idriss and 
Naismith 2000). TNFSF members, like their receptor counterparts, contain a region of 
homology within their C terminal, known as the TNF homology domain (THD). This 
conserved 150 amino acid sequence is rich in aromatic and hydrophobic residues, which 
assist in ligand binding to the CRD of its partnering receptor (Orlinick and Chao 1998; 
Bodmer, Schneider et al. 2002). There is thought to be 25-30% amino acid similarity 
between the different TNFSF members (Locksley, Killeen et al. 2001), although 15-
35% of the THD is divergent to allow for specific binding to members of the TNFRSF 
(Orlinick and Chao 1998; Bodmer, Schneider et al. 2002).  
 
 
 
 
 
 
Figure 1.1 Complete list of known TNFSF and TNFRSF members. TNFSF members are shown in purple and TNFRSF in yellow. The 
number of triangles correlates with the number of extracellular cysteine rich repeats. Death domain containing receptors are represented 
by a green star. Arrows represent TNFSF/TNFRSF interactions. Figure adapted from Ashkenazi (2002).  
  FASL        TL1A            TRAIL                     TNF           LTα      LTαβ    LIGHT           BAFF            RANKL        CD30L    GITRL         OX40L    EDA2 
                       TWEAK        APRIL   OPG     CD40L   CD27          41BBL     EDA1 
FAS         DR3          DR5                           DR6   TNFR1     LTβR           TWEAKR BMCA    RANK      CD40        CD27        4-IBB          EDAR      NGFR 
                       DR4                                                      TNFR2                                                                        CD30          GITR        OX40           TROY 
DcR3 
DcR1 
DcR2
OPG 
HVEM 
DcR3 
BAFFR 
TACI 
OPG 
XEDAR 
? 
? 
5 
 
1.1.3 Signalling 
The aromatic residues within the TNFSF members are predicted to be responsible for 
the assembly of ligand trimer complexes, which occur prior to receptor binding 
(Locksley, Killeen et al. 2001). The majority are non-covalently bound homotrimeric 
structures which can either be released from the membrane and exert their effects at a 
distance, or bind to their complimentary receptor via cell-cell contact (MacEwan and 
MacEwan 2002). After ligand binding, the cytoplasmic tails of the TNFRSF also 
oligomerise, to signal as trimeric complexes, ultimately forming a hexameric structure 
(Bodmer, Schneider et al. 2002). TNFR1 and 2 however, are an exception in that they 
pre-form receptor trimers before ligand binding via a pre-ligand binding assembly 
domain (PLAD) (Aggarwal 2003).  
 
The binding of TNFSF members to their respective ligands can mediate one of two 
intracellular signalling cascades, dependent upon the adaptor proteins recruited 
(Ashkenazi and Dixit 1998).  A proliferative response is initiated via the recruitment of 
the cytosolic 34kDa TNFR-associated death domain (TRADD), and receptor interacting 
protein (RIP) (MacEwan and MacEwan 2002). In death domain containing receptors, it 
is the motif itself which functions as the docking site, so encouraging homotypic 
binding. Following this, TNFR-associated factors (TRAFs) are recruited. These RING 
finger containing proteins act as adaptors which rapidly transduce the signal from the 
inert receptor to initiate downstream effects within the target cell (MacEwan and 
MacEwan 2002). There are 6 known TRAFs in humans, with different TRAFs being 
recruited by different receptors (Aggarwal 2003). In the case of TNFα-TNFR1, it is 
TRAF-2 which is recruited, leading to the association of the apoptotic adaptor cellular 
inhibitor of apoptosis proteins (c-IAP)1 and c-IAP2. These inhibitors of apoptosis 
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ensure that cell death does not occur, by blocking the action of caspase 8, thereby 
ensuring the NF-κB or AP-1 pathways are activated and cell proliferation is initiated, 
via the induction of immunomodulatory genes (Tartaglia and Goeddel 1992).  
 
This ‘canonical’ NF-κB signalling pathway involves the ubiquitination of molecules 
centrally involved in the signalling complex, most notably RIP (Skaug, Jiang et al. 
2009; Dynek, Goncharov et al. 2010; Verhelst, Verstrepen et al. 2011). Ubiquitination 
consists of a 3-enzyme post translational process whereby the 76 amino acid molecule 
ubiquitin, is joined to the target protein. An ATP dependent thiolester bond is formed 
between the C terminal of ubiquitin and the ubiquitin activating enzyme E1. Ubiquitin 
is then transported to the ubiquitin conjugating enzyme, E2, before being attached via 
its C terminal to the target protein, RIP, via an isopeptide bond with a lysine residue. 
This is performed by an ubiquitin protein ligase, known as E3, for which TRAF 2 and 
cIAP1/2 act in TNFR signalling (Varfolomeev, Goncharov et al. 2008). RIP1 is then 
poly-ubiquitinated with lysine ubiquitin chains, allowing further attachment of other 
ubiquitins formed by different lysine residues, allowing differential structural and 
downstream effects.  
 
Following the poly-ubiquitination of RIP, a mitogen activated 3 kinase (MAP3K) 
molecule is recruited, known as TAK1 as well as the IκB kinase complex (IKK). 
Binding occurs via TAB2, an adaptor protein of TAK1, and IKKγ, a modulator subunit 
of IKK to specialised ubiquitin binding domains (UBAN), thus ensuring stabilisation of 
the signalling complex (Skaug, Jiang et al. 2009). IKKγ is then activated by direct 
transformation, TAK1 phosphorylation of IKK or close proximity of IKKγ subsections 
due to ubiquitination, thereby promoting trans-autophosphorylation (Skaug, Jiang et al. 
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2009; Walczak, Iwai et al. 2012). Upon activation, IKK can then phosphorylate 
Inhibitor of kappa B (IκB) leading to its poly-ubiquitination and degradation, allowing 
NF-κB mediated gene transcription (Verhelst, Verstrepen et al. 2011).  
 
As well as the canonical NF-κB pathway, particular members of TNFRSF are also able 
to utilise non-canonical signalling, including BAFFR (Morrison, Reiley et al. 2005), 
TWEAKR (Enwere, Holbrook et al. 2012), CD40 (Homig-Holzel, Hojer et al. 2008), 
LTβR (Dejardin, Droin et al. 2002), RANK (Novack, Yin et al. 2003), CD30 (Nishikori, 
Ohno et al. 2005), CD27 (Ramakrishnan, Wang et al. 2004) and TNFR2 (Rauert, 
Wicovsky et al. 2010). Rather than the degradation of the inhibitor of IκB, which the 
canonical pathway relies upon, non-canonical signalling depends on a mechanism 
involving NF-κB inducing kinase (NIK) (Dejardin, Droin et al. 2002). Following 
TNFSF-TNFRSF ligand binding, TRAFs are recruited into the TRAF binding motif, 
promoting NIK activation. NIK, via the kinase IKKα, phosphorylates p100, which 
functions as an NF-κB inhibitor. This leads to its poly-ubiquitination, allowing NF-κB 
to translocate into the nucleus and induce the transcription of target genes (Sun 2011).  
 
As well as NF-κB activation, some DD containing members of the TNFRSF are also 
able to elicit an apoptotic response. The recruitment of TRADD leads to the association 
of  Fas-associated death domain (FADD), leading to initiator caspase interaction and the 
formation of the death inducing signalling complex (DISC) (Hsu, Shu et al. 1996; 
Locksley, Killeen et al. 2001). The complex initiates a series of downstream events such 
as the cleaving of effector caspases (caspase 8 and 10), ultimately leading to 
programmed cell death (Bodmer, Holler et al. 2000; Wang, Chun et al. 2001).  
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The type of response induced is dependent upon  cell type and configuration (MacEwan 
and MacEwan 2002), although apoptosis is commonly caused by the blocking of protein 
synthesis (Ashkenazi and Dixit 1998). The signalling mechanisms employed by the 
TNFSF ensure they have a wide range of biological functions that are dependent on 
context, from proliferation and differentiation to apoptosis.  
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1.2 Death Receptor 3 (DR3) 
 
1.2.1 Human DR3 
Discovered in 1996, Death Receptor 3, or TNFRSF25, immediately provoked interest 
due to its relatively high sequence homology to TNFR1, as well as its diverse effects 
when activated. DR3 however, was identified by more than one research laboratory, all 
of whom cloned the receptor at similar times, resulting in multiple names; TRAMP, 
LARD, Wsl-1, Apo-3 and TR3 (Chinnaiyan, Orourke et al. 1996; Kitson, Raven et al. 
1996; Marsters, Sheridan et al. 1996; Bodmer, Burns et al. 1997; Screaton, Xu et al. 
1997). The foremost approach to receptor discovery was screening cDNA databases 
using expressed sequence tags (EST) for sequence similarity to TNFR1 and/or Fas 
(Chinnaiyan, Orourke et al. 1996; Marsters, Sheridan et al. 1996; Bodmer, Burns et al. 
1997; Screaton, Xu et al. 1997). Kitson et al however, took a different approach and 
expressed the death domain of TNFR1 to screen a yeast-two hybrid library (Kitson, 
Raven et al. 1996). Nevertheless, the end result was the same-DR3 had been discovered.  
 
The human DR3 (hDR3) gene consists of 1665 base pairs in 10 exons. This encodes a 
417 amino acid protein (Kitson, Raven et al. 1996; Screaton, Xu et al. 1997) with 4 
CRDs within the extracellular region, as well as the characteristic death domain within 
its 193 amino acid cytoplasmic area (Bodmer, Burns et al. 1997). Moreover, 2 potential 
N-glycosylation sites were also found (Asn-X-Ser/Thr) (Chinnaiyan, Orourke et al. 
1996) at amino acid positions 67 and 106 (Marsters, Sheridan et al. 1996) as well as a 
conserved peptide sequence at the N terminus (Screaton, Xu et al. 1997). This 
conserved sequence may act as a signal peptide, targeting proteins to the secretory 
pathway. The gene for DR3 was mapped to chromosome 1p36.2 using fluorescent in-
10 
 
situ hybridisation (FISH) (Bodmer, Burns et al. 1997), in close proximity to other 
TNFRSF members including HVEM (Kwon, Tan et al. 1997), 4-IBBR (Kwon, Kozak 
et al. 1994), OX40-R (Birkeland, Copeland et al. 1995) and TNFR2 (Baker, Chen et al. 
1991), suggesting TNFRSF clustering in the genome. DR3 displayed significant relation 
to TNFR1, equating to 47% amino acid homology in the death domain (Chinnaiyan, 
Orourke et al. 1996), compared to 29% overall (Marsters, Sheridan et al. 1996).  
 
DR3 is thought to be alternatively spliced, with the number of predicted variants 
differing between individual scientific groups. Screaton et al, predicted at least 12 
variants, suggesting they were generated by the splicing out of one or more complete 
exons. The majority of these splice variants had premature stop codons, prior to the 
transmembrane region, resulting in soluble proteins (Screaton, Xu et al. 1997). Two 
further variants were described that had retained introns due to 101 and 200 base pair 
insertions which matched to consensus splice sites at the 3’ and 5’ end (Warzocha, 
Ribeiro et al. 1998). This alternative splicing was thought to be important for DR3 up-
regulation and function, much like TNFR1 which is cleaved from the membrane via the 
protease TNFα converting enzyme (TACE). The 13th DR3 splice variant was discovered 
relatively late and originally named DR3β. Insertions of 20 and 7 base pairs at positions 
612 and 667, made this the longest of the splice variants at 426 amino acids compared 
to the 417 amino acids of the original gene. The 28 amino acid difference between the 2 
variants was found to lie in the extracellular domain (Warzocha, Ribeiro et al. 1998).  
 
TL1A is the only known ligand for DR3 and was discovered by Migone et al sometime 
after the finding of the Receptor itself (Migone, Zhang et al. 2002).  
 
11 
 
1.2.2 Decoy Receptor 3 (DcR3) 
DcR3 is a soluble decoy receptor found in humans (Pitti, Marsters et al. 1998; Chen, 
Zhang et al. 2004), mapping to chromosome 20 region q13 (Ashkenazi 2002). Though 
structurally similar to DR3 in the extracellular region, DcR3 lacks a transmembrane 
domain, thus it can competitively bind DR3’s ligand TL1A without inducing cellular 
effects (Migone, Zhang et al. 2002). In addition to disrupting DR3/TL1A interactions, 
DcR3 can also bind other TNFSF members, namely Fas-L (Pitti, Marsters et al. 1998) 
and LIGHT (Yu, Kwon et al. 1999). Traditionally, this competitive binding has been 
viewed as anti-inflammatory, neutralising ligand effects, so dampening down the 
inflammatory response (Zhang, Salcedo et al. 2001). However, more recent studies in 
Crohn’s disease have suggested DcR3 can also promote inflammation by inhibiting 
apoptosis (Bai, Connolly et al. 2000; Macher-Goeppinger, Aulmann et al. 2008). As 
well as inflammatory disease, DcR3 is also over-expressed in cancerous tumours, 
suppressing T cell mediated immunity and preventing the apoptosis of malignant cells 
(Pitti, Marsters et al. 1998; Yu, Kwon et al. 1999; Zhang, Salcedo et al. 2001; Yang, 
Hsieh et al. 2004; Hsu, Wu et al. 2005; Han and Wu 2009). Indeed DcR3 has been cited 
as a prognostic marker in inflammatory disease and tumour progression, linked with 
severity (Roth, Isenmann et al. 2001; Chen, Yang et al. 2009).  
 
Hsu et al developed a transgenic model of DcR3, whereby the receptor was systemically 
over-expressed using the 3-phosphoglycerate kinase (PGK) promoter, an enzyme 
necessary in every cell for glycolysis (McBurney, Staines et al. 1994; Hsu, Wu et al. 
2005). When infected with Listeria monocytogenes, the mice displayed an attenuated 
Th1 response characterised by decreased IFNγ production. A Th2 based phenotype was 
instead observed, with the authors suggesting DcR3 assists tumour growth by 
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suppressing the cytotoxic Th1 response via down-regulation of the autocrine T cell 
growth factor IL-2 (Hsu, Wu et al. 2005). DcR3 transgenic mice demonstrated a 
tendency towards the Th2 response via the modulation of dendritic cell differentiation 
and maturation, inducing Th2 biased naive T cells (Hsu, Chang et al. 2002). This 
polarisation of the immune response has implicated DcR3 in lung inflammation (Cheng-
Yu, Kuang-Yao et al. ; Wortinger, Foley et al. 2003; Chen, Yang et al. 2009) and atopic 
disease (Chen, Yang et al. 2004). 
 
 
1.2.3 Murine DR3 
The murine homologue for hDR3 was isolated in 2001 by screening a 129Sv murine 
genomic library with full length hDR3 cDNA (Wang, Kitson et al. 2001). The 1619 
base pair murine DR3 cDNA displayed 55% homology to human DR3, whilst at the 
protein level, similarity was higher at 63% (Wang, Kitson et al. 2001). Considerable 
homology was noted in the death domains of murine and human DR3, at an estimated 
94%. In the extracellular domain this was just 52%. Like hDR3, the murine gene also 
consisted of 10 exons and retained 25 of the 28 cysteines present in hDR3 (Wang, 
Kitson et al. 2001). The chromosomal location of the murine DR3 gene was syntenic 
with human DR3 at chromosome 4 region E1 (Wang, Kitson et al. 2001). Murine DR3 
also contained 2 putative N-linked glycosylation sites. Despite the significant homology 
and structural similarities, the third CRD of murine DR3 was found to be substantially 
different from not only the human DR3 protein, but also TNFR1. Two cysteine residues 
were missing, resulting in alternative positioning of the second disulphide bond 
compared to hDR3. Additionally, 2 amino acid substitutions were discovered, with 
cysteine being replaced with a threonine and phenylalanine with a cysteine, with this 
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new cysteine being the proposed site of the shifted disulphide bond (Wang, Kitson et al. 
2001).  Nevertheless, the ability to bind ligand was conserved, as the required regions of 
the 2nd CRD and first half of the 3rd CRD were not altered (Banner, D'Arcy et al. 1993).  
 
Wang et al reported 3 murine DR3 splice variants; full length membrane bound variant 
1, soluble variant 2 and truncated membrane bound variant 3 (Wang, Kitson et al. 
2001). Investigations currently suggest DR3 mRNA may be differentially regulated 
following immune activation, indicating individual functions for each of the variants 
(Bamias, Mishina et al. 2006; Twohig, Marsden et al. 2012). However, the exact 
function of each isoform as well the factors determining their regulation remain 
unknown.  
 
In contrast to humans, no decoy receptor for mouse TL1A has yet been identified, 
although it has been suggested that murine soluble DR3, or variant 2, may perform a 
similar role (Bamias, Mishina et al. 2006; Pappu, Borodovsky et al. 2008). Studies have 
been undertaken using DcR3 analogues, as before modification of the human decoy 
receptor via the replacement of an arginine residue for a glutamine, DcR3 was degraded 
following subcutaneous injection in mice and primates, resulting in the loss of Fas-L 
binding (Wroblewski, Witcher et al. 2003). However, the more stable analogue, known 
as FLINT, bound both Fas-L and LIGHT and prevented a Fas-L induced murine model 
of pulmonary inflammation (Wortinger, Foley et al. 2003). Soluble murine DR3, unlike 
DcR3, does not hold the capacity to bind Fas-L or LIGHT.  
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1.2.4 DR3ko mouse  
DR3ko mice have played a major role in increasing our understanding of the gene and 
the effects it exerts in vivo. DR3ko mice were generated by replacing the whole coding 
region of the mouse DR3 gene, so eliminating the possibility of any splice variants. The 
coding region was replaced with a cassette containing an internal ribosome entry site 
(IRES), lacZ and neomycin resistance gene (Wang, Thern et al. 2001).  The DR3 
lacking construct was linearised and transfected into embryonic stem cells whereby 
clones were selected using the eukaryotic antibiotic G418, to which neomycin gives 
resistance. Selected recombinant clones were then microinjected into C57BL/6 
blastocysts followed by implantation into pseudopregnant C57BL/6 mice (Wang, Thern 
et al. 2001). The resulting male chimaeric mice (DR3het) were bred to generate germline 
homozygote DR3 null mice (DR3ko). To ensure no gene product remained, PCR was 
carried out, to which no transcripts were detected (Wang, Thern et al. 2001). DR3ko 
mice displayed significantly enlarged thymuses compared to DR3wt and DR3het mice, 
particularly at 29-32 weeks of age whereby the increase was reported to be 30%, 
compared to 10% at 2-5 weeks. However, this was not attributed to an increase in 
thymocyte proliferation or turnover, as little difference was seen in BrdU incorporation 
between DR3wt and DR3ko mice. DR3ko mice instead suffered an impairment in thymus 
negative selection, though no autoimmune disease symptoms were detected (Wang, 
Thern et al. 2001). Except in the thymus, DR3ko development was akin to DR3wt mice, 
with no obvious differences observed in the spleen, brain, heart, kidney, lymph node or 
Peyers patches. 
 
However, aged DR3ko mice display progressive loss of motor control compared to 
DR3wt and DR3het littermates (Twohig, Roberts et al. 2010). DR3ko behaviour was 
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characterised by abnormal gait, rapid head movement, disorientation and dyskinesia. 
Higher dopamine levels were also reported in the brains of DR3ko mice, whilst serotonin 
levels decreased by 73%  (Twohig, Roberts et al. 2010).   
 
 
1.2.5 DR3 signalling 
Like TNFR1, DR3 is able to trigger canonical NF-κB activation and apoptosis 
(Ashkenazi and Dixit 1998). NF-κB, a key regulator of the cell survival decision, is 
activated by DR3 in much the same way as TNFR1, likely due to the high homology 
between these death domain containing molecules. DR3 was found to dose dependently 
induce reporter gene activity using a NF-κB luciferase reporter gene assay (Bodmer, 
Burns et al. 1997). Dominant negative forms of TRAF-2 and RIP showed that upon 
ligand binding, DR3 was bound to the platform adaptor TRADD, leading to TRAF-2 
and RIP association (Chinnaiyan, Orourke et al. 1996), which has serine/theorine kinase 
activity (Ashkenazi and Dixit 1998). The death domain was also shown to be essential 
for signalling, as truncation resulted in limited interaction between DR3 and TRADD 
(Chinnaiyan, Orourke et al. 1996). TRADD too, was found to be fundamental to the 
whole signalling process as its absence inhibited recruitment of adaptor proteins, 
independent of cell fate (Chinnaiyan, Orourke et al. 1996). CD4+ and CD8+ T cells from 
TRADDko mice also failed to proliferate in response to TL1A, due to reduced NF-κB 
signalling (Pobezinskaya, Choksi et al. 2011).  
 
Similar to TNFR1, DR3 was also able to activate JNK, p38, and ERK1, 2 and MAPK,  
shifting cell fate towards survival (Wen, Zhuang et al. 2003). Supporting this, Wen et al 
found c-IAP2 to have a direct role in DR3 mediated signalling events within the CD34+ 
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progenitor cell line, TF-1, as inhibition sensitised cells to DR3 induced apoptosis. To 
prevent signalling in the absence of ligand, DR3 interacts with the silencer of death 
domains (SODD). Upon ligand binding, SODD is displaced by TRADD, commencing 
the proliferative response (Al-Lamki, Wang et al. 2008).  
 
DR3, whilst favouring cell survival (Wen, Zhuang et al. 2003), also has the capacity to 
initiate apoptosis, particularly when protein synthesis and proliferation signals are 
inhibited (Migone, Zhang et al. 2002). DR3 over-expression on 293 T cells resulted in 
an 18% increase in  cell death (Screaton, Xu et al. 1997), which was associated with the 
cytoplasmic death domain and the linker protein, FADD (Chinnaiyan, Orourke et al. 
1996; Kitson, Raven et al. 1996).  
  
     TNFα/TNFR1     DR3/TL1A 
Figure 1.1. DR3 and TNFR1 signalling cascades. Following TL1A or TNFα 
binding, the receptors recruit adaptor proteins to form a death inducing 
signalling complex (DISC). Dependent on the adaptor proteins, the receptors 
initiate an apoptotic response, via the caspase pathway and TRADD and 
FADD, or a proliferative response, via the NF-κB pathway and TRAF2. 
Figure adapted from Ashkenazi and Dixit (1998).  
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1.2.6 Human DR3 expression 
Unlike TNFR1, which is ubiquitously expressed on all cell types, DR3 was found to be 
restricted to certain tissues and leukocyte subtypes. Original studies used northern blot 
analysis to identify 3.4-4kb hDR3 RNA transcripts in the brain and prostate, as well as 
those that are lymphocyte rich, including the thymus, spleen, small intestine and 
peripheral blood T cells (Chinnaiyan, Orourke et al. 1996; Kitson, Raven et al. 1996; 
Marsters, Sheridan et al. 1996; Bodmer, Burns et al. 1997; Screaton, Xu et al. 1997). 
Later studies also discovered DR3 to be expressed in the cerebellum (Newman, Bond et 
al. 2000), foam cells in atherosclerotic plaques from carotid endoarterectomy samples 
(Kang, Kim et al. 2005; Kim, Kang et al. 2008), vascular endothelial cells and tubular 
epithelial cells of rejecting or injured renal allografts (Al-Lamki, Wang et al. 2008), the 
epidermis and dermis of skin (Bamias, Evangelou et al. 2011), as well as on peripheral 
blood monocytes (Kang, Kim et al. 2005), activated B cells (Cavallini, Lovato et al. 
2013), NK cells (Papadakis, Prehn et al. 2004) and bone marrow differentiated 
osteoblasts (Borysenko, Garcia-Palacios et al. 2006).  
 
 
1.2.7 Murine DR3 expression 
Similar to initial human studies, murine DR3 was detected by northern blot. A 7kb 
transcript was found in the murine brain, heart and kidney, whilst 2 smaller transcripts 
measuring 1.8kb and 2.8kb were identified in the spleen and thymus (Wang, Kitson et 
al. 2001). DR3 expression has also been confirmed on differentiated T cell subsets, 
including Th17 cells (Pappu, Borodovsky et al. 2008; Jones, Stumhofer et al. 2011), 
TregS (Pappu, Borodovsky et al. 2008; Schreiber, Wolf et al. 2010), CD8+ T cells (Fang, 
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Adkins et al. 2008; Twohig, Marsden et al. 2012) and NKT cells (Fang, Adkins et al. 
2008; Twohig, Marsden et al. 2012).  
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1.3 TNF-like protein 1A (TL1A) 
 
1.3.1 Discovery  
The currently accepted ligand for DR3 is the type II transmembrane protein, TNF-like 
protein 1A (TL1A). Discovered in 2002 using ESTs, TL1A was found to be a longer 
variant of vascular endothelium growth inhibitor (VEGI) (Migone, Zhang et al. 2002), 
which had previously been shown to be produced by the endothelium, preventing 
tumour development, angiogenesis and endothelial expansion (Haridas, Shrivastava et 
al. 1999; Zhai, Ni et al. 1999; Tian, Liang et al. 2009). Unlike VEGI, TL1A contains a 
transmembrane domain, with the membrane bound form being cleaved to generate a 
soluble protein (Chew, Pan et al. 2002; Migone, Zhang et al. 2002). Both TL1A and 
VEGI were mapped to the TNFSF15 gene on the long arm of chromosome 9 (Chew, 
Pan et al. 2002), although TL1A is produced in much greater quantities than VEGI from 
endothelial cells (Migone, Zhang et al. 2002). Co-immunoprecipitation studies using 
FLAG tagged TL1A, established TL1A as the sole ligand for DR3, ensuring no 
interaction with other members of the TNFRSF, except DcR3 (Migone, Zhang et al. 
2002; Bossen, Ingold et al. 2006).  
 
 
1.3.2 Structure  
The TL1A protein, standing at 251 amino acids in length was thought to be encoded by 
4 exons (Migone, Zhang et al. 2002), with 2 potential N-linked glycosylation sites 
(Kim, Zhang et al. 2005). TL1A displayed homology to TNFα and Fas-L, at 24.6% and 
22.9% respectively. It is predicted to circulate as a stable homotrimeric molecule, with 
each TL1A monomer measuring 21kDa (Kim, Zhang et al. 2005; Zhan, Yan et al. 
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2009), and holds high sequence similarity between humans and mice (63.7% cDNA) 
(Migone, Zhang et al. 2002).  
 
 
1.3.3 Expression 
TL1A expression was determined via RT-PCR, and was initially thought to be restricted 
to endothelial cells (Migone, Zhang et al. 2002), with significant levels also detected in 
the kidney, prostate, placenta, stomach, intestine, lung, spleen, thymus, skin, brain, renal 
allografts and artheromatous lesions (Migone, Zhang et al. 2002; Al-Lamki, Wang et al. 
2008; Twohig, Roberts et al. 2010; Bamias, Evangelou et al. 2011; Bamias, 
Stamatelopoulos et al. 2013). Later studies revealed TL1A production from multiple 
cell types beyond endothelial cells, including monocytes (Bamias, Martin et al. 2003; 
Bamias, Mishina et al. 2006; Cassatella, da Silva et al. 2007; Prehn, Thomas et al. 
2007), dendritic cells (Prehn, Thomas et al. 2007), T cells (Bamias, Martin et al. 2003; 
Meylan, Davidson et al. 2008), chondrocytes and fibroblasts (Zhang, Wang et al. 2009).  
 
 
1.3.4 Function 
TL1A exhibits several different functions, but was originally identified as a T cell co-
stimulator, promoting IL-2 dependent proliferation of CD4+ T cells and the secretion of 
pro-inflammatory cytokines, including IFNγ and GM-CSF (Migone, Zhang et al. 2002) 
via NF-κB associated pathways (Zhan, Yan et al. 2009). However, IFNγ release from 
CD4+ T cells and TL1A release from monocytes could be ablated by R848, a TLR8 
ligand (Saruta, Michelsen et al. 2009). The above cytokine profile suggested TL1A as a 
supporter of the Th1 phenotype. Together with IL-12 and IL-18, TL1A augments IFNγ 
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production by activated CD4+ T cells and NK cells, increasing levels 9 fold compared to 
IL-12 and 18 alone in the former (Papadakis, Prehn et al. 2004; Prehn, Mehdizadeh et 
al. 2004). TL1A was also seen to increase the cytotoxicity of IL-12/IL-18 activated NK 
cells (Heidemann, Chavez et al. 2010). As well as Th1 cells, TL1A has been cited as a 
promoter of the Th2 response, accumulating effector T cells and promoting IL-13 
release from NKT cells in a model of experimental acute allergic lung inflammation 
(Fang, Adkins et al. 2008). Effects were ablated upon the administration of an anti-
TL1A antibody (Fang, Adkins et al. 2008). Further in vivo studies have found DR3 to 
expand effector T cell populations involved in bacterial (Buchan, Taraban et al. 2012) 
and viral host defence (Twohig, Marsden et al. 2012).  
 
Studies have also implicated TL1A in the Th17 response, though reports describing 
conflicting underlying function exist. Pappu et al, using TL1Ako mice, reported TL1A 
as a supporter of Th17 differentiation and proliferation, as well as Th17 effector 
function (Pappu, Borodovsky et al. 2008). Meanwhile Jones et al, described TL1A as an 
inhibitor of Th17 differentiation from naive T cells, instead implicating TL1A as 
important in the maintenance of the Th17 phenotype (Jones, Stumhofer et al. 2011).  
TL1A has also been shown to co-stimulate Treg expansion, thereby rendering mice 
resistant to acute allergic lung inflammation (Schreiber, Wolf et al. 2010) and 
permitting cardiac allograft survival in a murine model of fully major histocompatibility 
complex mismatched ectopic heart transplant (Wolf, Schreiber et al. 2012). Despite 
expansion, the suppressive effects of TregS were overcome by the TL1A dependent 
CD4+ T cell effects in a model of intestinal inflammation (Taraban, Slebioda et al. 
2011), suggesting functional outcome may depend on the inflammatory context. TL1A 
has also been reported to expand CD8+ T cells in vivo in an IL-2 independent fashion 
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(Slebioda, Rowley et al. 2011). Naive OT-I T cells, which are MHC-I restricted OVA 
specific CD8+ T cells (Clarke, Barnden et al. 2000), were transferred into mice and 
challenged with OVA. Transfer T cell numbers increased 12 fold in the peripheral blood 
following challenge. However, administration of OVA alongside soluble TL1A 
increased OT-I T cells by 81 fold in the peripheral blood, with a similar effect also 
noted in the spleens. This increase was abolished by concurrent injection of a 
neutralising TL1A antibody, demonstrating that DR3 is capable of enhancing antigen 
specific CD8+ T cell expansion. Carboxyfluorescein succinimidyl ester (CFSE) studies, 
used to monitor lymphocyte proliferation, went on to show DR3 promoted OT-I T cell 
proliferation, whilst the generation and subsequent challenge of endogenous OVA 
specific memory CD8+ T cells with OVA and TL1A, confirmed DR3 function as a co-
stimulatory receptor for memory CD8+ T cells. TL1A was also found to trigger splenic 
CD8+ T cell differentiation into cytotoxic T cells, up-regulating the expression of 
granzyme B and perforin beyond that induced by OVA alone (Slebioda, Rowley et al. 
2011).  Consistent with this, DR3 was required for virus-specific CD8+ T cell expansion 
in a CD4+ and NK cell independent manner, which functioned to control viral 
replication (Twohig, Marsden et al. 2012). CD8+ T cell numbers expanded early in 
response to both MCMV and Vaccinia virus infection, unlike the work done by 
Slebioda et al, DR3 had no effect on the secondary memory response (Twohig, Marsden 
et al. 2012). Thus the DR3/TL1A axis plays a major part in the modulation of the 
immune response.  
 
 
 
 
DR3 
Figure 1.2. The role of TL1A in propagating the inflammatory response. 
TL1A expression can be induced in myeloid cells, such as DCs or 
macrophages, T cells and structural cells such as endothelial cells. TL1A 
binds DR3, causing cytokine release and proliferation. The response is 
individual to each T cell subset.  
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1.4 DR3/TL1A in disease 
 
Though the cellular pathways and expression profile of DR3 are fairly well understood, 
its role in disease initiation and progression are only just coming to light, largely thanks 
to experimentation in DR3ko mice, TL1Ako mice and DR3 over-expressing transgenic 
mice.  DR3 has been implicated in several inflammatory diseases, some of which will 
be discussed below.  
 
1.4.1 Rheumatoid arthritis 
DR3 involvement in rheumatoid arthritis (RA) has been widely reported. A duplication 
of the DR3 gene was identified almost 200kb upstream of its original position using 
FISH in 78% of RA patients, compared to a 39% occurrence in healthy controls 
(Osawa, Takami et al. 2004). TL1A was also found to be elevated in the serum of 
patients suffering from RA (Bamias, Siakavellas et al. 2008) and could be induced from 
RA patient mononuclear phagocytes and fibroblast-like synoviocytes in response to 
insoluble immune complexes as well as TNFα and IL-1β (Cassatella, da Silva et al. 
2007). This was associated with increased bone and cartilage destruction (Cassatella, da 
Silva et al. 2007; Bamias, Siakavellas et al. 2008; Zhang, Wang et al. 2009). Moreover, 
TL1A levels were suggested to correlate with disease activity and stage, as the cytokine 
was found more frequently in those with active disease as opposed to those in remission 
(Bamias, Siakavellas et al. 2008). In comparative modelling studies, DR3 mutations 
affecting ligand binding were linked to RA. DR3/TL1A interaction were predicted to 
destabilise, thereby conferring the aberrant response of bone cells to TL1A or T cell 
function, contributing to pathology and bone destruction in RA (Borysenko, Furey et al. 
2005).  
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Different murine models of RA have been used to study DR3 function; antigen-induced 
arthritis (AIA), representing localised disease, and collagen-induced arthritis (CIA), 
simulating systemic disease. DR3wt mice in both, displayed increased joint pathology 
compared to DR3ko littermates (Bull, Williams et al. 2008; Zhang, Wang et al. 2009). In 
AIA, DR3ko mice presented with reduced bone erosion and inflammatory cell infiltrate 
(Bull, Williams et al. 2008). In CIA, TL1A treatment of WT mice enhanced splenic 
germinal centre size and formation, as well as boosting serum anti-collagen titres 
(Zhang, Wang et al. 2009). Experimental manipulation of the DR3/TL1A pathway 
emphasised its therapeutic potential, as TL1A neutralisation ameliorated the 
inflammatory phenotype in both AIA and CIA (Bull, Williams et al. 2008; Zhang, 
Wang et al. 2009), whilst TL1A administration dose dependently exacerbated bone 
pathology in AIA (Bull, Williams et al. 2008). DR3 also promoted osteoclastogenesis in 
AIA, particularly in areas of bone erosion. The bone forming cells, osteoblasts, were 
also reported to express a soluble form of DR3 by cDNA based gene screening (Bu, 
Borysenko et al. 2003). TL1A has been proposed to enhance RA pathogenesis by acting 
as a Th1 inflammatory cytokine, increasing IL-17 and TNFα production (Zhang, Wang 
et al. 2009). 
 
DR3 may however, function differently depending on cell type and stage of disease. 
Thus Takami et al reported CpG hyper-methylation within the DR3 promoter region in 
the synovial cells of RA patients, inhibiting DR3 expression, suggesting this as a 
mechanism for providing resistance to apoptosis and therefore maintaining disease 
(Takami, Osawa et al. 2004).  
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1.4.2 Atherosclerosis  
TL1A is highly expressed in regions with abundant macrophages, from which foam 
cells derive, in carotid atherosclerotic plaques in humans (Kang, Kim et al. 2005; Kim, 
Kang et al. 2008). Furthermore, serum levels of TL1A correlated with the progression 
of carotid atheromatic plaque height, as well as disease progression as patients with low 
TL1A levels developed fewer new carotid plaques over the observation period (Bamias, 
Stamatelopoulos et al. 2013). Using the human macrophage like cell line THP-1, an 
anti-DR3 antibody was found to induce the matrix metalloproteinase (MMP)-1, MMP-9 
and MMP-13, which are thought to contribute to plaque instability (Kim, Lee et al. 
2001). Furthermore, addition of IFNγ concomitant with the anti-DR3 antibody led to the 
release of IL-8, CCL2 and TNFα. THP-1 treatment with TL1A induced MMP-9 in a 
dose dependent manner along with IL-8 (Kang, Kim et al. 2005). As well as MMPs, 
human monocyte derived macrophages treated with TL1A (in conjunction with IL-17), 
were shown to induce ADAMTS 1, 4 and 5, proteases which act on extracellular 
membrane substrates (Salter, Ashlin et al. 2010; Ashlin, Kwan et al. 2013). 
Collectively, these pro-atherogenic cytokines may help to destabilise the atherosclerotic 
plaque, leading to their rupture and consequently disease.  
 
The DR3/TL1A axis has also been implicated in the differentiation of macrophages to 
foam cells, reflecting other members of the TNFSF (Mei, Chen et al. 2007; Persson, 
Nilsson et al. 2008). TL1A was shown to promote cholesterol uptake and incorporation, 
via the up-regulation of scavenger receptors such as SR-A, CD36 and SR-PSOX, as 
well as reducing cholesterol efflux and removal by decreasing ABC transporter 
expression, such as ABCA-1, ABCG-1 and apo-E (McLaren, Calder et al. 2010). These 
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data suggest DR3 has a complex role in the balance of atherogenesis and 
atherosclerosis.  
 
 
1.4.3 Cancer  
The role of DR3 in cancer is not well understood. However, the ability to induce both 
proliferative and apoptotic responses suggests that DR3 could be an obvious and 
potentially important target for manipulation by tumour cells. In neuroblastoma cell 
lines, the DR3 gene locus was tandemly duplicated on chromosome 1p36.2, and upon 
MYC-N over-expression, deleted or translocated to another chromosome. As a result, 
DR3 protein was substantially reduced or eliminated in approximately 40% of 
neuroblastoma cell lines (Grenet, Valentine et al. 1998). In contrast, DR3 was present in 
all lymphoma tumour samples tested by Warzocha et al (Warzocha, Ribeiro et al. 
1998). TL1A has also been reported to enhance NK cell cytotoxicity against NK 
resistant tumour cell lines (Heidemann, Chavez et al. 2010; Park, Song et al. 2012) as 
well as colorectal adenocarcinoma epithelial derived cell lines by synergising with IL-
12 and IL-18 (Heidemann, Chavez et al. 2010). Furthermore, in an in vivo tumour 
model, mice were injected with plasmacytoma cells expressing TL1A. Tumours were 
rejected in a CD8+ T cell dependent manner, as CD8+ T cell depletion rendered mice 
unable to eliminate malignant cells (Slebioda, Rowley et al. 2011). DR3 has also been 
reported to assist in cancer cell survival and dissemination. The chemoresistant human 
pancreatic cancer cell line AsPC-1, was found to augment invasion via constitutive DR3 
mediated NF-κB activation (Ringel, Ibrahim et al. 1999). This was inhibited using the 
natural flavanoid, fistein, which instead triggered an apoptotic response (Murtaza, 
Adhami et al. 2009). A cohort of breast cancer patients revealed decreased DR3 
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expression compared to control patients which was coupled to a poor prognosis and a 
significantly shorter long term survival rate. However, targeting DR3 in breast cancer 
cell lines in vitro, impaired migration rates, suggesting a complex role for the Receptor 
(Ge, Sanders et al. 2013).  
 
DR3 has also been suggested to interact with the endothelial receptor E-selectin. Using 
the colon carcinoma cell line HT29, DR3 was reported to activate p38 and extracellular 
signal related kinase (ERK) mitogen activated protein kinase (MAPK) via E-selectin 
binding, conferring survival and metastatic advantages. DR3 knockdown using siRNA, 
decreased cancer cell adhesion to E-selectin, impairing HT29 transendothelial migration 
(Gout, Morin et al. 2006). Porquet et al went on to say that DR3 activated the NF-κB 
pathway in colon carcinoma cell lines, as well as undergoing alternative splicing to 
generate a variant lacking the transmembrane and death domains, rendering the 
Receptor unable to induce apoptosis (Porquet, Poirier et al. 2011). However, using G-
CSF mobilised human blood peripheral leukocytes to inflamed vascular endothelium, 
DR3 was not identified as an E-selectin ligand (Dagia, Gadhoum et al. 2006), despite 
using the same isolation techniques. Pull down assays were performed on membrane 
extracts of HT29 and LoVo cells (Gout, Morin et al. 2006) or human umbilical cord 
endothelial cells (HUVECs) (Dagia, Gadhoum et al. 2006) using E-selectin as a ligand. 
Gout et al found 3 bands that migrated at 180kDa, 66kDa and <45kDa, which were 
presumed to be DR3 (Gout, Morin et al. 2006), whilst Dagia et al observed 
glycoproteins migrating at 220kDa, 130kDa, 100kDa and 65kDa (Dagia, Gadhoum et 
al. 2006), none of which were identified as DR3, but included the known E-selectin 
ligands PSGL-1 and HCELL. Furthermore, Winkler et al also used pull down 
experiments on haematopoietic stem/progenitor cell extracts, whereby no DR3 was 
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detected (Winkler, Barbier et al. 2012). This data suggests that the role of DR3 in cancer 
requires further investigation.  
 
 
1.4.4 Inflammatory bowel disease (IBD) 
TL1A levels are up-regulated in IBD, particularly in areas involved in Crohn’s disease, 
correlating with disease severity and progression (Bamias, Martin et al. 2003; Bamias, 
Kaltsa et al. 2012). TL1A expression was localised to intestinal lamina propria 
macrophages, CD4+ and CD8+ T cells from Crohn’s disease patients, as opposed to 
plasma cells from ulcerative colitis samples (Bamias, Martin et al. 2003; Prehn, 
Mehdizadeh et al. 2004) and is thought to be up-regulated through the transcriptional 
activation of the NF-κB pathway (Endo, Kinouchi et al. 2010). DR3 expression was 
also noted on intestinal lamina propria lymphocytes from IBD patients, co-stimulating 
IFN-γ secretion (Bamias, Martin et al. 2003). Small intestine isolated CD4+ T cells 
expressing CCR9, a gut homing receptor, displayed a 37 to 105 fold increase of IFNγ 
production when stimulated with a cytokine cocktail of TL1A, IL-12 and IL-18 
(Papadakis, Zhu et al. 2005). Similarly, elevated TL1A and DR3 levels were observed 
in murine models of IBD. TL1A expression was associated with monocytes and 
CD11c+ dendritic cells (Prehn, Thomas et al. 2007) in the inflamed mucosa, whilst DR3 
was preferentially expressed on activated CD4+ memory T cells (Bamias, Mishina et al. 
2006). Akin to human data, TL1A was able to synergise with the IL-12/IL-18 pathway 
to induce IFNγ (Bamias, Mishina et al. 2006). DR3 has therefore been cited as a 
promoter of the Th1 effector phase in chronic intestinal inflammation (Papadakis, Zhu 
et al. 2005).  
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In addition to Th1 cells, the Th17 response is also believed to aid Crohn’s disease 
pathogenesis (Fuss, Neurath et al. 1996). IL-23 and TL1A were induced in lamina 
propria macrophages from Crohn’s disease patients in response to commensal bacteria 
stimulation, which in turn could synergistically enhance the production of IFNγ and IL-
17 by lamina propria T cells (Kamada, Hisamatsu et al. 2010). Human CD4+ CD161+ T 
cells, typically expressed in Th17 mediated mucosal inflammation, were also found to 
release TNFα in response to TL1A stimulation, as well as IFNγ when cross-linked with 
DR3 and TL1A, suggesting DR3 works upstream of TNFα (Cohavy, Shih et al. 2011; 
Jin, Chin et al. 2012). CD4+CD161+TL1A+ T cells were also increased in gut biopsies 
from IBD patients, implying TL1A function during the Th17 response (Jin, Chin et al. 
2012). TL1A, unlike IL-23, could also promote Th17 differentiation from naive lamina 
propria T cells (Kamada, Hisamatsu et al. 2010), a previously reported DR3 function 
(Pappu, Borodovsky et al. 2008), although DR3 involvement in Th17 differentiation has 
been questioned in other studies (Jones, Stumhofer et al. 2011). In a dextran sodium 
sulphate (DSS) model of chronic colitis, TL1A was observed to elicit dual responses; 
Th1, via the up-regulation of IFNγ, and Th17 via the release of IL-17, which themselves 
were induced by IL-12 and IL-23, respectively (Takedatsu, Michelsen et al. 2008). An 
anti-TL1A neutralising antibody prevented chronic colitis and attenuated disease when 
already established by down-regulating both Th1 and Th17 function. Similar results 
were found using G protein αi2-/- T cell transfer models, whereby G protein αi2-/- T cells 
were transferred into naive C57BL/6 mice, leading to spontaneous colitis (Takedatsu, 
Michelsen et al. 2008). T cells which lack the G protein subunit G αi2, located on 
chromosome 9, are able to induce colitis by skewing Th1 mediated immunity via 
increased release of cytokines such as IL-2, IFNγ and TNFα (Hörnquist, Lu et al. 1997). 
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The pathological effects of this have recently been discovered using constitutive TL1A 
expressing mice, which displayed spontaneous goblet cell hyperplasia, elevated IL-13 
levels, paneth cell hyperplasia in the small intestine, increased collagen levels and 
increased IL-13 and IL-17 producing CCR9+ T cells (Meylan, Richard et al. 2011; 
Taraban, Slebioda et al. 2011; Zheng, Zhang et al. 2013). When constitutively expressed 
by T cells and DCs, TL1A also caused an increase in FoxP3+ TregS, (Meylan, Richard et 
al. 2011) compared to expression by DCs, whereby mice displayed an increased Treg 
turnover. Pro-inflammatory signals overrode suppressive effects, as TL1A attenuated 
the ability of TregS to suppress conventional T cells (Taraban, Slebioda et al. 2011). 
TL1A over-expressing transgenic mice with DSS induced colitis displayed worsened 
inflammation, fibrostenosis, increased T cell activation markers and IL-17 expression. 
However, Rag1ko mice adoptively transferred with TL1A transgenic T cells displayed 
increased IFNγ but reduced IL-17 and Th17 cells (Shih, Barrett et al. 2011; Barrett, 
Zhang et al. 2012).  
 
Crohn’s disease patients exhibiting high levels of TL1A, also suffered intestinal 
fibrostenosis and worsened inflammation in the small intestine, suggesting TL1A as a 
prognostic marker (Shih, Barrett et al. 2011). Genetic polymorphisms of TL1A have 
been shown to correlate with the development of Crohn’s disease as well as risk. The 
TL1A gene has been associated with increased risk in Jewish patients (Michelsen, 
Thomas et al. 2009), whilst genome wide association studies have revealed TL1A to be 
a susceptibility gene in Japanese and European populations (Yamazaki, McGovern et al. 
2005; Barrett, Hansoul et al. 2008; Thiebaut, Kotti et al. 2009). Therefore TL1A has 
been nominated as a candidate therapeutic target for IBD development.  
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1.4.5 Neurological disease 
TL1A and DR3 are constitutively expressed in the brains of normal humans, rat and 
mice (Wang, Kitson et al. 2001; Twohig, Roberts et al. 2010), implicating the Receptor 
in the maintenance of normal neuronal function. DR3 was also shown to be elevated in 
the brains of patients suffering with Alzheimer’s disease, suggesting it was related to 
neuronal disease cell loss (Newman, Bond et al. 2000). Using an anti-DR3 peptide 
polyclonal antibody, Newman et al studied the localisation of DR3, finding that 
expression was neuron specific and within the same population of cells affected by 
Alzheimer’s (Newman, Bond et al. 2000). Increased DR3 expression was also detailed 
by Harrison et al in the human cerebellum, as well as in many regions of the rat brain 
(Harrison, Roberts et al. 2000). An in vivo model of ischaemia, which occurs as a 
consequence of stroke, demonstrated DR3 expression to be biphasic, peaking early and 
decreasing by 6 hours. DR3 was therefore proposed to be involved in neuronal 
elimination (Harrison, Roberts et al. 2000). DR3 function in neuropathology was further 
supported by Twohig et al, who suggested DR3 had a non-redundant role in maintaining 
normal motor control function during ageing in mice and that the basal levels found in 
the normal brain were essential for preventing the development of behavioural defects 
(Twohig, Roberts et al. 2010).  DR3 also preserved the balanced expression of striatal 
neurotransmitters, as its absence saw an increase in dopamine levels and decreased 
serotonin production, indicating DR3 as an important mediator in the maintenance of 
the normal brain phenotype.  
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1.4.6 Anti microbial immunity  
The DR3/TL1A pathway has been linked to both anti-bacterial (Shih, Kwan et al. 2009; 
Buchan, Taraban et al. 2012) and anti-viral immunity (J Reddy, Schreiber et al. 2012; 
Twohig, Marsden et al. 2012). Shih et al reported TL1A expression in human antigen 
presenting cells (APC), including monocytes and monocyte-derived DCs, in response to 
multiple bacteria, including gram negative organisms (E.coli, Salmonella typhimurium), 
gram positive bacteria (Listeria monocytogenes, Staphylococcus epidermis), partial 
anaerobes (Campylobacter jejuni) and obligate anaerobes (Bacteroides 
thetaiotaomicron, Bifidobacterium breve, Clostridium A4). TL1A expression peaked at 
4 hours in monocytes, compared to 8 hours in DCs and was dependent on p38 MAPK 
and NF-κB activation. When induced, TL1A potentiated CD4+ T cell effector function 
by enhancing IFNγ production (Shih, Kwan et al. 2009). In an in vivo model of bacterial 
stimulation, mice were infected with Salmonella enterica Typhimurium, where TL1A 
was found to be up-regulated on macrophages after 4 hours, peaking again at day 14 
concurrent with CD4+ T cell proliferation. In DR3ko mice, reduced IFNγ producing 
CD4+ T cells were seen, as cells retained a more immature phenotype, resulting in 
defective bacterial clearance (Buchan, Taraban et al. 2012).  
 
DR3 has also been shown to regulate virus specific T cell function in vivo following 
murine cytomegalovirus (MCMV) or Vaccinia virus infection. DR3ko mice presented 
with increased viral loads associated with a lack of CD4+ and CD8+ T cell expansion. 
This, like Salmonella enterica infection, resulted in reduced numbers of activated IFNγ 
producing T cells and faulty viral clearance, which could be lethal (Twohig, Marsden et 
al. 2012). In a model of herpes simplex virus 1 (HSV-1), an anti-DR3 antibody was 
found to expand DR3 expressing cells, which were observed to predominantly consist 
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of TregS, thus causing reduced cellular infiltrates into the inflammatory lesion, including 
CD4+ Th1 cells (J Reddy, Schreiber et al. 2012). The antibody was proved effective in 
disease prevention, when administered at the time of or before infection, as well as 
therapeutically, when administered with galectin-9 to limit effector T cell function and 
thereby orchestration of the immune response (J Reddy, Schreiber et al. 2012). 
 
 
1.4.7 Allergic lung inflammation 
Until recently, literature on DR3 had centred on its role in Th1/Th17 function and 
consequently, diseases that induce such a response. However allergic lung 
inflammation, though classically considered a Th2 mediated disease, was also found to 
be DR3 dependent (Fang, Adkins et al. 2008; Meylan, Davidson et al. 2008). Systemic 
priming with ovalbumin (OVA) and aluminium hydroxide (Alum) or aluminium 
potassium sulphate, followed by local challenge with OVA in DR3ko and dominant 
negative (DN) DR3 mice, rendered mice resistant to the development of acute allergic 
lung inflammation compared to WT littermates. Mice lacking DR3 function displayed 
fewer lung and bronchoalveolar lavage cell infiltrates, including CD4+ T cells, invariant 
NKT cells and eosinophils. As well as infiltration, mice also exhibited reduced mucin 
production and peribronchial inflammation, characterised by fewer T cells and 
macrophages localised in the interstitial and peribronchial airways. Expression of 
mRNA for IL-5 and IL-13, prominent Th2 cytokines, also decreased in comparison to 
WT mice, although IFNγ levels were unchanged (Fang, Adkins et al. 2008; Meylan, 
Richard et al. 2011). Similar results were achieved using a TL1A blocking antibody, 
which was capable of attenuating lung inflammation in mice already primed and 
exposed to antigen (Fang, Adkins et al. 2008). Using DR3ko mice, splenocyte 
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proliferation, cytokine production and antibody production were deemed to be normal 
following lung inflammation (Meylan, Davidson et al. 2008), whilst OVA IgE 
production was reduced in DN DR3 mice (Fang, Adkins et al. 2008). Meylan et al, 
proposed that DR3 was required for the recruitment of Th2 effector cells at the site of 
inflammation rather than systemically, suggesting that the gene’s absence resulted in 
defective Th2 cell accumulation and function (Meylan, Davidson et al. 2008).  
 
To determine whether the requirement for DR3 was T cell intrinsic, transfer 
experiments were performed using OT-II cells, defined as MHC-II restricted OVA 
specific CD4+ T cells (Barnden, Allison et al. 1998). DR3ko OT-II OVA specific T cells 
and OT-II controls were activated in vitro under Th2 cell differentiation conditions and 
subsequently transferred into naive host mice. Following respiratory challenge with 
OVA, DR3ko OT-II T cell recipient mice displayed defective OVA-specific T cell 
accumulation and proliferation in the lung, as well as the draining mediastinal lymph 
nodes. This corresponded with reduced inflammatory infiltrates in the BAL, implying 
DR3 expression upon T cells was necessary to initiate an appropriate and effective local 
response to invading antigen (Meylan, Davidson et al. 2008). 
 
Fang et al meanwhile, suggested DR3 was essential for IL-13 release from NKT cells, 
amplifying the Th2 response and driving allergic lung inflammation (Fang, Adkins et al. 
2008). OVA primed NKT cell deficient mice, which are resistant to allergic lung 
inflammation (Akbari, Stock et al. 2003), were adoptively transferred with DN DR3 
NKT cells and aerosol challenged with OVA. After 3 days, DN DR3 NKT cells 
transferred mice displayed no signs of lung inflammation, BALF eosinophilia or Th2 
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cytokine production, in comparison to WT NKT cells, which restored the features of 
allergic lung inflammation (Fang, Adkins et al. 2008).  
 
Furthermore, TregS have also been cited as important in acute allergic lung inflammation. 
Both an anti-DR3 antibody (Schreiber, Wolf et al. 2010) and TL1A-IgG fusion protein 
(Khan, Tsai et al. 2013) were found to expand TregS following acute allergic lung 
inflammation, reversing the ratio of conventional T cells to TregS. TregS made up 55% of 
CD4+ T cells compared to 22% in control mice using an anti-DR3 antibody, compared 
to a 66% and 25% using a soluble TL1A-IgG protein, suggesting the kinetics of 
expansion are similar between the two. This Treg expansion protected against lung 
inflammation, blocking cell infiltration, BALF eosinophilia and mucin production 
(Schreiber, Wolf et al. 2010; Khan, Tsai et al. 2013). These findings suggest the 
DR3/TL1A pathway is central to the development of acute allergic lung inflammation.  
 
 
.  
 
 
 
 
 
 
 
 
 
38 
 
1.5 Asthma 
 
1.5.1 Definition 
The World Health Organisation (WHO) define asthma as a disease characterised by 
recurrent attacks of breathlessness and wheezing, varying in frequency and severity 
between individuals. Asthma is increasing in prevalence and severity worldwide with an 
estimated 5.4 million people in Britain receiving treatment (Pawankar, Canonica et al. 
2012). This presents a huge economic burden in terms of direct (medication, 
hospitalisation) and indirect costs (work and school loss) (Bahadori, Doyle-Waters et al. 
2009). Clinical symptoms used to diagnose asthma include episodic wheezing, chest 
tightness, shortness of breath and coughing, leading to variable or reversible airflow 
obstruction (Hegele 2000), although several patients have shown poor reversibility 
(Bousquet, Jeffery et al. 2000).  
 
 
1.5.2 Pathophysiology  
Asthma is considered a chronic disease of the airways typified by lung inflammation, 
bronchial hyper-responsiveness, airway obstruction and airway remodelling in response 
to normally inert antigen (Hessel, Van Oosterhout et al. 1995; Kay 1996; Wills-Karp 
1999). The chronic nature of the disease is mediated by the infiltration of multiple 
inflammatory cell types into the airway submucosa, including eosinophils, mast cells 
and activated Th2 lymphocytes (Hamid and Tulic 2009). Originally thought to be 
exclusively Th2 mediated, the immune regulation and response to innocuous allergen is 
now considered to be highly heterogeneous (Moore, Meyers et al. 2010). As well as 
inappropriate immune activation, dysregulated endogenous immune regulatory 
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processes are also thought to contribute to the development of disease (Holt, Strickland 
et al. 2008; Lloyd and Hawrylowicz 2009; Robinson 2009). Chronic airway 
inflammation is thought to be contained to the large conducting airways, with the 
severity and chronicity of the disease determining migration to the small airways and in 
some cases, alveoli (Kraft 1999; Diamant and van der Molen 2005).  
 
Chronic inflammation is often accompanied by structural changes, which when 
referring to the asthmatic response, is known as airway remodelling. Alterations in 
airway architecture following chronic allergic lung inflammation encompass a range of 
changes, such as thickening of the airway walls, dysregulated extracellular matrix 
protein deposition and mucus gland hyperplasia (Hogaboam, Blease et al. 2000; 
Tattersfield, Knox et al. 2002; Lloyd and Robinson 2007). This complex and dynamic 
process is considered fundamental to the chronicity of the asthmatic disorder, as well as 
contributing to airway obstruction (Holgate 2007). Despite this, current therapies for 
asthma are directed towards the inflammatory response rather than structural 
remodelling (Di Valentin, Crahay et al. 2009), so whilst halting disease progression, 
they act to cause disease remission, thereby prolonging the asthmatic response (Jarman 
and Lamb 2005).  
 
Asthma can be classified as either intrinsic or extrinisic (Wardlaw, Brightling et al. 
2002). Intrinsic, or non atopic, asthma does not rely on allergens to trigger a response 
but rather internal signals, such as respiratory infections, an upper airway reflex or even 
exercise. As it is not hyper-sensitivity induced, levels of IgE remain comparable to 
those of non-asthmatics during a non-atopic response (Rackemann 1940; Walter and 
Holtzman 2005). Extrinsic, or atopic, asthma on the otherhand, is IgE mediated and 
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occurs as a result of hyper-sensitivity to an inhaled antigen which is otherwise 
considered harmless. Individuals become sensitised to allergen, and upon re-exposure 
initiate an inflammatory response (Walter and Holtzman 2005). As a result, extrinsic 
asthma is loosely considered to be composed of 2 phases, the sensitisation and effector 
phase.  
 
 
1.5.3 Sensitisation 
A fundamental feature of allergen sensitisation is uptake and processing. DCs, situated 
in the airway epithelium and submucosa, are generally considered the most potent APCs 
(von Garnier, Filgueira et al. 2005; Lambrecht and Hammad 2009). Allergen 
recognition often occurs by pattern recognition receptors (PRR), although uptake is 
enhanced by IgE binding to FCγR on DCs (de Heer, Hammad et al. 2005; Kitamura, 
Takeda et al. 2007; Kool, Hammad et al. 2012). Allergen recognition causes the up-
regulation of co-stimulatory molecules and migration to the lymph node via the 
chemokine receptor CCR7 and its ligands CCL19 and CCL21, and to a lesser extent 
CXCR4 and CXCL12 (Sallusto, Schaerli et al. 1998; Humrich, Humrich et al. 2006). 
However lymphotoxinko mice, which lack peripheral lymph nodes, were able to 
generate antigen specific T cell responses and clear influenza infection (Lund, Partida-
Sanchez et al. 2002). Furthermore, CCR7ko mice, though unable to traffic DCs from the 
lung to the lymph node, exhibited proliferation of antigen specific CD4+ T cells in 
response to Mycobacterium tuberculosis infection (Olmos, Stukes et al. 2010). These 
data suggest that T cell activation in the lung can occur outside of lymph nodes, as 
resident lung antigen presenting cells hold the capacity to promote T cell differentiation 
(Constant, Brogdon et al. 2002). Once allergen is internalised, it is processed by 
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Cathepsin S and presented on the surface of the cell via MHCII, enabling interaction, 
and therefore priming to form an antigen-specific effector T cell. However, anergy can 
also occur depending on the nature as well as efficiency of co-stimulatory molecule 
interaction between DCs (CD80/86) and T cells (CD28). The co-stimulatory molecule, 
cytotoxic T lymphocyte antigen 4 (CTLA 4), has a high affinity for CD28, preventing 
CD80/CD86 binding and thereby rendering T cells anergic. This is the basis for the RA 
therapy drug, abatacept (Weinblatt, Combe et al. 2006). However, in more severe 
asthma, alternative co-stimulatory molecules are engaged, including ICOS as well as the 
TNFSF members OX40/OX40L (Salek-Ardakani, Song et al. 2003; Burgess, Blake et 
al. 2005). In asthmatic patients a trend is seen towards Th2 differentiation by DCs, 
leading to the production of the Th2 signature cytokines IL-4, IL-5, IL-9 and IL-13, the 
majority of which are expressed on the long arm of chromosome 5 (Ryu, Jung et al. 
2006). This cytokine milieu acts to promote the Th2 response, initiating class switching 
and affinity maturation to produce IgE, recruiting secondary effector cells into the 
inflammatory zone and up-regulating FcεRI expression on the surface of mast cells and 
basophils. Basophils themselves have been implicated in the initiation of the Th2 
response, as early producers of IL-4. They have been shown to enhance allergen 
sensitisation in vivo, and polarise towards a Th2 response in vitro in the absence of DCs 
(Perrigoue, Saenz et al. 2009; Sokol, Chu et al. 2009; Yoshimoto, Yasuda et al. 2009). 
Others argue however, that they are dispensable for Th2 priming, only partially 
affecting sensitisation upon depletion, instead suggesting inflammatory DCs were 
necessary (Hammad, Plantinga et al. 2010). CCR9+ invariant NKT cells have also been 
linked to the inflammatory response in chronic asthma (Sen, Yongyi et al. 2005; Akbari, 
Faul et al. 2006), although it is the CCR4+ T cells which dominate the allergic immune 
response, correlating with disease severity (Ishida, Ishii et al. 2006).  
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1.5.4 Effector phase   
Following re-exposure to allergen, bronchoconstriction occurs due to allergen specific 
IgE cross linking upon the surface of mast cells as well as basophils via FcεRI binding, 
and leukocytes via the lower affinity FcεRII (Gould, Sutton et al. 2003). This binding 
leads to de-granulation, the release of multiple inflammatory mediators and continuation 
of the asthma pathogenesis.  
 
 
1.6 Characteristics of asthma  
 
1.6.1 Airway inflammation  
 
Airway inflammation is a cardinal feature of asthma, occurring in even mild forms of 
the disease (Laitinen, Laitinen et al. 1996). The extent of inflammation often correlates 
with disease severity, inducing the common symptoms of asthma (Walter and Holtzman 
2005). Despite not being naturally prone to allergic disease, mouse models have been 
shown to demonstrate this key symptom observed in asthmatic patients (Williams and 
Galli 2000; Kips, Anderson et al. 2003; Koerner-Rettberg, Doths et al. 2008). It is a 
multi-cellular process which due to the complex nature of asthma, cannot be attributable 
to a single cell type.    
 
 
1.6.1.1 Mast cells  
Due to their ability to release pro-inflammatory mediators, high affinity for IgE and 
proximity to blood vessels, smooth muscle and mucosal surfaces, mast cells are 
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considered a key contributor to the asthmatic response. Located in the airway 
epithelium, submucosa, deep airway wall and peripheral airways (Yu, Tsai et al. 2006), 
mast cells interact with smooth muscle through leukotriene D4, prostaglandin D2 and 
histamine, contributing to fibrogenesis, microvascular permeability and airway 
remodelling (Kaur, Saunders et al. 2006; Plante, Semlali et al. 2006). Mast cells, after 
cross linking by IgE, provide an early source of inflammatory mediators, such as IL-4, 
influencing effector T cells, and IL-5, promoting eosinophil recruitment and activation 
(Lorentz, Schwengberg et al. 1999). De-granulation also sees the release of preformed 
mediators, such as histamine, heparin and tryptase, as well as rapidly synthesised 
mediators, including lipid mediators and other cytokines and chemokines, including 
TNFα (Okayama, Tkaczyk et al. 2003; Bradding, Walls et al. 2006). This release helps 
to prolong the inflammatory response via the infiltration of further cell types.  Mast cell 
deficient mice which underwent sensitisation (without adjuvant) and repeated aerosol 
challenges, displayed reduced numbers of eosinophils, neutrophils and lymphocytes and 
impaired goblet cell hyperplasia (Yu, Tsai et al. 2006), which could not be restored 
using FcεR1ko cells (Yu, Eckart et al. 2011), TLR4ko cells (Nigo, Yamashita et al. 2006) 
or TNFαko cells (Suto, Nakae et al. 2006), supporting the idea that mast cells contribute 
towards airway inflammation.  
 
 
1.6.1.2 Eosinophils  
Eosinophils were originally described as the signature cell type of atopic asthma, 
dominating the infiltrate of asthma patients as well as correlating with disease severity 
in some patients (Bousquet, Jeffery et al. 2000; Kay 2005). Found within the BAL as 
well as the sputum (Kay 2005; Lemiere, Ernst et al. 2006), eosinophils are recruited as 
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CD34+ precursors from the bone marrow in response to IL-3, GM-CSF, CCL2 and 
CCL5 amongst other soluble factors (Robinson, North et al. 1999; Sehmi, Dorman et al. 
2003). IL-5 however, is considered particularly important for eosinophil recruitment, 
differentiation, proliferation and maturation (Foster, Mould et al. 2001). However, its 
blockade, though reducing eosinophil numbers, did not cause the abolition of airway 
inflammation (Flood-Page, Menzies-Gow et al. 2003), despite beliefs it was centrally 
involved in asthma development and inflammation. Eosinophil depletion was instead 
found to affect extracellular matrix protein deposition (Flood-Page, Menzies-Gow et al. 
2003), reinforcing the complex nature of asthma pathogenesis. Upon activation, 
eosinophils release cationic proteins, such as major basic protein (MBP) and eosinophil 
peroxidase (EPO), as well as inflammatory mediators such as Th2 cytokines, 
prostaglandins and leukotrienes (Kariyawasam and Robinson 2006), amplifying the 
immune response. Eosinophil deficient mouse studies have shown a conflicting role for 
eosinophils in the allergic lung response. Whilst those on a C57BL/6 background 
displayed reduced airway hyper-reactivity (Lee, Dimina et al. 2004) and Th2 cytokines, 
correlating with a reduced ability to recruit effector T cells (Jacobsen, Ochkur et al. 
2008), BALB/c mice failed to replicate this phenotype. They instead displayed reduced 
remodelling (Humbles, Lloyd et al. 2004), although this has since been disputed 
(Fattouh, Al-Garawi et al. 2011). Nonetheless, when crossed onto a C57BL/6 
background, BALB/c mice too displayed airway hyper-reactivity attenuation and a 
failure to recruit CD4+ T cells via CCL17 and CCL22 (Walsh, Sahu et al. 2008).  
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1.6.1.3 Macrophages  
The precise role of macrophages in mediating tissue damage and pathology is yet to be 
defined. Macrophages have been cited as a regulator of allergic lung inflammation via 
the release of IL-10 and TGFβ (Soroosh, Doherty et al. 2013), as well as a promoter of 
eosinophilic inflammation (Moon, Kim et al. 2007) and airway remodelling (Mautino, 
Henriquet et al. 1999). Alveolar macrophages (AMs), which  some suggest originate 
from interstitial macrophages (Landsman and Jung 2007), release CCL2 to attract 
monocytes to inflamed tissue (Brieland, Jones et al. 1992). Th2 cytokines skew 
macrophages towards an M2 phenotype, causing the release of inflammatory factors, 
which although intended to maintain pulmonary homeostasis in asthma, actually lead to 
aggravated lung injury (Moreira and Hogaboam 2011). Macrophages have also been 
reported to inhibit T cell proliferation and DC induced T cell activation (Holt, Oliver et 
al. 1993; Bedoret, Wallemacq et al. 2009) as transfer of un-sensitised AMs to sensitised 
mice initiated protection and suppressed pro-inflammatory functions (Careau, Proulx et 
al. 2006). In contrast, there are also reports of alveolar macrophages promoting 
inflammation by releasing IL-17 in an OVA mouse model of allergic lung inflammation 
(Song, Luo et al. 2008), controlling the proteolytic activity of macrophages (Sergejeva, 
Ivanov et al. 2005). These contrasting data suggests further work needs to be done to 
explore the role of macrophages in the allergic response.  
 
 
1.6.1.4 CD4+ T cells 
Th2 cells, through the production of cytokines, can initiate and maintain the cardinal 
features of allergic lung disease, though epithelial derived cytokines such as IL-25 
(Tamachi, Maezawa et al. 2006), IL-33 (Kurowska-Stolarska, Kewin et al. 2008) and 
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thymic stromal lymphopoietin (TSLP) (Zhou, Comeau et al. 2005) recently emerged 
with a role. The number of Th2 cells in patient asthmatic airways correlates with disease 
severity (Walker, Kaegi et al. 1991). IL-4 and IL-13 promote IgE class switching, 
mucus secretion and fibrosis, and together with IL-9, cell recruitment, whilst IL-5 
supports eosinophil activation. Th2 cells have therefore been established as a central 
cell type in the asthma paradigm.  
 
 
1.6.1.5 CD8+ T cells  
The role of CD8+ T cells in asthma remains controversial, as they have been reported to 
exhibit both beneficial and deleterious effects. Depletion of CD8+ T cells in rats led to 
an enhancement of airway inflammation and remodelling (Laberge, Wu et al. 1996; 
Tsuchiya, Isogai et al. 2009), thought to be mediated by IFNγ and IL-12 (Wells, Cowled 
et al. 2007; Takeda, Dow et al. 2009). In contrast, CD8+ T cells have also been observed 
to enhance the asthmatic phenotype by collaborating with sensitised CD4+ T cells 
(Miyahara, Swanson et al. 2004; Koya, Miyahara et al. 2007). In these latter studies, 
CD8+ T cell deficient mice were less susceptible to allergic lung inflammation, 
measured by decreased airway eosinophilia, cytokine production and goblet cell 
metaplasia, suggesting CD8+ T cells were required for chronic disease. Phenotype could 
be restored upon transfer of in vitro primed WT effector memory CD8+ T cells, but not 
those from IL-13ko mice, suggesting CD8+ T cells were activated in the airways and 
produce IL-13 locally (Miyahara, Swanson et al. 2004).  
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1.6.1.6 Innate like T cells  
Aside from αβ T cells, innate like lymphocytes have recently been reported to have a 
role in allergic lung inflammation. NK cells are present in the naive lung, expressing a 
variety of receptors so enabling immune surveillance (Grégoire, Chasson et al. 2007). 
Increased numbers of NK cells were observed in asthma patients (Weissler, Nicod et al. 
1987). Under steady state conditions, resident lung NK cells expressed fewer activating 
receptors, adhesion/migration receptors and co-stimulatory molecules compared to 
splenic NK cells, instead displaying a higher frequency of inhibitory receptors. It was 
thus suggested that NK cells were quiescent, with activation being tightly regulated by 
the pulmonary environment (Wang, Li et al. 2012). Mouse models however support a 
role for NK cells in allergic lung inflammation, as their depletion before OVA 
sensitisation or during challenge inhibited eosinophilia, T cell infiltration and 
inflammatory mediator release, suggesting NK cells contributed to both the initiation 
and maintenance of the Th2 inflammatory response (Korsgren, Persson et al. 1999).  
 
NKT cells, which recognise glycolipids through CD1d on APCs, have also been 
implicated in the asthmatic response using mouse studies. NKT deficient mice retained 
eosinophilic inflammation but failed to develop airway hyper-reactivity, though this was 
restored upon the transfer of purified WT NKT cells, though not IL-4-ko or IL-13ko cells 
(Akbari, Stock et al. 2003). The glycolipid NKT ligand, α-galactosylceramide (α-
GalCer), promoted IL-13 and TSLP release from NKT cells, as well as NKT mediated 
allergen sensitisation when administered with antigen (Kim, Kim et al. 2004; Nagata, 
Kamijuku et al. 2007). An increase in CD4+ α-GalCer loaded CD1d tetramer cells was 
also noted in the BAL of asthmatic children compared to controls, suggesting a role for 
NKT cells in disease (Pham-Thi, de Blic et al. 2006).  
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An increase in pulmonary γδ T cells has also been reported in asthmatic patients, 
particularly during asthma exacerbations (Molfino, Doherty et al. 1996; Spinozzi, Agea 
et al. 1996). In allergic lung inflammation mouse models, γδ T cells were shown to act 
as regulators of lung inflammation, as increased airway hyper-reactivity was observed 
upon depletion (Lahn, Kanehiro et al. 1999; Hahn, Taube et al. 2003), particularly when 
co-infected with rhinovirus (Glanville, Message et al. 2013). Others however, suggest 
γδ T cells are pro-inflammatory, potentiating the activation of the Th2 response 
(Schramm, Puddington et al. 2000; Svensson, Lilliehook et al. 2003).  
 
ILC2 cells, a relatively new population involved in innate defence, have also been found 
in the lung (Monticelli, Sonnenberg et al. 2011). They are functionally characterised by 
the production of IL-5 and IL-13 in response to the stimulating cytokines IL-25 and IL-
33 (Neill, Wong et al. 2010; Price, Liang et al. 2010). Both IL-5 and IL-13 have already 
distinguished roles in allergic lung inflammation, promoting eosinophil proliferation 
and maturation, as well as goblet cell hyperplasia and antibody class switching. Roles 
have also emerged for both IL-25 and IL-33 in allergic lung inflammation. IL-25, a 
member of the IL-17 family, is thought to promote Th2 immunity via the induction of 
IL-4, IL-5 and IL-13 (Fort, Cheung et al. 2001). Similarly, IL-33, a member of the IL-1 
cytokine family, has been shown to induce eosinophilia and increased IgE production in 
vivo (Schmitz, Owyang et al. 2005), as well as reduce symptom severity when blocked 
(Oboki, Nakae et al. 2011). IL-33 is thought to act as a danger signal, released by 
epithelial cells in response in allergen (Pichery, Mirey et al. 2012), in turn leading to the 
accumulation of ILC2’s and Th2 mediated inflammation. Adoptive transfer of ILC2’s to 
IL-13ko mice restored airway hypereactivity (Chang, Kim et al. 2011), whilst intranasal 
administration of IL-25 and IL-33 in mice, initiated an asthmatic phenotype via 
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increased accumulation of ILC2’s in the lung and BAL, even in the absence of T cells 
(Wolterink, KleinJan et al. 2012).  
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Figure 1.3. Inflammatory and immune cells involved in asthma.  Inhaled 
allergen is presented by DCs causing Th2 differentiation and the release of 
multiple cytokines. IL-4 and IL-13 initiate antibody class switching, IL-13 
contributes to airway remodelling, IL-5 causes eosinophil maturation and IL-
9 enhances mast cell proliferation. IgE cross links on the mast cell surface, 
releasing bronchoconstrictors such as histamine, leukotrienes and 
prostaglandins. These collective events lead to bronchoconstriction, airway 
remodelling and airway inflammation.  
 
 
  
 
51 
 
1.6.2 Airway hyper-responsiveness (AHR) 
 
AHR is a clinical feature of asthma, though intensity often varies between patients  
(Busse 2010). It is defined as a greater degree of airway closure via increased sensitivity 
to stimuli (O’Connor, Crowther et al. 1999).  AHR occurs in response to a range of 
direct stimuli, including histamine and methacholine, which act directly on specific 
smooth muscle receptors to cause constriction. Histamine acts on H1, whilst 
methacholine exerts its effects through muscarinic receptors, increasing in the 
eosinophil mediated absence of the regulatory muscarinic receptor 2 (Elbon, Jacoby et 
al. 1995; Castro, Resende et al. 2013). Methacholine is often used in a diagnostic test 
for asthma, as a lesser concentration is required to achieve airway contraction. Indirect 
stimuli, such as cold air, exercise and adenosine monophosphate (AMP) also induce 
AHR, though they do not act directly upon smooth muscle. AMP is thought to stimulate 
mast cells, causing the release of mediators independent of IgE (O'Byrne, Gauvreau et 
al. 2009). The developmental process of AHR remains unknown, though structural 
changes have been implicated, as epithelial damage exposes nerve endings, thereby 
increasing response to stimuli, whilst airway thickening results in narrower airways and 
so greater constriction when stimulated (Jeffery, Wardlaw et al. 1989; Oliver, Fabry et 
al. 2007). However, it is not clear whether there is a change in airway smooth muscle 
mechanically, increasing its contractile ability, or structurally, increasing in mass and 
thickness (An, Bai et al. 2007).  
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1.6.3 Airway remodelling  
 
Chronic airway inflammation is often accompanied by structural changes, termed 
airway remodelling in asthmatic patients. These changes include collagen and 
fibronectin deposition, thickening of the sub-epithelial basement membrane, goblet cell 
hyperplasia, increased smooth muscle mass and size and fibrosis, all of which 
contribute to a thickening of the airway wall, obstructing airflow via a reduction in 
airway diameter (Bousquet, Jeffery et al. 2000; Hamid and Tulic 2009).  
 
 
1.6.3.1 Goblet cell hyperplasia 
Goblet cell hyperplasia and increases in mucin secretion have long been associated with 
asthma, as increased levels were observed in asthmatic airways compared to controls 
(Aikawa, Shimura et al. 1992), while the levels of the predominant mucin gene, 
MUC5AC are raised in asthmatic disease (Ordonez, Khashayar et al. 2001). MUC5AC 
has previously been linked to mucus hyper-secretion and is the most abundant gel 
forming mucin present at the airway surfaces (Young, Williams et al. 2007). This 
increase in goblet cells, which parallels with a reduction in ciliated and Clara cells 
(Reader, Tepper et al. 2003), leads to increased bronchial obstruction due to mucus 
plugging in both the central and peripheral airways (Andoh, Aikawa et al. 1992; 
Ordonez, Khashayar et al. 2001; Kuyper, Pare et al. 2003). Inflammation is thought to 
stimulate the activation of epidermal growth factor (EGF) and IL-13, inducing Clara 
and ciliated cells to differentiate into goblet cells via the transcription factors FoxA2, 
thyroid transcription factor 1 (TTF-1) and SAM pointed domain ETS transcription 
factor (SPDEF) (Evans, Williams et al. 2004; Wan, Kaestner et al. 2004; Tyner, Kim et 
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al. 2006; Chen, Korfhagen et al. 2009; Cras, Acciani et al. 2011). This leads to the up-
regulation of MUC5AC and increased mucin granules, which fuse to the plasma 
membrane through the myristoylated alanine rich C kinase substrate (MARCKS) (Li, 
Martin et al. 2001; Singer, Martin et al. 2004), soluble N-ethylmaleimide sensitive 
factor attachment receptors (SNAREs) and the accessory Munc proteins, allowing 
plasma membrane fusion to occur and mucin release into the airway lumen (Curran and 
Cohn 2010).  
 
IL-13 is essential for goblet cell hyperplasia, regulating the chloride channel GOB5, 
involved in mucin regulation, composition and secretion from goblet cells (Thai, Chen 
et al. 2005; Long, Sypek et al. 2006), as well as acting directly on the airway epithelium 
in a STAT6 dependent manner (Kuperman, Huang et al. 2002; Kuperman, Huang et al. 
2005; Fujisawa, Ide et al. 2008). IL-9 induced expression of MUC5AC is also IL-13 
dependent (Steenwinckel, Louahed et al. 2007). Irrespective of the mechanism, the over 
production of mucus is a hallmark of the asthmatic lung, contributing to airway 
obstruction, and in extreme cases, mortality (Sheehan, Richardson et al. 1995).  
 
 
1.6.3.2 Fibrosis 
Sub-epithelial fibrosis is associated with thickening of the basement membrane caused 
by deposition of ECM proteins (Roche, Beasley et al. 1989), particularly collagen types 
I and III, fibronectin and proteoglycans (Freyer, Billington et al. 2004). Type I collagen 
lends support to the alveolar and bronchial walls, whilst type III is essential for type I 
fibrillogenesis (Bradley, McConnell-Breul et al. 1974; Bienkowski, Ripley et al. 1990). 
The thickness of the sub-epithelial layer was reported to increase with the severity of 
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disease (Boulet, Laviolette et al. 1997; Chetta, Foresi et al. 1997), though others found 
no correlation (Chu, Halliday et al. 1998). Sub-epithelial fibroblasts and myofibroblasts, 
normally responsible for tissue repair, are increased in asthma, where they are thought 
to contribute to increased basement membrane thickening and ECM deposition, 
including collagen (Brewster, Howarth et al. 1990; Morishima, Nomura et al. 2001; 
Matsumoto, Niimi et al. 2005). TGFβ promotes the differentiation of fibroblasts to 
contractile myofibroblasts, triggering proliferation and the release of fibroblast growth 
factor (FGF) and connective tissue growth factor (CTGF) (Khalil, Xu et al. 2005; Le, 
Cho et al. 2007; Michalik, Pierzchalska et al. 2009). Eosinophils are thought to be a 
major source of TGFβ, as their depletion in the asthmatic airways led to reduced levels 
(Flood-Page, Menzies-Gow et al. 2003). The loss of epithelial characteristics and 
subsequent acquisition of mesenchymal features, giving rise to fibroblasts and 
myofibroblasts has also been cited as a mechanism behind the alterations in lung 
architecture. This emerging concept, known as epithelial mesenchymal trophic unit, is 
also thought to be mediated in part by TGFβ (Jill, Paul-Andre et al. ; Hackett, Warner et 
al. 2009; Holgate, Roberts et al. 2009; Heijink, Postma et al. 2010; Grainge, Lau et al. 
2011; Johnson, Roos et al. 2011) in response to allergen induced epithelial damage and 
inflammatory insults (Holgate, Lackie et al. 2001). In vivo, TGFβ blockade led to a 
reduction in peribronchiolar ECM deposition during established allergic lung disease 
(McMillan, Xanthou et al. 2005), whilst over-expression of the cytokine induced severe 
fibrosis and increased ECM deposition (Kolb, Bonniaud et al. 2002).  
 
In addition, the dysregulated function of MMPs, particularly MMP-9, has been reported 
in the asthmatic airway (Mattos, Lim et al. 2002; McMillan, Kearley et al. 2004; Lim, 
Cho et al. 2006), altering ECM remodelling and degradation, as well as platelet derived 
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growth factor (PDGF) (Clark, Folkvord et al. 1989; Ito, Fixman et al. 2009) and IL-13 
(Lee, Homer et al. 2001; Bellini, Marini et al. 2012).  
 
 
1.6.3.3 Smooth muscle and vascularity 
Increased smooth muscle mass, due to hyperplasia and hypertrophy, is a major 
determinant of airflow obstruction together with fibrosis (Benayoun, Druilhe et al. 
2003; Woodruff, Dolganov et al. 2004). However, difficulties have arisen in 
distinguishing hyperplasia and hypertrophy in asthmatic patients, as Ebina et al noted 
hyperplasia in the large airways in some patients, whereas hypertrophy in the large and 
small airways of others (Ebina, Takahashi et al. 1993). In the case of hyperplasia, it is 
unknown if smooth muscle cells proliferate and receive sustained survival signals 
(Trian, Benard et al. 2007; Kaur, Hollins et al. 2010), or cells, such as fibrocytes, are 
recruited, transforming into smooth muscle cells (Kaur, Saunders et al. 2006; Saunders, 
Siddiqui et al. 2009). Therefore, although smooth muscle levels have been recognised to 
increase in asthma, by 200-400% in fatal cases and 50-200% in non fatal asthma (Bai, 
Cooper et al. 2000), the mechanisms remain unknown. Similarly, published data 
suggests angiogenesis and vascular remodelling occurs in asthma via vascular 
endothelial growth factor (VEGF), although it is unclear whether this is due to an 
increase in blood vessel formation or just size (Carroll, Cooke et al. 1997; Baluk, Lee et 
al. 2004; Bhandari, Choo-Wing et al. 2006).  
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Figure 1.4. A schematic diagram of normal and asthmatic airways.  Inhaled 
allergen initiates the release of multiple cytokines and growth factors  from 
immune cells as well as components of the airway wall. This leads to 
dysregulation of the pulmonary airways including goblet cell hyperplasia, 
smooth muscle hyperplasia and hypertrophy, sub-epithelial fibrosis and 
angiogenesis .  
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1.7 Mouse models of asthma 
 
Unlike cats (Venema and Patterson 2010) and horses (Herszberg, Ramos-Barbon et al. 
2006), which display particular features, mice do not spontaneously develop asthma. 
Consequently, it must be induced using allergen sensitisation and challenge. Several 
different allergens can be used to elicit an asthmatic response, including house dust mite 
(Cates, Fattouh et al. 2004), short ragweed extracts (Chapoval, Nabozny et al. 1999) and 
ovalbumin (Smith and Broadley 2007). OVA is the most commonly used allergen and is 
often injected alongside the adjuvant Alum to induce sensitisation.  
 
Acute models of allergic lung disease focus on inflammatory mechanisms linked to 
manifestations of asthma in humans, as inflammation is predominantly restricted to the 
proximal airways (Wegmann, Fehrenbach et al. 2005). Whilst useful for investigating 
targets directly relating to mast cells, acute models remain problematic in their ability to 
assess other disease processes, such as airway wall changes, and novel therapies 
targeting the evolution of asthma in established disease. Chronic models of allergic lung 
inflammation experience allergen exposure over a longer period, simulating the chronic 
nature of human asthma. These models allow treatments to be tested in a therapeutic 
rather than a preventative setting. However, limitations still exist with regards to human 
asthma, as remodelling shows a tendency towards fibrosis rather than smooth muscle 
thickening as occurs in humans (Holmes, Solari et al. 2011) and inflammation occurs in 
the lung parenchyma, particularly perivascular and peribronchiolar areas, rather than 
within the airway wall as seen in humans (Kumar and Foster 2002).  
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Mice do however provide several advantages over their larger counterparts, such as 
lower costs, a well characterised immune system and the availability of KO mice. As 
such, murine models of asthma are becoming ever more prevalent (Kumar and Foster 
2002; McMillan and Lloyd 2004). However, despite being instrumental in 
understanding the mechanistic and underlying pathways of disease, debate continues as 
to the suitability of mice modelling what is predominantly considered a human disease 
(Gelfand 2002; Persson 2002; Holmes, Solari et al. 2011).  
 
 
1.8 Treatments  
 
Inhaled corticosteroids and β2-adrenoreceptor agonists, both short acting (SABA) and 
long acting (LABA), are currently utilised for asthma treatment. Corticosteroids 
suppress Th2 mediated inflammation by targeting cytokines, chemokines and adhesion 
molecules. They diffuse across the cell membrane and interact with cytoplasmic 
glucocorticoid receptors, causing activation, translocation to the nucleus and either the 
transactivation or repression of target genes. However, corticosteroids, though effective 
in suppressing airway inflammation, do not influence disease progress (Holgate and 
Polosa 2008). Inhaled corticosteroids are absorbed from the lungs and thus hold 
potential for systemic side effects. This has resulted in a search for safer treatments with 
reduced adsorption from the lungs and inactivation in the circulation, allowing the 
administration of higher doses in severe cases of asthma. Dissociated steroids attempt to 
separate these side effects mediated by transactivation from the anti-inflammatory 
effects conducted by transrepression (Heike, Arndt et al. 2004). Bronchodilators, the 
most predominant being β2-agonists, assist in the management of asthma via the 
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prevention of bronchoconstriction. LABAs, the most common being formoterol and 
salmeterol, are often used in conjunction with inhaled corticosteroids to prevent further 
exacerbations (McIvor, Pizzichini et al. 1998; Jaeschke, O'Byrne et al. 2008), inducing 
bronchodilation for up to 12 hours (Usmani, Ito et al. 2005). Inhaled SABAs, such as 
salbutamol and terbutaline, are currently used for the rapid relief of asthma. Once bound 
to β2-adrenoreceptor, adenylate cyclase is induced, converting adenosine trisphosphate 
(ATP) into cycle adenosine monophosphate (cAMP), thereby activating protein kinase 
A. This then leads to smooth muscle relaxation, phosphorylation of myosin light chain 
kinase, opening of the Ca2+ dependent K+ channel, ultimately relieving 
bronchoconstriction in asthma.  
 
Although widely used, severe asthmatics are often unable to adhere to treatments such 
as corticosteroids, resulting in a lack of effectiveness (Chapman, Boulet et al. 2008). 
Corticosteroids are unable to decrease the levels of TNFα, which are often increased in 
severe cases (Truyen, Coteur et al. 2006), thus the TNF receptor fusion protein 
etanercept was trialled in small studies with reported efficacy (Howarth, Babu et al. 
2005; Berry, Hargadon et al. 2006). Omalizumab has also been shown to inhibit 
allergen induced inflammatory responses in mice and humans by blocking IgE binding 
to FcεRI and FcεRII (Corne, Djukanovic et al. 1997; Busse, Morgan et al. 2011; 
Hanania, Alpan et al. 2011), whilst mast cell stabilising drugs, such as masitinib, have 
been reported to limit mast cell survival via the inhibition of c-kit and thereby stem cell 
factor (SCF) (Humbert, De Blay et al. 2009). Cytokine therapy has also been 
volunteered as a potential asthma treatment, although due to the redundancy that exists 
between them, results have sometimes proved disappointing (Hart, Blackburn et al. 
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2002; Linhart, Bigenzahn et al. 2007). IL-13 however, is still being considered as a 
therapeutic target (Spahn, Szefler et al. 1996; Wenzel, Wilbraham et al. 2007).  
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1.9 Aims and Hypothesis 
 
Hypothesis:  DR3 exerts differential effects in acute versus chronic allergic lung 
  inflammation. 
 
In order to test this hypothesis, the residing aims of this thesis are to use OVA/Alum 
induced in vivo experimental models of lung inflammation to investigate the effects of 
the DR3/TL1A pathway during homeostasis, acute allergic lung inflammation and 
chronic allergic lung inflammation, thus exploring its potential as a therapeutic target in 
asthmatic disease More specifically, this thesis intends to: 
 
• Determine DR3 expression on leukocytes and within the lung using both flow 
cytometry and immunohistochemistry and a newly commercially available DR3 
antibody. DR3 expression will be examined in the naive and inflammatory 
states. 
 
• Characterise leukocyte populations from the lung, peripheral blood and spleens 
of naive DR3wt and DR3ko mice to investigate whether DR3 influences 
leukocyte homeostasis. 
 
• Investigate the role of DR3 in the accumulation of leukocyte populations into 
the lung, BALF and spleen following acute allergic lung inflammation, as well 
as allergic antibody levels and airway remodelling.  
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• Investigate the role of DR3 in the accumulation of leukocyte populations into 
the lung, BALF and spleen following chronic allergic lung inflammation, as well 
as allergic antibody levels and airway remodelling.  
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    Chapter 2: 
Materials and Methods 
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2.1 Reagents 
2.1.1 Chemicals 
All chemicals were purchased from Sigma Aldrich Ltd (Poole, Dorset, UK) unless 
otherwise stated. 
 
2.1.2 Solutions 
Distilled Water (dH2O) 
dH2O was generated by a reverse osmosis system with filtration through two ion residue 
columns using a Millipore-Q System. 
RPMI 10: 
RPMI 61 with 2mM L-glutamine, 10 units ml-1 Penicillin Streptomycin, 10% heat 
inactivated Foetal Calf Serum (FCS). 
Dulbecco’s Modified Eagle’s Media (DMEM)-10: 
DMEM with 2mM L-glutamine, 10 units ml-1 Penicillin Streptomycin, 10% FCS. 
MACS buffer: 
PBS containing 0.5% FCS and 5mM EDTA. 
DNA Lysis Buffer: 
25mM Tris-HCL (pH 8.0), 10% SDS, 1M EDTA, 1M NaCl, 2mg Proteinase K (Roche 
Diagnostics), 5ml dH2O.  
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Protein Lysis Buffer: 
50mM Tris, 150mM NaCl, 1% Triton X, 1mM EDTA, 100mM PMSF, Protease 
inhibitor cocktail EDTA free (Roche).  
DNA Loading Buffer Orange G: 
2.5mg/ml Orange G loading dye in 2X TBE containing 30% glycerol. 
Freezing Media: 
90% FCS with 10% Dimethyl sulfoxide (DMSO) (v/v). 
FACS buffer: 
PBS containing 1% FCS and 2mM EDTA. 
Wash Buffer: 
PBS containing 0.05% Tween-20. 
Eosin Solution: 
10mg/ml Eosin dissolved in dH2O. 
Celestine Blue 
400ml dH2O, 20g Ammonium Ferric Sulphate (III), 2g Celestine Blue, 14ml Glycerol.  
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2.2 Animals and in vivo models  
 
2.2.1 Housing and Home Office approval 
 
Animals were housed in the Joint Biological Services Unit of Cardiff University. 
Animals were maintained at a constant temperature and humidity on a 12 hour 
light/dark cycle within filter top cages, until experiments commenced, whereby mice 
were transferred to conventional caging. Food and water were available to animals ad 
libitum. DR3 mice were bred on a C57BL/6 background within the facility, with 
genotype being confirmed via ear snip digests and PCR (Section 2.2.2). All procedures 
performed were Home Office regulated and within the license 30/2580 held by Dr 
E.C.Y. Wang.  
 
2.2.2 Genotyping  
 
2.2.2.1 Genomic DNA isolation 
Earsnip samples were resuspended in 750μl of lysis buffer and incubated overnight at 
56˚C in a waterbath. A DNA salt extraction was performed by adding 310μl of 5M 
NaCl, whereby the sample was vortexed and left at room temperature for 30 minutes 
before being spun at 16060g for 25 minutes. The aqueous phase (800μl) was then 
removed and added to 500μl of ice cold isopropanol, before the sample was again 
vortexed and the precipitated DNA spun down at 16060g for 10 minutes. The 
supernatant was removed and 500μl of 70% ethanol was added before leaving at room 
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temperature for 30 minutes. The DNA was once again spun and as much liquid removed 
as possible, followed by a 37˚C incubation for 1 hour or until all ethanol had 
evaporated. The remaining pellet was then resuspended in 50μl of distilled water and 
left overnight at 37˚C to allow the DNA to dissolve, ready for PCR amplification.  
 
2.2.2.2 Genotyping PCR 
To thin walled PCR tubes, 20μl of dH20 was added, along with 8μl of genomic DNA. A 
master mix was made up consisting of:   
5μl 4mM dNTP 
4μl 10X PCR buffer 
1.2μl 50mM MgCl2 
0.2μl 100uM AV1 primer (CAT CGC CTT CTA TCG CCT TC) 
0.4μl 100uM 4F primer (AGA AGG AGA AAG TCA GTA GGA CCG) 
0.8μl 100uM 2R primer (GAA AGG ATG AAA CTT GCC TGT TGG) 
0.5μl Taq polymerase  
 
12.1 μl of master mix was added to each reaction tube and the PCR programme begun 
using a Thermocycler (Hangzhou Long Gene Scientific Instruments Co, Zhejiang, 
China) with the program below: 
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Denaturation:  94˚C 5 minutes 
Annealing:  62.5˚C 30 seconds   1 Cycle 
Extension:       72˚C 40 seconds 
 
Denaturation:  94˚C 30 seconds 
Annealing:  62.5˚C 30 seconds   33 Cycles 
Extension:  72˚C 40 seconds 
 
Denaturation:  95˚C 30 seconds 
Annealing:  62.5˚C 40 seconds   1 Cycle 
Extension:  72˚C 5 minutes 
 
Once thermocycling was complete, 4μl of Orange G was added to the samples which 
were then loaded onto a 1.6% agarose gel and run for 90 minutes at 100V. The gel was 
visualised under UV light (Ultra-Violet Products Ltd, Cambridge, UK), with the 
wildtype band lying at 280bp and the knockout band at 320bp.  
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2.2.2.3 Agarose gel 
Powdered agarose (2.4g) was added to 150ml of 1X TBE and microwaved for 95 
seconds with regular shaking. Ethidium Bromide (7.5μl of 10mg/ml) was then added to 
the mixture and cooled under cold tap water for 90 seconds. This was then poured into a 
gel tank, where combs were inserted to allow for the addition of sample. The gel was 
left to set for at least 20 minutes, whereby the combs were removed and 20μl of sample 
added to each well or 5μl of 1KB DNA ladder (Life Technologies Ltd, Paisley, UK). 
 
2.2.3 Measuring lung function in mice 
 
2.2.3.1 Whole body plethysmography 
Enhanced Pause (Penh) is an established method for measuring lung function in 
conscious mice. Mice are un-restrained during the technique resulting in decreased 
stress for the animal and ideally ‘normal’ breathing patterns. However, mice still need 
to be conditioned to sit within the airtight chamber, for a minimum of 2 weeks 5 
minutes/day before any readings can be taken. The process relies on an exchange of air 
between the body and the chamber, so causing pressure changes within the chamber 
(Mo, Chung et al. 2011). A single chamber whole body plethysmograph was used 
(Buxco Electronics Inc, Wilmington, NC, USA). Mice were exposed to nebulised PBS 
within the chamber for 3 minutes to establish baseline Penh readings. Values were then 
averaged for each mouse.  
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Figure 2.1. The box pressure wave in inspiration (down) and expiration (up) from 
which Penh can be derived. Diagram taken from Hamelmann et al (1997).  
 
Waveform from flow whole body plethysmography can be divided into 2 regions, Ti or 
inspiratory time, the time from the start of inspiration to the end, and Te the expiratory 
time, or the time from the end of inspiration till the start of the next inspiration. Tr, or 
relaxation time, is the seconds taken for the pressure to decay to 36% of total expiratory 
pressure. Levels of peak inspiration (PIP) and peak expiration (PEP) are used to 
calculate Penh, a dimensionless value, which reflects changes in the waveform of the 
box pressure signal, indicative of pulmonary resistance and airway responsiveness.  A 
positive percentage change in Penh values signifies bronchoconstriction, and negative 
values bronchorelaxation.  
 
2.2.3.2 Hyper-responsiveness in mice 
Hyper-responsiveness in naive mice was measured using aerosolised Methacholine 
(Sigma Aldrich, Dorset, UK) at 30mg/ml. Mice were exposed for 3 minutes to 
nebulised Methacholine, and recordings averaged for each mouse.   
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2.2.3.3 Analysis of mouse activity  
Mice were habituated to the whole body plethysmography chamber for 2 weeks, during 
which time a basic assessment was made of their activity in the chamber and ability to 
remain still.  Scores of 0, for no activity, and 1 for movement, were assigned depending 
on the behaviour of the mice. Video recordings were also made of this habituation 
period.  
 
2.2.4 Separation of murine serum   
 
2.2.4.1 Murine serum seperation 
Serum was collected to allow the identification of Immunoglobin antibodies following 
the induction of inflammation. Up to 1ml of obtained blood was placed into specially 
designed serum separator tubes (Becton Dickinson Ltd, Oxford, UK), inverted and then 
left at room temperature for at least 30 minutes. The microtainers were then centrifuged 
at 9503g for 2 minutes at RT and the top layer of serum removed. Serum was frozen at -
70˚C for later use.  
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2.2.5 Harvesting of the lung, bronchoalveolar lavage, peripheral blood and splenic 
cell populations  
 
2.2.5.1 Collagenase lung digestion 
Once animals were sacrificed, lungs were exposed by removing the ribcage and cutting 
the diaphragm. Lungs were perfused with 5ml of PBS via injection into the heart and 
immediately harvested from the mouse, whereby they were stored on ice in PBS. They 
were then chopped into small fragments using dissection scissors and placed into 2ml of 
1mg/ml collagenase D (Roche Diagnostics Ltd, West Sussex, UK) in serum free media. 
Lungs were placed in a 37˚C waterbath for 45 minutes with occasional shaking. 
Digested lungs were then passed though a 70μm cell strainer and flushed with media 
several times. The flow through was then spun at 425g for 3 minutes at 4˚C, and a RBC 
lysis performed if necessary (Section 2.2.6.1). Cells were then suspended in 1ml of 
FACS buffer.   
 
2.2.5.2 Bronchoalveolar lavage (BAL) of mice 
Once animals were sacrificed, the peritoneal cavity was opened and the diaphragm 
carefully cut away from the thorax, so allowing for inflation of the lungs. The trachea 
was exposed and a 23g catheter needle inserted. PBS/2mM EDTA (1ml) was then 
slowly injected via the catheter, inflating the lungs. Lavage fluid was carefully 
withdrawn 10-15 seconds later and kept on ice. The process was repeated with fresh 
lavage fluid to enhance cell recovery. Fluid was then centrifuged at 370g for 4 minutes 
at 4˚C and cells resuspended in 500μl of FACS buffer. 
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2.2.5.3 Spleen harvest 
Once mice were sacrificed, the peritoneal cavity of the mouse was opened and the 
intestines pushed to one side. The spleen was then carefully removed and placed into 
5ml of FACS buffer and kept on ice. It was then mashed though a 70μm cell strainer 
which was flushed with media several times. The flow through was centrifuged at 425g 
for 3 minutes at 4˚C and a RBC lysis performed (Section 2.2.6.1). After washing (x2) 
with 5ml of FACS buffer, the spleen cell pellet was resuspended in 5ml FACS buffer.  
 
2.2.5.4 Cardiac puncture 
Once mice were sacrificed, the peritoneal cavity of the mouse was cut and the ribcage 
removed to expose the heart. A 21g needle containing 1μl of heparin was carefully 
inserted into the right ventricle and the blood slowly extracted to avoid collapse of the 
heart. Acquired blood was kept at room temperature. A RBC lysis was performed 
(Section 2.2.6.1), cells washed in 1ml of FACS buffer at 272g for 4 minutes at 4˚C and 
later resuspended in 1ml of FACS buffer. 
 
 
 
 
 
 
74 
 
2.2.6 Determining lung, bronchoalveolar lavage, peripheral blood and splenic total 
cell number 
 
2.2.6.1 Red blood cell lysis 
Following cell isolation, red blood cells were lysed to ensure they did not interfere with 
later analysis or skew total cell number. For the lung, BAL and spleen, cells were 
resuspended in 2ml of 1X RBC lysis buffer (Biolegend Co, Cambridge, UK) and left for 
2 minutes. FACS buffer was then added (3ml) to halt the lysis, and the cells centrifuged 
at 425g for 3 minutes at 4˚C. Cells were then resuspended in an appropriate volume of 
FACS buffer. RBC lysis of the peripheral blood required 10ml of 1X RBC lysis buffer. 
Cells were gently vortexed and left for 15 minutes at RT. FACS buffer (15ml) was then 
added to stop the lysis reaction and cells centrifuged at 325g for 3 minutes, whereby the 
supernatant was removed and the procedure repeated if necessary. Cells were then 
washed in FACS buffer and resuspended.  
 
2.2.6.2 Total cell counts 
All cell counts were performed using a Neubauer Haemocytometer and the viability 
dye, trypan blue (Sigma Aldrich Ltd, Dorset, UK). Live cells actively exclude the dye 
due to a functioning membrane, compared to dead or dying cells which feature a 
compromised membrane, resulting in stained cells. The coverslip of the 
haemocytometer was misted and then immediately placed over the haemocytometer 
counting chamber. A 1:1 dilution of cell suspension was prepared with trypan blue and 
used to load the haemocytometer.  Cells were then viewed under a microscope at 10x 
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magnification and the number of viable cells within each of the 4 1mm2 areas 
determined. Cell concentration was calculated using the following formula: 
 
Total Cell Number/ml= (total No. of cells/No. of squares counted) x (dilution factor) x
         (chamber volume)       
  
 
Chamber volume= 1x104 
Sample dilution= 2 
Squares counted= 4 
 
 
2.2.6.3 Cryopreservation of cells 
Cells to be frozen were centrifuged at 370g for 4 minutes at 4˚C. Once counted, they 
were again centrifuged and resuspended in freezing mix to ensure approximately 
1x106cells/ml. Each 1ml was aliquoted into cryogenic freezing vials and then 
immediately placed into a Nalgene 5100 Cryo 1˚C freezing container to allow for a slow 
reproducible freezing rate to ensure good cell recovery. This was placed into the -70˚C 
freezer overnight with vials then being transferred to a liquid nitrogen tank. If vials were 
to be thawed, they were placed into a waterbath at 37˚C and gently agitated until 
completely thawed. Cells were transferred to a 15ml falcon and 10ml of warm RPMI-10 
slowly added. Cells were spun and counted to calculate recovery following freezing.  
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2.2.7 Allergic lung inflammation 
 
2.2.7.1 Sensitisation  
The allergen used throughout the study was Ovalbumin (OVA) (VWR International 
Ltd, Leicestershire, UK), a major protein found in avian egg whites, which has 
previously been shown to induce sensitisation and allergic pulmonary inflammation. 
Mice were sensitised via an intra-peritoneal injection with a mix containing OVA 
(100μg) and aluminium hydroxide (50mg) (Fisher Scientific UK Ltd, Loughborough, 
UK) in PBS (Life Technologies). The mixture was stirred for at least 2 hours prior to 
injection to ensure the aluminium hydroxide had completely dissolved and to assist with 
homogenisation. Mice were injected intra-peritoneally with 0.5ml of the sensitisation 
mix using a 25g needle on days 0 and 5 unless otherwise stated.  All procedures 
commenced on day 15 for allergic lung inflammation experiments, a method developed 
by Rodriguez et al (Fernandez-Rodriguez, Ford et al. 2008). Mice were observed 
following injection, in line with Home Office License 30/2580 regulations.  
 
2.2.7.2 Sensitisation process for aluminium hydroxide dosing 
Mice were immunised via an intra-peritoneal injection of 100μg OVA with or without 
different concentrations of adjuvant, aluminium hydroxide. Naive mice were untreated, 
whilst the control group were injected with PBS. Aluminium hydroxide concentrations 
were tested at 0.1mg, 0.4mg, 1mg, 2mg, 10mg and 50mg. The mixtures were stirred for 
at least 2 hours prior to a single injection, which occurred on day 0. Mice were culled on 
day 7, weighed, and the necessary organs harvested. 
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2.2.7.3 Acute allergic lung inflammation   
Following sensitisation on days 0 and 5, mice were challenged via inhalation with a 
0.5% (w/v) solution of OVA, or in the case of the control groups PBS, on day 15. Mice 
were challenged twice, 4 hours apart, with each challenge lasting 1 hour.  Two 
challenges were necessary as literature had previously stated that 1 OVA challenge was 
not sufficient to provoke a pulmonary inflammatory response in mice (Ohkawara, Lei et 
al. 1997). Exposure was carried out in a Perspex box measuring 38cm x 20cm x 20 cm 
(Buxco Electronics Inc, Wilmington, NC, USA) attached to a Wright nebuliser 
(Pulmostar, Devillbiss Healthcare Ltd, Stourbridge, UK), which delivered the OVA or 
saline at an air pressure of 20lb p.s.i and a rate of 0.3ml/min. Mice were sacrificed 24 or 
72 hours post challenge, whereby the lungs and spleen were removed, bronchoalveolar 
lavage performed and blood extracted to allow for the isolation of serum.  
 
Figure 2.2. The sensitisation and challenge protocol used to induce acute allergic 
lung inflammation in DR3wt and DR3ko mice. Mice were injected via the peritoneal 
cavity on days 0 and 5. On day 15, mice underwent two 1 hour inhalation challenges 
with OVA or PBS, 4 hours apart. Mice were sacrificed either 24 or 72 hr post inhalation 
challenge.  
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2.2.7.4 Chronic allergic lung inflammation 
Mice were sensitised using the same sensitisation procedure (Section 2.2.7.1), as well as 
the same timescale (days 0 and 5) as the acute allergic lung inflammation protocol 
(Section 2.2.7.3). However, the challenge process was different, with mice being 
exposed to nebulised OVA or saline aerosol 3 days/ week for 6 weeks from day 15. The 
final challenge occurred on day 57, resulting in a total of 18 challenges. Each challenge 
lasted for 30 minutes, excluding the final challenge which lasted for 1 hour. The chronic 
protocol used a 2% OVA aerosol, as it was known that tolerance could develop with 
such repeated exposures (Fernandez-Rodriguez, Ford et al. 2008). Chronic exposures 
utilised the same equipment as that in the acute protocol. Mice were sacrificed 24 and 
72 hours post final inhalation challenge, whereby the lungs and spleen were harvested, 
bronchoalveolar lavage performed and blood extracted to allow for serum isolation.  
 
Figure 2.3. The sensitisation and challenge protocol used to induce chronic allergic 
lung inflammation in DR3wt and DR3ko mice. Mice were injected via the peritoneal 
cavity on days 0 and 5. On day 15, inhalation challenges began with either OVA or 
PBS. Challenges occurred 3 days/ week for 6 weeks for 30 minutes. The 18th and final 
challenge lasted for 1 hour inhalation. Mice were sacrificed either 24 or 72 hr post final 
inhalation challenge.  
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2.2.8 Phenotypic analysis of cells using flow cytometry 
 
2.2.8.1 Preparation of cells for flow cytometry 
Cells were processed, resuspended in an appropriate volume of FACS buffer (Section 
2.2.5) and total cell number determined (Section 2.2.6.2). Cells (200μl) were then added 
to the assigned well of a U bottomed 96 well plate. Plates were centrifuged at 483g for 2 
minutes at 4˚C, whereby the supernatant was removed without disturbing the cell pellet. 
An FC block (CD16/32) was then applied to all wells at a volume of 50μl/ well, so 
ensuring that any staining seen was due to specific antibody/cell surface antigen 
interaction. Plates were left for 15 minutes at 4˚C and then spun at 483g for 2 minutes at 
4˚C. Following this, 50μl of primary conjugated antibodies were added to the 
designated wells, at predetermined concentrations. Antibodies were incubated at 4˚C for 
25 minutes to allow for antibody binding, and later washed twice with FACS buffer. 
Isotype controls and compensation controls were prepared in the same way as test 
antibodies. Optimum antibody concentrations were determined by earlier titration 
experiments. If a secondary biotinylated antibody was required, this was added after 
washing and incubated for 25 minutes at 4˚C, followed by 2 washes with FACS buffer. 
Lastly, cells were resuspended into a 200μl volume and immediately processed using 
the Beckman Coulter CyAN Flow Cytometer machine (Beckman Coulter Ltd, High 
Wycombe, UK). For each experiment, an unstained sample was required to set channel 
voltages, as well as positive single stains to allow for compensation of samples during 
analysis. 
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2.2.8.2 DR3 staining for analysis by flow cytometry 
DR3 staining was achieved following the steps outlined in Section 2.2.8.1, up to the 
addition of 50μl of FC Block (CD16/CD32) in diluted FACS buffer. Following this, 
cells were resuspended in 200μl of FACS buffer containing 2% (v/v) normal goat serum 
and incubated for 30 minutes at 4˚C. Cells were then centrifuged at 483g for 2 minutes 
at 4˚C and the supernatant discarded. The polyclonal biotinylated DR3 antibody (or 
biotinylated Goat IgG isotype control) along with any other primary antibodies were 
then added at their optimum concentration in FACS buffer containing 0.5% (v/v) 
normal goat serum and incubated for 30 minutes at 4˚C. The remainder of the steps 
outlined in Section 2.2.8.1, including the addition of a fluorochrome conjugated 
secondary antibody, were then followed. 
 
2.2.8.3 Murine antibodies used for flow cytometry 
Different antibody panels were used to classify specific cell types within the lung, BAL, 
peripheral blood and spleen (Table 2.1). Combinations of antibody markers meant that a 
range of cells from both the myeloid and lymphocytic lineage could be identified and 
therefore populations defined (Table 2.3).  
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Table 2.1. Murine antibodies used for flow cytometry 
Antibodies  Antibody 
Dilution 
Supplier Clone  Raised in Isotype Control 
MHCII FITC 1/800 BD Pharmingen 2G9 Rat IgG2a, κ 
7/4(Ly6B) PE 1/100 Serotec 7/4 Rat IgG2a 
B220 PE Texas 
Red  
1/200 BD Pharmingen RA3- 6B2 Rat IgG2a, κ 
CD11c PE Cy7 1/100 BD Pharmingen HL3 Hamster IgG1  
Ly6G V450 1/100 BD Pharmingen 1AE Rat IgG2a, κ 
Aqua Live Dead 1/800 Invitrogen    
F4/80 APC 1/200 Invitrogen BM8 Rat IgG2a 
CD11b APC Cy7 1/800 BD Pharmingen M1/70 Rat IgG2b, κ 
NK1.1- FITC 1/200 BD Pharmingen PK136 Mouse IgG2a, κ 
CD4 PE 1/200 Invitrogen RM 4-5 Rat IgG2a 
CD4 PE Cy5.5 1/200 BD Pharmingen RM 4-5 Rat IgG2A, κ 
TCRγδ PE Cy7 1/200 Biolegend GL3 Hamster IgG 
CD8 PE Cy7 1/200 Invitrogen 5H10 Rat Not given 
CD44 V450 1/200 BD Pharmingen IM7 Rat IgG2b 
CD4 Pacific 
Orange 
1/200 Invitrogen RM 4-5 Rat IgG2a 
CD8 Pacific 
Orange 
1/200 Invitrogen 5H10 Rat IgG2b 
TCRB- APC 1/200 BD Pharmingen H57-597 Hamster IgG2, ƛ 
CD3 APC Cy7 1/200 BD Pharmingen 17A2 Rat IgG2b, κ 
DR3 Biotin 1/100 R&D  polyclonal Goat IgG  
Streptavidin PE 1/500 Invtirogen - -  
CD16/32 1/200 BD Pharmingen 2.4.G2 - - 
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2.2.8.4 Flow cytometry acquisition  
Once stained, cells (including the unstained, isotype and compensation controls) were 
run through a Beckman Coulter CyAn™ ADP Analyzer Flow Cytometer (Beckman 
Coulter Ltd, High Wycombe, UK). All analysis and compensation was carried out 
offline using Summit software v4.2 (Beckman Coulter Ltd, High Wycombe, UK).  
 
2.2.8.5 Multi-parameter flow cytometry compensation  
The Beckman Coulter CyAn™ ADP Analyzer Flow Cytometer allows 9 fluorescence 
markers to be analysed at once. Single stained compensation controls helped ensure that 
any signal seen was not a result of spectral overlap, or fluorescence emission into a 
neighbouring channel, resulting in false positives in other detectors. Compensation 
accounts for a fluorochrome being detected in a channel that was not allocated to 
measure it, which can be resolved using the compensation function in the summit 
software, as outlined in the manufacturer’s instructions. Table 2.2 shows the emission 
spectra for each of the fluorochromes used throughout this study.  
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Table 2.2. Lasers, Excitation Wavelength and Emission Spectra of fluorochromes 
used for flow cytometry. 
Parameters Fluorochrome Emission Peak (nm) Laser Light Source (nm) 
FL1 FITC 521 488 
FL2 PE 578 488 
FL3 PE Texas Red 615 488 
FL4 PE Cy5/.5 695 488 
FL5 PE Cy7 767 488 
FL6 V450 448 405 
FL7 Pacific Orange 551 405 
FL8 APC 660 660 
FL9 APC Cy7 767 660 
 
 
 
 
2.2.8.6 Defining cell populations using flow cytometry 
Once compensated, a live cell FSC/SSC gate was applied to samples, as well as a 
doublet exclusion gate (Figure 2.5). Cell populations could then be recognised using 
extracellular cell markers and appropriately drawn ‘gates’ (Table 2.3) (Figure 2.4) 
(Figure 2.5) (Figure 2.6). Once identified, cell numbers and percentages were calculated 
relative to the previously determined total cell number. 
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Figure 2.4. Flow cytometry gating pattern for the identification of myeloid cell subsets. Cells were passed through a flow cytometer and 
analysed accordingly using monoclonal antibodies to known myeloid cellular markers. (A) Neutrophils (7/4+ Ly6G+ CD11b+), (B) 
Eosinophils (F4/80+ SSChi CD11b+), (C) 7/4- Monocytes (F4/80low 7/4- SSClow CD11b+), (D) 7/4+ Monocytes (F4/80low 7/4+ SSClow CD11b+), 
(E) Splenic Macrophages (F4/80+ CD11blow), (F) Myeloid Dendritc Cells (CD11b+ CD11c+ MHCII+), (G) Plasmacytoid Dendritic Cells 
(CD11c+ B220+ CD11b- ). 
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Figure 2.5. Flow cytometry gating pattern for the identification of  T and NK cell subsets. Cells were passed through a flow cytometer 
and analysed accordingly using monoclonal antibodies to known T lymphocyte cellular markers. (A) CD3+ T cells (CD3+ TCRβ+ ),  (B) 
CD4+ T cells (CD3+ TCRβ+ CD4+), (C) CD8+ T cells (CD3+ TCRβ+ CD8+ ),  (D) NKT cells (NK1.1+ CD3+ TCRβ+ ), (E) γδ T cells 
(CD3+ TCRγδ+), (F)NK cells (NK1.1+ CD3- TCRβ- ).  
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Figure 2.6. Flow cytometry gating pattern for the identification of  B cells. Cells were passed through a flow cytometer and 
analysed accordingly using monoclonal antibodies to known lymphocyte cellular markers. B cells (CD11blow B220+ MHCII+ ). 
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Table 2.3. Cell markers used to phenotype the stated cells within the lung, BAL, 
spleen and peripheral blood samples. 
Cell Type Cell Markers 
Alveolar Macrophages CD11blow CD11c+ 
Splenic  Macrophages F4/80+ CD11blow 
Neutrophils 7/4+ Ly6G+ CD11b+ 
Eosinophils F4/80+ SSChi CD11b+ 
7/4+ Monocytes F4/80low 7/4+ SSClow CD11b+ 
7/4- Monocytes F4/80low 7/4- SSClow CD11b+ 
Myeloid Dendritic Cells CD11b+ CD11c+ MHCII+ 
Plasmacytoid Dendritic Cells CD11c+ B220+ CD11b- 
B cells CD11b- B220+ MHCII+ 
CD4+ T cells CD3+ TCRβ+ CD4+ 
CD8+ T cells CD3+ TCRβ+ CD8+ 
NK Cells NK1.1+ CD3- TCRβ- 
NKT Cells NK1.1+ CD3+ TCRβ+ 
γδ T cells CD3+ γδTCR+ 
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2.2.9 Enzyme Linked Immunosorbent Assay (ELISA) 
 
A murine Total IgE ELISA kit was purchased from Biolegend (Biolegend Inc, 
Cambridge, UK). Human TL1A ELISA was purchased from Peprotech (Peprotech EC 
Ltd, London UK). All other ELISAs were purchased from R&D systems unless 
otherwise stated and were carried out in accordance with manufacturer’s instructions 
(Table 2.4). The OVA specific IgG ELISA was developed in-house using individual 
antibodies.  
 
2.2.9.1 Kit ELISAs 
ELISAs were performed according to the manufacturer’s instructions. Briefly a 96 well 
plate was coated with a 100μl of capture antibody in PBS at a specified concentration. 
This was left overnight at 4˚C. Plates were washed the following day with Wash Buffer 
(x4), before the addition of 200μl of Blocking Reagent (1% BSA PBS). Block was left 
for at least 1 hour at RT, at which point plates were once again washed (x4) and diluted 
sample and standard were added to the appropriate wells in duplicate. Samples were left 
for 2 hours at RT, followed by another washing cycle and the addition of 100μl of 
biotinylated detection antibody, which was left for 2 hours at RT. Plates were once 
again washed to remove any unbound antibody and Streptavidin HRP was added for 30 
minutes at RT. This was followed by a stringent cycle of 5 washes, with wells being 
soaked in wash buffer for 30 seconds to 1 minute to minimise background readings. 
Freshly prepared 3,3′,5,5′-Tetramethylbenzidine (TMB)  was then added to the wells 
and incubated in the dark until colour change occurred. The reaction was stopped using 
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Sulphuric acid (H2SO4) (2M), turning wells from blue to yellow. Absorbance was read 
at 450nm using a FLUOstar microplate reader (Omega BMG Labtech Ltd, 
Buckinghamshire, UK).  Sample concentration was calculated via reference to the 
standard curve, and multiplied by the dilution factor of the sample. 
 
 
Table 2.4. ELISA assays and working antibody concentrations. 
 
 
 
 
 
Target Capture 
antibody 
conc.  
Detection 
antibody 
conc. 
Top 
standard  
 
Supplier  Product 
Code 
TL1A 
 
IgE 
 
CXCL1 (KC) 
 
1µg/ml 
 
- 
 
2.0 µg/mL 
500ng/ml 
 
- 
 
200 ng/mL 
4000 
pg/ml 
   10,000 
pg/ml 
1000 
pg/mL 
Peprotech 
 
Biolegend 
 
RnD 
Systems 
900-K290 
 
432405 
 
DY453 
CXCL2 (MIP-2) 
 
2.0 µg/mL 75 ng/mL 1000 
pg/mL 
RnD 
Systems 
DY452 
CXCL10 (IP-10) 
 
2.0 µg/mL 600 ng/mL 4000 
pg/mL 
RnD 
Systems 
DY446 
CXCL13 (BCA-1) 1.0 µg/mL 200 ng/mL 
 
1000 
pg/mL 
RnD 
Systems 
DY470 
CCL3 (MIP-1α) 
 
0.4 µg/mL 100 ng/mL 500  
pg/mL 
RnD 
Systems 
DY450 
CCL4 (MIP-1β) 
 
4.0 µg/mL 800 ng/mL 1000 
pg/mL 
RnD 
Systems 
DY451 
CCL5 (RANTES)                    
 
2.0 µg/mL 400 ng/mL 2000 
pg/mL 
RnD 
Systems 
DY478 
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2.2.9.2 OVA specific IgG ELISA 
Levels of OVA specific IgG were measured using an indirect ELISA method. Briefly, 
100μl of 100μg/ml OVA (w/v) in PBS was plated per well of a 96 well plate. This was 
left at 4˚C overnight. Wells were then washed with Wash Buffer 4 times to wash away 
any unbound protein. Plates were blocked with 200μl of 5% non fat milk (w/v) in PBS 
for 2 hours at RT. Following washes (x4), 100μl of PBS diluted serum was added to the 
wells at a concentration of 1/1000 and left at room temperature for 2 hours. Unbound 
sample was removed following a wash cycle, after which goat anti-mouse IgG detection 
antibody (Biolegend Inc, Cambridge, UK) was added at a concentration of 20ng/ml in 
100μl of PBS. This was left for 2 hours at RT, before a further 4 washes and the 
addition of Streptavidin HRP (R&D Systems Ltd, Abingdon, UK), at a dilution of 1/200 
in PBS. After 30 minutes at RT, wells were washed thoroughly 5 times with Wash 
buffer, after which TMB (Becton Dickenson Ltd, Oxford, UK) was added, and the 
ELISA was allowed to develop. When judged to have developed, Sulphuric acid (2M) 
(Fisher Scientific UK Ltd, Loughborough, UK) was added to stop the reaction and the 
absorbance determined at 450nm. Without a standard curve, the ELISA was deemed to 
have worked by varying the dilution of serum by half, so reducing the absorbance by 
approximately half. If a dose response relationship was seen between optical density 
levels and the dilution titer of the OVA IgG positive standard serum, the ELISA was 
classed to have worked. This positive reaction was not seen in the absence of the 
capture antibody (OVA), serum, or the detection antibody (anti mouse IgG), with these 
readings used as blanks to indicate background sensitivity. Once achieved, the serum 
dilution (1/1000) was decided upon for experimental use.  
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2.2.10 Murine splenocyte tissue culture 
 
2.2.10.1 In vitro proliferation assay 
Splenocytes (1x105/well) were plated in a flat bottomed 96 well plate in RPMI-10 
containing 50mM β mercaptoethanol. Cells were then either left untreated or stimulated 
with 10μg/ml Ovalbumin, 50μg/ml Ovalbumin or 10μg/ml Concanavalin A. 
Stimulations were performed in triplicate for each sample. Plates were kept at 37˚C 5% 
CO2 for 48 hours. Following this, 100μl of supernatant was removed and 3H-thymidine 
(Perkins Elmer Inc, Cambridge, UK) was added at a concentration of 0.37Mbq/well. 
Cells were pulsed for 18 hours at 37˚C 5% CO2, at which point plates were frozen for 
later analysis or harvested immediately onto filtermats (Perkins Elmer Inc, Cambridge, 
UK) using a Tomtec Cell Harvester (Tomtec Inc, Connecticut, USA). Scintillant 
(Perkins Elmer Inc, Cambridge, UK) was melted onto the radioactive filter mats and 3H-
thymidine incorporation was measured using a Micro β Counter (Perkins Elmer Inc, 
Cambridge, UK). Counts were automatically corrected to account for quenching. 
Filtermats were then disposed of in line with radiation regulations.  
 
2.2.10.2 Spleen lysate  
Spleens were removed from the mouse, placed into an eppendorf and snap frozen using 
liquid nitrogen. They were then homogenised in 1ml of ice cold protein lysis buffer 
containing phenylmethylsulfonyl fluoride (PMSF) and a cocktail of protease inhibitors 
(Roche). Homogenisation was performed using an T10 basic homogeniser (IKA Werke 
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GMBH & Co, Staufen, Germany). Spleens were then spun at 483g for 5 minutes at 4˚C 
and the supernatant removed. Supernatant was stored at -20˚C for analysis by ELISA.  
 
2.2.11 Organ fixing for histological analysis 
 
2.2.11.1 Lung fixing for paraffin embedding   
Once lungs were harvested, they were placed into individually labelled tissue histology 
cassettes, which were subsequently placed into a bottle of 10% neutral buffered 
formalin (Sigma Aldrich Ltd, Dorset, UK). Tissue was left at 4˚C for at least 24 hours to 
allow the formalin to penetrate and thereby ‘fix’ the whole lung.  
 
2.2.11.2 Paraffin embedding 
Lungs were embedded in paraffin wax via an automated Shandon Tissue Processor 
(Fisher Scientific UK Ltd, Loughborough, UK) (Table 2.5). Lungs underwent 
increasing cycles of alcohol concentrations and xylene, in order to hydrate the samples, 
followed by permeation with molton wax (60˚C). Samples remained in wax until the 
machine was manually drained, and immediately transferred to the Shandon Histocentre 
(Fisher Scientific UK Ltd, Loughborough, UK), used for embedding samples in wax 
blocks. Lung samples were placed into metal histology cassettes, where molton wax 
was poured into the moulds and left to set on a cold plate.  
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Table 2.5. Shandon Tissue Processor cycle to assist in the fixing and subsequently 
the paraffin embedding of murine lung tissue. 
 
 
 
 
 
 
Stage Time Temperature   
70% Alcohol empty tank 
 
30 minutes Room temperature 
90% Alcohol empty tank 
 
60 minutes Room temperature 
100% Alcohol empty tank 
 
60 minutes Room temperature 
100% Alcohol empty tank 
 
60 minutes Room temperature 
100% Alcohol empty tank 
 
60 minutes Room temperature 
100% Alcohol empty tank 
 
60 minutes Room temperature 
100% Alcohol empty tank 
 
60 minutes Room temperature 
Xylene empty tank 
 
60 minutes 37˚C 
Xylene empty tank 
 
60 minutes 37˚C 
Xylene empty tank 
 
60 minutes 45˚C 
Wax empty tank 
 
90 minutes 60˚C 
Wax empty tank 
 
60 minutes 60˚C 
Wax empty tank 
 
60 minutes 60˚C 
Wax empty tank 
 
60 minutes 60˚C 
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2.2.11.3 Microtome sectioning 
Embedded lungs were stored at -20˚C for at least 24 hours prior to sectioning to allow 
for easier cutting. All tools used during the procedure were also kept on ice. Lungs were 
sectioned at 5-7μm using a microtome. Cut sections were placed into distilled water 
heated to 60˚C and then transferred onto neutrally charged superfrost slides. Slides were 
incubated overnight at 60˚C to dry and later stored at room temperature until required.  
 
2.2.12 Histological analysis of murine lung 
 
Sections were stained with Haematoxylin and Eosin (Sigma Aldrich Ltd, Dorset, UK), 
Periodic Acid Schiff (Leica Biosystems Ltd, Peterborough, UK) and Van Gieson 
Solution (Sigma Aldrich Ltd, Dorset, UK) to help evaluate the severity of lung 
inflammation. Following each of the stains, DPX mountant media (Sigma Aldrich Ltd, 
Dorset, UK) was added to the slides, and a coverslip placed on top ensuring no air 
bubbles were trapped underneath. Photographs of slides were taken using an Olympus 
Camedia C-3030 Digital Camera (Olympus UK) attached to a Olympus BX41 
microscope (Olympus, UK), at various magnifications.  
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2.2.12.1 Haematoxylin and Eosin staining protocol 
A Haematoxylin and Eosin stain was used to look at general lung morphology, so 
allowing differentiation between treatment groups (Table 2.6) (Figure 2.7).  
 
Table 2.6. Protocol used for the Haematoxylin and Eosin staining of murine lung. 
Process Time 
Xylene 5 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
IMS  100% 3 minutes  
IMS  100% 3 minutes  
IMS  90% 3 minutes  
IMS  70% 3 minutes  
Running tap water 5 minutes 
Rinse in distilled water - 
Harris Haematoxylin 90 seconds 
Running tap water 5 minutes 
Dip in 1X Scotts tap water 10 seconds 
Running tap water 5 minutes 
Rinse in distilled water - 
1% Eosin 90 seconds 
Running tap water 5 minutes 
Rinse in distilled water - 
IMS 90% 3 minutes 
IMS  100% 3 minutes  
IMS  100% 3 minutes  
Xylene 5 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
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Figure 2.7. A DR3wt treated chronic ovalbumin challenged mouse lung stained with 
Haematoxylin and Eosin (Section 2.2.7.4) (Section 2.2.12.1). The stain was used for 
general lung morphology analysis. Scale bar=100μm. 
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2.2.12.2 Haematoxylin and Eosin analysis 
Haematoxylin and Eosin stained sections were used for qualitative and semi-quantative 
analysis, with a score being applied to each treated mouse depending on the number of 
inflammatory cells present in the peribronchiolar area (the periphery of the airways). 
Slides from each treatment protocol were assessed by eye by 2 blind scorers according 
to the following scoring regime below (Figure 2.8).  
 
0= normal lung 
1= minor perivascular inflammation and inflammatory cell infiltration. 
2= slight perivascular inflammation and peribronchiolar inflammation.  
3= moderate peribronchiolar inflammation and perivascular and airway cuffing.  
4= marked peribronchial and perivascualr inflammation and cuffing.  
5= severe peribronchial and perivascular inflammation and cuffing (almost solid lungs). 
 
Scores were then averaged for each mouse and graphed appropriately.   
 
 
 
 
 
 
 
 
 
 
    0= Normal lung                  1=  minor perivascular inflammation  
                                             and inflammatory cell infiltration 
 
 
 
 
 
 
 
 
 
 2= slight perivascular inflammation     3= moderate peribronchiolar inflammation  
   and peribronchiolar inflammation           and perivascular and airway cuffing 
 
 
 
 
 
 
 
 
 
     
                          4= marked peribronchial and            5 = severe peribronchial and perivascular 
                   perivascualr inflammation and cuffing                  inflammation and cuffing  
                                 (almost solid lungs) 
 
 
Figure 2.8. Representative examples of the scoring regime for Haematoxylin and 
Eosin stained lungs. Lungs were scored from 0 (normal lung) to 5 (severely inflamed 
lung) and scores averaged for each lung. Scale bar=250μm.  
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2.2.12.3 Periodic Acid Schiff staining protocol 
 A Periodic Acid Sciff (PAS) stain was used to look at the presence of mucus and goblet 
cells in the lung following challenge (Table 2.7) (Figure 2.9).  
 
Table 2.7. Protocol used for the Periodic Acid Schiff staining of murine lung. 
Process Time 
Xylene 5 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
IMS  100% 3 minutes  
IMS  100% 3 minutes  
IMS  90% 3 minutes  
IMS  70% 3 minutes  
Running tap water 5 minutes 
Rinse in distilled water - 
Periodic Acid 5 minutes 
Running tap water 5 minutes 
Schiff’s Reagent  10 minutes 
Running tap water 8 minutes 
Rinse in distilled water - 
Harris Haematoxylin 30 seconds 
Running tap water 5 minutes 
Rinse in distilled water - 
IMS 90% 3 minutes 
IMS  100% 3 minutes  
IMS  100% 3 minutes  
Xylene 5 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
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Figure 2.9. A DR3wt treated chronic ovalbumin challenged mouse lung stained with 
Periodic Acid Schiff Stain (Section 2.2.7.4) (Section 2.2.12.3).  The stain was used to 
highlight mucin associated goblet cells. Goblet cells stain bright pink as shown above. 
Scale bar=100μm.  
 
 
 
2.2.12.4 Periodic Acid Schiff analysis 
The number of mucin associated goblet cells was quantified using Leica Qwin V3 
software (Leica Biosystems Ltd, Peterborough, UK). The airway area was drawn 
manually and the goblet cells within the area identified based upon their bright pink 
staining. The airway spaces were then identified and the % of goblet cells calculated as 
a % of the airway. The average goblet cell % was then calculated for each mouse. 
 
 
Mucin associated  Goblet cells  
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2.2.12.5 Van Gieson solution staining protocol 
A Van Gieson stain was used to look at collagen presence, as well as smooth muscle in 
challenged murine lungs (Table 2.8) (Figure 2.10).  
 
Table 2.8. Protocol used for a Van Gieson stain on murine lung. 
Process Time 
 Xylene  5 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
IMS  100% 3 minutes  
IMS  100% 3 minutes  
IMS  90% 3 minutes  
IMS  70% 3 minutes  
Running tap water 5 minutes 
Rinse in distilled water - 
Celestine Blue 5 minutes 
Running tap water 5 minutes 
Rinse in distilled water - 
Harris Haematoxylin 5 minutes 
Running tap water 5 minutes 
Rinse in distilled water - 
Van Gieson Solution 5 minutes 
Rinse in distilled water - 
IMS 90% 3 minutes 
IMS  100% 3 minutes  
IMS  100% 3 minutes  
Xylene 5 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
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Figure 2.10. A DR3wt treated chronic ovalbumin challenged mouse lung stained with 
Van Gieson Solution (Section 2.2.7.4) (Section 2.2.12.5).  The stain was used to 
display collagen, which stains bright red as shown above. Scale bar=100μm. 
 
 
 
 
 
 
 
 
Collagen  
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2.2.12.6 Van Gieson stain analysis 
Levels of collagen, as identified by the Van Gieson stain, change during allergic lung 
inflammation as airway remodelling occurs, and consequently pulmonary fibrosis. The 
severity of this pulmonary fibrosis was assessed using a numerical scale known as the 
‘Ashcroft Score’ (Ashcroft, Simpson et al. 1988). Photos were taken of each slide, with 
each photo being scored. The average score of these photos was then calculated to give 
an overall measure of fibrosis. Slides from each treatment protocol were assessed by eye 
by 2 blind scorers according to the following scoring regime (Figure 2.11).  
 
0= normal lung 
1= minimal fibrosis thickening of alveolar/bronchial walls 
3= moderate thickening of walls without obvious damage to lung architecture 
5= increased fibrosis with definite damage to lung architecture and formation of fibrosis          
bonds/ fibrosis masses 
7= severe distortion of architecture and large fibrosis area 
8= total fibrosis obliteration of field 
 
 
 
 
 
 
0= normal lung        1= minimal fibrosis thickening of alveolar 
   alveolar/bronchial walls 
 
 
 
 
 
 
 
 
 
 
 
     3= moderate thickening of walls           5 = increased fibrosis with definite  
         without obvious damage to                 damage to lung architecture and 
                 lung architectured                     formation of fibrosis bonds/masses 
 
Figure 2.11. Representative examples of  the Ashcroft scoring regime for Van Gieson 
stained lungs.  Scores run from 0 (normal lung) to maximum of 5 (fibrosis with loss of 
lung architecture) for this project, therefore there were no examples of score 6-8 in my 
dataset (Ashcroft, Simpson et al. 1988).  Scores were averaged for each lung. Scale 
bar=250μm.  
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2.2.12.7 DR3 immunohistochemistry upon paraffin fixed lungs 
Once stained, sections were mounted with DPX mounting media and photographs taken 
using an Olympus Camedia C-3030 Digital Camera (Table 2.9) (Figure 2.12).  
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Table 2.9. Protocol used for DR3 immunohistochemistry using murine tissue. 
Location Process Time 
 
Fume Hood 
Xylene 5 minutes 
Xylene 5 minutes 
Xylene 5 minutes 
IMS  100% 3 minutes  
IMS  100% 3 minutes  
IMS  90% 3 minutes  
IMS  70% 3 minutes  
Running tap water 5 minutes 
Blot excess water - 
 
Humidity 
chamber 
Peroxidase Block 5 minutes 
TBS wash 5 minutes 
Serum Blocking reagent D 15 minutes 
Avidin Block 15 minutes 
Biotin Block 15 minutes 
TBS wash 5 minutes 
Goat anti mDR3- biotin/goat IgG  
control (20ug/ml) 
2 hours 
3x TBS washes 5 minutes 
HSS-HRP 30 minutes 
3 x TBS washes 2 minutes 
DAB  5 minutes 
Running tap water 5 minutes 
 
Fume Hood 
Harris Haematoxylin 90 seconds 
Running tap water 5 minutes 
90% IMS 3 minutes 
100% IMS 3 minutes 
100% IMS 3 minutes 
Xylene 5minutes 
Xylene 5minutes 
Xylene 5minutes 
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2.2.12.8 DR3 immunohistochemistry analysis 
The % of DR3 was quantified using Leica Qwin V3 software (Leica Biosystems Ltd, 
Peterborough, UK). DR3 was identified within the perimeter of the photo based upon 
the brown DAB staining. The % of DR3 was then calculated as a % of the lung area 
shown. The average DR3% was then calculated for each mouse. 
 
 
Figure 2.12. A DR3wt treated chronic ovalbumin challenged mouse lung stained with 
DR3 (Section 2.2.7.4) (Section 2.2.12.7).  DR3 identified as the brown staining.  Scale 
bar=100μm.  
 
 
 
 
 
DR3+ 
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2.3 Statistical analysis 
All results were graphed as the mean ± the standard error of the mean (SEM) and were 
analysed using GraphPad Prism v5. P values of <0.05 were considered significant. 
Various statistical tests have been used within the study, including an Unpaired T Test 
for data that could be assumed to be normally distributed and 1 way and 2 way 
ANOVA’s, to compare more than 2 groups or variables, followed by a Bonferroni post 
test. 
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Chapter 3: 
Characterisation of leukocyte subsets 
within the lung, spleen and peripheral 
blood of naive DR3 mice  
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3.1 Introduction 
Mice deficient in death receptor 3 (DR3) were generated by Wang et al (Wang, Thern et 
al. 2001), so allowing the in vivo functions of DR3 to be studied.  Complete lack of 
DR3 was guaranteed by replacing the whole gene with a cassette, so ensuring that none 
of the 3 murine DR3 splice variants were expressed. It was found that DR3 had a non-
redundant role in TCR induced apoptosis as an impairment in the negative selection of 
thymocytes was noted (Wang, Thern et al. 2001). The generation of DR3ko mice has 
provided important advances in discovering the role of the receptor in various 
inflammatory models, such as regulating the expansion of effector T cells in the gut 
(Meylan, Song et al. 2011),  enhancing joint disease in models of arthritis (Bull, 
Williams et al. 2008), and mediating acute allergic lung inflammation (Meylan, 
Davidson et al. 2008). The lung is known to predominantly possess alveolar 
macrophages as well as CD3+ lymphocytes (van Rijt, Kuipers et al. 2004). Following 
the induction of acute allergic lung inflammation, numbers of CD4+ lymphocytes, 
eosinophils and NKT cells also increase (Fang, Adkins et al. 2008; Meylan, Davidson et 
al. 2008) in DR3wt mice in comparison to mice lacking DR3 expression and function. 
 
Despite the receptor already being implicated in immune regulation (Migone, Zhang et 
al. 2002), and more specifically, acute allergic lung inflammation (Fang, Adkins et al. 
2008; Meylan, Davidson et al. 2008), the influence of DR3 upon  resident lung cells in 
the naive state was unknown. With this in mind, initial baseline experiments were 
conducted to ensure that DR3ko mice suffered no defect in the homeostatic trafficking of 
leukocytes within the lung or general lung make-up, prior to the induction of allergic 
lung inflammation.  
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In addition, as the majority of cells are recruited from the peripheral blood following an 
inflammatory stimulus, (Anderson and Anderson 1976; Lukacs, Strieter et al. 1995), 
detailed baseline measurements were undertaken to ensure that DR3ko mice suffered no 
impairment in leukocyte number. Furthermore, the cellular compositions of DR3wt and 
DR3ko spleens provided an added insight into the workings of the immune response in 
these mice.  
 
Upon commencement of the project, expression patterns of DR3 within an un-sensitised 
murine lung were unknown, although a recently marketed antibody had proved 
successful in detecting murine DR3 on CD8+ splenocytes (Twohig, Marsden et al. 
2012). The degree of receptor expression in steady state conditions was required to 
enable any differences to be identified when inflammation was induced, thereby 
providing insight to the way in which DR3 is regulated. DR3 levels were also 
investigated on numerous leukocyte cell types from the lung and spleen, to aid in the 
identification of cells that were potentially responsive to TL1A.    
 
Airway inflammation is one of many defining hallmarks of asthma, as is airway hyper-
responsiveness, although these have never been measured in DR3 mice. Therefore, an 
attempt was made to quantify these features in DR3ko mice at a baseline level to 
establish whether any inherent differences existed between DR3wt and DR3ko mice in 
basic lung function and airway hyper-responsiveness.   
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3.2 Aims 
The aim of this Chapter was to phenotypically determine the composition of both 
myeloid and lymphocytic cells in the naive lung cavities, airway passages, peripheral 
blood and spleens of DR3ko mice and so determine whether leukocyte subset numbers 
varied compared to their WT counterpart prior to immune challenge.  DR3 expression 
was also quantified within the lung and upon various cell types within the lung and 
spleen using a recently marketed antibody. Furthermore, lung function measurements 
were assessed in DR3ko mice to determine whether they suffered any deficiencies or 
difficulties in response to broncho-constricting agents as well as at baseline level.  
 
3.2.1 Objectives 
i) Characterisation of the lungs of DR3wt and DR3ko mice. 
ii) Phenotypic characterisation of the spleens of DR3wt and DR3ko mice. 
iii) Quantifying DR3 expression within the lungs and spleen of DR3wt and 
DR3ko mice 
iv) Phenotypic characterisation of the peripheral blood of DR3wt and DR3ko 
mice. 
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3.3 Results 
3.3.1 Characterisation of the naive lungs of DR3wt and DR3ko mice  
 
3.3.1.1 Phenotypic analysis of cells within the lungs of DR3wt and DR3ko mice 
3.3.1.1.1 Total cell number from the lungs of unchallenged DR3wt and DR3ko mice did 
not differ 
Lungs from DR3wt and DR3ko mice were perfused and the cells extracted using 
collagenase lung digestion (Section 2.2.5.1). To investigate whether DR3 affected total 
leukocyte number within the naive lung, cells were counted using a haemocytometer 
(Section 2.2.6). Results showed that DR3ko mice (9.7±0.5 x105) did not significantly 
differ in total leukocyte number compared to DR3wt mice (9.4±1 x105) (p=0.570) 
(Figure 3.1).  
 
3.3.1.1.2 There were no significant baseline differences between DR3ko and DR3wt lung 
derived myeloid or lymphocytic cells 
Although the loss of DR3 had no effect on lung total cell number, individual subsets 
were analysed to examine whether DR3 had any role in maintaining these cell 
populations. Cells were analysed using flow cytometry (Section 2.2.8) and an extensive 
panel of antibodies to identify a range of myeloid cells (CD11b, CD11c, Ly6G, 7/4, 
F4/80 and FSC/SSC properties) and lymphocytic cells (CD3, CD4, CD8, TCRβ, B220, 
NK1.1 and FSC/SSC properties) via well characterised extracellular markers (Table 2.3) 
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(Figure 2.4) (Figure 2.5) (Figure 2.6).  No significant differences were found between 
naive DR3ko and DR3wt mice in any leukocyte cell subset considered (Table 3.1).  
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Figure 3.1.  Total lung leukocyte cell number in naive DR3wt and DR3ko mice. Lung 
cells were extracted via collagenase digestion and counted using a haemocytometer 
with trypan blue. Data is representative of 2 individual experiments. Each symbol 
represents data from a single mouse. Results showed no significant differences using 
an Unpaired T test. 
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3.3.1.2 Phenotypic analysis of cells within the alveolar passage of DR3wt and DR3ko 
mice 
3.3.1.2.1 Total cell numbers from the alveolar passage of unchallenged DR3wt and 
DR3ko mice did not significantly differ 
Cells of the bronchial passage were isolated from unchallenged DR3wt and DR3ko mice 
via a lavage. Cells were counted using a haemocytometer to determine total leukocyte 
number (Section 2.2.6.2). Statistical analysis showed that there were no significant 
differences in alveolar leukocytes isolated from DR3wt (2.2±0.7 x105) and DR3ko 
(2.2±0.6 x105) (p=0.972) mice (Figure 3.2). 
 
3.3.1.2.2 There were no significant baseline differences between DR3ko and DR3wt 
airway derived myeloid or lymphocyte derived cells 
To investigate the effects of DR3 loss upon cells of the alveolar passage, cells were 
stained with a broad panel of antibodies and analysed using flow cytometry.  Results 
identified alveolar macrophages (defined as CD11blow CD11c+) as making up the 
majority of myeloid cells within the BAL fluid, although numbers were comparable 
between DR3wt (11.8±4.9 x104) and DR3ko (14.8±5.2 x104) (p=0.653) mice (Table 3.1). 
Following suit, all other cell types examined of both myeloid and lymphocyte lineage 
presented similar numbers between DR3wt and DR3ko mice (Table 3.1).  
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Figure 3.2. Total BAL leukocyte number isolated from naive DR3wt and DR3ko mice. 
Cells were isolated via a bronchoalveolar lavage and counted using a haemocytometer 
with trypan blue. Data is representative of 2 individual experiments. Each symbol 
represents data from a single mouse. Results showed no significant differences using 
an Unpaired T test. 
                       Lung*                                                                  Bronchoalveolar Lavage^ 
 
Cell Subset DR3wt DR3ko Significance$ DR3wt DR3ko Significance$ 
Leukocytes 9.7 ± 0.5 x105 9.4 ± 1 x105 N.S.D 2.2 ± 0.7 x105 2.2 ± 0.6 x105 N.S.D 
Alveolar macrophages 5.4 ± 0.5 x105 6.1 ± 0.6 x105 N.S.D 11.8 ± 4.9 x104 14.8 ± 5.2 x104 N.S.D 
Myeloid DCs 2.6 ± 0.4 x103 2.3 ± 0.4 x103 N.S.D 0.6 ± 0.1 x103 0.6 ± 0.1 x103 N.S.D 
Neutrophils 5.6 ± 0.8 x104 5.9 ± 0.9 x104 N.S.D 1.5 ± 0.5 x103 1.5 ± 0.4 x103 N.S.D 
Eosinophils 7.6 ± 1.1 x103 7.0 ± 2.6 x103 N.S.D 3.2 ± 1.9 x102 1.5 ± 0.8 x102 N.S.D 
7/4+ Monocytes 1.6± 0.2 x102 1.3 ±0.2 x102 N.S.D 29.2 ± 8.0 47.7 ± 17.8 N.S.D 
7/4- Monocytes 3.4 ± 0.4 x104 3.0 ± 0.4 x104 N.S.D 9.1 ± 2.2 x102 8.4 ± 1.5 x102 N.S.D 
T cells 8.6 ± 1.1 x104 7.1 ± 1.3 x104 N.S.D 3.6 ± 0.8 x103 2.7 ± 0.4 x103 N.S.D 
CD4+ T cells 3.8 ± 0.5 x104 2.9 ± 0.5 x104 N.S.D 2.3 ± 0.5 x103 1.6 ± 0.3 x103 N.S.D 
CD8+ T cells 2.5 ± 0.4 x104 2.5 ± 0.4 x104 N.S.D 1.1 ± 0.3 x103 1.0 ± 0.2 x103 N.S.D 
B cells 3.5 ± 0.3 x104 3.5 ± 0.6 x104 N.S.D 0.8 ± 0.3 x103 0.6 ± 0.2 x103 N.S.D 
NK cells 2.7 ± 0.6 x104 2.8 ± 0.5 x104 N.S.D 1.4 ± 0.5 x103 1.1 ± 0.3 x103 N.S.D 
NKT cells 5.8 ± 0.9 x103 4.0 ± 0.6 x103 N.S.D N/A† N/A† N/A† 
 
*Values correspond to number of leukocytes within the lung ± SEM (n=10)  
^ Values correspond to number of leukocytes in the alveolar passage ± SEM (n= 10)  
† N/A corresponds to subsets either not being present or numbers too low to be tested 
$ Significance between the two genotypes using an Unpaired T test, N.S.D = no significant difference  
Table 3.1. Comparison of cell numbers isolated from the lung and BAL of DR3wt and DR3ko mice  
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3.3.1.3 Measuring lung function in DR3wt and DR3ko mice  
3.3.1.3.1 Lung function measurements in DR3wt and DR3ko mice were inconsistent 
Lung function was measured in unrestrained mice as Penh using a Buxco whole body 
plethysmography system. Results suggested that naive DR3ko mice possessed no 
intrinsic defect in lung function, as there were no significant differences in Penh values 
when mice were challenged with PBS (DR3wt 0.6±0.2, DR3ko 0.9±0.3) or Methacholine 
(30mg/ml) (DR3wt 0.7±0.3, DR3ko 1.4±0.7) (2 way ANOVA; Interaction=0.623, 
Treatment=0.460, Genotype=0.211) (Figure 3.3), a drug typically used to induce 
bronchoconstriction and therefore study potential changes in respiratory mechanics.  
However, there was variation in the responses of individual mice to both PBS and 
Methacholine, independent of genotype, shown by the Residual Error value (Residual 
Error=13.87). As well as this, DR3ko mice failed to remain still within the 
plethysmography chamber, despite habituation alongside DR3wt mice. A basic analysis 
of mouse activity was performed by scoring mice according to their level of movement, 
with 1 representing activity, and 0 allocated for mice which had settled. Over a 5 day 
period, DR3ko mice moved significantly more than DR3wt mice, which became 
accustomed to the chamber and had settled by day 3 (Figure 3.3) (2 way ANOVA; 
Interaction=0.821, Genotype=0.0006, Mouse=0.498). The possible reasons for this will 
be discussed further (Section 3.4). Overall, results to study lung function differences 
between DR3wt and DR3ko mice proved inconclusive. 
 
 
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
Figure 3.3. Airway hyper-responsiveness, determined using Penh and activity in naive 
DR3wt and DR3ko mice. (A) Average Penh readings from naive mice receiving no 
treatment and Methacholine (30mg/ml) measured using plethysmography. Bars 
represent mean ± SEM (n=5). Not significant by 2 way ANOVA. (B) Activity of DR3wt 
and DR3ko mice over a 5 day period. 0 represents still mice, 1 represents active. Bars 
represent mean ± SEM (n=5). Results significant by 2 way ANOVA ***p<0.001 
(Interaction=0.8209, Genotype= ***0.0006, Mouse=0.4979).  
DR
3w
t
DR
3k
o
0
1
2
3
4
PBS
Methacholine
Residual error=13.47
Pe
nh
1 2 3 4 5
0.0
0.5
1.0
1.5
WT
KO
p=***0.0006
Days
Ac
tiv
ity
121 
 
3.3.1.4 DR3 expression patterns within the lung of DR3 mice 
3.3.1.4.1 DR3 expression can be detected within the lungs of naive DR3wt mice 
Prior to this study, the expression profile of DR3 within unchallenged lungs had not 
been researched meaning the receptor’s location and degree of expression were 
unknown. Using immunohistochemistry (IHC) and a polyclonal DR3 antibody, DR3 
levels were analysed in the airways of DR3wt and DR3ko mice. A control IgG antibody 
was also used to ensure antibody specificity. Using this method, positive DR3 signals 
were noted throughout the DR3wt lung, particularly within the smooth muscle, 
peribronchial areas and occasionally within the alveolar network (Figure 3.4). DR3 
concentration was quantified using Leica Qwin V3 software (Section 2.2.12.8) and five 
different fields of view from each lung. Results were then averaged and DR3 expression 
quantified for each mouse.  DR3 baseline expression patterns in naive DR3wt lung were 
established at 10.4±1.2%, significantly higher than DR3ko lung (1.6±0.14%) (p<0.0001) 
and antibody control stained sections (0.02±0.007%) (p<0.0001) (Table 3.2). Figure 3.4 
shows representative photos of DR3 expression within the naive lungs.  
 
 
 
 
 
 
 
Figure 3.4 DR3 expression in naive lungs. (A) Representative pictures of DR3wt and 
DR3ko lungs stained with DR3 or IgG isotype control (Scale bar=100μm). Arrows 
show DR3 staining in the peribronchiolar and alveolar network. (B) DR3 expression 
in the lung was analysed using 5 fields of view of each lung and measuring the % of 
positive (brown) in each field of view. This was then averaged for each mouse. 
Analysis was performed using Leica Qwin V3 Software. Bars represent mean ± SEM 
(n=5). Results are significant using 1 way ANOVA  with Bonferroni post test 
(***p<0.0001). 
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3.3.2 Phenotypic characterisation of the naive spleens of DR3wt and DR3ko mice 
 
3.3.2.1 Phenotypic analysis of cells within the spleens of DR3wt and DR3ko mice 
3.3.2.1.1 Total splenocyte number was not significantly different between naive DR3wt 
and DR3ko mice 
Splenocytes were isolated from DR3wt and DR3ko mice before undergoing a RBC lysis, 
with the remaining leukocytes being counted using a haemocytometer to determine total 
spleen cell number (Section 2.2.6). Results showed that there were no significant 
differences in splenocyte numbers isolated from DR3wt (6.5±0.5 x107) compared to 
DR3ko (6.8±0.8 x107) (p=0.687) (Figure 3.5) mice, suggesting DR3 is not required to 
sustain leukocyte number within the spleen.  
 
3.3.2.1.2 There were no significant baseline differences between splenic DR3ko and 
DR3wt myeloid and lymphocyte populations 
To test whether a lack of DR3 affected individual cell subset numbers within the spleen, 
splenocytes from DR3 transgenic mice were analysed using flow cytometry and a range 
of antibodies. Findings confirmed that DR3ko mice suffered no impairment in myeloid 
or lymphocyte populations within the spleen, as all cell types examined presented 
similar numbers to their DR3wt equivalent (Table 3.3).  
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Figure 3.5. Total leukocyte number from the spleens of  naive DR3wt and DR3ko 
mice. Splenocytes were extracted via mashing of the spleen and counted using a 
haemocytometer with trypan blue. Each symbol represents data from a single mouse. 
Results showed no significant differences using an Unpaired T test.  
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3.3.3 Quantifying DR3 expression in the naive lungs and spleens of DR3wt mice 
 
3.3.3.1 DR3 was constitutively expressed on T cells within the naive spleen and lung of 
DR3wt mice 
Whole splenocyte and lung populations from naive DR3wt and DR3ko mice were 
assayed for DR3 expression, using flow cytometry and a polyclonal DR3 antibody. 
Appropriate isotype controls were also used to ensure that staining was specific and 
confirm that DR3 binding was due to a specific antibody/cell surface antigen 
interaction. Median Fluorescent Intensity (MFI) was used to evaluate the DR3 signal as 
total population shifts were noted. Despite numerous blocking steps (Section 2.2.8.2), a 
degree of non specific binding was observed from the polyclonal DR3 antibody, as 
although T cells from DR3wt mice presented a significant shift in fluorescence compared 
to control IgG treated samples, DR3ko cells also increased. To increase the reliability 
and accuracy of DR3 quantification upon cell types, relative fluorescence (RF) of DR3wt 
and DR3ko signal over control samples was calculated, by dividing the test MFI by that 
of the IgG isotype. Using this method, CD4+ T cells from the spleens of naive DR3wt 
mice were found to exhibit statistically more signal than DR3ko CD4+ T cells (DR3wt  
13.5±2.4, DR3ko 3.3±0.4) (p=0.003) (Figure 3.6) (Figure 3.7) (Table 3.2). The same 
was also true of the CD8+ T cell subset (DR3wt 4.1±0.7, DR3ko 2.2±0.3) (p=0.003) 
(Figure 3.6) (Figure 3.7), although DR3 was expressed to a lesser extent (Table 3.2). In 
contrast, NKT cells, although fewer in number, expressed DR3 to a high level, with 
DR3wt mice displaying a RF of 21.5±2.3 compared to 2.3±0.2 in DR3ko mice 
(p<0.0001) (Figure 3.6) (Figure 3.7) (Table 3.2). These statistically significant results 
within the naive spleen were mimicked in the lung as both the resident CD4+ T cell 
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subset (DR3wt 18.8±0.2, DR3ko 4.0±0.3) (p<0.0001) and CD8+ subset (DR3wt 5.4±0.4, 
DR3ko 0.9±0.2) (p<0.0001) were observed to express DR3 (Figure 3.8) (Figure 3.9) 
(Table 3.2), although CD4+ T cells expressed roughly 3.5 times more. Conversely, DR3 
could not be detected on NKT cells within the naive lung due to low cell numbers, 
despite constitutive DR3 expression upon the same cell type within the spleen. 
However, no significant difference in DR3 signal relative to control was seen on NK 
cells within the spleen in either DR3wt or DR3ko mice (Figure 3.10). Moreover, myeloid 
DCs, displayed non-specific staining for the polyclonal antibody, as although DR3wt 
levels increased in comparison to control antibody, DR3ko cells followed the same 
pattern (Figure 3.10).   
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Figure 3.6. Flow cytometry dot plots representing DR3 expression on resident T cell 
populations from the spleens of DR3wt and DR3ko mice. Representative flow cytometry 
dot plots following staining with DR3 or control IgG antibody and the % shift of the 
population. CD4+ T cells identified using CD3+, TCRβ + and CD4+. CD8+ T cells 
identified using CD3+, TCRβ+ and CD8+. NKT cells identified using CD3+, TCRβ+ and 
NK1.1+ .   
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Figure 3.7. Ratio of DR3 MFI’s on resident T cell populations in the naive spleens of 
DR3wt and DR3ko  mice. Ratio DR3 expression was calculated by the MFI fold increase 
compared to the control IgG antibody. (A) CD4+ T cells identified using CD3+, TCRβ+ 
and CD4+ (**p=0.0029). (B) CD8+ T cells identified using CD3+, TCRβ+ and CD8+ 
(**p=0.0027). (C) NKT cells identified using CD3+, TCRβ+ and NK1.1+ 
(***p<0.0001). Each symbol represents data from a mouse. Values represent mean ± 
SEM. Results analysed using an Unpaired T test whereby **p<0.01, ***p<0.001.  
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Figure 3.8. Flow cytometry dot plots representing DR3 expression on resident T cell 
populations from the lungs of DR3wt and DR3ko mice. Representative flow cytometry 
dot plots following staining with DR3 or control IgG antibody and the % shift of the 
population. CD4+ T cells identified using CD3+, TCR+ and CD4+. CD8+ T cells 
identified using CD3+, TCRβ+ and CD8+. 
DR
3w
t
DR
3k
o
0
10
20
30 ***
Ra
tio
 o
f D
R3
 M
FI
 o
n 
lu
ng
 C
D
4+
T 
ce
lls
DR
3w
t
DR
3k
o
0
2
4
6
8 ***
Ra
tio
 o
f D
R3
 M
FI
 o
n 
lu
ng
 C
D
8+
T 
ce
lls
Figure 3.9. Ratio of DR3 MFI’s on resident T cell populations in the naive lungs of 
DR3wt and DR3ko mice. Ratio DR3 expression was calculated by the MFI fold increase 
compared to the control IgG antibody. (A) CD4+ T cells identified using CD3+, TCRβ+ 
and CD4+ (***p<0.0001). (B) CD8+ T cells identified using CD3+, TCRβ+ and CD8+  
(***p<0.0001). Each symbol represents data from a mouse. Values represent mean ± 
SEM. Results analysed using an Unpaired T test whereby ***p<0.001.   
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Figure 3.10.  DR3 expression on DR3wt NK cells or Myeloid DC’s within the naive 
spleen. Splenocytes were isolated and identified (NK cells; CD3- and NK1.1+. mDC’s; 
CD11c+ and CD11b+). (A) Representative flow cytometry dot plots following staining 
with DR3 or control IgG antibody and the % shift of the population. (B) Representative 
histograms following staining with DR3 (green=DR3ko, blue=DR3wt) or control IgG 
antibody (red) on NK cells and (C) mDCs.  
2.0%   2.1% 5.9% 
2.0% 9.5% 10.2% 
DR3 
          DR3 Expression 
Cell Subset DR3wt Surface Expression Score^ DR3ko Significance$ 
% DR3 in  naive Lung* 10.4 ± 1.2 N/A† 1.6 ± 0.3 ***p<0.0001 
DR3 MFI ratio on Lung CD4+ T cells 18.8 ± 0.8 ++ 4.0 ± 0.3 ***p<0.0001 
DR3 MFI ratio on Lung CD8+ T cells 5.4 ± 0.4 + 0.9 ± 0.2 ***p<0.0001 
DR3 MFI ratio on Spleen CD4+ T cells 13.5 ± 2.4 ++ 3.3 ± 0.1 **p=0.003 
DR3 MFI ratio on Spleen CD8+ T cells 4.1 ± 0.7 + 2.2 ± 0.3 **p=0.003 
DR3 MFI ratio on Spleen NKT cells 21.5 ± 2.3 +++ 2.3 ± 0.2 ***p<0.0001 
* % DR3 expression within the naive lungs of DR3wt and DR3ko mice via IHC (n=5)   
^ Surface expression scores of DR3 are estimates for comparison purposes + low expression to +++high expression 
† N/A corresponds to subsets either not being present or numbers too low to be tested 
$ Significance between two genotypes using Unpaired T Test (**p<0.01, ***p<0.001). 
Median fluorescence intensity (MFI) ratio calculated by dividing the test median by the isotype following gating on the specified population ± SEM 
following flow cytometry  
 
Table 3.2. Summary of DR3 expression 
133 
 
3.3.4 Phenotypic characterisation of the peripheral blood in naive DR3wt and 
DR3ko mice 
 
3.3.4.1 Phenotypic analysis of cells within the peripheral blood of DR3wt and DR3ko 
mice 
3.3.4.1.1 Total leukocyte number in the peripheral blood of unchallenged DR3wt and 
DR3ko mice did not significantly differ 
To examine whether DR3 had any part to play in maintaining the total number of cells 
within the peripheral blood in a naive mouse, blood was acquired via a cardiac puncture 
(Section 2.2.5.4). Red blood cells were lysed and leukocytes counted using a 
haemocytometer (Section 2.2.6). Results confirmed that the absence of DR3 had no 
effect on the total number of leukocytes within the peripheral blood as no significant 
differences were seen between DR3ko (1.6±0.3 x106) and DR3wt (1.8±0.3 x106) 
(p=0.818) mice (Figure 3.11). 
 
3.3.4.1.2 There were no significant baseline differences between DR3wt and DR3ko 
myeloid and lymphocyte derived peripheral blood cells 
Individual cell subsets were isolated from total leukocytes using flow cytometry to 
investigate whether DR3 had any effect upon specific populations in the naive state. 
Findings showed that DR3ko mice had no defect in any myeloid or lymphocyte cell 
types examined, as the 2 genotypes displayed analogous cell subset numbers (Table 
3.3).  
Figure 3.11. Total leukocyte number isolated from the peripheral blood of naive 
DR3wt and DR3ko mice. Cells were isolated via cardiac puncture and counted using a 
haemocytometer with trypan blue. Each symbol represents data from a single mouse. 
Results showed no significant differences using an Unpaired T test. 
 
DR
3w
t
DR
3k
o
0
1
2
3
4
To
ta
l P
er
ip
he
ra
l B
lo
od
 C
el
l N
um
be
r/m
l (
x1
06
)
                          Spleen*                                                                                        Peripheral Blood^ 
Cell Subset DR3wt DR3ko Significance$ DR3wt DR3ko Significance$ 
Leukocytes 6.5 ± 0.5 x107  6.8 ± 0.8 x107  N.S.D 1.6 ± 0.3 x106  1.8 ± 0.3 x106  N.S.D 
 Macrophages 16.1 ± 4.0 x105  15.0 ± 3. x105  N.S.D N/A†  N/A†  N/A†  
Myeloid DCs 6.2 ± 2.2 x105  5.4 ± 1.4 x105  N.S.D N/A†  N/A†  N/A†  
Plas. DCs 1.2 ± 0.3 x105 0.9 ± 0.2 x105 N.S.D N/A†  N/A†  N/A†  
Neutrophils 6.4 ± 1.8 x105  8.8 ± 3.7 x105  N.S.D 1.3 ± 0.3 x105  1.6 ± 0.2 x105  N.S.D 
Eosinophils 1.5 ± 0.4 x105 1.4 ± 0.4 x105 N.S.D 4.5 ± 1.0 x104 3.6 ± 0.8 x104 N.S.D 
7/4+ Monocytes 6.6± 1.2 x105  6.7 ±1.3 x105  N.S.D 8.0 ± 0.2 x104 5.9 ± 0.9 x104  N.S.D 
7/4- Monocytes 13.6 ± 3.4 x105 14.2± 5.1 x105 N.S.D 2.8 ± 0.5 x105 3.3 ± 0.6 x105 N.S.D 
T cells 1.4 ± 0.2 x107  1.5 ± 0.2 x107  N.S.D 3.2 ± 0.7 x105  3.6 ± 0.7 x105  N.S.D 
CD4+ T cells 0.9 ± 0.1 x107  0.9 ± 0.1 x107  N.S.D 1.5 ± 0.4 x105  1.9 ± 0.4 x105  N.S.D 
CD8+ T cells 0.5 ± 0.1 x107  0.5 ± 0.1 x107  N.S.D 1.4 ± 0.3 x105  1.6 ± 0.3 x105  N.S.D 
B cells 1.7 ± 0.4 x107  1.5 ± 0.3 x107  N.S.D 5.3 ± 1.1 x105  5.8 ± 1.2 x105  N.S.D 
NK cells 2.0 ± 0.5 x106  1.9 ± 0.4 x106  N.S.D 1.5 ± 0.3 x104  1.7 ± 0.2 x104  N.S.D 
NKT cells 4.7 ± 0.7 x105  4.9 ± 0.7 x105  N.S.D 6.6± 1.5 x 104  1.7± 0.2 x 104  N.S.D 
Table 3.3. Comparison of cell numbers isolated from the spleen and peripheral blood of DR3wt and DR3ko mice  
* Values correspond to number of leukocytes within the spleen ± SEM (n=6)  
^ Values correspond to number of leukocytes in the peripheral blood± SEM per ml of blood (n= 6)  
† N/A corresponds to subsets either not being present or numbers too low to be tested 
$ Significance between the two genotypes using an Unpaired T test, N.S.D = no significant difference 
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3.4 Discussion 
 
3.4.1 Cellular phenotypes of the lung, alveolar passage, spleen and blood of DR3wt 
and DR3ko mice 
Previous to this study, no data had been published on the cellular components of the 
lung, alveolar passage or peripheral blood of naive DR3ko mice, knowledge essential for 
the interpretation of effects following immune challenge. The spleen on the other hand 
had been studied before (Wang, Thern et al. 2001; Meylan, Davidson et al. 2008), 
although not to the level of detail described within this Chapter. Overall, no significant 
differences were found in the lungs or airways of DR3wt and DR3ko mice in the cell 
types examined, suggesting DR3 has no role in the maintenance of leukocytes in the 
naive state. This result not only confirms that no intrinsic differences exist in the lungs 
of DR3ko mice at baseline levels, but also allows a comparison to be drawn when 
studying mice which have been allergen challenged. Similarly, no significant 
differences were seen in the peripheral blood or spleen of DR3wt and DR3ko mice at 
baseline level, ensuring that upon inflammation, both DR3wt and DR3ko mice are able to 
recruit from sources with equal numbers of leukocytes. The data of this Chapter implies 
that DR3 has a non-redundant role in upholding the cellular composition of the organs 
examined in un-challenged mice.  
 
3.4.2 DR3 expression patterns in the lung 
The detection of DR3 within the lung via IHC proved successful, despite a small degree 
of non specific binding exhibited by the polyclonal antibody. DR3 expression has 
previously been found on healthy and psoriatic skin lesions (Bamias, Evangelou et al. 
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2011) and the naive peritoneal membrane (Perks, 2013 PhD). However, Receptor 
expression patterns had never been determined in the lung, although studies have been 
published which link DR3 to lung inflammation (Fang, Adkins et al. 2008; Meylan, 
Davidson et al. 2008; Schreiber, Wolf et al. 2010). Being able to not only quantify DR3, 
but also observe the pattern of expression provides a novel advantage to other methods 
previously used to look at DR3 expression, such as Northern Blot analysis (Wang, 
Kitson et al. 2001) and RT-PCR  (Bamias, Mishina et al. 2006; Bull, Williams et al. 
2008; Pappu, Borodovsky et al. 2008; Taraban, Slebioda et al. 2011).  Nevertheless, 
IHC does present a major disadvantage in comparison to the said techniques. Using RT-
PCR and Southern blotting, it was found that DR3 had three murine splice variants; full 
length, membrane bound truncated and soluble isoforms (Wang, Kitson et al. 2001). 
Whilst, RT-PCR is able to detect all 3 murine splice variants, the antibody used for DR3 
IHC cannot. Consequently, although a general DR3 signal can be detected within the 
lung, the exact splice variant and therefore functionality of the Receptor cannot.  
 
3.4.3 Leukocyte DR3 expression within the lung and spleen 
Lack of suitable commercial murine DR3 reagents has hindered progress within this 
field of research, as murine models prove to play an ever increasing role in studying the 
effects of the Receptor. Previous attempts within the lab to generate a monoclonal 
antibody to mouse DR3 failed (Bull, 2008), although other labs have had more success, 
notably Fang et al. Although DR3 expression was detected on T lymphocytes in the 
naive lung and spleen, binding of the polyclonal reagent showed a degree of non-
specificity despite several additional blocking steps (Section 2.2.8.2). One reason for 
this may be the DR3 antibody itself, which as a polyclonal may bind not only to DR3 
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this may be the DR3 antibody itself, which as a polyclonal may bind not only to DR3 
but also proteins which exhibit homology to the receptor, such as TNFR1 which 
demonstrates 28% amino acid similarity to DR3 (Chinnaiyan, Orourke et al. 1996; 
Kitson, Raven et al. 1996; Marsters, Sheridan et al. 1996; Screaton, Xu et al. 1997). 
This may explain the small signal detected by the DR3 antibody upon DR3ko T cells.   
 
Notwithstanding this small degree of non-specificity, DR3 was found to be expressed 
on naive CD4+ T cells, CD8+ T cells and NKT cells in the spleen, results which accord 
with published data (Fang, Adkins et al. 2008; Twohig, Marsden et al. 2012), as well as 
the novel finding of DR3 on CD4+ and CD8+ T cells in the lung.  Adding to this, DR3 
has been found to be expressed on CD4+ T cells of the Th1 (Bamias, Martin et al. 2003), 
Th2 (Fang, Adkins et al. 2008) and Th17 (Pappu, Borodovsky et al. 2008) response, as 
well as regulatory T cells (Schreiber, Wolf et al. 2010). Although not expressed on 
naive murine B cells (Fang, Adkins et al. 2008), Cavallini et al have reported the 
presence of DR3 on IgM stimulated human B cells isolated from blood. Furthermore, it 
appears that antigen-stimulated B cells within the murine spleen white pulp region 
express DR3, although DR3’s influence on antibody production were not examined 
(Cavallini, Lovato et al. 2013). The above subsets would be interesting to study using 
DR3ko mice, in both a naive and allergen challenge situation, allowing a clear 
comparison between cells which express DR3 and those which do not as well as their 
differential regulation.  
 
Despite the presence of DR3 on T cells, the antibody does not allow distinction between 
the 3 murine splice variants, which are known to be differentially expressed following 
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activation (Bamias, Mishina et al. 2006; Twohig, Marsden et al. 2012). Using RT-PCR, 
it has been reported that naive CD8+ cells from OT-1 transgenic DR3wt mice express 
both truncated and full length DR3 mRNA transcripts at low levels. Following 
activation however, full length DR3 mRNA transcripts dominated with an increase also 
seen in the variant thought to encode a soluble form of the receptor (Twohig, Marsden 
et al. 2012). High levels of truncated DR3 have been reported on TregS, whilst Th17 cells 
are thought to express full length DR3 (Pappu, Borodovsky et al. 2008), resulting in 
TL1A driven proliferation of Th17 cells as opposed to TregS. This data only highlights 
the need to understand the DR3 isoform/s being expressed in the basal state as they 
determine the functional response.  
 
Myeloid DCs on the other hand, displayed similar DR3 signals between DR3wt and 
DR3ko cells, although both shift in comparison to control IgG, suggesting DR3 is 
present on these cells but cannot be distinguished from the DR3ko sample. The lack of 
antibody specificity and general ‘stickiness’ of myeloid cells means that DR3 
expression cannot be quantified on myeloid cells using flow cytometry and this 
particular reagent.  However, published data states that DR3 is expressed on naive 
CD11c+ cells within the spleen and lymph nodes, a typical myeloid marker found upon 
myeloid DCs (Fang, Adkins et al. 2008), suggesting this monoclonal antibody and the 
polyclonal used within the study differ in their ability to detect DR3 and its splice 
variants.  DR3 expression has been recorded on un-stimulated cells of the human 
macrophage cell line, THP-1, using both flow cytometry (Kang, Kim et al. 2005; Su, 
Chang et al. 2006) and RT-PCR (McLaren, Calder et al. 2010), perhaps suggesting that 
DR3 is to be found upon murine myeloid cells. However, with 13 known human DR3 
spice variants and the inability to distinguish between them using the above techniques, 
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it is difficult to draw comparisons to the murine system. Fang et al also reported DR3 
expression on a subpopulation of NK cells using their monoclonal antibody, whilst the 
commercial polyclonal antibody used in this study was unable to detect any DR3 on NK 
cells within the DR3wt spleen, as no shift was noted from either DR3wt or DR3ko cells in 
comparison to control IgG samples. These inconsistencies may be due to a number of 
reasons, such as low receptor expression on NK cells making signal detection difficult, 
or the preferential binding of the different antibodies to specific DR3 isoforms, a 
difficulty previously suggested when measuring DR3 expression (Taraban, Ferdinand et 
al. 2011).  Without access to the monoclonal antibody and testing it alongside the 
commercial polyclonal, the differences between the detection abilities of the 2 
antibodies are difficult to pinpoint.  
 
DR3 expression was not examined in bronchoalveolar lavage samples due to poor cell 
recovery in naive mice. Few immunological cells reside in the alveolar passage of naive 
mice, making the detection of DR3 very difficult without the pooling of multiple 
samples from different mice. 
 
3.4.4 Lung function and airway reactivity of DR3wt and DR3ko mice  
Results from the lung function tests were inconsistent between individual mice, 
irrespective of genotype. The Residual Error, used to define variation amongst sampling 
units, showed that the variation was too great within the results. Using a Power 
Equation, it was calculated that 70 mice of each genotype would be required to 
overcome this variation when measuring airway hyper-responsiveness in DR3ko mice, 
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which is neither feasible nor ethical. Additionally, despite habituation to the Buxco 
chamber, selective DR3ko mice still continued to move when experimental readings 
were recorded, which most likely contributed to the variation observed.  Considering 
the results already obtained, this method of measuring airway hyper-responsiveness in 
DR3ko mice is neither dependable nor consistent.  
 
Published studies have already demonstrated that DR3ko mice suffer with a form of 
hyper-activity and behavioural defects (Twohig, Roberts et al. 2010), which although 
thought to be age dependent, could explain their inability to remain still within the 
Buxco chamber (Figure 3.12) in comparison to DR3wt mice. DR3 is expressed 
constitutively within both the murine and human brain (Harrison, Roberts et al. 2000; 
Wang, Kitson et al. 2001; Twohig, Roberts et al. 2010) and its  genetic loss is thought to 
be responsible for murine neurological disease in the form of disorientation, abnormal 
gait and general decline in motor control function (Twohig, Cuff et al. 2011). However, 
these features were only noted in mice 24 weeks and above. Figure 3.12 (video) 
suggests similar characteristics surface in DR3ko mice as young as 8 weeks, as despite 
habituation to the plethysmography chamber, DR3ko mice appeared to exhibit 
behavioural abnormalities compared to DR3wt mice. Over the acclimatisation period, 
DR3wt mice seemed to display memory in that they gradually became accustomed to the 
Buxco chamber, remaining relatively calm by the end of the 2 week time allowance 
(Figure 3.12 video). In contrast, DR3ko mice looked to display no habituation to the 
chamber procedure despite daily introductions over the same time course, suggesting 
early penetrance of a behavioural phenotype.  This ultimately resulted in inconclusive 
lung function tests. With this in mind, the use of plethysmography in this project was 
discontinued. 
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Whole body unrestrained plethysmography itself has been questioned as a suitable 
means by which to test for airway hyper-reactivity and bronchoconstriction. 
Plethysmography is generally used due to its ease, as mice do not need to be restrained 
and are conscious during the procedure, thereby encouraging normal breathing patterns. 
Whole body plethysmography works by measuring two changes in box pressure; the 
reduction in air caused by mouse inspiration and an increase due to lungs expanding 
(Fernandez-Rodriguez, Ford et al. 2008). In normal circumstances these flows cancel 
each other out.  Following airway responsiveness to a bronchoconstrictor, the change in 
box pressure during expiration is more pronounced than that during inspiration (Archer, 
Cramton et al. 2004; Fernandez-Rodriguez, Ford et al. 2008). However, debate 
continues as to the reliability of the method. Zhang et al suggested Penh alone was not 
enough to confirm airway resistance in BALB/c mice and that a more invasive 
technique was required to evaluate airway responsiveness, particularly within the lower 
airway, where the majority of allergic responses occur (Zhang, Lai et al. 2009). Data 
suggested that plethysmography presented false positives, as mice with mild 
inflammation demonstrated airway resistance using Penh as an index, but not with the 
more invasive technique. However, the invasive technique involved anaesthetised mice 
and intubation, followed by the monitoring of flow using thoracic movements and 
ultimately trans-pulmonary pressure and lung resistance.  As well as this, mice with 
severe inflammation required less Methacholine to initiate airway hyper-responsiveness 
according to plethysmography than those measured using the invasive endotracheal 
intubation method (Zhang, Lai et al. 2009). Adler et al  suggested that Penh was strain 
specific, in that it responded differently for mice of BALB/c and C57BL/6 lineage 
(Adler, Cieslewicz et al. 2004), whilst Albertine et al found that Penh readings were 
inconsistent with measurements taken from anaesthetised cannulated mice during the 
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latter stages of an OVA challenge protocol (days 18-22) when using C57BL/6 mice 
(Albertine, Wang et al. 2002). Nevertheless, Hamelmann et al argue that whole body 
plethysmography is an effective indicator of airway hyper-responsiveness following 
allergic sensitisation, as Penh readings correlated with other hallmarks of bronchial 
asthma such as eosinophil lung infiltration and increased IgE production (Hamelmann, 
Schwarze et al. 1997; Schwarze, Hamelmann et al. 2005). In addition, BALB/c mice 
responded to Methacholine in the same way using both the invasive and non-invasive 
techniques, leading Hamelmann et al to conclude that Penh is a suitable index of airway 
kinetics. It appears that the controversy regarding plethysmography is ongoing, as both 
the advantages and limitations of the technique continue to be published and debated. 
Despite the ease of Penh as a measure of airway obstruction, DR3ko mice were unable to 
remain still within the chamber resulting in skewed readings, agitated mice and an 
inability to study lung mechanics.  
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3.5 Summary 
Attempts to examine lung function and airway hyper-reactivity in unchallenged DR3ko 
mice were inconclusive. Results implied that there was no difference in the lung 
mechanics of DR3wt and DR3ko mice but the method used to examine this, 
plethysmography, was neither reliable nor suitable for studying DR3ko mice. 
Collectively, the data contained in this Chapter confirms DR3 expression on murine T 
cells in the spleen and presents novel findings of DR3 expression in the naive lungs of 
DR3wt mice. However, despite constitutive Receptor expression, it is not involved in the 
maintenance of cell populations in either the spleen, lung, alveolar passage or blood, 
suggesting function only arises during inflammatory episodes. 
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Chapter 4: 
The role of DR3 in an acute murine 
model of allergic lung inflammation  
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4.1 Introduction 
Asthma is defined as a chronic disease of the airways, characterised by airway 
inflammation, airway hyper-responsiveness and airway remodelling. Although no in 
vivo model is able to replicate all of these morphological and functional features, animal 
models have been used to study specific aspects of the disease.  
 
Models of acute allergic lung inflammation have long been employed to identify the 
mechanisms underlying the immunological and inflammatory responses of asthma, 
replicating the initiating events leading to disease. This short-term exposure is sufficient 
to imitate airway inflammatory events, allowing the relationship between cells and 
inflammatory mediators to be investigated and so potential novel targets for drug 
therapy to be identified.   
 
DR3 has previously been implicated in acute models of inflammatory disease, including 
acute allergic lung inflammation (Fang, Adkins et al. 2008; Meylan, Davidson et al. 
2008). Using both DR3ko and dominant negative (DN) DR3 transgenic mice, it was 
found that DR3 was responsible for cellular accumulation into the alveolar passage, Th2 
cytokine production and lung immune pathology. However, it is known the nature of the 
inflammatory response is influenced by the challenge and sensitisation protocols 
employed (Kumar and Foster 2002; Zosky and Sly 2007), as well as the readouts used 
to assess disease. As these differ between the existing published data, it is difficult to 
compare these results in the context of this project. Therefore, the role of DR3 in acute 
allergic lung inflammation was assessed using the same sensitisation protocol to be 
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utilised for chronic allergic lung inflammation (Chapter 5), adapted from Fernandez-
Rodriguez et al (2008), to allow comparisons to be drawn between the 2 models 
(Fernandez-Rodriguez, Ford et al. 2008).  
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4.2 Aims 
The aim of this Chapter was to investigate the role of DR3 in acute allergic lung 
inflammation. DR3wt and DR3ko mice were sensitised using i.p. injection of OVA and 
Alum before short-term exposure to OVA or PBS. Mice were harvested at 24 and 72 
hours post inhalation challenge, which occurred on day 15 (Section 2.2.7.3). To dissect 
the impact of DR3 on the allergic responses, leukocyte influx into the lung and BAL 
were measured, as well as allergic antibody levels in the serum. Histological 
examination of the lung determined the degree of airway remodelling and analysis of 
spleen cell subsets the systemic effect of DR3.  
 
4.2.1 Objectives 
i) Determine the local inflammatory response following acute allergic lung 
inflammation  
 ii) Analyse and quantify airway remodelling  
 iii) Determine the systemic response following acute allergic lung inflammation 
 
 
 
 
 
 
149 
 
4.3 Results 
4.3.1 Airway inflammation following acute allergic lung inflammation 
 
4.3.1.1 Analysis of cellular accumulation into the lung  
4.3.1.1.1 DR3 did not regulate leukocyte accumulation into the lung  
Lung cells were extracted following collagenase treatment and counted using a 
haemocytometer. Results showed there were no significant differences in lung total cell 
numbers between DR3wt OVA or DR3ko OVA treated mice at the 24 or 72hr harvest 
points. However, OVA treated mice of both genotypes did have significantly higher 
number of leukocytes compared to PBS challenged animals at 24hrs (DR3wt OVA 
3.3±0.4 x106, DR3ko OVA 2.9±0.2 x106, DR3wt PBS 1.9±0.1 x106, and DR3ko PBS 
1.8±0.1 x106) (p=0.0002) (Figure 4.1), thus suggesting that DR3 does not control the 
accumulation of leukocytes in the lung following allergen challenge.  
 
 
  
 
 
 
 
 
 
 
  
Figure 4.1. Total leukocyte number from the lungs of DR3wt and DR3ko mice 
following acute allergic lung inflammation. Mice were sacrificed (A) 24hrs and (B) 
72hr post final inhalation challenge with either OVA or PBS. Cells were isolated via a 
lung digest and counted using a haemocytometer. (A) **p=0.006 using 1 way ANOVA 
and Bonferroni post test (B) n.s.d using 1 way ANOVA. Values represent mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001. Each symbol represents data from a single mouse.  
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4.3.1.1.2 DR3wt OVA treated lungs had significantly more 7/4- monocytes than DR3ko 
OVA lungs at 24 but not 72hrs post inhalation  
At 24hrs post inhalation, significant differences were seen between DR3wt OVA and 
DR3ko OVA mice in 7/4- monocytes within the lung (DR3wt 8.2 ± 1.2 x104, DR3ko 4.9 ± 
0.5 x104) (p<0.05) (Figure 4.2), but no other myeloid cell subset. However, mice that 
had undergone OVA inhalation consistently displayed higher cell subset numbers in 
comparison to PBS treated animals. This was significant between DR3wt OVA and 
DR3ko PBS mice when comparing alveolar macrophages, as DR3wt OVA mice had 
8.2±1.3 x105 macrophages, with DR3ko PBS mice at 4.3±0.3 x105 (p=0.008) (Figure 
4.2). Lungs of DR3wt and DR3ko OVA mice contained significantly higher numbers of 
myeloid DCs compared with PBS treated animals (DR3wt OVA 1.8±0.4 x104, DR3ko 
OVA 1.9±0.2 x104, DR3wt PBS 0.5±0.3 x104, DR3ko PBS 0.7±0.1 x104) (p=0.001) 
(Figure 4.2). No significant differences in eosinophils were seen between DR3wt OVA 
(15.4±2.4 x104) and DR3ko OVA mice (14.1±2.6 x104), but the numbers in these 
treatment groups were significantly higher than control PBS challenged animals (DR3wt 
PBS 5.1±1.2 x104, DR3ko PBS 14.1±2.6 x104) (p=0.0003) (Figure 4.2).  
 
At 72hrs post-inhalation, DR3wt OVA lungs contained 4.9±1.0 x105 eosinophils, more 
than all other treatment groups and significantly more than DR3wt PBS mice (1.9±0.3 
x105) (p=0.026) (Figure 4.3).  This trend was also observed when studying myeloid 
DCs, alveolar macrophages and 7/4+ monocytes, although no statistical significance was 
reached. In contrast to 24hr post inhalation, mice showed equivalent numbers of 7/4- 
monocytes and neutrophils irrespective of treatment and genotype (Figure 4.3).  
 
Figure 4.2. Myeloid cell subsets from the digested lungs of DR3wt and DR3ko mice 24hrs 
post acute allergic lung inflammation. Mice were sacrificed 24hr post final inhalation 
challenge with either OVA or PBS. Lung cells were isolated via collagenase lung digestion 
and subsets determined using antibody cell markers.  Alveolar Macrophages (**p=0.008), 
Neutrophils (*p=0.035), Eosinophils (***p=0.0003), 7/4+ Monocytes (*p=0.010), 7/4- 
Monocytes (***p=0.0001), Myeloid DCs (***p=0.001). Values represent mean ± SEM. 
Significance determined using 1 way ANOVA and Bonferroni post test; *p<0.05, 
**p<0.01, ***p<0.001. Each symbol represents data from a single mouse.  
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Figure 4.3. Myeloid cell subsets from the digested lungs of DR3wt and DR3ko mice 
72hrs post acute allergic lung inflammation. Mice were sacrificed 72hr post final 
inhalation challenge with either OVA or PBS. Lung cells were isolated via collagenase 
lung digestion and subsets determined using antibody cell markers.  Alveolar 
Macrophages (*p=0.045), Neutrophils n.s.d, Eosinophils (*p=0.026), 7/4+ Monocytes 
n.s.d, 7/4- Monocytes n.s.d, Myeloid DCs n.s.d. Values represent mean ± SEM. 
Significance determined using 1 way ANOVA and Bonferroni post test; *p<0.05. Each 
symbol represents data from a single mouse.  
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4.3.1.1.3 DR3wt OVA lungs had significantly more NK and NKT cells compared to 
DR3ko OVA lungs at 24 but not 72hrs post inhalation 
Significant differences were seen at 24hrs post inhalation in multiple lymphocytic cell 
subsets. Most significant was the increase in NKT cells and NK cells in DR3wt OVA 
lungs (NKT 12.7±1.5 x104, NK 3.1±0.5 x105) compared to DR3ko OVA (NKT 7.1±1.0 
x104, NK 1.9±0.2 x105) (p<0.0001 and p=0.0005 respectively) (Figure 4.4). The lungs 
of OVA treated groups were also observed to have more CD3+ T cells than PBS 
challenged animals (DR3wt OVA 13.2±2.1 x105, DR3ko OVA 10.7±1.2 x105, DR3wt 
PBS 5.1±1.0 x105, DR3ko PBS 5.5±0.3 x105) (p=0.0004), corresponding to a significant 
increase in CD4+ T cells (DR3wt OVA 7.6±1.3 x105, DR3ko OVA 5.7±0.7 x105, DR3wt 
PBS 2.5±0.5 x105, DR3ko PBS 2.6±0.2 x105) (p=0.0002) and activated (CD44+) CD4+ T 
cells (DR3wt OVA 3.9±0.6 x105, DR3ko OVA 3.3±0.5 x105, DR3wt PBS 1.5±0.2 x105, 
DR3ko PBS 1.4±0.1 x105) (p=0.0005) (Figure 4.4).  When analysing CD8+ T cells, only 
DR3wt OVA lungs displayed significance over PBS mice (DR3wt OVA 4.3±0.8 x105, 
DR3wt PBS 2.1±0.4 x105, DR3ko PBS 2.3±0.2 x105) (p=0.005) (Figure 4.4). B cell 
numbers were also significantly greater in DR3wt OVA lungs compared with PBS 
treated mice (DR3wt OVA 1.5±0.3 x105, DR3wt PBS 0.7±0.1 x105, DR3ko PBS 0.6±0.1 
x105) (p=0.010) (Figure 4.4), although levels were higher overall compared with all 
other treatment groups. 
 
No such trends were seen at 72hrs post inhalation, as DR3wt and DR3ko mice displayed 
comparable numbers of T and B cells (Figure 4.5). However, DR3wt OVA mice did 
have significantly more NKT cells than DR3ko PBS mice, with 12.8±2.8 x104 compared 
to 3.3±0.8 x104 (p=0.018) (Figure 4.5).  
Figure 4.4. Lymphocyte subsets from the digested lungs of DR3wt and DR3ko mice 24hrs 
post acute allergic lung inflammation. Mice were sacrificed 24hr post final inhalation 
challenge with either OVA or PBS. Lung cells were isolated via collagenase lung digestion 
and subsets determined using antibody cell markers. CD3+ T cells (***p=0.0004), CD4+ T 
cells (***p=0.0002), CD8+ T cells (**p=0.005), Activated CD4+ T cells (***p=0.0005), 
Activated CD8+ T cells(*p=0.018), NKT cells (***p<0.0001), NK cells (***p=0.0005), B 
cells (*p=0.010).  Values represent mean ± SEM. Significance determined using 1 way 
ANOVA and Bonferroni post test; *p<0.05, **p<0.01, ***p<0.001. Each symbol 
represents data from a single mouse.  
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Figure 4.5. Lymphocyte subsets from the digested lungs of DR3wt and DR3ko mice 72hrs 
post acute allergic lung inflammation. Mice were sacrificed 72hr post final inhalation 
challenge with either OVA or PBS. Lung cells were isolated via collagenase lung digestion 
and subsets determined using antibody cell markers. CD3+ T cells n.s.d, CD4+ T cells 
n.s.d, CD8+ T cells n.s.d, Activated CD4+ T cells n.s.d, Activated CD8+ T cells n.s.d, NKT 
cells (*p=0.018), NK cells n.s.d, B cells n.s.d.  Values represent mean ± SEM. 
Significance determined using 1 way ANOVA and Bonferroni post test; *p<0.05. Each 
symbol represents data from a single mouse 
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4.3.1.2 Analysis of cellular infiltration into the alveolar passage   
4.3.1.2.1 DR3wt OVA mice had significantly more leukocytes in the alveolar passage 
than DR3ko OVA mice  
At 24hrs post inhalation, DR3wt OVA mice had 4.8±1.4 x105 cells within the alveolar 
passage, significantly more than DR3ko OVA mice at 1.5±0.3 x105 and PBS treated 
animals (DR3wt PBS 1.2±0.2 x105, DR3ko PBS 1.5±0.3 x105) (p=0.0096) (Figure 4.6). 
Similarly, at 72hrs post inhalation, BAL fluid from DR3wt OVA treated mice was found 
to contain 5.2±1.3 x105 cells, significantly more than DR3ko OVA mice (1.0±0.3 x105) 
(p=0.013) (Figure 4.6), suggesting DR3 regulates cellular accumulation into the 
bronchoalveolar passage.  
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Figure 4.6. Total leukocyte number from the alveolar passage of DR3wt and DR3ko 
mice following acute allergic lung inflammation. Mice were sacrificed (A) 24hrs and 
(B) 72hrs post final inhalation challenge with either OVA or PBS. Cells were isolated 
via a bronchoalveolar lavage and counted using a haemocytometer. (A) **p=0.0096 
using 1 way ANOVA and Bonferroni post test. (B) *p=0.013 using 1 way ANOVA and 
Bonferroni post test; *p<0.05. Values represent mean ± SEM. Each symbol represents 
data from a single mouse.  
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4.3.1.2.2 DR3wt OVA mice had significantly more 7/4- monocytes and myeloid DCs in 
the alveolar passage than DR3ko OVA mice 
BAL fluid isolated from DR3wt OVA mice displayed increased cell numbers in 
numerous myeloid cell subsets in comparison to DR3ko OVA mice at both 24 and 72hrs 
post inhalation. At 24hrs post inhalation, DR3wt OVA mice had significantly more 7/4- 
monocytes (14.4±7.8 x104) and myeloid DCs (6.5±3.5 x103) than DR3ko OVA (7/4- 
monocytes 0.1±0.1 x104, mDCs 0.2±0.1 x103) and DR3ko PBS mice (7/4- monocytes 
0.2±0.1 x104, mDCs 0.3±0.1 x103) (p=0.017) (p=0.018) (Figure 4.7). Similarly, there 
were 3.0±1.7 x104 eosinophils within the DR3wt OVA alveolar passage, significantly 
more than the 0.1±0.02 x104 in DR3ko PBS mice (p=0.031) (Figure 4.7). In contrast, 
DR3wt OVA and DR3ko OVA groups displayed comparable numbers of alveolar 
macrophages.  
 
Myeloid cell subset numbers at 72hrs post inhalation were akin to those seen at 24hrs. 
DR3wt OVA BAL was observed to contain significantly more 7/4- monocytes (4.7±1.3 
x103) and myeloid DCs (2.3±0.6 x103) than DR3ko OVA BAL fluid (7/4- monocytes 
0.2±0.04 x103, mDCs 0.4±0.1 x103), with the difference being significant for both the 
monocyte (p=0.015) and dendritic cell subset (p=0.038) (Figure 4.8).  
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Figure 4.7. Myeloid cell subsets from the BAL of DR3wt and DR3ko mice 24hrs post 
acute allergic lung inflammation. Mice were sacrificed 24hr post final inhalation 
challenge with either OVA or PBS. Alveolar cells were isolated via lavage and subsets 
determined using antibody cell markers.  Alveolar Macrophages n.s.d, Neutrophils 
n.s.d, Eosinophils (*p=0.031), 7/4+ Monocytes n.s.d, 7/4- Monocytes (*p=0.017), 
Myeloid DCs (*p=0.018). Values represent mean ± SEM. Significance determined 
using 1 way ANOVA and Bonferroni post test; *p<0.05. Each symbol represents data 
from a single mouse. 
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Figure 4.8. Myeloid cell subsets from the BAL of DR3wt and DR3ko mice 72hrs post 
acute allergic lung inflammation. Mice were sacrificed 72hr post final inhalation 
challenge with either OVA or PBS. Alveolar cells were isolated via lavage and subsets 
determined using antibody cell markers.  Alveolar Macrophages (*p=0.0396), 
Neutrophils n.s.d, Eosinophils (*p=0.035), 7/4+ Monocytes n.s.d, 7/4- Monocytes 
(*p=0.015), Myeloid DCs (*p=0.0378). Values represent mean ± SEM. Significance 
determined using 1 way ANOVA and Bonferroni post test; *p<0.05. Each symbol 
represents data from a single mouse.  
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4.3.1.2.3 DR3wt OVA mice had significantly more CD4+ T cells in the alveolar passage 
than DR3ko OVA treated mice  
At 24hrs post inhalation, DR3wt OVA treated mice displayed increased numbers of 
multiple lymphocytic subset examined in comparison to DR3ko OVA mice, including 
NKT cells, which displayed an overall p value of 0.034, and B cells (p=0.041). When 
examining NK cells, significance was only detected between DR3wt OVA (15.0±5.8 
x103) and DR3ko PBS mice (1.9±0.9 x103) (p=0.024) (Figure 4.9). Analysis of CD3+ T 
cells showed significantly higher numbers in DR3wt OVA lavage fluid at 37.0±8.2 x104, 
compared to 2.2±0.1 x104 in DR3ko OVA, 5.2±1.9 x104 in DR3wt PBS and 8.4±3.1 x104 
in DR3ko PBS mice (Figure 4.9) (p<0.0001). CD4+ T cells and CD8+ T cells were 
higher in DR3wt OVA treated animals (CD4+ T cells 24.4±6.4 x103, CD8+ T cells 
11.0±1.8 x103) than DR3ko OVA (CD4+ T cells 1.3±0.4 x103, CD8+ T cells 0.7±0.4 
x103) (p=0.0002 and p<0.0001, respectively) (Figure 4.9). Likewise, DR3wt OVA mice 
had considerably more activated T cells than DR3ko OVA mice, for both activated CD4+ 
(DR3wt OVA 13.1±3.7 x103, DR3ko OVA 1.0±0.4 x103) (p=0.0003) and activated CD8+ 
T cell (DR3wt OVA 3.7±1.0 x103, DR3ko OVA 0.4±0.3 x103) (p=0.005) subsets (Figure 
4.9).  
 
Similarly to the 24hr timepoint, more lymphocytes were isolated from the BAL fluid of 
DR3wt OVA mice than DR3ko OVA 72hr post inhalation.  DR3wt OVA mice displayed 
increased numbers of CD3+ T cells, at 14.7±3.7 x103 compared to 1.0±0.5 x103 and 
3.3±0.4 x103 in DR3ko OVA  and DR3wt PBS mice, respectively (p=0.008) (Figure 
4.10). Equally, DR3wt OVA lavage fluid contained significantly more CD4+ T cells 
(12.2±2.9 x103) than DR3ko OVA (2.1±0.7 x103) and DR3wt PBS (2.3±0.3 x103) groups 
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(p=0.010) (Figure 4.10). Interestingly however, no significant differences were seen 
when studying CD8+ T cells or B cells. One-way ANOVA analyses indicated 
significant differences in NKT cell number between DR3wt OVA mice (15.6±6.7 x103) 
and other treatment groups (DR3ko OVA 1.3±0.6 x103, DR3wt PBS 2.1±0.3 x103, DR3ko 
PBS 2.7±2.2 x103) (p=0.018), as well as NK cells, whereby significance was noted 
between DR3wt OVA (15.0±5.8 x103) and DR3ko OVA (3.4±2.6 x103) mice (p=0.015) 
(Figure 4.10). Overall, DR3wt OVA treated mice presented with consistently higher 
numbers of lymphocyte cell subsets, particularly those of CD4+ origin.  
 
In summary, DR3ko mice display reduced numbers of multiple cell subsets in both the 
lung and BAL following the induction of acute allergic lung inflammation (Table 4.1).  
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Figure 4.9. Lymphocyte subsets from the BAL of DR3wt and DR3ko mice 24hrs post 
acute allergic lung inflammation. Mice were sacrificed 24hr post final inhalation 
challenge with either OVA or PBS. Alveolar cells were isolated via lavage and subsets 
determined using antibody cell markers. CD3+ T cells (***p<0.0001). CD4+ T cells 
(***p=0.0002), CD8+ T cells(***p<0.0001), Activated CD4+ T cells (***p=0.0003), 
Activated CD8+ T cells (**p=0.005), NKT cells (*p=0.034), NK cells (*p=0.024), B cells 
(*p=0.041)  Values represent mean ± SEM. Significance determined using 1 way ANOVA 
and Bonferroni post test; *p<0.05, **p<0.01, ***p<0.001. Each symbol represents data 
from a single mouse.  
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Figure 4.10. Lymphocyte subsets from the BAL of DR3wt and DR3ko mice 72hrs post 
acute allergic lung inflammation. Mice were sacrificed 72hr post final inhalation 
challenge with either OVA or PBS. Alveolar cells were isolated via lavage and subsets 
determined using antibody cell markers. CD3+ T cells (**p=0.008). CD4+ T cells 
(*p=0.010), CD8+ T cells n.s.d, NKT cells (*p=0.018), NK cells (*p=0.015), B cells 
n.s.d  Values represent mean ± SEM. Significance determined using 1 way ANOVA and 
Bonferroni post test; *p<0.05, **p<0.01. Each symbol represents data from a single 
mouse.  
 
 
Table 4.1 Summary of significant cell differences between DR3wt and DR3ko mice in the lung and BAL at 24hrs and 72hrs post inhalation 
                                                                                        Lung*                                                                      Bronchoalveolar Lavage^ 
                                                                                 Significance$                                                                            Significance$  
Cell subset 24hr∆ 72hrs¥ 24hrs∆ 72hrs¥ 
Myeloid DCs - - * * 
7/4- Monocytes * - * * 
CD3+ T cells - - *** * 
CD4+ T cells - - *** * 
CD8+ T cells - - ** - 
Act. CD4+ T cells - - *** N/A† 
Act. CD8+ T cells - - ** N/A† 
NKT cells ** - * * 
NK cells * - - * 
B cells - - * - 
* Corresponds to cells isolated from the lung 
^ Correspond to cells isolated from the alveolar passage  
∆ Corresponds to cells harvested 24hrs post inhalation 
¥ Corresponds to cells harvested 72hrs post inhalation 
† N/A corresponds to subsets not being tested 
$ Significance between DR3wt and DR3ko cell numbers measured by 1 way ANOVA. Values represent the degree of significance (* p<0.05, ** p<0.01, *** p<0.001) 
as measured by 1 way ANOVA between DR3wt and DR3ko mice in cell subsets from both the lung and BAL 24hrs and 72hrs post inhalation.  
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4.3.1.3 Analysis of DR3 expression in the lung   
4.3.1.3.1 DR3wt OVA CD4+ T cells expressed significantly more DR3 than DR3wt PBS 
challenged lymphocytes  
DR3 expression was determined on particular lymphocyte populations 24hrs post 
inhalation by dividing the test MFI by that of the isotype control, thus giving a relative 
DR3 fluorescence signal (RF). Results showed that CD4+ T cells from DR3wt OVA 
treated mice had an RF of 9.8±0.4, significantly more than the 8.2±0.4 exhibited by 
DR3wt PBS mice (p<0.001) (Figure 4.11) (Table 4.2). Moreover, this up-regulation of 
DR3 corresponded to increased expression on activated CD4+ T cells  from DR3wt OVA 
cells (RF of 12.1±0.5) (Figure 4.11) (Table 4.2). Overall, activated CD4+ T cells 
exhibited more DR3 than naive CD44- CD4+ T cells (p<0.01). Both naive and effector 
CD4+ T cell subsets of DR3wt genotype, expressed significantly higher signal than 
control DR3ko mice (CD4+ T cell p<0.0001) (activated CD4+ T cell p<0.0001) (Figure 
4.11) (Table 4.2).   
 
No significant differences were found between the RF signals of DR3wt OVA and PBS 
challenged animals when examining CD8+ T cells and activated CD8+ T cells, although 
again, both were significantly higher than DR3ko populations (CD8+ T cell p<0.0001) 
(activated CD8+ T cell p<0.0001) (Figure 4.11) (Table 4.2). DR3 expression was found 
to be similar between naive and activated CD8+ T cells, although both expressed less 
DR3 than CD4+ T cell subsets.  
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Figure 4.11. Ratio of DR3 MFI’s on T cell populations in the lung 24hrs post acute 
allergic lung inflammation. Mice were sacrificed 24hr post final inhalation challenge 
with either OVA or PBS. Cells were stained with DR3 antibody. Ratio DR3 was calculated 
by the MFI fold increase compared to control IgG antibody (n=5). Bars represent mean ± 
SEM. Results are significant using 2 way ANOVA (Interaction=***<0.0001, 
Genotype=***<0.0001, Cell Type= ***<0.0001).  
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4.3.1.3.2 DR3wt OVA lungs expressed more DR3 than DR3wt PBS lungs at 24 but not 
72hrs post inhalation 
DR3 expression was detected in naive DR3wt lungs (Section 3.3.1.4.1), therefore 
expression levels following the induction of inflammation were investigated. Results 
showed that at 24hrs post inhalation, lungs from DR3wt OVA treated mice expressed 
6.5±3.0% DR3, significantly more than DR3wt PBS treated lungs (1.2±0.1%) (p<0.05) 
and isotype control samples (0.03±0.01%) (p<0.05) (Figure 4.12) (Table 4.2). DR3 
expression was focused within the peribronchiolar areas of the lung, with occasional 
signal noted in the alveolar spaces. Importantly, DR3ko OVA (0.6±0.1%) and DR3ko 
PBS (0.3±0.1%) mice expressed significantly less signal than DR3wt mice (p=0.042) 
(Figure 4.12), indicating staining was specific.  
 
At 72hrs post inhalation, no significant differences were observed in DR3 expression 
between DR3wt OVA (4.3±2.3%) and DR3wt PBS lungs (1.9±1.0%) (p>0.05) (Figure 
4.13) (Table 4.2), although DR3wt mice did exhibit higher signal than control DR3ko 
mice (p=0.042) (Figure 4.13). Therefore, whilst inhalation treatment is significant at 
24hrs (p=0.032), affecting the expression levels of DR3 between DR3wt OVA and PBS 
treated mice, this trend did not continue to 72hrs post inhalation.   
 
 
 
 
 
 
 
Figure 4.12.  DR3 expression 24hrs post acute allergic lung inflammation. Mice were 
sacrificed 24hr post final inhalation challenge with either OVA or PBS. Lungs were 
stained with DR3 antibody. Shown are representative photos of DR3wt OVA, DR3ko OVA 
DR3wt PBS, DR3ko PBS, DR3wt isotype and DR3ko isotype (Scale bar=100μm). DR3 
expression in the lung was analysed using 5 fields of view of each lung and measuring the 
% of positive (brown) in each field of view. This was then averaged for each mouse (n=5). 
Analysis was performed using Leica Qwin V3 Software.. Bars represent mean ± SEM. 
Results are significant using 2 way ANOVA whereby *p<0.05 (Interaction=0.064, 
Genotype=*0.042, Inhalation Treatment= * 0.032). 
OV
A
Sa
lin
e
Iso
typ
e
0
2
4
6
8
10
WT
KO
Av
er
ag
e/
m
ou
se
 %
 D
AB
 p
os
iti
ve
ar
ea
s
OVA   PBS    Isotype  
DR3wt 
 
 
 
 
 
 
 
 
 
 
DR3ko 
Figure 4.13. DR3 expression 72hrs post acute allergic lung inflammation. Mice were 
sacrificed 72hr post final inhalation challenge with either OVA or PBS. Lungs were 
stained with DR3 antibody. Shown are representative photos of DR3wt OVA, DR3ko OVA 
DR3wt PBS, DR3ko PBS, DR3wt isotype and DR3ko isotype (Scale bar=100μm). DR3 
expression in the lung was analysed using 5 fields of view of each lung and measuring the 
% of positive (brown) in each field of view. This was then averaged for each mouse (n=5). 
Analysis was performed using Leica Qwin V3 Software.. Bars represent mean ± SEM. 
Results are significant using 2 way ANOVA whereby *p<0.05 (Interaction=0.220, 
Genotype=*0.042, Inhalation treatment=0.196). 
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Table 4.2 Summary of DR3 expression  
               DR3wt                                                                  DR3ko 
Cell Subset PBS* OVA^ PBS* OVA^ Significance$ 
% DR3 in  Lung (72hrs)€ 
% DR3 in Lung€ 
1.9 ± 1.0 
         1.1 ± 0.2 
4.4 ± 2.3 
6.5 ± 3.0 
0.5 ± 0.2 
          0.3 ± 0.1 
0.2±0.1 
           0.6 ± 0.1 
N.S.D 
*p<0.05 
DR3 MFI ratio on CD4+ T cells 8.2 ± 0.4 9.8 ± 0.4 2.0 ± 0.1 2.2 ± 0.1 **p<0.01 
DR3 MFI ratio on CD8+ T cells 3.6 ± 0.1 3.6 ± 0.1 1.9 ± 0.1 1.6 ± 0.2 N.S.D 
DR3 MFI ratio on Activated 
CD4+ T cells 
10.9 ± 0.8 12.1 ± 0.5 1.9 ± 0.04 1.9 ± 0.1 *p<0.05 
DR3 MFI ratio on Activated 
CD8+ T cells 
3.6 ± 0.2 4.4 ± 0.2 2.0 ± 0.3 2.1 ± 0.04 N.S.D 
€ % DR3 expression within the naive lungs of DR3wt and DR3ko mice via IHC 
 *PBS corresponds to mice challenged via inhalation with PBS 
^ OVA corresponds to mice challenged via inhalation with OVA 
$ Significance between DR3wt PBS and DR3wt OVA groups using 1 way ANOVA and Bonferroni post test. N.S.D= no significant difference, *p<0.05, **p<0.01.  
Median fluorescence intensity (MFI) ratio calculated by dividing the test median by the isotype following gating on the specified population ± SEM  following flow 
cytometry. All analysis shown from 24hr post inhalation unless otherwise stated.  
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4.3.1.4 Levels of chemoattractants in the BAL fluid of DR3wt and DR3ko mice 
4.3.1.4.1 Chemokine levels were analogous between DR3wt and DR3ko mice following 
acute allergic lung inflammation  
To assess whether recruitment was responsible for the differences in cell numbers, 
chemoattractant levels were tested in the BAL fluid following acute allergic lung 
inflammation. Multiple chemokines reported to be involved in the recruitment of both 
myeloid (CXCL1, CCL3, CCL4, CCL5) and lymphocyte populations (CXCL2, 
CXCL10, CXCL13) were analysed. No significant differences were found between any 
treatment groups for any of the chemokines tested either 24 or 72hrs after the final 
inhalation challenge (Figure 4.14) (Figure 4.15) (Table 4.3). CXCL1, CCL3, CCL4 and 
CCL5 were below the detection level of the ELISA assays used (Table 4.3).  
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Figure 4.14. Chemokine levels within the BAL of DR3wt and DR3ko mice 24hrs post 
acute allergic lung inflammation. Mice were sacrificed 24hr post final inhalation 
challenge with either OVA or PBS. BAL fluid was isolated and the supernatant used to 
determine chemokine levels using ELISA. CXCL2 n.s.d, CXCL10 n.s.d and CXCL13 
n.s.d. No significant differences seen. Significance determined using 1 way ANOVA 
and Bonferroni post test Bars represent mean ± SEM (n=5).  
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Figure 4.15. Chemokine levels within the BAL of DR3wt and DR3ko mice 72hrs post 
acute allergic lung inflammation. Mice were sacrificed 72hr post final inhalation 
challenge with either OVA or PBS. BAL fluid was isolated and the supernatant used to 
determine chemokine levels using ELISA. CXCL2 n.s.d, CXCL10 n.s.d and CXCL13 
n.s.d. No significant differences seen. Significance determined using 1 way ANOVA 
and Bonferroni post test Bars represent mean ± SEM (n=5).  
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Table 4.3 Chemoattractant levels in BAL fluid at 24 and 72hrs post inhalation 
                 DR3wt                                                             DR3ko  
 Chemokine 
(pg/ml) 
PBS* OVA^ PBS* OVA^ Significance$ 
24hrsε CXCL2 90±21 107±7 144±55 85±18 N.S.D 
 CXCL10 310±36 342±26 359±72 275±33 N.S.D 
 CXCL13 229±34 275±52 456±180 292±39 N.S.D 
72hrs¥ CXCL2 191±25 219±28 281±115 223±28 N.S.D 
 CXCL10 419±61 412±94 641±314 477±49 N.S.D 
 CXCL13 296±47 352±62 677±348 358±35 N.S.D 
* PBS corresponds to mice challenged via inhalation with PBS 
^ OVA corresponds to mice challenged via inhalation with OVA 
ε 24hrs corresponds to mice harvested 24hrs after the final inhalation challenge 
¥ 72hrs corresponds to mice harvested 72hrs after the final inhalation challenge 
$ $ Significance between DR3wt OVA and DR3ko OVA groups using 1 way ANOVA and 
Bonferroni post test. N.S.D = no significant difference.   
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4.3.2 Airway remodelling following acute allergic lung inflammation 
 
4.3.2.1 Analysis of airway remodelling and lung pathology  
4.3.2.1.1 Lung pathology was comparable between DR3wt and DR3ko OVA treated mice 
Lungs were analysed post inflammation for the development of pathology as judged 
against a scoring regime (Section 2.2.12.2). Results indicated that DR3 had no role in 
the progression of lung pathology at this early stage, as no significant differences were 
seen between DR3wt and DR3ko OVA mice at either 24 or 72hr post inhalation (Figure 
4.16) (Figure 4.17) (Table 4.4). At 72hrs post inhalation however, DR3wt OVA mice 
(3.8±0.4) were judged to have significantly worse lung pathology, evident by 
peribronchial and perivascular cuffing, compared to PBS treated groups (DR3wt 2.0±0.6, 
DR3ko 1.4±0.3) (p=0.002) (Figure 4.17) (Table 4.4).  
 
 
 
 
 
 
 
  
(A) 
Figure 4.16. Lung pathology in DR3wt and DR3ko mice 24hrs post acute allergic lung 
inflammation. Mice were sacrificed 24hr post final inhalation challenge with either OVA 
or PBS. Lungs were stained with Haematoxylin and Eosin. Shown are representative 
photos of DR3wt OVA, DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=250μm). 
Lungs were blind scored by 2 individuals for pathology and an average taken for each 
lung. (A). Values represent mean ± SEM. Results are not significant using 1 way ANOVA. 
Each symbol represents data from a single mouse.  
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Figure 4.17. Lung pathology in DR3wt and DR3ko mice 72hrs post acute allergic lung 
inflammation. Mice were sacrificed 72hr post final inhalation challenge with either OVA 
or PBS. Lungs were stained with Haematoxylin and Eosin. Shown are representative 
photos of DR3wt OVA, DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=100μm). 
Lungs were blind scored by 2 individuals for pathology and an average taken for each 
lung. (A). Results are significant using 1 way ANOVA (**p=0.002) and Bonferroni post 
test; *p<0.05, **p<0.01. Values represent mean ± SEM. Each symbol represents data from 
a single mouse.  
DR3wt                        DR3ko   
OVA 
 
 
 
 
 
 
 
 
PBS 
WT
 Sa
lin
e
WT
 O
VA
KO
 Sa
lin
e
KO
 O
VA
0
2
4
6 *
**
M
ea
n 
Pa
th
ol
og
y 
Sc
or
e
180 
 
4.3.2.1.2 Mucin associated goblet cell number following acute allergic lung 
inflammation 
Goblet cell hyperplasia is a marker of airway remodeling and a major feature of the 
asthmatic response. Analysis of goblet cells following acute allergic lung inflammation 
indicated no significant differences between any treatment groups at 24hrs post 
inhalation. However, both DR3wt and DR3ko OVA treated mice averaged higher at 
1.3±0.9% and 2.2±1.9% compared to DR3wt PBS (0.06±0.06%) and DR3ko PBS mice, 
where no mucin positive areas were identified (Figure 4.18) (Table 4.4). At 72hrs post 
inhalation, DR3wt OVA lungs were calculated as having 10.3±5.4% mucin positive 
areas, compared to just 0.8±0.4% in DR3ko OVA mice, 0.2±0.2% in DR3wt PBS animals 
and none in DR3ko PBS mice (Figure 4.19) (Table 4.4). This was deemed to be 
significant overall by 1 way ANOVA (p=0.043).  
 
 
 
 
 
 
 
 
 
Figure 4.18. Goblet cell hyperplasia in DR3wt and DR3ko mice 24hrs post acute allergic 
lung inflammation. Mice were sacrificed 24hr post final inhalation challenge with either 
OVA or PBS. Lungs were stained with Periodic Acid Schiff. Shown are representative 
photos of DR3wt OVA, DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=100μm). 
The area of PAS+ cells was taken as a % of the airway surround using Leica Qwin V3 
software, and an average calculated for each lung (A). Values represent mean ± SEM. 
Results are not significant using 1 way ANOVA. Each symbol represents data from a single 
mouse.  
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Figure 4.19. Goblet cell hyperplasia in DR3wt and DR3ko mice 72hrs post acute allergic 
lung inflammation. Mice were sacrificed 72hr post final inhalation challenge with either 
OVA or PBS. Lungs were stained with Periodic Acid Schiff. Shown are representative 
photos of DR3wt OVA, DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=100μm). 
The area of PAS+ cells was taken as a % of the airway surround using Leica Qwin V3 
software, and an average calculated for each lung. (A). Results are significant using 1 way 
ANOVA (*p=0.043) whereby *p<0.05. Values represent mean ± SEM. Each symbol 
represents data from a single mouse.  
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4.3.2.1.3 Lung fibrosis scores were comparable between DR3wt and DR3ko OVA treated 
mice 
Lung fibrosis was measured by comparing the levels of collagen as an indication of 
alterations to the lung architecture following acute allergen induced inflammation. 
These levels were then scaled against the Ashcroft Score of fibrosis (Ashcroft, Simpson 
et al. 1988). There was no significant difference in the degree of fibrosis at 24hrs post 
inhalation between OVA challenged mice (DR3wt 1.6±0.2, DR3ko 1.2±0.5) (Figure 4.20) 
(Table 4.4). Likewise, at the 72hr timepoint, DR3wt and DR3ko OVA treated mice 
displayed equivalent scores of fibrosis, although levels in both were significantly higher 
than scores in PBS treated mice (DR3wt OVA 2.6±0.2, DR3ko OVA 2.7±0.2, DR3wt PBS 
1.2±0.2, DR3ko PBS 0.7±0.3) (p<0.0001) (Figure 4.21) (Table 4.4) 
 
 
 
 
 
 
 
 
 
  
Figure 4.20. Fibrosis in DR3wt and DR3ko mice 24hrs post acute allergic lung 
inflammation. Mice were sacrificed 24hr post final inhalation challenge with either OVA 
or PBS. Lungs were stained with Van Gieson solution. Shown are representative photos of 
DR3wt OVA, DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=100μm). Lungs 
were blind scored by 2 individuals using Ashcroft score of fibrosis and an average taken 
for each lung. (A).Values represent mean ± SEM. Results are not significant using 1 way 
ANOVA. Each symbol represents data from a single mouse.  
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Figure 4.21. Fibrosis in DR3wt and DR3ko mice 72hrs post acute allergic lung 
inflammation. Mice were sacrificed 72hr post final inhalation challenge with either OVA 
or PBS. Lungs were stained with Van Gieson solution. Shown are representative photos of 
DR3wt OVA, DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=100μm). Lungs 
were blind scored by 2 individuals using Ashcroft score of fibrosis and an average taken 
for each lung (A). Results are significant using 1 way ANOVA (***p<0.0001) and 
Bonferroni post test; *p<0.05, **p<0.01, ***p<0.001. Values represent mean ± SEM. 
Each symbol represents data from a single mouse.  
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Table 4.4 Lung pathology and degree of staining following histological staining 24 and 
72hrs post inhalation  
                 DR3wt                                                             DR3ko  
 Stain PBS* OVA^ PBS* OVA^ Significance$ 
24hrsε H&E 
 
2.0±0. 
+ 
3.2±0.5 
+++ 
1.0±0.2 
+ 
2.8±0.6 
+++ 
N.S.D 
 PAS 
 
0.06±0.06 
+ 
1.3±0.9 
+++ 
0 
+ 
2.2±1.9 
+++ 
N.S.D 
 VG 
 
1.2±0.2 
++ 
1.6±0.2 
+++ 
0.3±0.3 
+ 
1.2±0.5 
++ 
N.S.D 
72hrs¥ H&E 
 
2.0±0.6 
+ 
3.8±0.4 
+++ 
1.4±0.3 
+ 
3.0±0.3 
+++ 
N.S.D 
 PAS 
 
0.2±0.2 
+ 
10.3±5.4 
+++ 
0 
+ 
0.8±0.4 
++ 
*p=0.043 
 VG 
 
1.2±0.2 
+ 
2.6±0.2 
+++ 
0.7±0.3 
+ 
2.7±0.2 
+++ 
N.S.D 
* PBS corresponds to mice challenged via inhalation with PBS 
^ OVA corresponds to mice challenged via inhalation with OVA 
ε 24hrs corresponds to mice harvested 24hrs after the final inhalation challenge 
¥ 72hrs corresponds to mice harvested 72hrs after the final inhalation challenge 
$ Significance between DR3wt OVA and DR3ko OVA groups using 1 way ANOVA and 
Bonferroni post test. N.S.D = no significant difference, *p<0.05.  
An arbitrary method of staining intensity was used with + meaning low and +++ meaning high 
H&E scores are representative of a scoring regime found in Chapter 2, PAS scores represent the 
% of PAS+ areas as a % of the lung, VG scores are representative of the Ashcroft score of 
fibrosis, found in Chapter 2.  
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4.3.3 The systemic response in acute allergic lung inflammation 
 
4.3.3.1 Splenic responses in acute allergic lung inflammation 
4.3.3.1.1 Splenocyte total cell number was significantly higher in DR3wt OVA mice 
compared to DR3ko OVA mice  
Total cell number within the spleen was analysed following acute allergic lung 
inflammation. At 24hrs post inhalation, DR3wt OVA treated mice contained 13.2±1.0 
x107 splenocytes, significantly greater than the 9.5±0.3 x107 in DR3ko PBS (p<0.05) 
and 9.1±0.9 x107 in DR3ko OVA animals (p=0.005) (Figure 4.22). 
 
 
 
 
 
 
  
Figure 4.22. Total leukocyte number from the spleens of DR3wt and DR3ko mice 
following acute allergic lung inflammation. Mice were sacrificed 24hrs post final 
inhalation challenge with either OVA or PBS. Splenocytes were extracted via mashing 
of the spleen and counted using a haemocytometer Results significant using 1 way 
ANOVA and Bonferroni post test (**p= 0.005) whereby *p<0.05, **p<0.01. Values 
represent mean ± SEM. Each symbol represents data from a single mouse.  
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4.3.3.1.2 Myeloid cell subsets in the spleen were significantly higher in DR3wt mice 
Multiple myeloid cell subset numbers were higher in DR3wt OVA spleens at 24hrs post 
inhalation, although in the case of macrophages and eosinophils, this increase was not 
significant (Figure 4.23). However, significant increases were seen in DR3wt OVA 7/4- 
monocytes and plasmacytoid DCs in comparison to all other treatment groups, and 
myeloid DCs in comparison to DR3ko mice. DR3wt OVA mice had 3.8±0.4 x106 7/4- 
monocytes, compared to 1.8±0.1 x106 in DR3ko OVA mice, 1.5±0.2 x106 in DR3ko PBS 
and 2.6±0.2 x106 in DR3wt PBS mice (p<0.0001) (Figure 4.23). Similarly, DR3wt OVA 
mice had 6.0±0.7 x105 plasmacytoid DCs, significantly higher than the 2.7±0.3 x105 in 
DR3ko OVA, 2.8±0.3 x105 in DR3ko PBS and 3.9±0.2 x105 in DR3wt PBS mice 
(p=0.0001) (Figure 4.23). DR3wt OVA myeloid DCs (7.2±1.0 x105) too were 
statistically higher in number compared to DR3ko OVA (3.8±0.6 x105) and DR3ko PBS 
(3.7±0.6 x105) groups (p=0.004), but not DR3wt PBS mice (5.2±0.2 x105) (Figure 4.23). 
Interestingly, 7/4+ monocytes appeared to be increased in DR3ko animals compared to 
DR3wt, with significance between DR3ko PBS (1.7±0.1 x106) and DR3wt PBS mice 
(1.0±0.1 x106) (p=0.032). The same trend was also seen when analysing neutrophils, 
although no significance was noted (Figure 4.23).  
 
 
 
 
 
 
Figure 4.23. Myeloid cell subsets from the spleens of DR3wt and DR3ko mice 24hrs 
post acute allergic lung inflammation. Mice were sacrificed 24hr post final inhalation 
challenge with either OVA or PBS. Splenocytes were isolated and subsets determined 
using antibody cell markers. Macrophages n.s.d, Neutrophils n.s.d, Eosinophils n.s.d, 
7/4+ Monocytes (*p=0.032), 7/4- Monocytes (***p<0.0001), Myeloid DCs 
(**p=0.004), Plasmacytoid DCs (***p=0.0001). Values represent mean ± SEM. 
Significance determined using 1 way ANOVA and Bonferroni post test; *p<0.05, 
**p<0.01, ***p<0.001. Each symbol represents data from a single mouse.  
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4.3.3.1.3 Lymphocyte cell subsets in the spleen were significantly higher in DR3wt mice  
At 24hrs post inhalation, all lymphocyte cell subsets examined were significantly higher 
in DR3wt OVA mice compared to all other treatment groups. This included CD3+ T cells 
(DR3wt OVA 14.1±1.7 x106, DR3wt PBS 8.6±0.9 x106, DR3ko OVA 6.0±0.7 x106, 
DR3ko PBS 7.7±0.8 x106) (p=0.0002), which were subdivided into CD4+ T cells (DR3wt 
OVA 8.6±1.0 x106, DR3wt PBS 5.0±0.5 x106, DR3ko OVA 3.7±0.4 x106, DR3ko PBS 
4.8±0.5 x106) (p=0.0002), activated CD4+ T cells (DR3wt OVA 2.7±0.5 x106, DR3wt 
PBS 1.2±0.2 x106, DR3ko OVA 1.0±0.2 x106, DR3ko PBS 1.3±0.2 x106) (p=0.001), 
CD8+ T cells (DR3wt OVA 4.3±0.9 x106, DR3wt PBS 2.1±0.4 x106, DR3ko OVA 1.3±0.2 
x106, DR3ko PBS 1.8±0.2 x106) (p=0.002), activated CD8+ T cells (DR3wt OVA 0.5±0.2 
x106, DR3wt PBS 0.2±0.04 x106, DR3ko OVA 0.2±0.02 x106, DR3ko PBS 0.2±0.03 
x106) (p=0.002) and NKT cells (DR3wt OVA 7.7±1.2 x105, DR3wt PBS 3.4±0.4 x105, 
DR3ko OVA 3.1±0.4 x105, DR3ko PBS 3.2±0.3 x105) (p=0.0001) (Figure 4.24). NK 
cells were also higher in DR3wt OVA mice (1.1±0.1 x106) compared to all other 
inhalation groups (DR3wt PBS 0.7±0.04 x106, DR3ko OVA 0.5±0.1 x106, DR3ko PBS 
0.6±0.1 x106) (p<0.0001), as were γδ T cells (DR3wt OVA 5.9±0.8 x105, DR3wt PBS 
3.6±0.4 x105, DR3ko OVA 2.5±0.2 x105, DR3ko PBS 2.5±0.2 x105) (p=0.0001) (Figure 
4.24).  
 
 
 
 
 
 
Figure 4.24. Lymphocyte subsets from the spleens of DR3wt and DR3ko mice 24hrs post 
acute allergic lung inflammation. Mice were sacrificed 24hr post final inhalation 
challenge with either OVA or PBS. Splenocytes were isolated and subsets determined 
using antibody cell markers. CD3+ T cells (***p=0.0002)  CD4+ T cells (***p=0.0002), 
CD8+ T cells (**p=0.002), Activated CD4+ T cells (**p=0.001), Activated CD8+ T cells 
(**p=0.002), NKT cells (***p=0.0001), NK cells (***p<0.0001), γδ T cells 
(***p=0.0001). Values represent mean ± SEM. Significance determined using 1 way 
ANOVA and Bonferroni post test; *p<0.05, **p<0.01, ***p<0.001. Each symbol 
represents data from a single mouse.  
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4.3.3.2 Analysis of DR3 expression in the spleen  
4.3.1.3.1 DR3wt OVA CD4+ T cells and NKT cells expressed significantly more DR3 
than DR3wt PBS challenged lymphocytes  
DR3 expression was examined on the surface of splenic T cells, many of which are 
known to express DR3 in the basal state (Chapter 3). Results showed that at 24hrs post 
inhalation, DR3wt OVA CD4+ T cells exhibited an RF signal of 5.2±0.2, significantly 
more than DR3wt PBS treated mice (4.1±0.5) (p<0.05) (Figure 4.25). However, this up-
regulation of DR3 on DR3wt OVA cells did not correspond to an increase in expression 
on activated CD4+ T cells. Likewise, no significant differences were found between 
DR3wt OVA and PBS mice in DR3 expression on CD8+ T cells or activated CD8+ T 
cells. DR3wt OVA NKT cells were found to exhibit significantly higher levels of DR3, 
with an RF of 5.7±0.3, compared to 4.4±0.2 on DR3wt PBS NKT cells (p<0.01) (Figure 
4.25). In all cell subsets examined, DR3wt mice showed significantly greater RF signals 
than DR3ko mice, indicating the specificity of the staining.  
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Figure 4.25. Ratio of DR3 MFI’s on T cell populations in the spleen 24hrs post acute 
allergic lung inflammation. Mice were sacrificed 24hr post final inhalation challenge 
with either OVA or PBS. Cells were stained with DR3 antibody. Ratio DR3 was calculated 
by the MFI fold increase compared to control IgG antibody. Bars represent mean ± SEM 
(n=5). Results are significant using 2 way ANOVA (Interaction=***<0.0001, 
Genotype=***<0.0001, Cell Type= ***<0.0001).  
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4.3.3.3 The B cell response in acute allergic lung inflammation 
4.3.3.3.1 B cell number and antibody production in acute allergic lung inflammation 
Allergic antibody levels were measured in the serum by ELISA to determine whether a 
normal systemic immune response had been mounted following acute allergic lung 
inflammation. At the 24hr timepoint, no significant differences were seen between any 
treatment group in the levels of Total IgE (DR3wt PBS 1701±944, DR3wt OVA 
299±100, DR3ko PBS 378±284, DR3ko OVA 1243±676) or OVA specific IgG (DR3wt 
PBS 0.3±0.1, DR3wt OVA 0.3±0.02, DR3ko PBS 0.4±0.02, DR3ko OVA 0.3±0.01), 
although both increased in comparison to naïve controls (Figure 4.26). This is despite 
higher numbers of B cells in the spleens of DR3wt OVA mice (3.3±0.5 x107) compared 
to DR3wt PBS (1.9±0.2 x107), DR3ko OVA (1.3±0.2 x107) and DR3ko PBS animals 
(1.7±0.2 x107) (p=0.0006) (Figure 4.26). 
 
 
  
  
(A) 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
(C) 
Figure 4.26. The B cell response of DR3wt and DR3ko mice 24hrs post acute allergic 
lung inflammation. Mice were sacrificed 24hr post final inhalation challenge with either 
OVA or PBS. (A) B cells were identified using specific antibody markers (***p=0.0006). 
Serum was isolated from blood obtained from cardiac puncture. Serum was tested for 
concentrations of  (B) Total IgE (n.s.d) and (C) OVA specific IgG (n.s.d) by ELISA. Each 
point represents the mean of doublets from different mice. Values represent mean ± 
SEM. Significance determined using 1 way ANOVA and Bonferroni post test; *p<0.05, 
**p<0.01, ***p<0.001. Each symbol represents data from a single mouse.  
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4.4 Discussion 
4.4.1 DR3 influence on airway inflammation 
Following the induction of acute allergic lung inflammation, lung preparations from 
DR3ko mice presented with reduced numbers of 7/4- monocytes and NKT cells at 24hrs 
post inhalation, and NK cells 72hrs post inhalation. This is in contrast to published data 
from Meylan et al, who in addition to NKT cells, also found reduced percentages of 
CD3+ T cells, CD4+ T cells and eosinophils within the lung (Meylan, Davidson et al. 
2008). There are several possible reasons for this discrepancy, one being the use of 
different sensitisation and aerosolisation protocols, which have previously been 
suggested as a reason for conflicting results within the literature of murine asthma 
models (Kumar and Foster 2002). Meylan et al sensitised mice with an OVA/Alum mix 
on days 0 and 7, followed by an intra-tracheal challenge on day 14 and intranasal 
challenge on day 15 (Meylan, Davidson et al. 2008). In this thesis, mice were sensitised 
with an OVA/Alum mix on days 0 and 5, followed by 2 OVA aerosolisation challenges 
on day 15. Furthermore, whilst Meylan et al harvested mice at 48 and 72hrs after the 
final challenge, the protocol employed for this Chapter used 24 and 72hr timepoints. 
The difference in the timing of assessment may also have contributed to divergent 
results. 
 
Previous papers have reported DR3 to affect NKT cell function, with Fang et al 
suggesting DR3 co-stimulates IL-13 production from glycosphingolipid activated NKT 
cells (Fang, Adkins et al. 2008). NKT cells are considered instrumental to the allergic 
response, as NKT deficient mice fail to develop airway hyper-reactivity, airway 
eosinophilia and OVA specific IgE antibodies in comparison to WT littermates (Akbari, 
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Stock et al. 2003; Lisbonne, Diem et al. 2003). Moreover, Fang et al adoptively 
transferred splenic Dominant Negative (DN) DR3 transgenic NKT cells into 
OVA/Aluminum potassium sulphate primed NKT cell deficient mice prior to aerosol 
challenge. Results showed WT NKT cells could instigate eosinophil exudation and Th2 
cytokine production, while DN DR3 NKT cells could not, thus demonstrating the 
importance of DR3 signals from NKT cells (Fang, Adkins et al. 2008). Korsgren et al 
however, suggest that it is NK cells alone and not NKT cells which drive allergic lung 
inflammation. CD1d mutant mice, deficient in NKT cells but normal NK cells, still 
developed lung tissue eosinophilia and allergen specific IgE similar to WT mice 
(Korsgren, Persson et al. 1999), implying further research is required on the role of 
these innate cells in allergic lung inflammation. 
 
The function of DR3 on NK cells has not been broadly studied. Fang et al found DR3 
expression on a sub-population of NK cells within the naive spleen (Fang, Adkins et al. 
2008), although this observation could not be reproduced by us (Chapter 3) or by others 
(Twohig, Marsden et al. 2012). Using a model of MCMV in C57BL/6 mice, the kinetics 
of NK cell expansion were observed to be similar between DR3wt and DR3ko mice 
(Twohig, Marsden et al. 2012). However, using DBA-1 mice, which cannot mount 
efficient NK mediated resistance to MCMV, DR3ko mice displayed critical weight loss 
and increased viral titres in comparison to DR3wt mice, suggesting DR3 is crucial for 
survival in the absence of protective DR3 independent NK cell responses (Twohig, 
Marsden et al. 2012). Human peripheral blood derived NK cells have been shown to 
release IFNγ via TL1A synergisation with the IL-12/IL-18 pathway (Papadakis, Prehn 
et al. 2004). Heidemann et al went on to show that TL1A augments IL-12/IL-18 
cytotoxicity against NK cell resistant tumor cell lines (Heidemann, Chavez et al. 2010). 
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These differences emphasise the variation that can arise when performing experiments 
in vitro compared to in vivo, as well as comparing the responses of human cells to those 
in a mouse model. Therefore, although numbers of NK cells increased in DR3wt mice 
following acute allergic lung inflammation at 72hrs post inhalation, the consequences of 
this are unclear.  
 
Similar to published data, total cell numbers were higher in the BALF of DR3wt OVA 
challenged compared to DR3ko mice (Fang, Adkins et al. 2008; Meylan, Davidson et al. 
2008). However, unlike Fang et al, who reported reduced eosinophil numbers using 
both DN DR3 transgenic mice and TL1A antibody blockade, no significant differences 
were noted in eosinophils using our model. This may again be due to the different 
protocols employed to induce allergic lung inflammation or alternative means of 
identifying eosinophils. Whilst flow cytometry was utilised to identify eosinophils in 
this thesis, defined as F4/80+ SSChi CD11b+, Fang et al used differential cell counts and 
therefore were reliant on cell morphology and microscopy (Fang, Adkins et al. 2008). 
Despite the lack of statistical difference in BALF eosinophil number, significant 
differences were seen in the numbers of 7/4- monocytes, myeloid DCs, CD3+ T cells 
and CD4+ T cells at 24 and 72hrs post inhalation along with CD8+ T cells 24hrs after 
the final challenge.  
 
Acting as a transient reservoir of myeloid precursors, monocytes harbor the potential to 
differentiate into macrophages and dendritic cells (Gordon and Taylor 2005), including 
lung macrophages and pulmonary DCs under inflammatory conditions (Geissmann, 
Jung et al. 2003; Landsman, Varol et al. 2007; Varol, Landsman et al. 2007; Yona and 
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Jung 2010). When transferred into mice lacking the essential co-stimulatory molecules 
CD80 and CD86, monocytes were observed to restore the CD4+ T cell response after 
inflammatory challenge (Landsman, Varol et al. 2007), suggesting monocyte derived 
DCs share the same priming properties as classical DCs. In asthmatic patients, allergen 
challenge led to the accumulation of myeloid DCs in the airways, concomitant with a 
reduction in circulating CD11c+ cells, suggesting cells were recruited from the blood 
stream (Jahnsen, Moloney et al. 2001). Given the plasticity and mobility of monocytes, 
the increase in 7/4- monocytes may account for the increase observed in myeloid DCs.  
 
DCs act as a link between innate and adaptive immunity, sensitising T cells to inhaled 
allergen, as well as contributing to the inflammatory response via the up-regulation of 
co-stimulatory molecules and the re-activation of allergen primed T cells following 
challenge (Vermaelen and Pauwels 2003). DCs accumulate in the airway submucosa, 
forming multiple contacts with CD4+ T cells (Constant, Brogdon et al. 2002; Huh, 
Strickland et al. 2003). Their depletion from the airways abolished the characteristic 
features of asthma, including eosinophilic inflammation, goblet cell hyperplasia, 
bronchial hyper-reactivity and Th2 cytokine release from CD4+ T cells, all of which 
were restored upon adoptive transfer of DCs (van Rijt, Jung et al. 2005; Van Rijt and 
Lambrecht 2005). Using SCID mice engrafted with T cells from house dust mite 
allergic patients, it was shown that allergen pulsed monocyte derived DCs were 
sufficient to exacerbate inflammation when delivered to sensitised lungs, inducing Th2 
effector function following migration to the mediastinal lymph nodes (Hammad, 
Lambrecht et al. 2002). Differentiated DCs have also recently been reported to 
proliferate within the lung after aeroallergen treatment, particularly within the epithelial 
and sub-epithelial layers of the airway mucosa (Veres, Voedisch et al. 2013). 
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Both human peripheral blood derived DCs and monocytes have been cited to release 
TL1A in response to FCγR stimulation as well as immune complexes (Cassatella, da 
Silva et al. 2007; Prehn, Thomas et al. 2007). Moreover, murine DCs have also been 
shown to produce TL1A (Bamias, Mishina et al. 2006) in response to the TLR 
stimulants LPS and Soluble Tachyzoite Antigen (STag), as well as cross linked IgG 
(Meylan, Davidson et al. 2008). The increased numbers of myeloid DCs within the 
DR3wt allergic alveolar passage may therefore re-activate allergen primed T cells 
explaining the increased numbers of CD4+ and activated CD4+ T cells within the BALF.  
 
DR3 was originally thought to be restricted to T cells (Chinnaiyan, Orourke et al. 1996; 
Kitson, Raven et al. 1996), thus several studies have concentrated on this aspect of DR3 
function. Numerous reports have described reduced CD4+ T cell infiltration in DR3ko 
mice during an immune response, in both systemic situations, whereby fewer CD4+ T 
cells were noted in the spleen in a Salmonella enterica bacterial model (Buchan, 
Taraban et al. 2012), and localised models such as EAE, where fewer CD4+ T cells were 
recorded in the spinal cord (Meylan, Davidson et al. 2008; Pappu, Borodovsky et al. 
2008), implying DR3 is essential for CD4+ T cell effector responses. DR3ko mice also 
exhibited reduced CD4+ T cells in the lung and BALF following acute allergic lung 
inflammation (Meylan, Davidson et al. 2008). Their depletion was found to abolish 
eosinophilic inflammation and airway hyper-reactivity (Gavett, Chen et al. 1994), 
emphasising the importance of CD4+ T cells for disease development.  
 
DR3 expression was found to be higher on activated lung CD4+ T cells than naïve CD4+ 
T cells, although levels of both from DR3wt OVA mice significantly increased in 
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comparison to DR3wt PBS mice. This up-regulation of DR3 may render OVA 
challenged CD4+ T cells more responsive to TL1A. However, the use of the polyclonal 
antibody in this study does not distinguish between the different murine splice variants, 
as discussed in Chapter 3. Published data does suggest that the activation status of T 
cells determines the DR3 isoform expressed. Bamias et al measured mRNA levels of 
full length DR3 from the terminal ileum of inflamed SAMP1/YitFC and TNF∆ARE mice 
(Bamias, Mishina et al. 2006), concluding that activated cells up-regulated the full 
length DR3 isoform which correlate with the severity of inflammation. DR3 expression 
has also been shown to tally with disease phases in a model of experimental 
autoimmune uveitis (EAU) (Qin 2011). Inflammation was detected at day 7, peaked at 
day 14 and thereafter rapidly resolved, correlating with DR3 mRNA and protein 
expression on CD4+ T cells from the draining lymph node. CD4+ T cells from the peak 
of disease also produced more IL-17 when co-cultured with TL1A compared to cells 
isolated from the naïve or recovery phase (Qin 2011), emphasising the Receptor’s 
capacity to potentiate T cell responses. Therefore, the increase in DR3 expression 
observed on OVA challenged CD4+ T cells could represent alterations in splice variant 
expression triggered by activation 
 
DR3 has previously been linked to cell activation via the NF-κB pathway (Migone, 
Zhang et al. 2002) and has more recently been shown to influence the cellular 
proliferation of CD4+ T cells both in vitro, using suboptimal doses of anti-CD3 (Pappu, 
Borodovsky et al. 2008; Jones, Stumhofer et al. 2011), and in vivo (Buchan, Taraban et 
al. 2012), whereby BrdU incorporation was reduced in DR3ko CD4+ T cells post 
Salmonella enterica Typhimurium infection. It has also been suggested that DR3 exerts 
a far greater proliferative effect over activated CD44+ CD4+ T cells compared to naïve 
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CD44- cells (Bamias, Mishina et al. 2006). Furthermore, DR3ko OT-II OVA specific T 
cells transferred into naïve congenic host mice failed to proliferate when challenged 
with OVA, corresponding with reduced numbers of inflammatory cells in the BAL 
(Meylan, Davidson et al. 2008). These experiments confirm that DR3 is necessary for 
the proliferation of locally re-stimulated T cells, and may be the mechanism by which 
CD4+ T cell numbers increased in DR3wt OVA mice.  
 
Chemoattractants have been shown to play a significant role in murine models of 
allergic lung inflammation, with some suggesting they orchestrate the immune response 
(Gonzalo, Lloyd et al. 1998; D'Ambrosio, Mariani et al. 2001) and maintain disease 
(Murdoch and Finn 2000; Lloyd 2002). Therefore, their levels were assessed as a means 
by which DR3 could further contribute to the increase in leukocyte numbers observed in 
DR3wt OVA mice, especially as data from a peritonitis system in the laboratory had 
indicated that DR3/TL1A signaling was upstream of chemokine production (Perks, 
2013 PhD). Although no significant differences were observed, this may be due to the 
timing of chemokine assessment, chemokine promiscuity, or the restriction of the panel 
tested. DCs for example, are a prominent source of the Th2 attracting chemokines 
CCL17 and CCL22 during allergic lung inflammation, neither of which were 
investigated within this study (Beaty, Rose et al. 2007; Medoff, Seung et al. 2009). 
Adding to this, CCL11 neutralisation led to reduced eosinophil numbers, whilst the 
blocking of CCL2 caused a decrease in monocytes as well as Th2 cytokines (Gonzalo, 
Lloyd et al. 1998; Rose, Lannigan et al. 2010). Without measuring chemokine levels at 
multiple timepoints through the course of the model, along with a broader panel of 
chemoattractants, the potential contribution of DR3 via leukocyte recruitment cannot be 
discounted.  
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DR3 has also been reported to interact with E-selectin, an adhesion receptor found on 
endothelial cells. E-selectin is typically expressed at sites of inflammation or injury, 
allowing leukocyte homing via the activated vasculature (Kansas 1996). Mice deficient 
in E-selectin, or their receptors, have displayed defects in leukocyte migration (Frenette, 
Mayadas et al. 1996). Furthermore, in vitro data showed DR3 silencing to decrease 
colon cancer cells adhesion to E-selectin, impairing trans-endothelial migration (Gout, 
Morin et al. 2006; Porquet, Poirier et al. 2011). Therefore, it is a possible that the 
differences observed in this Chapter were due to an inability of DR3ko leukocytes to 
adhere to the endothelium via E-selectin, resulting in an impairment in extravasation. 
However, whilst both Gout et al and Porquet et al have reported E-selectin/DR3 
interaction, others have failed to replicate this result. Dagia et al investigated G-CSF 
mobilised peripheral blood leukocyte adhesion to TNFα activated vascular endothelium 
using the same E-selectin pulldown system to identify ligands. Whilst DR3 was not 
identified as a binding partner in this study, (Dagia, Gadhoum et al. 2006), Gout et al 
failed to identify known E-selectin ligands such as CD44 in their studies. Furthermore, 
Winkler et al attempted to characterise E-selectin ligands on haematopoietic stem and 
progenitor cells using lysates from Selplg-/- CD44-/- mice. However, by quantitative RT-
PCR no DR3 was detected (Winkler, Barbier et al. 2012), suggesting further research is 
required regarding DR3’s proposed capacity to bind E-selectin. 
 
More unexpected was the increase seen in CD8+ T cells in the alveolar lavage of DR3wt 
OVA mice. The exact function of CD8+ T cells in murine allergic lung inflammation is 
unknown, with some suggesting they regulate the immune response via the inhibition of 
airway hyper-reactivity and limiting IgE production (Stock, Kallinich et al. 2004), 
whilst others argue they may contribute to the severity of disease via the release of IFNγ 
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(Cembrzynska-Nowak, Szklarz et al. 1993), and IL-13 in concert with CD4+ T cells 
(Koya, Miyahara et al. 2007), both of which DR3 signalling has previously been shown 
to induce (Bamias, Martin et al. 2003; Papadakis, Prehn et al. 2004; Prehn, Mehdizadeh 
et al. 2004; Bamias, Mishina et al. 2006; Meylan, Song et al. 2011; Taraban, Slebioda et 
al. 2011).  DR3 has also been shown to influence CD8+ T cell proliferation in vivo. 
Following MCMV infection, DR3wt mice had more splenic CD8+ T cells than DR3ko 
mice, correlating with an increase in Ki67 expression on DR3wt CD8+ T cells (Twohig, 
Marsden et al. 2012). Similarly, adoptive transfer of OT-I T cells treated with OVA in 
combination with TL1A increased CD8+ T cell expansion 81 fold, in comparison to 12 
fold with OVA alone (Slebioda, Rowley et al. 2011), suggesting that like CD4+ T cells, 
CD8+ T cell proliferation is DR3 dependent. However, the mechanisms behind this are 
thought to differ between the 2 cell types, as whilst CD4+ T cell expansion appears to be 
IL-2 dependent (Meylan, Davidson et al. 2008), CD8+ T cells cell expansion does not 
(Slebioda, Rowley et al. 2011). The exact function of DR3 on CD8+ T cells in allergic 
lung inflammation would require further study. 
 
DR3 it appears is vital for the accumulation and possibly expansion of multiple cell 
types during acute allergic lung inflammation. The up-regulation of DR3 on T cells, 
particularly memory T cells, may coincide with the release of TL1A from monocyte 
derived myeloid DCs, which themselves expand in response to allergic challenge. This 
could lead to DR3 dependent T cell proliferation within the lung and the release of 
multiple cytokines, influencing the development of multiple allergic lung inflammation 
features, such as airway remodelling. 
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4.4.2 DR3 and airway remodelling in acute allergic lung inflammation 
No significant differences were observed between DR3wt and DR3ko OVA treated mice 
in lung pathology, mucin production or fibrosis 24hrs post inhalation, despite the 
significant cell increases seen in the BALF. However, 72hrs after the final challenge, 
DR3ko OVA lungs demonstrated decreased mucin levels, similar to data already 
published on the role of DR3 in acute allergic lung inflammation (Fang, Adkins et al. 
2008; Meylan, Davidson et al. 2008). Decreased CD4+ and NKT cell derived IL-13 was 
proposed to be responsible for this lack of goblet cell hyperplasia (Fang, Adkins et al. 
2008; Meylan, Davidson et al. 2008), much like that seen in the intestine (Meylan, Song 
et al. 2011; Taraban, Slebioda et al. 2011). However, results were variable, as two out of 
the five experimental DR3wt OVA mice failed to produce any goblet cell derived mucus 
at all. 
 
Additionally, no significant differences were found between DR3wt and DR3ko mice 
lung pathology, contrasting with data from Fang et al and Meylan et al, who described 
reduced histopathology scores, including peribronchial inflammation in DR3ko mice 
(Meylan, Davidson et al. 2008), whilst DN lungs exhibited reduced numbers of 
infiltrating cells around blood vessels and bronchioli (Fang, Adkins et al. 2008). Lung 
pathology differences may in part be due to the subjective nature of histo-pathological 
scoring methods. Both groups combined the assessment of mucus production and lung 
infiltration, whereas they were scored individually in this Chapter, thereby 
distinguishing between these 2 readouts. 
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No data has been published on the role of DR3 in lung fibrosis, with the results of this 
Chapter suggesting the Receptor is not required for its development following acute 
lung inflammation. Though fibrotic scores were generally quite low, DR3ko mice 
displayed comparable collagen levels to DR3wt mice. Airway fibrosis is charactersied by 
increased collagen deposition in the reticular basement membrane layer, a process 
influenced by matrix metalloproteinase (MMP)-9 amongst others (Hoshino, Nakamura 
et al. 1998; Atkinson and Senior 2003). DR3 has previously been shown to influence 
MMP-9 levels, as stimulation of the human macrophage cell line THP-1, with an anti-
DR3 antibody and IFNγ (Kim, Lee et al. 2001) or recombinant human TL1A (Kang, 
Kim et al. 2005), induced MMP-9 expression in a dose-dependent manner. Moreover, 
down-regulation of DR3 on pancreatic cancer cells using a natural flavonoid, fisetin, led 
to decreased levels of activated MMP-9 (Murtaza, Adhami et al. 2009). These reports 
imply that DR3 is able to control MMP-9 activation, though no work has been reported 
to date on MMP-9 in murine models of disease. The absence of differences between 
DR3wt and DR3ko collagen levels would not support this hypothesis, but more extensive 
research into the relationship between DR3 expression and MMPs is required before 
any firm conclusions can be drawn.  
 
Alternatively, the lack of differences may be due to the model employed to examine 
fibrosis. Models of acute allergic lung inflammation do not generally exhibit the 
characteristics of airway remodelling, particularly fibrosis, which generally occurs as a 
result of chronic responses as opposed to short-term exposures.  Acute models are 
believed to induce an inflammatory response as opposed to structural alterations 
(Jarman and Lamb 2005). Overall, it seems that DR3 has little influence on these 
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processes within the acute phase of allergic lung inflammation, potentially due to the 
short-term nature of this acute model of disease.  
 
4.4.3 DR3 expression in the lung  
Increased DR3 expression was observed throughout the lung in DR3wt OVA treated 
mice in comparison to DR3wt PBS challenged animals, with the difference being 
significant at 24hrs post inhalation. This may be linked to the increased numbers of 
leukocytes seen within the alveolar passage at the same timepoint, many of which are 
known to express DR3. However, DR3 expression was also detected in the airway 
epithelium. Multiple human studies have reported the up-regulation of DR3 in tissues 
undergoing inflammatory situations, most recently Bamias et al in psoriatic skin lesions 
(Bamias, Evangelou et al. 2011), as well as Al-Lamki et al who published DR3 up-
regulation on renal tubular epithelial cells during acute transplant rejection (Al-Lamki, 
Wang et al. 2003).  This is the first report of DR3 expression in the murine lung, and 
more importantly, its increased expression in response to inflammation.  
.  
4.4.4 The effect of DR3 on the systemic response following acute allergic lung 
inflammation 
DR3 has been described as dispensable for systemic priming against antigen in acute 
allergic inflammation (Meylan, Davidson et al. 2008). DR3ko splenocytes produced 
comparable levels of IL-5 and IL-13 to DR3wt mice following OVA and Alum 
challenge (Meylan, Davidson et al. 2008), whilst Kayamuro et al have reported an 
increase in the levels of IL-4 and IL-5 from OVA/TL1A challenged splenocytes 
compared to OVA alone following intranasal immunisation (Kayamuro, Yoshioka et al. 
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while analysis in this Chapter revealed DR3wt OVA challenged mice had significantly 
higher splenocyte numbers than DR3ko mice at 24hrs post inhalation. Spleens of DR3ko 
OVA mice displayed reduced accumulation of all T cell subsets examined, as well as 
7/4- monocytes, myeloid DCs and plasmacytoid DCs. This is the first report of 
differences in splenic cell populations from DR3ko mice challenged with non-infectious 
antigen.  
 
Systemic function was assessed via Total IgE and OVA specific IgG measurement. 
Despite an increase in splenic DR3wt B cell number at 24hrs post inhalation, no 
significant differences were detected in antibody levels, similar to previous reports 
(Meylan, Davidson et al. 2008). However, Fang et al reported reduced OVA specific 
IgE levels in the serum of DN DR3 OVA challenged animals (Fang, Adkins et al. 
2008), suggesting DR3 is required for the humoral response. In support of this, elevated 
levels of TL1A have also been associated with rheumatoid arthritis specific auto-
antibody production in RA patients, including rheumatoid factor (RF) IgG and RF-IgM. 
Moreover, peripheral blood mononuclear cells from RA patients stimulated with TL1A, 
also displayed increased antibody production (Sun, Zhao et al. 2013). Similarly, TL1A 
was found to augment OVA specific IgG and IgA responses in the serum and mucosal 
surfaces of mice when administered intranasally with OVA (Kayamuro, Yoshioka et al. 
2009). Collectively, the results of this Chapter imply that DR3 is required for more than 
the accumulation of effector T cells at the site of inflammation, describing a distinct 
phenotype in the spleen, the biological impact of which, remain unknown. This will be 
further investigated in Chapter 6. 
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4.5 Summary 
The data in this Chapter corroborates published literature stating that loss of DR3 
function ameliorates acute allergic lung inflammation, shown by reduced cellular 
infiltration into the BALF and goblet cell hyperplasia, thus suggesting DR3 as a 
potential therapeutic target. A novel phenotype was also observed in the spleens of 
DR3wt OVA mice, warranting further investigation into systemic and more specifically 
splenic responses in DR3wt mice (Chapter 6).  
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Chapter 5: 
The role of DR3 in a chronic murine 
model of allergic lung inflammation  
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5.1 Introduction 
Asthma is a chronic disease of the airways characterised by lung inflammation, 
bronchial hyper-responsiveness, airway obstruction and airway remodelling (Hessel, 
Van Oosterhout et al. 1995; Kay 1996; Wills-Karp 1999). The chronic nature of the 
disease is mediated by the infiltration of multiple inflammatory cell types into the 
airway submucosa, including eosinophils, mast cells and activated Th2 lymphocytes 
(Hamid and Tulic 2009), which in turn lead to structural changes in the airway wall. 
Airway remodelling is a term that encompasses a range of changes, such as thickening 
of the airway walls, abnormal extracellular matrix protein deposition and mucus gland 
hyperplasia (Hogaboam, Blease et al. 2000; Tattersfield, Knox et al. 2002; Lloyd and 
Robinson 2007). This complex and dynamic process is thought to contribute to the 
dysregulation of airway function, therefore prolonging the asthmatic response and 
typifying human asthma.  
 
Originally thought to be exclusively Th2 mediated, the immune regulation and response 
to innocuous allergen is now considered to be highly heterogeneous (Moore, Meyers et 
al. 2010). This in part, is due to the increasing use of in vivo models of this complex 
disease which reflect the varied nature of asthma. Although substantial differences exist 
between human asthma and murine models, the latter can still provide clues to the 
mechanisms behind this condition. Mice can be easily manipulated using the several 
immunological tools available. As well as this, mouse models have been well-
characterised and used throughout the literature (Kips, Anderson et al. 2003).  Despite 
this frequency of use, limitations also exist. Mice do not spontaneously develop asthma; 
it is experimentally induced using allergen and more often than not, adjuvant. In order 
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to mimic the chronic nature of asthma, the mice also undergo multiple airway 
challenges, as occurs with asthmatic patients that are chronically exposed to allergen. 
No model however is able to replicate the entire asthma phenotype, so extrapolation of 
results to human asthma should be made with caution.  
 
DR3 has been known to play a prominent role in several chronic inflammatory diseases, 
including Crohns disease (Bamias, Martin et al. 2003; Takedatsu, Michelsen et al. 2008; 
Kamada, Hisamatsu et al. 2010) and Rheumatoid Arthritis (Cassatella, da Silva et al. 
2007; Bamias, Siakavellas et al. 2008; Zhang, Wang et al. 2009). The use of murine 
models have established DR3 as a key player in the proliferation (Pappu, Borodovsky et 
al. 2008), differentiation (Bull, Williams et al. 2008) and maintenance (Jones, 
Stumhofer et al. 2011) of leukocyte populations during these chronic diseases. DR3 has 
been cited as a critical trigger of murine acute allergic lung inflammation, promoting 
CD4+ cell effector function, co-stimulating IL-13 and IL-5 release and enhancing 
general lung pathology (Fang, Adkins et al. 2008; Meylan, Davidson et al. 2008). 
However, DR3’s role in chronic lung inflammation is undefined and worth exploring 
considering immune responses to chronic virus infections are not impaired in DR3ko 
mice (Twohig, Marsden et al. 2012).  
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5.2 Aims 
The aim of this Chapter was to investigate the role of DR3 in chronic allergic lung 
inflammation. DR3wt and DR3ko mice underwent recurrent inhalation challenges with 
OVA or PBS over an 8 week period and were harvested at 24 and 72 hours (hrs) post 
final inhalation challenge, which occurred on day 57 (Section 2.2.7.4). Myeloid and 
lymphocyte cell influx was measured in the lung and alveolar passages using flow 
cytometry, serum antibody measurements (Total IgE and OVA specific IgG) 
determined the allergic antibody response and histological examination of the lung was 
used to assess airway remodelling. The accumulation of leukocytes in the spleen was 
also examined to determine whether inflammatory responses were localised or systemic.  
Despite being a hallmark of the asthma phenotype, airway hyper-responsiveness could 
not be measured in DR3ko mice, as discussed in Chapter 3.   
 
5.2.1 Objectives 
i) Determine the local inflammatory response following chronic allergic lung 
inflammation  
 ii) Analyse and quantify airway remodelling  
iii) Determine the systemic response following chronic allergic lung 
inflammation 
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5.3 Results 
5.3.1 Cellular accumulation following chronic allergic lung inflammation  
 
5.3.1.1 Analysis of cellular accumulation into the lung  
5.3.1.1.1 DR3 did not regulate leukocyte accumulation into the lung 
Following chronic allergic lung inflammation, one lung lobe was harvested specifically 
to assess leukocyte accumulation. There were no significant differences in the total lung 
cell numbers of DR3wt and DR3ko OVA treated lungs at either the 24hr (DR3wt 2.2±0.1 
x106, DR3ko 2.8±0.1 x106) (p=0.094) or 72hr timepoint (DR3wt 2.0±0.3 x106, DR3ko 
3.1±0.3 x106) (p=0.097), suggesting that DR3 does not control the accumulation of 
leukocytes into the lung following multiple allergen challenges. However, the total lung 
cell number of mice which underwent OVA inhalation was higher than those treated 
with PBS of the same genotype. This was significant at 24hrs post inhalation between 
DR3ko PBS and DR3ko OVA treated mice (1.9±0.2 x106, 2.8±0.1 x106) (p=0.022). 
Significance was also noted between DR3wt PBS and DR3ko OVA mice at 72hrs 
(1.8±0.2 x106, 3.1±0.4 x106) (p=0.022) (Figure 5.1).  
 
 
 
 
 
Figure 5.1. Total leukocyte cell number from the lungs of DR3wt and DR3ko mice 
following chronic allergic lung inflammation. Mice were sacrificed (A) 24hr and (B) 
72hr post final inhalation challenge with either OVA or PBS. Cells were isolated via a 
lung digest and counted using a haemocytometer. Total cell number from the lung 
showed significant differences at 24hr (*p=0.022) and 72hr (*p=0.022). Significance 
determined using 1 way ANOVA and Bonferroni post test; *p<0.05. Values represent 
mean ± SEM. Each symbol represents data from a single mouse.  
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5.3.1.1.2 There were significantly more myeloid dendritic cells in DR3wt OVA treated 
lungs compared to DR3ko OVA treated lungs at 24 but not 72hrs post inhalation 
At 24hrs post inhalation, significant differences were seen between DR3wt OVA and 
DR3ko OVA mice in myeloid DC number (DR3wt 1.4±0.1 x103, DR3ko 0.5±0.1 x103) 
(p<0.0001) (Table 5.1), but no other myeloid cell subset. However, mice that had 
undergone OVA inhalation treatment as opposed to PBS, appeared to trend towards 
increased numbers, with this increase being significant between DR3wt 7/4- monocytes 
and PBS subsets (p=0.0006).  
 
At 72hrs post inhalation, no differences were seen in myeloid DCs between DR3wt and 
DR3ko OVA treatment groups, as DR3wt PBS mice instead showed the highest numbers, 
this increase being significant over DR3ko PBS mice (p=0.023). Interestingly, DR3ko 
OVA mice appeared to display a statistically greater number of alveolar macrophages 
compared to all other treatment groups, including DR3wt OVA mice and PBS controls 
(p=0.0003) (Table 5.2). All other myeloid cell subsets studied showed equivalent 
numbers between treatment groups.   
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5.3.1.1.3 Lymphocyte accumulation into the lung at 24 and 72hr post inhalation  
At 24hrs post inhalation, DR3ko OVA mice displayed a significantly higher number of 
CD3+ T cells compared to PBS treatment groups (p=0.004), although this difference 
was not statistically significant between DR3wt OVA and DR3ko OVA mice. This 
corresponded to a significant increase in CD4+ T cells over all other treatment groups 
(p=0.002) as well as CD8+ T cells, although like CD3+ T cells, significance was only 
seen between DR3ko OVA and PBS challenged mice (p=0.015) (Table 5.1). There were 
also significantly increased numbers of NK cells in OVA treated lungs compared to 
PBS challenged mice (p=0.037) (Table 5.1).  
 
In comparison, at 72hrs post inhalation, no significant differences were seen between 
any treatment groups when studying CD3+, CD4+ or CD8+ T cells (Table 5.2). 
However, DR3ko OVA mice did have lower numbers of CD8+ activated T cells, defined 
by the marker CD44, in comparison to DR3wt OVA treated mice (p=0.017) (Table 5.2). 
DR3ko PBS mice had significantly more NKT cells than DR3ko OVA mice (p=0.010) 
(Table 5.2), whilst DR3wt PBS mice displayed increased NK cell numbers over all other 
treatment groups, irrespective of inhalation treatment and genotype (p=0.002) (Table 
5.2). Overall, results were inconsistent. At the 24hr timepoint OVA treated mice 
appeared to show increased cell numbers compared to PBS challenged animals, thus 
suggesting that DR3 does not regulate the accumulation of lymphocytes into the lung 
following chronic allergic inflammation.  
 
 
*Corresponds to mice challenged with PBS  
^ Corresponds to mice challenged with OVA  
$ Significance tested between DR3wt and DR3ko OVA groups using 1 way ANOVA and Bonferroni post test; N.S.D = no significant difference, ***p<0.001  
                                DR3wt                                                                      DR3ko 
Cell Subset PBS* OVA^ PBS* OVA^ Significance$ 
Alveolar Macrophages 4.4 ± 0.6 x105 7.0 ± 0.5 x105 5.1 ± 0.5 x105 6.5 ± 0.9 x105 N.S.D 
Myeloid DCs 0.5 ± 0.1 x103 1.4 ± 0.1 x103 0.3 ± 0.1 x103 0.5 ± 0.1 x103 ***p<0.0001 
Neutrophils 3.5 ± 0.7 x104 4.1 ± 0.9 x104 4.5 ± 1.6 x104 5.1 ± 1.6 x103 N.S.D 
Eosinophils 0.2 ± 0.1 x104 1.2 ± 0.6 x104 0.2 ± 0.04 x104 0.02 ± 0.1 x104 N.S.D 
7/4+ Monocytes 1.5± 0.3 x104 2.7 ±0.2 x104 1.8 ± 0.5 x104 2.3 ± 0.4 x104 N.S.D 
7/4- Monocytes 1.7 ± 0.3 x104 3.7 ± 0.3 x104 1.7 ± 0.2 x104 2.4 ± 0.4 x104 N.S.D 
T cells 1.1 ± 0.1 x106 1.5 ± 0.2 x106 1.1 ± 0.3 x106 2.3 ± 0.3 x104 N.S.D 
CD4+ T cells 7.4 ± 0.7 x105 8.7 ± 1.3 x105 7.9 ± 0.8 x105 14.7 ± 1.8 x105 N.S.D 
CD8+ T cells 1.7 ± 0.3 x105 3.0 ± 0.5 x105 1.7 ± 0.4 x105 4.6 ± 1.0 x105 N.S.D 
B cells 3.7 ± 0.8 x104 6.6 ± 0.7 x104 3.8 ± 1.0 x104 7.0 ± 1.5 x104 N.S.D 
NK cells 3.1 ± 0.3 x104 4.7 ± 0.7 x104 2.3 ± 0.3 x104 4.0 ± 0.7 x104 N.S.D 
NKT cells 1.8 ± 0.3 x104 3.1 ± 0.4 x104 1.8 ± 0.4 x104 3.7 ± 0.9 x104 N.S.D  
Table 5.1 Comparison of cell numbers isolated from the lungs of DR3wt and DR3ko mice 24hr post inhalation 
                              DR3wt                                                                         DR3ko 
Cell Subset PBS* OVA^ PBS* OVA^ Significance$ 
Alveolar Macrophages 3.9 ± 0.4 x105 4.4 ± 0.7 x105 4.4 ± 0.7 x105 8.1 ± 0.9 x105 **p=0.01 
Myeloid DCs 0.9 ± 0.1 x103 0.6 ± 0.2 x103 0.3 ± 0.1 x103 0.4 ± 0.1 x103 N.S.D 
Neutrophils 10.4 ± 1.4 x104 8.9 ± 1.6 x104 13.4 ± 0.7 x104 10.3 ± 2.3 x104 N.S.D 
Eosinophils 2.4 ± 0.5 x104 2.0 ± 0.2 x104 2.1 ± 0.4 x104 2.2 ± 0.3 x104 N.S.D 
7/4+ Monocytes 3.5± 0.5 x104 4.1 ± 0.4 x104 4.9 ± 1.2 x104 3.4 ± 0.7 x104 N.S.D 
7/4- Monocytes 2.3 ± 0.4 x104 1.7 ± 0.2 x104 2.7 ± 0.4 x104 2.2 ± 0.9 x104 N.S.D 
T cells 1.2 ± 0.2 x106 1.8 ± 0.3 x106 1.5 ± 0.2 x106 1.0 ± 0.1 x106 N.S.D 
CD4+ T cells 6.5 ± 0.9 x105 9.5 ± 1.6 x105 7.5 ± 0.9 x105 6.9 ± 0.8 x105 N.S.D 
CD8+ T cells 5.3 ± 0.7 x105 7.6 ± 1.2 x105 6.8 ± 1.0 x105 4.1 ± 0.6 x105 N.S.D 
Act. CD4+ T cells 1.3 ± 0.3 x105 1.8 ± 0.5 x105 0.8 ± 0.1 x105 1.1 ± 0.2 x105 N.S.D 
Act. CD8+ T cells 0.9 ± 0.1 x105 1.1 ± 0.2 x105 0.6 ± 0.1 x105 0.5 ± 0.04 x105 *p=0.017 
B cells 8.9 ± 2.0 x104 10.7 ± 2.2 x104 12.1 ± 2.5 x104 8.3 ± 1.3 x104 N.S.D 
NK cells 2.4 ± 0.4 x104 1.4 ± 0.1 x104 1.4 ± 0.2 x104 1.0 ± 0.1 x104 N.S.D 
NKT cells 0.6 ± 0.1 x104 0.8 ± 0.1 x104 0.9 ± 0.1 x104 0.5 ± 0.1 x104 N.S.D 
*Corresponds to mice challenged with PBS  
^ Corresponds to mice challenged with OVA  
$ Significance tested between DR3wt and DR3ko OVA groups using 1 way ANOVA and Bonferroni post test; N.S.D = no significant difference, **p<0.01  
Table 5.2 Comparison of cell numbers isolated from the lungs of DR3wt and DR3ko mice 72hr post inhalation 
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5.3.1.3 Analysis of cellular accumulation into the alveolar passage  
5.3.1.2.1 Leukocyte accumulation in the alveolar passage 
Following chronic allergic lung inflammation, the alveolar passages of mice were 
lavaged and total cell number determined. At 24hrs post inhalation, DR3wt mice that had 
undergone PBS inhalation displayed significantly fewer leukocytes than DR3ko mice 
that had suffered OVA inhalation challenges (DR3wt PBS 1.1±0.1 x105, DR3ko OVA 
2.2±0.3 x105) (p=0.004) (Figure 5.2). The same trend was seen at 72hrs post inhalation, 
although results were not significant (DR3wt PBS 1.5±0.4 x105, DR3wt OVA 1.9±0.4 
x105, DR3ko PBS 2.5±0.5 x105, DR3ko OVA 3.1±0.6 x105) (p=0.204) (Figure 5.2).  
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Figure 5.2. Total leukocyte number from the alveolar passage of DR3wt and DR3ko 
mice following chronic allergic lung inflammation. Mice were sacrificed (A) 24hr and 
(B) 72hr post final inhalation challenge with either OVA or PBS. Cells were isolated via 
a bronchoalveolar lavage and counted using a haemocytometer. Total cell number from 
the BAL showed significant differences at 24hr (*p=0.004) but not 72hr n.s.d. 
Significance determined using 1 way ANOVA and Bonferroni post test; *p<0.05, 
**p<0.01. Values represent mean ± SEM. Each symbol represents data from a single 
mouse. 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
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5.3.1.2.2 Myeloid cell subsets in the alveolar passage did not significantly differ 
between DR3wt and DR3ko OVA challenged mice 
At both 24 and 72hrs post inhalation no significant differences were noted for any of the 
myeloid cell subsets studied within the bronchoalveolar lavage (Table 5.3) (Table 5.4).  
 
 
5.3.1.2.3 Lymphocyte accumulation into the alveolar passage did not significantly differ 
between DR3wt and DR3ko OVA challenged mice 
After the final inhalation challenge (24hrs), OVA challenged mice of both genotypes 
contained a significantly higher number of CD3+ T cells than DR3wt PBS challenged 
mice (p=0.005) (Table 5.3). This corresponded with higher numbers of CD4+ T cells 
(p=0.005) and CD8+ T cells (p=0.018), but not NKT cells. When studying B cells, 
DR3ko PBS mice displayed increased cell numbers over both DR3wt OVA and DR3wt 
PBS mice (p=0.008), whilst equivalent numbers of NK cells were observed (Table 5.3).  
 
However, at 72hrs post inhalation no significant differences were observed between 
treatment groups (Table 5.4).  
 
 
 
  
                               DR3wt                                                                       DR3ko 
Cell Subset PBS* OVA^ PBS*                       OVA^ Significance$ 
Alveolar Macrophages 1.5 ± 0.5 x104 1.8 ± 0.2 x104 5.5 ± 1.4 x104 4.2 ± 1.8 x104 N.S.D 
Myeloid DC’s 0.2 ± 0.1 x103 0.2 ± 0.1 x103 0.5 ± 0.2 x103 0.7 ± 0.3 x103 N.S.D 
Neutrophils 1.1 ± 0.3 x104 0.7 ± 0.4 x104 0.5 ± 0.1 x104 2.0 ± 0.5 x104 N.S.D 
Eosinophils 0.5 ± 0.1 x103 0.8 ± 0.2 x103 0.7 ± 0.2 x103 0.7 ± 0.2 x103 N.S.D 
7/4+ Monocytes 0.2 ± 0.1 x103 0.4 ±0.1 x103 0.4 ± 0.1 x103 0.3 ± 0.1 x103 N.S.D 
7/4- Monocytes 0.3 ± 0.1 x103 0.6 ± 0.2 x103 0.9 ± 0.3 x103 1.1 ± 0.3 x103 N.S.D 
T cells 2.3 ± 0.3 x104 9.0 ± 2.3 x104 0.3 ± 0.1 x104 7.5 ± 1.2 x104 N.S.D 
CD4+ T cells 0.8 ± 0.2 x104 6.9 ± 2.2 x104 1.9 ± 0.5 x104 5.6 ± 1.2 x104 N.S.D 
CD8+ T cells 0.3 ± 0.03 x104 0.7 ± 0.2 x104 0.5 ± 0.1 x104 0.5 ± 0.1 x104 N.S.D 
B cells 1.1 ± 0.3 x104 3.4 ± 0.5 x104 3.4 ± 0.5 x104 2.4 ± 0.8 x104 N.S.D 
NK cells 0.5 ± 0.1 x103 1.2 ± 0.5 x103 2.7 ± 2.2 x103 1.0 ± 0.1 x103 N.S.D 
NKT cells 1.1 ± 0.3 x103 0.9 ± 0.3 x103 3.4 ± 0.5 x103 0.7 ± 0.1 x103 N.S.D  
*Corresponds to mice challenged with PBS  
^ Corresponds to mice challenged with OVA  
$ Significance tested between DR3wt and DR3ko OVA groups using 1 way ANOVA and Bonferroni post test; N.S.D = no significant difference,  
Table 5.3 Comparison of cell numbers isolated from the alveolar passage of DR3wt and DR3ko mice 24hrs post inhalation 
                              DR3wt                                                                        DR3ko 
Cell Subset PBS* OVA^ PBS* OVA^ Significance$ 
Alveolar Macrophages 3.2 ± 1.0 x104 3.2 ± 0.1 x104 8.6 ± 2.0 x104 6.7 ± 2.2 x104 N.S.D 
Myeloid DC’s 0.5 ± 0.1 x103 0.7 ± 0.3 x103 0.6 ± 0.2 x103 0.6 ± 0.2 x103 N.S.D 
Neutrophils 2.1 ± 1.1 x104 3.4 ± 1.8 x104 4.4 ± 1.5 x104 12.4 ± 6.3 x104 N.S.D 
Eosinophils 0.3 ± 0.1 x103 8.5 ± 3.7 x103 0.8 ± 0.4 x103 6.9 ± 3.3 x103 N.S.D 
7/4+ Monocytes 0.6 ± 0.4 x103 1.1 ± 0.6 x103 0.8 ± 0.4 x103 2.7 ± 1.6 x103 N.S.D 
7/4- Monocytes 0.3 ± 0.2 x103 1.2 ± 0.5 x103 0.6± 0.3 x103 1.6 ± 0.7 x103 N.S.D 
T cells 0.3 ± 0.1 x104 1.8 ± 0.9 x104 0.3 ± 0.1 x104 1.7 ± 0.6 x104 N.S.D 
CD4+ T cells 2.2 ± 1.0 x103 15.0 ± 7.3 x103 1.9 ± 0.5 x103 13.7 ± 4.8 x103 N.S.D 
CD8+ T cells 0.9 ± 0.4 x103 2.6 ± 1.4 x103 0.9 ± 0.2 x103 2.4 ± 0.8 x103 N.S.D 
B cells 3.3 ± 2.3 x103 2.6 ± 1.3 x103 11.1 ± 6.5 x103 2.9 ± 0.6 x103 N.S.D 
NK cells 2.0 ± 0.1 x102 3.4 ± 1.0 x102 3.7 ± 1.2 x102 3.6 ± 0.5 x102 N.S.D 
NKT cells 0.9 ± 0.5 x103 3.1 ± 1.5 x103 0.9 ± 0.3 x103 3.1 ± 1.1 x103 N.S.D  
*Corresponds to mice challenged with PBS  
^ Corresponds to mice challenged with OVA  
$ Significance tested between DR3wt and DR3ko OVA groups using 1 way ANOVA and Bonferroni post test; N.S.D = no significant difference,  
Table 5.4 Comparison of cell numbers isolated from the alveolar passage of DR3wt and DR3ko mice 72hrs post inhalation 
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5.3.2 Airway remodelling following chronic allergic lung inflammation  
 
5.3.2.1 Analysis of airway remodelling and lung pathology 
5.3.2.1.1 Lung pathology was more severe in DR3wt mice that had been exposed to 
OVA inhalation than DR3ko mice 
A H&E stain was used to assess general lung pathology. Lungs were graded according 
to a severity scale with a maximum score of 5 (Section 2.2.12.2). Staining revealed that 
at both 24 and 72hrs post inhalation, DR3wt OVA mice exhibited worse lung pathology, 
marked by increased peribronchial and perivascular inflammation and cellular cuffing 
compared to all other treatment groups. At 24hrs post inhalation, DR3wt OVA mice 
scored an average of 4.5±0.3, compared to DR3wt PBS (2.2±0.5), DR3ko OVA (2.5±0.3) 
and DR3ko PBS (2.0±0.4) mice (p=0.003) (Figure 5.3) (Table 5.5). This was also true at 
the 72hr timepoint whereby DR3wt OVA samples displayed a mean lung pathology 
score of 4.0±0.5, significantly higher than  DR3wt PBS (2.4±0.3), DR3ko OVA (2.6±0.5) 
and DR3ko PBS (2.4±0.3) mice (p=0.035) (Figure 5.4) (Table 5.5), thus suggesting the 
development of lung pathology during chronic allergic lung inflammation was DR3 
dependent.  
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Figure 5.3. Analysis of lung pathology 24hrs post chronic allergic lung inflammation. 
Mice were sacrificed 24hr post final inhalation challenge with either OVA or PBS. Lungs 
were stained with Haematoxylin and Eosin. Shown are representative photos of DR3wt 
OVA, DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=250μm).(A) Lungs were 
blind scored by 2 individuals for pathology and an average taken for each lung. Results 
were significant using 1 way ANOVA (*p=0.003) whereby *p<0.05, **p<0.01, 
***p<0.001. Values represent mean ± SEM. Each symbol represents data from a single 
mouse 
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Figure 5.4. Analysis of lung pathology 72hrs post chronic allergic lung inflammation. 
Mice were sacrificed 72hr post final inhalation challenge with either OVA or PBS. Lungs 
were stained with Haematoxylin and Eosin. Shown are representative photos of DR3wt 
OVA, DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=100μm).(A) Lungs were 
blind scored by 2 individuals for pathology and an average taken for each lung. Results 
were significant using 1 way ANOVA (*p=0.035) whereby *p<0.05. Values represent 
mean ± SEM. Each symbol represents data from a single mouse.  
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5.3.2.1.2 Mucin associated goblet cell number was significantly different between 
DR3wt and DR3ko mice  
Lungs were stained with Periodic Acid Schiff to quantitate levels of mucin producing 
goblet cells. Results showed that the lungs of DR3wt OVA treated mice produced 
significantly more mucin than all other experimental groups at both 24 and 72hrs post 
inhalation. This goblet cell hyperplasia was particularly apparent 24hrs after the final 
aerosolisation challenge, as DR3wt OVA mice presented with 4.1±0.5% of its airways as 
positive, compared to 1.7±0.8% in DR3ko OVA chronically challenged airways, 
0.08±0.05% in DR3wt PBS mice and 0.1±0.06% in DR3ko PBS mice (p<0.0001) (Figure 
5.5) (Table 5.5). A similar pattern was detected at 72hrs post inhalation, as DR3wt OVA 
mice had significantly more goblet cells than other experimental groups (DR3wt OVA 
7.6±3.6%, DR3wt PBS 0.07±0.05%, DR3ko OVA 2.0±1.1%, DR3ko PBS 0.02±0.01%) 
(p=0.030) (Figure 5.6) (Table 5.5).  
 
 
 
 
 
 
 
 
 
Figure 5.5. Analysis of goblet cell numbers 24hrs post chronic allergic lung 
inflammation. Mice were sacrificed 24hr post final inhalation challenge with either OVA 
or PBS. Lungs were stained with Periodic Acid Schiff. Shown are representative photos 
of DR3wt OVA, DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=250μm). (A) 
The area of PAS+ cells was taken as a % of the airway surround using Leica Qwin V3 
software, and an average calculated for each lung. Results were significant using 1 way 
ANOVA (***p<0.0001) whereby *p<0.05, **p<0.01, ***p<0.001. Values represent 
mean ± SEM. Each symbol represents data from a single mouse.  
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Figure 5.6. Analysis of goblet cell numbers 72hrs post chronic allergic lung 
inflammation. Mice were sacrificed 72hr post final inhalation challenge with either OVA 
or PBS. Lungs were stained with Periodic Acid Schiff. Shown are representative photos 
of DR3wt OVA, DR3ko OVA,  DR3wt PBS and DR3ko PBS lungs (Scale bar=100μm). (A) 
The area of PAS+ cells was taken as a % of the airway surround using Leica Qwin V3 
software, and an average calculated for each lung. Results were significant using 1 way 
ANOVA (*p=0.030) whereby *p<0.05. Values represent mean ± SEM. Each symbol 
represents data from a single mouse.  
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5.3.2.1.3 Lung fibrosis scores were comparable between DR3wt and DR3ko OVA mice 
Lungs were stained with Van Gieson solution to assay the level of collagen and thereby 
acquire an arbitrary measure of fibrosis. Lung fibrosis following multiple allergen 
challenge was not DR3 dependent at either the 24 or 72hr timepoint, as both DR3wt 
OVA (24hrs 3.4±0.3, 72hrs 3.0±0.3)  and DR3ko OVA (24hrs 2.8±0.3, 72hrs 1.8±0.5) 
treated mice scored comparably using the Ashcroft measure of Fibrosis (Ashcroft, 
Simpson et al. 1988). Both OVA challenged groups displayed higher scores than mice 
challenged consecutively with PBS, with this difference being significant at the 24hr 
(DR3wt OVA 3.4±0.3, DR3wt PBS 1.5±2.6, DR3ko OVA 2.8±0.3, DR3ko PBS 1.1±0.3) 
(p<0.0001) (Figure 5.7) and 72hr timepoints (DR3wt OVA 3.0±0.3, DR3wt PBS 1.4±0.3, 
DR3ko PBS 1.1±0.3) (p=0.009) (Figure 5.8) (Table 5.5).  
    
 
 
 
 
 
 
 
 
 
 
(A) 
Figure 5.7. Analysis of fibrosis 24hrs post chronic allergic lung inflammation. Mice 
were sacrificed 24hr post final inhalation challenge with either OVA or PBS. Lungs were 
stained with Van Gieson solution. Shown are representative photos of DR3wt OVA, 
DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=100μm). (A) Lungs were blind 
scored by 2 individuals using Ashcroft score of fibrosis and an average taken for each 
lung. Results were significant using 1 way ANOVA (***p<0.0001) whereby *p<0.05, 
**p<0.01, ***p<0.001. Values represent mean ± SEM. Each symbol represents data from 
a single mouse.  
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Figure 5.8. Analysis of fibrosis 72hrs post chronic allergic lung inflammation. Mice 
were sacrificed 72hr post final inhalation challenge with either OVA or PBS. Lungs 
were stained with Van Gieson solution. Shown are representative photos of DR3wt OVA, 
DR3ko OVA, DR3wt PBS and DR3ko PBS lungs (Scale bar=100μm). (A) Lungs were 
blind scored by 2 individuals using Ashcroft score of fibrosis and an average taken for 
each lung. Results were significant using 1 way ANOVA (**p=0.009) whereby 
*p<0.05, **p<0.01. Values represent mean ± SEM. Each symbol represents data from a 
single mouse.  
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Table 5.5 Lung pathology and degree of staining following histological analysis 24 and 
72hrs post inhalation  
                 DR3wt                                                             DR3ko  
 Stain PBS* OVA^ PBS* OVA^ Significance$ 
24hrsε H&E 
 
2.2±0.5 
+ 
4.5±0.3 
+++ 
2.0±0.4 
+ 
2.5±0.3 
+ 
*p<0.05 
 PAS 
 
0.08±0.05 
+ 
4.1±0.5 
+++ 
0.1±0.06 
+ 
1.7±0.8 
++ 
*p<0.05 
 VG 
 
1.5±2.6 
+ 
3.4±0.3 
+++ 
1.1±0.3 
+ 
2.8±0.3 
+++ 
N.S.D 
72hrs¥ H&E 
 
2.4±0.3 
+ 
4.0±0.5 
++ 
2.4±0.3 
+ 
2.6±0.5 
+ 
*p=0.035 
 PAS 
 
0.07±0.05 
+ 
7.6±3.6 
+++ 
0.02±0.01 
+ 
2.0±1.1 
++ 
*p=0.030 
 VG 
 
1.4±0.3 
+ 
3.0±0.3 
+++ 
1.1±0.3 
+ 
1.8±0.5 
++ 
N.S.D 
* PBS corresponds to mice challenged via inhalation with PBS 
^ OVA corresponds to mice challenged via inhalation with OVA 
ε 24hrs corresponds to mice harvested 24hrs after the final inhalation challenge 
¥ 72hrs corresponds to mice harvested 72hrs after the final inhalation challenge 
$ Significance between DR3wt OVA and DR3ko OVA groups using 1 way ANOVA and 
Bonferroni post test. N.S.D = no significant difference, *p<0.05.  
An arbitrary measure of staining intensity was used with + meaning low and +++ meaning high 
H&E scores are representative of a scoring regime found in Chapter 2, PAS scores represent the 
% of PAS+ areas a % of the lung, VG scores are representative of the Ashcroft core of fibrosis, 
found in Chapter 2  
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5.3.2.2 DR3 expression following chronic allergic lung inflammation  
5.3.2.2.1 DR3 expression in the lungs was similar between DR3wt OVA and DR3wt PBS 
challenged mice  
DR3 signals were analogous between DR3wt OVA (7.0±2.8%) and DR3wt PBS 
(6.5±2.7%) mice at 72hrs post inhalation, although both were significantly greater than 
their DR3ko counterparts (p=0.025) and isotype controls (Figure 5.10). At 24hrs post 
inhalation however, DR3wt PBS mice showed 11.0±4.1% DR3 signal, significantly 
more than DR3wt OVA treated mice at 8.9±1.7% (p=0.006). Both treatments groups of 
DR3wt genotype gave significantly greater signals than DR3ko mice (p=0.004) (Figure 
5.9). DR3 expression appeared to be focused in the epithelium of the mouse 
bronchioles, in a similar location to the goblet cells identified using Periodic Acid 
Schiff stain (Section 5.3.2.1.2). Occasional signals were also noted in the alveolar 
spaces and smooth muscle.  
 
 
 
 
 
 
 
 
OVA   PBS    Isotype  
 
 
DR3wt 
 
 
 
 
 
 
 
 
 
 
DR3ko 
Figure 5.9. DR3 expression 24hrs post chronic allergic lung inflammation. Mice were 
sacrificed 24hr post final inhalation challenge with either OVA or PBS. Lungs were 
stained with DR3 antibody. Shown are representative photos of DR3wt OVA, DR3ko OVA, 
DR3wt PBS, DR3ko PBS, DR3wt isotype and DR3ko isotype (Scale bar=100μm). DR3 
expression in the lung was analysed using 5 fields of view of each lung and measuring the 
% of positive (brown) in each field of view. This was then averaged for each mouse (n=5). 
Analysis was performed using Leica Qwin V3 Software. Results were significant using 2 
way ANOVA (Interaction=0.073, Genotype=**0.004, Inhalation treatment=**0.006) 
whereby *p<0.05, **p<0.01. Bars represent mean ± SEM.  
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Figure 5.10. DR3 expression 72hrs post chronic allergic lung inflammation. Mice 
were sacrificed 72hr post final inhalation challenge with either OVA or PBS. Lungs 
were stained with DR3 antibody. Shown are representative photos of DR3wt OVA, 
DR3ko OVA DR3wt PBS, DR3ko PBS, DR3wt isotype and DR3ko isotype (Scale 
bar=100μm). DR3 expression in the lung was analysed using 5 fields of view of each 
lung and measuring the % of positive (brown) in each field of view. This was then 
averaged for each mouse (n=6). Analysis was performed using Leica Qwin V3 
Software. Results were significant using 2 way ANOVA (Interaction=0.266, Genotype= 
*0.025, Inhalation treatment=0.054) whereby *p<0.05. Bars represent mean ± SEM.  
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5.3.3 The systemic response in chronic allergic lung inflammation 
 
5.3.3.1 Splenic responses in chronic allergic lung inflammation 
5.3.3.1.1 Splenocyte total cell number was significantly higher in DR3wt OVA mice  
The spleen was harvested following chronic allergic lung inflammation to assess 
whether a systemic response had occurred. At 24hrs post inhalation, DR3wt OVA mice 
contained 11.1±1.0 x107 splenocytes, significantly more than DR3ko PBS (6.2±0.8 x107) 
and DR3ko OVA (5.3±1.0 x107) mice (p=0.002) (Figure 5.11). At 72hrs post inhalation 
both DR3wt OVA (13.2±1.1 x107) and PBS (11.5±1.1 x107) groups displayed 
significantly more leukocytes than DR3ko OVA (5.3±0.6 x107) and PBS (7.8±0.7 x107) 
groups (p<0.0001) (Figure 5.11).  
 
 
 
 
 
 
 
 
 
Figure 5.11. Total leukocyte number from the spleens of DR3wt and DR3ko mice 
following chronic allergic lung inflammation. Mice were sacrificed at (A) 24hr and 
(B) 72hr post final inhalation challenge with either OVA or PBS. Splenocytes were 
extracted via mashing of the spleen and counted using a haemocytometer. Total 
splenocyte number showed significant differences at 24hr (**p=0.002) and 72hr 
(***p<0.0001). Significance determined using 1 way ANOVA and Bonferroni post test; 
*p<0.05, **p<0.01, ***p<0.001. Values represent mean ± SEM. Each symbol 
represents data from a single mouse.  
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5.3.3.1.2 Myeloid cell subsets in the spleen were significantly higher in DR3wt groups  
Multiple myeloid cell subsets were significantly higher in DR3wt OVA mice compared 
to other treatment groups at 24hrs post inhalation. There were significantly more 
monocytes/macrophages at 1.4±0.1 x107 compared to DR3ko OVA mice at 0.5±0.1 x107 
(p=0.001), as well as neutrophils (DR3wt OVA 1.1±0.2 x106, DR3ko OVA 0.5±0.1 x106) 
(p=0.012) (Figure 5.12). Dendritic cells, both myeloid and plasmacytoid, also differed 
between DR3wt OVA mice and other treatment groups, at 0.3±0.03 x106 myeloid DCs in 
contrast to 0.2±0.06 x106 in DR3ko PBS and 0.1±0.06 x106 in DR3ko OVA groups 
(p=0.001). Similarly, plasmacytoid DC cell number was significantly higher in DR3wt 
OVA mice (2.6±0.2 x105) than DR3wt PBS (1.5±0.2 x105), DR3ko OVA (1.3±0.2 x105) 
and DR3ko PBS (1.2±0.3 x105) treated animals (p=0.001) (Figure 5.12). Eosinophils 
were not significantly different at the 24hr harvest timepoint (p=0.20).  
 
At 72hrs post inhalation, DR3wt groups again presented with higher myeloid cell 
numbers than DR3ko mice. There were significantly more splenic macrophages in 
DR3wt OVA (1.4±0.2 x107) and DR3wt PBS mice (1.4±0.1 x107) than DR3ko OVA 
(0.3±0.1 x107) and DR3ko PBS (0.3±0.03 x107) groups (p<0.0001), as well as 7/4+ 
monocytes (DR3wt OVA 3.6±0.5 x106, DR3wt PBS 3.8±0.3 x106, DR3ko OVA 0.8±0.2 
x106, DR3ko PBS 0.7±0.1 x106) (p<0.0001) and 7/4- monocytes (DR3wt OVA 10.9±0.8 
x106, DR3wt PBS 9.9±1.3 x106, DR3ko OVA 3.7±1.1 x106, DR3ko PBS 2.8±1.2 x106) 
(p<0.0001) (Figure 5.13). Similarly, DR3wt OVA (2.1±0.3 x106) and DR3wt PBS 
(2.4±0.3 x106) mice had significantly higher levels of neutrophils than DR3ko OVA 
(0.4±0.1 x106) and DR3ko PBS (0.3±0.04 x106) (p<0.0001) treated animals. In contrast 
to 24hrs post inhalation, eosinophils were also different at the 72hr timepoint. DR3wt 
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genotypes had increased subset numbers in relation to DR3ko mice (DR3wt OVA 1.0±0.2 
x106, DR3wt PBS 1.4±0.2 x106, DR3ko OVA 0.2±0.04 x106, DR3ko PBS 0.2±0.03 x106) 
(p<0.0001) (Figure 5.13). When studying DCs, it was found that whilst myeloid DCs 
followed the trend of reduced cell numbers in DR3ko groups (DR3wt OVA 1.6±0.3 x106, 
DR3wt PBS 1.9±0.2 x106, DR3ko OVA 0.3±0.1 x106, DR3ko PBS 0.3±0.1 x106) 
(p<0.0001), plasmacytoid DCs were comparable between DR3wt OVA, DR3wt PBS and 
DR3ko PBS. It was only DR3ko OVA mice that showed diminished plasmacytoid DC 
number, this being significantly different between DR3wt PBS (1.6±0.2 x106) and DR3ko 
OVA (0.5±0.2 x106) groups (p=0.027) (Figure 5.13).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12. Myeloid cell subsets  from the spleens of DR3wt and DR3ko mice 24hrs 
post chronic allergic lung inflammation. Mice were sacrificed 24hr post final 
inhalation challenge with either OVA or PBS. Splenocytes were isolated and subsets 
determined using antibody cell markers. Monocytes/Macrophages (**p=0.001), 
Neutrophils (*p=0.012), Eosinophils n.s.d, Myeloid DCs (**p=0.001), Plasmacytoid 
DCs (**p=0.001). Significance determined using 1 way ANOVA and Bonferroni post 
test; *p<0.05, **p<0.01, ***p<0.001. Values represent mean ± SEM. Each symbol 
represents data from a single mouse.  
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Figure 5.13. Myeloid cell subsets from the spleens of DR3wt and DR3ko mice 72hrs post 
chronic allergic lung inflammation. Mice were sacrificed 72hr post final inhalation 
challenge with either OVA or PBS. Splenocytes were isolated and subsets determined using 
antibody cell markers. Macrophages (***p<0.0001), Neutrophils (***p<0.0001), 
Eosinophils (***p<0.0001), 7/4+ Monocytes (***p<0.0001), 7/4- Monocytes 
(***p<0.0001), Myeloid DCs (***p<0.0001) and Plasmacytoid DCs (*p=0.027). 
Significance determined using 1 way ANOVA and Bonferroni post test; *p<0.05, **p<0.01, 
***p<0.001. Values represent mean ± SEM. Each symbol represents data from a single 
mouse.  
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5.3.3.1.3 Lymphocyte cell subsets in the spleen were significantly higher in DR3wt 
groups  
To examine T cell accumulation in the spleen, lymphocyte cell subset numbers were 
analysed following chronic inhalation challenges. DR3wt OVA mice displayed more T 
cells at 24hrs post inhalation, shown by the increase in CD3+ cells compared to other 
treatment groups. DR3wt OVA mice had 2.5±0.5 x107 T cells whilst DR3ko PBS and 
DR3ko OVA had 1.1±0.2 x107 and 1.0±0.2 x107 respectively. This difference was 
significant by 1 way ANOVA (p=0.009), and translated into significant differences in 
CD3+ T cell subsets, such as CD4+ T cells (DR3wt OVA 15.4±2.9 x106, DR3wt PBS 
7.5±1.3 x106, DR3ko OVA 5.5±1.3 x106, DR3ko PBS 6.3±0.9 x106) (p=0.007), CD8+ T 
cells (DR3wt OVA 9.3±1.9 x106, DR3ko OVA 3.4±0.9 x106, DR3ko PBS 4.0±0.6 x106) 
(p=0.015) and NKT cells (DR3wt OVA 1.0±0.3 x106, DR3ko OVA 0.3±0.1 x106) 
(p=0.015) (Figure 5.14). Moreover, differences were also noted in the numbers of NK 
cells, as DR3wt OVA mice had 2.9±0.3 x106 cells, compared to 1.8±0.1 x106 in DR3wt 
PBS, 1.5±0.1 x106 in DR3ko PBS and 1.4±0.2 x106 in DR3ko OVA groups, this being 
significant (p=0.0002) (Figure 5.14). 
 
At 72hrs post inhalation, the increase in splenic T cell numbers was not just restricted to 
DR3wt OVA treated mice, as DR3wt PBS challenged animals also displayed 
considerable increases compared to DR3ko mice. At 72hrs, the disparity between the 
groups appeared to be genotype specific as opposed to treatment specific, as both OVA 
and PBS aerosolised DR3wt mice consistently showed significantly higher T cell subset 
numbers in comparison to the DR3ko genotype. CD3+ T cells measured at 2.2±0.3 x107 
and 2.1±0.2 x107 in DR3wt OVA and DR3wt PBS mice, compared to 0.4±0.1 x107 and 
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0.3±0.04 x107 in DR3ko OVA and DR3ko PBS, a significant difference of p<0.0001 
(Figure 5.15). This difference converted into the relevant T cell subsets as DR3wt CD4+ 
T cells were significantly higher than that of DR3ko mice, (DR3wt OVA 12.2±1.6 x106, 
DR3wt PBS 10.7±0.7 x106, DR3ko OVA 1.7±0.2 x106, DR3ko PBS 1.6±0.2 x106) 
(p<0.0001), as were CD8+ T cells (DR3wt OVA 8.5±0.8 x106, DR3wt PBS 8.0±0.7 x106, 
DR3ko OVA 1.6±0.2 x106, DR3ko PBS 1.3±0.2 x106) (p<0.0001) and NKT cells (DR3wt 
OVA 4.2±0.7 x105, DR3wt PBS 4.6±0.5 x105, DR3ko OVA 0.9±0.1 x105, DR3ko PBS 
0.6±0.1 x105) (p<0.0001) (Figure 5.15). In addition to total T cells being higher in 
DR3wt groups, activated T cell numbers, defined by the marker CD44, were also 
significantly greater in the CD8+ T cell lineage (DR3wt OVA 1.8±0.6 x106, DR3wt PBS 
1.9±0.2 x106, DR3ko OVA 0.3±0.04 x106, DR3ko PBS 0.2±0.02 x106) (p=0.0003) and 
CD4+ cells, although significance was only seen between DR3wt OVA mice (2.7±09 
x106) and DR3ko groups (DR3ko OVA 0.3±0.1 x106, DR3ko PBS 0.3±0.03 x106) 
(p=0.001) in this subset (Figure 5.15). Splenic NK cell numbers also increased in DR3wt 
OVA (7.3±1.0 x106) and DR3wt PBS (7.4±0.8 x106) mice after chronic allergic lung 
inflammation in comparison to DR3ko OVA (1.6±0.1 x106) and DR3ko PBS animals 
(1.2±0.2 x106) (p<0.0001) (Figure 5.15).  
 
 
 
 
 
 
Figure 5.14. T cell subsets from the spleens of DR3wt and DR3ko mice 24hrs post 
chronic allergic lung inflammation. Mice were sacrificed 24hr post final inhalation 
challenge with either OVA or PBS. Splenocytes were isolated and subsets determined 
using antibody cell markers. CD3+ T cells (**p=0.009), CD4+ T cells (**p=0.007), CD8+ 
T cells (*p=0.015), NKT cells (*p=0.015), NK cells (***p=0.0002). Significance 
determined using 1 way ANOVA and Bonferroni post test; *p<0.05, **p<0.01, 
***p<0.001. Values represent mean ± SEM. Each symbol represents data from a single 
mouse.  
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Figure 5.15. T cell subsets from the spleens of DR3wt and DR3ko mice 72hrs post 
chronic allergic lung inflammation. Mice were sacrificed 72hr post final inhalation 
challenge with either OVA or PBS. Splenocytes were isolated and subsets determined 
using antibody cell markers. CD3+ T cells (***p<0.0001), CD4+ T cells (***p<0.0001), 
CD8+ T cells (***p<0.0001), Activated CD4+ T cells (**p=0.001), Activated CD8+ T 
cells (**p=0.0003), NKT cells (***p<0.0001), NK cells (***p<0.0001). Significance 
determined using 1 way ANOVA and Bonferroni post test; *p<0.05, **p<0.01, 
***p<0.001. Values represent mean ± SEM. Each symbol represents data from a single 
mouse.  
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5.3.3.2 The B cell response in chronic allergic lung inflammation 
5.3.3.2.1 B cell number and antibody production in chronic allergic lung inflammation 
Splenic B cell numbers were also quantified as were the levels of Total IgE and OVA 
specific IgG. Following OVA priming and the subsequent induction of chronic 
inflammation, DR3ko mice displayed comparable antibody responses to DR3wt mice. At 
both 24 and 72hrs, there were no significant differences in either Total IgE or OVA 
specific IgG antibody levels, although both increased in comparison to naive mice 
(Figure 5.16) (Figure 5.17) (Table 5.6). This was despite a greater number of B cells 
within the spleens of DR3wt OVA mice at 24hrs (DR3wt OVA 2.8±0.5 x107, DR3ko 
OVA 1.1±0.3 x107, DR3ko PBS 1.1±0.2 x107) (p=0.006) (Figure 5.16) and DR3wt OVA 
and PBS mice at 72hrs (DR3wt OVA 1.4±0.2 x107, DR3wt PBS 2.0±0.3 x107, DR3ko 
OVA 0.3±0.1 x107, DR3ko PBS 0.3±0.1 x107) (p<0.0001) (Figure 5.17).  
 
 
 
 
 
 
 
 
 
  
Figure 5.16. The B cell response of DR3wt and DR3ko mice 24hrs post chronic allergic 
lung inflammation. Mice were sacrificed 24hr post final inhalation challenge with either 
OVA or PBS.  (A) B cells were identified using specific antibody markers (*p=0.006). 
Serum was isolated from blood obtained from cardiac puncture. Serum was tested for 
concentrations of (B) IgE (n.s.d) and (C) OVA specific IgG (n.s.d) by ELISA. Each point 
represents the mean of doublets from different mice. Significance tested using 1 way 
ANOVA and Bonferroni post test; *p<0.05. Values represent mean ± SEM. Each symbol 
represents data from a single mouse.  
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Figure 5.17. The B cell response of DR3wt and DR3ko mice 72hrs post chronic allergic 
lung inflammation. Mice were sacrificed 72hr post final inhalation challenge with either 
OVA or PBS.  (A) B cells were identified using specific antibody markers (***p<0.0001). 
Serum was isolated from blood obtained from cardiac puncture. Serum was tested for 
concentrations of (B) IgE (n.s.d) and (C) OVA specific IgG (n.s.d) by ELISA. Each point 
represents the mean of doublets from different mice. Significance tested using 1 way 
ANOVA and Bonferroni post test; ***p<0.001. Values represent mean ± SEM. Each 
symbol represents data from a single mouse.  
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Table 5.6 Antibody levels following chronic allergic lung inflammation harvested 
24 and 72hrs post inhalation challenge 
                                                              DR3wt                                                      DR3ko Significance$ 
 Antibody PBS* OVA^ PBS* OVA^  
24hrsε Total IgE 2172±955 700±177 805±286 1899±835 N.S.D 
 OVA IgG 0.3±0.03 0.3±0.01 0.3±0.01 0.3±0.01 N.S.D 
72hrs¥ Total IgE 1417±798 1407±141 1476±102 1351±441 N.S.D 
 OVA IgG 0.3±0.01 0.3±0.01 0.3±0.01 0.3±0.02 N.S.D 
* PBS corresponds to mice challenged via inhalation with PBS 
^ OVA corresponds to mice challenged via inhalation with OVA 
ε 24hrs corresponds to mice harvested 24hrs after the final inhalation challenge 
¥ 72hrs corresponds to mice harvested 72hrs after the final inhalation challenge 
$ Significance between DR3wt OVA and DR3ko OVA groups using 1 way ANOVA, N.S.D = no 
significant difference  
Values represent the mean±SEM. Total IgE (pg/ml) measured by ELISA. OVA IgG scores are 
the optical density reading from the OVA specific IgG ELISA using serum from DR3wt and 
DR3ko mice  
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5.4 Discussion 
 
5.4.1 DR3 influence on airway inflammation  
To date, no data has been published on the role of DR3 in chronic allergic lung 
inflammation. Results within this Chapter suggest that leukocyte accumulation into the 
lungs following chronic challenge is variable. Twenty four hours after the final 
inhalation challenge, both DR3wt and DR3ko OVA challenged mice displayed increased 
numbers of multiple cell types compared to PBS challenged animals, although this was 
rarely significant. Similarly, mice harvested 72hrs post inhalation showed similar 
numbers of numerous cell types, including monocytes, T cells and B cells. It can 
therefore be said that for the majority of subsets studied and in contrast to the acute 
model, a lack of DR3 did not significantly affect leukocyte accumulation into the lungs 
or BALF during chronic allergic lung inflammation.  
.  
An exception however, were myeloid DCs, as DR3wt OVA lungs contained significantly 
more than all other treatment groups, though this increase did not correlate with an 
increase in T cells. Myeloid DCs are thought to be key in the generation of an allergen 
specific T cell response (van Rijt, Jung et al. 2005; Lambrecht and van Rijt 2006) and 
are found throughout the murine lung, within the intraepithelial layer of the large 
conducting airways as well as in the lung interstitium (Wikstrom and Stumbles 2007). 
Upon allergen exposure, DCs migrate to the draining lymph nodes in response to 
homing chemokines and undergo maturation. It has also been suggested that airway 
epithelial cells control DC activation and migration. Chimaeric mice with radioresistant 
stromal cells and radiosensitive haematopoietic cells, but deficient in the LPS receptor 
TLR4, were challenged via inhalation with LPS. Results demonstrated that DC 
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migration to lymph nodes was dependent on TLR4 signalling on epithelial cells 
(Hammad, Chieppa et al. 2009), suggesting that as well as lymph node homing 
chemokines, epithelial cells also function to control DC activity. Upon maturation, DCs 
are able to directly prime naive T cells to differentiate into effector T cells. It has been 
reported that human DCs activated by thymic stromal lymphopoietin (TSLP), a DC 
modulating cytokine, could also directly prime CD4+ T cells to differentiate into pro-
inflammatory Th2 cells via the release of the TNFSF ligand, OX40-L (Ito, Wang et al. 
2005). Furthermore, TSLP has been shown to play a significant role in murine DC 
responses to antigen, as mice that conditionally over-expressed the cytokine mounted 
vigorous Th2 responses (Headley, Zhou et al. 2009), compared to TSLPRko mice which 
failed to develop an antigen-specific response unless adoptively transferred with WT 
CD4+ T cells (Al-Shami, Spolski et al. 2005). It would be interesting to investigate 
whether TL1A release by both stimulated human (Prehn, Thomas et al. 2007) and 
murine (Bamias, Mishina et al. 2006; Meylan, Davidson et al. 2008)  DCs, could be 
influenced by TSLP similar to OX40-L.  
 
Previous studies have found DR3 to have an active role in cellular infiltration and 
accumulation in chronic disease models. In the AIA model of Rheumatoid Arthritis, 
DR3ko mice displayed reduced cellular infiltration at day 21, correlating with reduced 
structural damage to the joint, assessed by absence of synovial hyperplasia, lack of 
pannus formation and no bone erosion (Bull, Williams et al. 2008). Moreover, anti-
TL1A treatment at the point of arthritic induction significantly reduced clinical signs of 
disease in a collagen induced model of arthritis (CIA). This was partly characterised by 
reduced leukocyte infiltration into the synovial tissue (Bull, Williams et al. 2008). 
Similarly in a CIA model, human TL1A was found to aggravate disease and enhance 
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disease manifestation, including increased cartilage damage, pannus formation and cell 
infiltration (Zhang, Wang et al. 2009). In a DSS model of chronic colitis, increased 
levels of memory T cells and B cells were noticed in the lamina propria, as well as 
levels of IFNγ and IL-17. However, administration of an anti-TL1A antibody 
neutralised these effects, as mice demonstrated reduced CD4+ T cells and cytokine 
production from the gut associated lymphoid tissue as well as mucosal T cells 
(Takedatsu, Michelsen et al. 2008). In a G protein αi2-/- T cell transfer model, 
spontaneous development of colitis can be abrogated by injection of anti-TL1A, 
reducing inflammatory cell infiltration into the mucosa and down-regulating T cell 
activation (Takedatsu, Michelsen et al. 2008). Furthermore, reduced numbers of CD4+ T 
cells were detected in the spinal cords of DR3ko and TL1Ako mice compared to DR3wt 
mice following the induction of EAE (Meylan, Davidson et al. 2008; Pappu, 
Borodovsky et al. 2008), all suggesting that the DR3/TL1A axis is important in the 
development of disease which is often concurrent with cellular infiltration. However, 
whilst allergic lung inflammation is predominately considered a Th2 mediated disease, 
experimental antigen induced arthritis, DSS induced chronic colitis and EAE, are 
believed to be Th1/Th17 mediated.  
 
When studying the immune response to Toxoplasma gondii, DR3wt and DR3ko mice 
were immunised via the peritoneal cavity with cysts from the brains of infected animals. 
Infection and survival rates were comparable between the 2 genotypes, as were levels of 
infiltrating CD3+ T cells. Stimulated spleen cells also produced equivalent amounts of 
TNFα, IFNγ and IL-10 in response to STAg, suggesting that this chronic model of 
infection was not DR3 dependent (Meylan, Davidson et al. 2008). As well as this, in a 
chronic model of peritoneal fibrosis, whereby mice were injected weekly over a 4 week 
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period with an inactivated bacterial suspension of Staphylococcus epidermis (SES), no 
differences were seen in the recruitment of leukocytes into the peritoneal cavity at day 
49.  However, a difference was seen between DR3wt and DR3ko mice in fibrosis 
development (Perks, 2013 PhD), indicating that structural measures of disease 
pathology do not necessarily correlate with leukocyte accumulation.  
 
Numerous cell subset numbers, including eosinophils, did not significantly differ within 
the lung or BALF from DR3wt and DR3ko mice following multiple aerosolisation 
challenges. This is in keeping with published literature (Sakai, Yokoyama et al. 2001) 
and a common occurrence when modelling chronic allergic lung protocols, which 
continues to be problematic in exhibiting the characteristics of human asthma. Koerner-
Rettberg et al noted sustained airway lymphocytosis but short lived eosinophilia upon 
long term challenge (Koerner-Rettberg, Doths et al. 2008). Meanwhile, Swirski et al 
describes diminishing eosinophilia by 3 weeks and complete resolution after 4 weeks of 
antigen exposure (Swirski, Sajic et al. 2002), suggesting that chronic exposure to 
antigen does not sustain airway inflammation but rather leads to airway 
unresponsiveness. This could explain the apparent lack of differences between OVA 
and PBS challenged mice, with inflammation not being a predominant feature of some 
chronic asthma mouse models (Locke, Royce et al. 2007). This apparent lack of airway 
inflammation after multiple aerosol challenges is not just restricted to DR3 amongst the 
TNFRSF. TNFRko mice, deficient in both TNFR1 and 2, have also shown no 
differences compared to WT mice, in airway hyper-responsiveness, BAL leukocyte 
numbers and cytokine levels after 7 days of consecutive OVA aerosolisation, suggesting 
that TNFα alone is unable to abrogate allergic lung inflammation and other cytokines 
have the ability to compensate for its loss (Rudmann, Moore et al. 2000). 
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Another potential explanation for my observations is the development of immune 
mediated tolerance alongside long-term challenge (Jungsuwadee, Benkovszky et al. 
2004; Van Hove, Maes et al. 2007). One suggested regulatory method is an alteration in 
the interaction between DCs and T cells via the suppression of the co-stimulatory 
molecules CD28 and ICOS, thereby inhibiting DC maturation (Van Hove, Maes et al. 
2007). This would be consistent with the lack of T cell expansion within the lung 
following chronic challenges, despite increased myeloid DC number. The measurement 
of these co-stimulatory molecules would therefore make an interesting point of study. 
Furthermore, regulatory T cells, which hold the ability to ablate inflammation upon 
transfer into an established chronic allergic lung inflammation mouse model (Kearley, 
Barker et al. 2005; Kearley, Robinson et al. 2008), could also be measured upon repeat 
of these experiments. 
 
Regulatory T cells are known to express DR3 (Pappu, Borodovsky et al. 2008; 
Schreiber, Wolf et al. 2010; Taraban, Ferdinand et al. 2011; Taraban, Slebioda et al. 
2011), though controversy exists as to the levels in comparison to conventional CD4+ T 
cells. Schreiber et al reported preferential binding of a monoclonal DR3 antibody to 
Tregs, suggesting DR3 expression is higher on Tregs than conventional CD4+ T cells 
(Schreiber, Wolf et al. 2010), whilst Taraban et al, reported similar DR3 expression 
between the 2 subsets using a different commercially available polyclonal DR3 
antibody. This was supported with data using soluble recombinant TL1A, which bound 
equally well to both conventional and regulatory CD4+ T cells (Taraban, Ferdinand et 
al. 2011).  These differences may be due to the use of different reagents, which may 
preferentially bind specific isoforms on TregS. It has previously been shown that TregS 
express less full length DR3 in comparison to Th17 cells (Pappu, Borodovsky et al. 
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2008), with Taraban et al stating that the antibody used throughout their studies was 
capable of detecting both full length and truncated DR3, confirmed through retroviral 
expression studies with the 2 isoforms in the mouse embryo fibroblast cell line, NIH3T3 
(Taraban, Ferdinand et al. 2011). It is therefore possible that the antibody used by 
Schreiber et al, binds epitopes of DR3, that detect splice variants that are differentially 
expressed on distinct CD4+ T cells subsets. 
 
Functional effects of DR3 signalling on the Treg subset have also been studied, with 
Schreiber et al using an agonistic DR3 antibody to expand the pool of Tregs within the 
lung, reversing the ratio of conventional T cells to Tregs. This was reported to lead to the 
suppression of acute allergic lung inflammation (Schreiber, Wolf et al. 2010). Similarly, 
Reddy et al observed Treg expansion in mice virally infected with Herpes Simplex Virus-
1 (HSV-1), reducing the severity of stromal keratitis lesions, particularly when 
administered with galectin-9 (J Reddy, Schreiber et al. 2012). However, in a model of 
small intestinal inflammation, Taraban et al argued that whilst DR3 activation did 
increase the levels of Tregs, it also conferred co-stimulatory effects on conventional 
CD4+ T cells, causing a suppressive effect on the ability of Tregs to attenuate 
inflammation (Taraban, Ferdinand et al. 2011; Taraban, Slebioda et al. 2011). In 
response to this, Schreiber et al suggested that the balance between DR3 triggering 
regulatory or effector immunity was likely dependent upon the availability of cognate 
antigen to the Treg or effector T cell subsets, rather than the difference in receptor 
expression (Schreiber, Khan et al. 2011). This conflicting data emphasises the need to 
study Tregs in more detail in this particular chronic model of allergic lung inflammation.  
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Alternatively, the lack of lung leukocyte differences between OVA and PBS challenged 
mice, and possibly DR3wt and DR3ko mice, may be the extraction method employed 
throughout this study. Once lungs were removed, they were sliced into small pieces, 
treated with collagenase and passed through a cell strainer (Section 2.2.5.1). This 
process resulted in relatively high levels of cell death. However, the protocol also 
allowed access to the cells locked within the lung compartments, which would 
otherwise not have been examined. Intriguingly, despite flow cytometry results 
suggesting few differences in leukocyte accumulation, the H&E stains showed greater 
cellular infiltration in the peribronchial and perivascular areas of DR3wt OVA mice. 
This discrepancy could be explained by inefficient extraction of leukocyte subsets 
and/or preferential viability dependent on DR3 expression. However, alternative 
methods also have disadvantages. Mechanical digestion or mincing are more aggressive 
than enzymatic digestion, whilst multi-colour microscopy on lung sections are more 
limited in the number of fluorescence markers that can be used to differentiate cell 
subsets.  
 
Myeloid cells, particularly macrophages, are known to be especially adhesive when 
activated (Taylor, personal communication), which may be enhanced amid repeated 
exposure to allergen, making cells more difficult to extract. Having said this, the lack of 
leukocyte differences between DR3wt and DR3ko mice following chronic allergic lung 
inflammation may be model rather than DR3 related. 
 
Aside from myeloid DCs, no other cell subset was observed to significantly increase in 
number in comparison to DR3ko mice. It is therefore unsurprising that no chemokine 
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differences were observed in the BALF of DR3ko and DR3wt mice (Appendix figure 1.1) 
(Appendix Table 1.1).  
 
 
5.4.2 Effects of DR3 on airway remodelling  
Whilst chronic models of allergic lung disease have been shown to have modest levels 
of inflammation, airway remodelling is considered a fundamental characteristic feature 
of the disease. My results showed that the lungs of DR3wt OVA mice underwent airway 
remodelling to a significantly higher degree than DR3ko OVA mice, implying DR3 is 
involved in the regulation of lung pathology. DR3wt OVA mice had higher levels of 
mucin than DR3ko OVA mice and PBS treated groups. Mucin production is a key 
contributor to asthma and via the production of mucus plugs, also to fatalities (Locke, 
Royce et al. 2007). It is unknown however, whether this increase in mucin is due to the 
differentiation or proliferation of goblet cells. The transcription factor SPDEF is thought 
to be involved in the conversion of Clara cells, goblet cell precursors, into mucin 
producing goblet cells (Chen, Korfhagen et al. 2009). Loss of function experiments 
using SPDEF would confirm if the observed goblet cell increase was due to 
differentiation or proliferation, and whether DR3 acted upstream or downstream of this 
transcription factor. Moreover, DR3 has already been shown to have a role in goblet cell 
hyperplasia, albeit in a model of small intestinal inflammation (Meylan, Song et al. 
2011; Shih, Barrett et al. 2011; Taraban, Slebioda et al. 2011). Mice which 
constitutively expressed TL1A on both T cells (Meylan, Davidson et al. 2008) and DCs 
(Taraban, Slebioda et al. 2011) spontaneously developed small bowel disease which 
was characterised by goblet cell hypertrophy and hyperplasia.  This was shown to be IL-
13 driven.  
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IL-13 has been shown to be a key contributor to goblet cell hyperplasia in the lung 
(Wills-Karp, Luyimbazi et al. 1998; Chen, Sivaprasad et al. 2013), along with IL-5 
(Lee, McGarry et al. 1997). Compared to DN DR3 or DR3ko mice, DR3wt animals were 
found to have increased numbers of goblet cells in acute allergic lung inflammation, 
which correlated with increases in IL-13 (Fang, Adkins et al. 2008; Meylan, Davidson 
et al. 2008). While CD4+ Th2 cells are considered one of the main sources for this 
cytokine, Doherty et al found that CD4+ T cell depletion had no effect on remodelling 
progression (Doherty, Soroosh et al. 2009), indicating the central source of IL-13 may 
lie elsewhere. Epithelial cells themselves have been implicated in the release of 
remodelling cytokines (Polito and Proud 1998; Holgate, Lackie et al. 2000; 
Allahverdian, Harada et al. 2008), as have more recently, a population of innate cells 
known as nuocytes or type 2 innate lymphoid cells (ILC) (Barlow, Bellosi et al. 2012). 
ILC2s can be found in the lung (Monticelli, Sonnenberg et al. 2011) and have the 
capacity to release IL-13 in response to IL-33 and IL-25, which themselves have been 
implicated in the airway remodelling process. IL-33 release from epithelial cells triggers 
goblet cell hyperplasia, Th2 cytokine production, as well as Th2 cell differentiation via 
the programming of DCs through the IL-33 receptor ST2 (Rank, Kobayashi et al. 2009). 
Alveolar macrophages too have been shown to release IL-33 and in turn, induce 
remodelling. Macrophage depletion abolished airway remodelling as opposed to CD4+ 
T cell depletion, where the process continued to occur (Mizutani, Nabe et al. 2013).  IL-
25, a member of the IL-17 cytokine family has also been implicated in the airway 
remodelling process following allergic lung inflammation. Released by differentiated 
Th2 cells (Fort, Cheung et al. 2001), activated eosinophils, bone marrow derived mast 
cells, FcεRI activated basophils and epithelial cells (Hammad, Chieppa et al. 2009), IL-
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25 is thought to act on stromal cells (Swaidani, Bulek et al. 2009) and macrophages 
(Yang, Grinchuk et al. 2013). IL-25 levels have been shown to increase in response to 
MMP-7, which is induced in allergen activated epithelial cells, cleaving the cytokine to 
its more active form to promote Th2 cytokine production (Goswami, Angkasekwinai et 
al. 2009). Systemic administration of recombinant IL-25 for 10 days in C57BL/6 mice 
induced peripheral blood, lung and spleen eosinophilia, elevated serum antibody levels 
and pulmonary goblet cell metaplasia. It would be interesting to investigate the 
interaction between these cytokines and the DR3/TL1A pathway in regulation of mucin 
production in the lung. 
 
When studying the fibrotic response, there were no significant differences between 
DR3wt and DR3ko OVA mice in collagen production. The DR3/TL1A pathway has 
previously been shown to be involved in intestinal fibrosis (Shih, Barrett et al. 2011; 
Barrett, Zhang et al. 2012; Zheng, Zhang et al. 2013). Mice which constitutively 
expressed TL1A exhibited enhanced gut fibrosis compared to WT mice (Barrett, Zhang 
et al. 2012), which correlated with an increase in TGFβ1 (Shih, Barrett et al. 2011), a 
known mediator of fibrosis (Le, Cho et al. 2007). Furthermore, TL1A and crosslinking 
of DR3 with a monoclonal antibody has been shown to induce TGFβ1 in vitro from the 
macrophage cell line, THP-1 (Lee, Kim et al. 2010). Thus, whilst published work 
suggests a role for the DR3/TL1A pathway in the induction of TGFβ1 and therefore 
collagen production, the data described in this Chapter does not. Further work would be 
required to determine how much this is due to organ and animal model-specific DR3 
function.  
 
263 
 
Interestingly, other TNFR members have been found to have a role in the fibrotic 
response during chronic allergic lung inflammation. Inhibition of LIGHT led to a 
reduction in the level of fibrosis as well as smooth muscle mass, thought to be mediated 
via the inhibition of TGFβ and IL-13 release (Doherty, Soroosh et al. 2011). Similarly, 
TNFR p55/p75 deficient mice demonstrated significantly reduced peribronchial fibrosis, 
smooth muscle layer and deposition of extracellular matrix proteins in a model of 
chronic allergic lung inflammation (Cho, Kwon et al. 2006). The lack of differences 
seen within this Chapter suggests that among the TNFRSF, DR3 is not essential for the 
initiation and development of lung fibrosis.  
 
 
5.4.3 DR3 expression in the lungs following chronic allergic lung inflammation  
DR3 expression in the lung was comparable between DR3wt OVA and PBS treated mice 
following chronic allergic lung inflammation at 72hrs, but significantly higher in DR3wt 
PBS mice at 24hrs post inhalation. However, as mentioned previously (Section 3.4.2) 
the DR3 antibody used was unable to distinguish between the 3 murine splice variants; 
a full-length membrane-bound variant, a soluble form and truncated membrane-bound 
form (Wang, Kitson et al. 2001). Expression of the different isoforms has already been 
shown to change depending on cellular activation (Bamias, Mishina et al. 2006; 
Twohig, Marsden et al. 2012), prompting careful consideration of DR3 splice variant 
function following T cell activation. Without the identification of the splice variant 
within the chronic lungs of DR3wt OVA and PBS mice, it is difficult to draw 
conclusions regarding function. Additionally, DR3 has been shown to have a transient 
nature in certain cell subsets, namely CD8+ T cells. Purified splenocyte derived T cells 
were stimulated in vitro with an anti-CD3 antibody, and the pattern of DR3 expression 
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observed. CD8+ T cells up-regulated DR3 rapidly, peaking at 24hrs, before declining to 
baseline levels at 72hrs post stimulation (Twohig, Marsden et al. 2012). DR3 expression 
may be transient in the lungs of DR3wt OVA challenged mice, explaining the temporary 
decrease in DR3 signal at 24hrs in comparison to DR3wt PBS mice.   
 
DR3 signal was predominately observed in the epithelial areas of the lung bronchioles, 
correlating with the location of goblet cells. Given the significant and consistent 
differences noted in goblet cell specific signal, it is tempting to speculate that DR3 is 
expressed on these mucin producing cells, with signalling through the receptor directly 
driving mucin production. However, attempts to test this using a dual PAS/DR3 stain 
proved unsuccessful. Despite the complexity in isolating goblet cells from mice, Wang 
et al have reported Clara cells can be identified using flow cytometry with a marker 
known as Clara cell secretory protein (CSSP) (Wang, Keefe et al. 2012). Purified 
CSSP+ cells can then be grown in a culture to mimic the lung environment (Wang, 
Keefe et al. 2012). This could potentially provide a means to analyse DR3 expression 
on goblet cells, although removal of cells for expansion in vitro may change their 
physiological and phenotypic properties.  
 
 
5.4.4 The effects of DR3 on the systemic response  
DR3 had no effect on the production of allergic antibodies as comparable levels of Total 
IgE and OVA specific IgG were seen between DR3wt and DR3ko mice, agreeing with 
previously published acute allergic lung inflammation findings (Meylan, Davidson et al. 
2008).  This is also similar to Bull et al, who following the induction of AIA, observed 
normal anti-BSA antibody levels in DR3ko mice (Bull, Williams et al. 2008). In a model 
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of CIA however, the addition of TL1A acted to increase the levels of collagen specific 
IgG and IgG2a, suggesting TL1A can enhance the humoral response. This was 
supported with an increase in the size of splenic germinal centres in mice treated with 
TL1A daily for 10 days, required for B cell activation and differentiation into antibody 
producing plasma cells (Zhang, Wang et al. 2009).  
 
DR3 has previously shown to be expressed on human antigen stimulated B cells in the 
germinal centres of tonsils and the spleen (Cavallini, Lovato et al. 2013). Human in 
vitro studies have shown that TL1A is able to reduce the proliferation of B cells which 
have been suboptimally activated with IgM and IL-2 (Cavallini, Lovato et al. 2013), 
contrasting with the results of Zhang et al who suggest TL1A supports the humoral 
response and potentially B cell proliferation. These discrepancies may be due to the use 
of different systems and species to examine the relationship between DR3 and B cells. 
Results within this Chapter also suggests DR3 regulates splenic B cell number 
following antigen challenge, though the immunological impact of this remains obscure 
as quantitative antibody production was unaffected.  
 
The effects on the central immune system were further scrutinised via the analysis of 
leukocyte subsets in the spleen following chronic allergic lung inflammation. Data 
showed that DR3wt OVA mice at 24hrs and DR3wt OVA and PBS mice at 72hrs had 
significantly higher numbers of both myeloid and lymphocytic cells than DR3ko mice, 
suggesting DR3 regulates global cellular accumulation in the spleen, in this case after 
repeated localised exposure to antigen in the lung. The analogous production of OVA 
specific IgG between DR3wt and DR3ko OVA aerosolised animals implies that the 
sensitisation stages in this model were not impaired. Others have also reported that DR3 
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is not required for central immune responses following acute allergic lung inflammation 
(Meylan, Davidson et al. 2008). Another possible explanation for the data presented in 
this Chapter is a defect in leukocyte recirculation from the spleen to the lung upon 
allergen challenge. Potential reasons for these considerable differences will be discussed 
further in Chapter 6.  
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5.5 Summary 
The relationship between airway inflammation, impaired lung function and airway 
remodelling is poorly understood. This is made more difficult by the variety of 
sensitisation and challenge protocols as well as the array of read-outs used to assess the 
responses. In this model of chronic allergic lung inflammation, it was found that airway 
inflammation and allergic antibody production were not DR3 dependent. However, 
DR3 did regulate mucin production and peribronchiolar cellular infiltration, although 
the underlying mechanisms behind this are unknown.  There was also a clear phenotype 
within the spleen, as DR3ko mice displayed decreased leukocyte numbers, the 
mechanisms for which will be investigated further in Chapter 6.  
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Chapter 6: 
Investigating the role of DR3 in early 
priming events 
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6.1 Introduction 
The phenotypes observed in Chapter’s 4 and 5 were both striking and unexpected. 
Despite the use of DR3ko mice to study allergic lung inflammation, no defects in the 
splenic responses following antigenic challenge had been reported (Meylan, Davidson 
et al. 2008). Therefore, this clear-cut defect in DR3ko mice was explored further using a 
single priming event with a range of Alum concentrations in conjunction with OVA.  
  
Alum is a commonly used adjuvant in both murine research and human vaccines, 
although the mechanisms by which it exerts its stimulatory effects are poorly 
understood. It has been suggested that the adjuvant forms an antigen depot at the site of 
injection, thereby prolonging the exposure to antigen and so the immune response 
(Glenny and Barr 1931). However, this theory has been challenged by several reports, 
which demonstrate that Alum is in fact absorbed within hours of injection (Weissburg, 
Berman et al. 1995; Gupta, Chang et al. 1996). More recently, Hutchinson et al also 
discredited the theory, claiming that removal of the injection site as early as 2hrs post 
injection had no effect on the development of antigen specific B or T cell responses 
(Hutchison, Benson et al. 2012). 
 
Immuno-stimulation has also been cited as a mechanism of Alum action. Arguments 
persist as to whether Alum is able to directly activate antigen presenting cells 
(Mannhalter, Neychev et al. 1985; Sun, Pollock et al. 2003; Sokolovska, Hem et al. 
2007), as the adjuvant was observed to increase antigen uptake by DCs in vitro, as well 
as enhance antigen presentation magnitude and duration (Morefield, Sokolovska et al. 
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2005). As well as antigen uptake, Alum is also thought to reduce the rate of antigen 
degradation once internalised, thereby sustaining presentation (Ghimire, Benson et al. 
2012).  In vivo, the effects of Alum were abolished upon depletion of CD11c+ 
monocytes or DCs, suggesting a central role for the cell type in Alum induced antigen 
uptake, as well as maturation (Kool, Soullie et al. 2008). Despite previously being 
thought to utilise the TLR pathway (Schnare, Barton et al. 2001), the use of MyD88-
TRIF double mutant mice confirmed that the adjuvant works independently of TLRs 
(Gavin, Hoebe et al. 2006).  
 
It has recently been suggested that the NALP3 inflammasome is required for Alum 
activity via the release of IL-1β (Li, Nookala et al. 2007; Eisenbarth, Colegio et al. 
2008; Kool, Petrilli et al. 2008; Li, Willingham et al. 2008), promoting antigen specific 
IgE responses (Kool, Petrilli et al. 2008). Adding to this, Alum induced proliferation of 
antigen specific T cells in the draining lymph nodes was found to be dependent on uric 
acid, a known activator of NALP3. It was therefore hypothesised that Alum caused 
necrosis of target cells, resulting in the production of uric acid, activation of the NALP3 
inflammasome, which in turn activated caspase 1 to process pro-IL-1β, pro-IL-18 and 
pro-IL-33 into their mature bioactive forms (Kool, Soullie et al. 2008; Martinon, Mayor 
et al. 2009). Neutralisation of uric acid before Alum injection by the uric acid degrading 
enzyme, uricase, abolished the recruitment of inflammatory monocytes to the draining 
lymph nodes (Kool, Willart et al. 2011), suggesting uric acid has a prominent role in 
Alum mediated activation of the innate immune reaction. Furthermore, phagocytosis of 
Alum was shown to induce phagosomal destabilisation, resulting in the release of the 
lysosomal protease Cathepsin B into the cytosol, initiating the activation of the NALP3 
inflammasome (Hornung, Bauernfeind et al. 2008). However, the involvement of 
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NALP3 has been disputed by others (Franchi and Nunez 2008), whilst the use of 
NALP3 deficient mice only partially reduced IL-6 production and inflammatory 
monocyte influx after intra-peritoneal administration of Alum (Kool, Petrilli et al. 
2008). In addition, the use of caspase 1 deficient mice, which cannot produce IL-1β, had 
no effect on Alum induced inflammation (McKee, Munks et al. 2009), suggesting Alum 
may work through NALP3 independent mechanisms. Kuroda et al suggest a crucial role 
for prostaglandin E2 (PGE2) to induce Alum mediated effects, via the induction of 
cyclooxygenase-2 (COX-2) and membrane associated PGE synthease-1 (mPGES-1). 
Antigen specific IgE levels were reduced in mPGES-1 deficient mice following 
immunisation with Alum, whilst immunisation with nitrous oxide, which induces PGE2 
secretion but not IL-1β, enhanced antibody titres, thus suggesting the mechanism was 
IL-1β independent. COX-2 and mPGES-1 require induction via a pro-inflammatory 
stimulus, whilst Alum acts to cause lysosomal damage, leading to cytosolic 
phosopolipase A2 (cPLA2) activation, resulting in the release of arachidonic acid from 
membrane lipids, a precursor for PGE2 (Kuroda, Ishii et al. 2011).  
 
It has also been suggested that Alum stimulates the release of host cell DNA, which like 
uric acid, acts as a potent immuno-stimulatory danger signal. Host DNA was reported to 
induce primary B cell responses and IgG1 production, whilst also promoting canonical 
Th2 responses, leading to IgE isotype switching through interferon response factor 3 
(Irf-3) dependent mechanisms. Antibody responses, as well as the migration of 
inflammatory monocytes, were reduced in the presence of DNase alongside Alum and 
antigen (Marichal, Ohata et al. 2011). However, DNase treatment was found to have no 
effect on the appearance of antigen loaded DCs in the draining lymph node, nor the 
expression of co-stimulatory molecules on these cells, instead prolonging the length of 
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interaction time between antigen loaded cells and antigen specific T cells and the ability 
of DCs to present peptide to CD4+ T cells using MHCII molecules. It was thus 
suggested that Alum acts to allow host DNA access to the cytoplasm of DCs, activating 
pathways to increase peptide presentation to antigen specific T cells in the draining 
lymph node (McKee, Burchill et al. 2013).  
 
Despite the debate concerning Alum, it is frequently used to encourage the Th2 
phenotype in murine models of allergic lung inflammation, promoting an immune 
response to otherwise non-immunogenic antigens. Although adjuvant free protocols 
have been described using OVA, (Blyth, Pedrick et al. 1996; Blyth, Wharton et al. 
2000; Janssen, van Oosterhout et al. 2000), multiple exposures are often required to 
achieve suitable sensitisation. Furthermore, the strain of mouse was also found to be 
important when utilising adjuvant free protocols, as C57BL/6 mice (the strain used in 
these studies) were observed to exhibit a lesser inflammatory response to allergen in 
comparison to BALB/c animals (Conrad, Yildirim et al. 2009). 
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6.2 Aims 
Considering the results obtained previously (Chapters 4 and 5), the aim of this Chapter 
was to examine the splenic response of DR3ko mice following a single injection via the 
peritoneum with different concentrations of Alum alongside OVA on day 0 and 
harvesting on day 7. As DR3 has previously been reported to influence the efficiency of 
the T cell response to antigen (Meylan, Davidson et al. 2008), various concentrations of 
adjuvant were considered necessary. Upon harvest, leukocyte accumulation was 
examined as well as chemokine levels. To determine the T cell response, splenocytes 
were stimulated with OVA ex vivo and proliferation measured by 3H-thymidine uptake, 
whilst the B cell response was assessed via OVA specific IgG measurements 
 
6.2.1 Objectives  
i) Determine cellular accumulation in the spleens of DR3wt and DR3ko mice in 
response to varying concentrations of Alum 
ii) Examine antigen specific responses  
iii) Assess the mechanisms involved in cellular accumulation 
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6.3 Results 
6.3.1 Cellular accumulation in the spleen 
 
 
6.3.1.1 DR3 regulated leukocyte accumulation into the spleen but had no effect on 
spleen mass as a % of body mass 
Ascending concentrations of Alum (0.1mg-50mg) mixed with OVA, as well as OVA 
alone were used to look at the response of DR3 to adjuvant and antigen challenge in the 
spleen. Mice were injected i.p once and spleens harvested after 7 days. Weights of the 
mice and their spleens were also recorded. Results showed that DR3 had no effect on 
spleen mass, expressed as a % of total body mass, as no genotype specific differences 
were seen (p=0.242). Increasing concentrations of Alum were significantly associated 
with increases in spleen mass in both DR3ko and DR3wt mice (p<0.0001), which also 
corresponded with higher total cell numbers in the spleen (p=0.013). DR3 was, 
however, found to regulate cellular accumulation in the spleen (p=0.004), as DR3ko 
mice consistently displayed lower cell numbers compared to DR3wt animals, 
particularly when suboptimal doses of Alum were used (Alum 50mg DR3wt 11.8±1.2 
x107, DR3ko 8.8±1.2 x107, Alum 0.4mg DR3wt 8.8±1.1 x107, DR3ko 5.3±1.1 x107) 
(Figure 6.1). 
 
 
 
 
Figure 6.1. Total leukocyte number and spleen mass of DR3wt and DR3ko mice 
injected with Alum and OVA. Mice were injected on day 0 via the peritoneal cavity and 
sacrificed on day 7. Splenocytes were extracted via mashing of the spleen and counted 
using a haemocytometer. Total cell number (Interaction=0.206, Genotype=**0.004, 
Alum=*0.013). Spleen mass was calculated as a % of total body mass. Spleen mass 
(Interaction=0.755, Genotype=0.242, Alum=***p<0.0001).  Significance determined 
using 2 way ANOVA; *p<0.05, **p<0.01, ***p<0.001. Bars represent mean ± SEM 
(n=6). Data shown is a combination of  2 individual experiments.  
 
OV
A 
Al
um
 0.
1m
g
Al
um
 0.
4 m
g
Al
um
 1m
g
Al
um
 2 
mg
Al
um
 10
 m
g
Al
um
 50
 m
g
0
5
10
15
WT
KO
To
ta
l C
el
l N
um
be
r(
x1
07
)
OV
A 
Al
um
 0.
1m
g
Al
um
 0.
4 m
g
Al
um
 1m
g
Al
um
 2 
mg
Al
um
 10
 m
g
Al
um
 50
 m
g
0.0
0.2
0.4
0.6
0.8
Sp
le
en
 m
as
s 
(%
)
276 
 
6.3.1.2 DR3ko mice displayed reduced numbers of dendritic cells at all concentrations of 
Alum 
DR3ko mice displayed decreased numbers in several myeloid cell subsets examined. The 
most consistent of these were DCs, including both myeloid and plasmacytoid DCs. 
DR3wt myeloid DC number did not change in relation to Alum (p=0.718), with similar 
cell numbers being seen across all the concentrations tested. DR3wt myeloid DC number 
was reliably increased compared to DR3ko mice at all Alum concentrations, from 0.1mg 
(DR3wt 0.9±0.1 x106, DR3ko 0.7±0.1 x106) to 50mg (DR3wt 1.2±0.2 x106, DR3ko 
0.7±0.1 x106) (p<0.0001) (Figure 6.2). However, DR3ko mice injected with OVA alone, 
displayed analogous cell numbers to DR3wt mice (DR3wt 1.0±0.1 x106, DR3ko 1.1±0.2 
x106), suggesting Alum, is required to induce the differences seen, which resulted in a 
fall of numbers in DR3ko mice.  
 
In contrast, DR3wt plasmacytoid DCs varied relative to Alum concentration. Cell 
numbers were similar between doses 0.4mg-1mg, at which point plasmacytoid DCs 
increased in a dose dependent manner (p=0.031). DR3wt numbers were higher than 
DR3ko mice at all concentrations, ranging from 1.5±0.3 x105 compared to 0.8±0.1 x105 
at 0.1mg Alum, respectively, to 2.3±0.9 x105 compared to a DR3ko average of 1.2±0.3 
x105 using 50mg Alum dose (p<0.0001) (Figure 6.2). Interestingly, unlike myeloid 
DCs, numbers of plasmacytoid DC in DR3ko and DR3wt spleens were not found to be 
dependent on the presence of Alum, as significant differences were noted after priming 
with OVA alone (DR3wt 1.5±0.3 x105, DR3ko 0.8±0.2 x105), suggesting that antigenic 
stimulation without adjuvant is sufficient to induce this phenotype. However, results 
from both cell subsets imply DR3 is essential for DC accumulation in the spleen.  
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As well as DC differences, DR3wt mice were also observed to have higher numbers of 
macrophages when injected with 2mg of Alum (DR3wt 3.3±0.5 x106, DR3ko 2.2±0.3 
x106) upwards to 50mg (DR3wt 5.2±0.9 x106, DR3ko 3.4±0.4 x106) (p=0.004), as well as 
eosinophils between the same concentrations (Alum 2mg DR3wt 0.8±0.2 x106, DR3ko 
0.6±0.1 x106, Alum 50mg DR3wt 1.0±0.2 x106, DR3ko 0.7±0.1 x106) (p=0.030) (Figure 
6.2).  
 
Neutrophil accumulation was significantly affected by the higher concentrations of 
Alum (p<0.0001), as both genotypes immunised with 50mg of Alum displayed higher 
cell numbers than all other experimental groups (DR3wt 4.0±0.9 x106, DR3ko 2.6±0.4 
x106). No significant differences were noted when analysing the 7/4+ or 7/4- monocyte 
subsets (Figure 6.2).  
 
Overall, the absence of DR3 affected the content of multiple myeloid cell subsets in the 
spleen following challenge. At all concentrations of Alum, myeloid DC numbers were 
lower in DR3ko mice, whilst the same was true for plasmacytoid DCs but included OVA 
immunisation without Alum. Decreased macrophage and eosinophil numbers in DR3ko 
mice was dependent on Alum dose, as decreases were seen between the 2mg and 50mg 
Alum range.    
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Figure 6.2. Myeloid cell subsets from the spleens of DR3wt and DR3ko mice injected with 
Alum and OVA. Mice were injected on day 0 via the peritoneal cavity and sacrificed on day 
7. Splenocytes were isolated and subsets determined using antibody cell markers. 
Macrophages (Interaction=0.528, Genotype=**0.004, Alum=0.053), Neutrophils 
(Interaction=0.224, Genotype=0.382, Alum=***p<0.0001), Eosinophils 
(Interaction=0.579, Genotype=*0.031, Alum=***p<0.0001), 7/4+ Monocytes n.s.d, 7/4- 
Monocytes n.s.d, Myeloid DCs (Interaction=0.310, Genotype=***p<0.0001, Alum=0.718), 
Plasmacytoid DCs (Interaction=0.841, Genotype=***p<0.0001, Alum=*0.031). 
Significance determined using 2 way ANOVA; *p<0.05, **p<0.01, ***p<0.001. Values 
represent mean ± SEM (n=6). Data shown is a combination of 2 individual experiments.  
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6.3.1.3 DR3 regulated the accumulation of multiple lymphocyte subsets into the spleen 
following Alum/OVA injection 
Multiple lymphocytic subsets were affected by the loss of DR3. DR3ko mice displayed 
reduced numbers of CD3+ T cells, with evidence of differences noted at 0.4mg (DR3wt 
2.0±0.2 x107, DR3ko 1.0±0.3 x107) and 10mg of Alum (2.7±0.3 x107, DR3ko 2.0±0.1 
x107) (p=0.001) (Figure 6.3). This correlated with decreased numbers of CD4+ T cells 
(Alum 0.4mg DR3wt 1.2±0.1 x107, Alum 10mg 1.6±0.2 x107, DR3ko 1.2±0.1 x107) 
(p=0.005) and CD8+ T cells at the same Alum doses (Alum 0.4mg DR3wt 0.7±0.1 x107, 
Alum 10mg 1.0±0.1 x107, DR3ko 0.7±0.04 x107) (p=0.0001) (Figure 6.3). Numbers of 
activated T cells in DR3ko mice, detected via the marker CD44, were also lower at all 
concentrations of Alum as well as when injected with OVA alone. This was true of both 
activated CD4+ (DR3wt 2.8±0.2 x106, DR3ko 1.9±0.3 x106) and CD8+ T cell populations 
(DR3wt 1.6±0.2 x106, DR3ko 1.2±0.3 x106) (Figure 6.3). DR3ko mice were found to have 
significantly fewer B cells than DR3wt mice (p<0.0001), even in the absence of adjuvant 
(DR3wt 2.7±0.2 x107, DR3ko 2.1±0.4 x107). This depletion in DR3ko B cells continued 
across the majority of Alum doses, barring Alum 1mg, whereby numbers were found to 
be equivalent between the 2 genotypes (DR3wt 2.1±0.3 x107, DR3ko 2.1±0.3 x107) 
(Figure 6.3) 
 
NKT cell number also differed between DR3wt and DR3ko mice across all 
concentrations of Alum, with both factors influencing the results (Genotype p<0.0001, 
Alum p=0.0008). Like activated T cell subsets, the DR3wt spleen contained greater 
numbers of NKT cells after OVA stimulation alone (DR3wt 0.8±0.1 x106, DR3ko 
0.6±0.1 x106). Genotype was also found to significantly effect γδ T cell number 
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(p=0.003), particularly when using 0.1mg Alum (DR3wt 6.5±1.6 x105, DR3ko 3.9±0.2 
x105), 0.4mg Alum (DR3wt 4.2±1.4 x105, DR3ko 1.5±0.1 x105) and 10mg Alum (DR3wt 
7.1±1.2 x105, DR3ko 4.4±0.6 x105). No significant differences were observed between 
DR3wt and DR3ko mice in NK cells, although Alum had a significant effect on cell 
accumulation in both genotypes by 2 way ANOVA (p=0.032) (Figure 6.4).   
 
In summary, DR3 controlled the accrual and/or retention of many lymphocyte subsets 
into the spleen including CD4+ T cells, CD8+ T cells, B cells, NKT cells and γδ T cells. 
Adding to this, the absence of DR3 also decreased the numbers of activated T cells 
noted within the spleen.  
 
 
 
 
 
 
 
  
Figure 6.3. Lymphocyte subsets from the spleens of DR3wt and DR3ko mice injected with 
Alum and OVA. Mice were injected on day 0 via the peritoneal cavity and sacrificed on 
day 7. Splenocytes were isolated and subsets determined using antibody cell markers. 
CD3+ T cells (Interaction=0.413, Genotype=**0.001, Alum=***0.0006), CD4+ T cells 
(Interaction=0.494, Genotype=**0.005, Alum=***0.0005), CD8+ T cells 
(Interaction=0.538, Genotype=***0.0001, Alum=***0.0008), Act. CD4+ T cells 
(Interaction=0.813, Genotype=***p<0.0001, Alum=***p<0.0001), Act. CD8+ T cells 
(Interaction=0.977, Genotype=***p<0.0001, Alum=0.071), B cells (Interaction=0.524, 
Genotype=***p<0.0001, Alum=*0.042). Significance determined using 2 way ANOVA; 
*p<0.05, **p<0.01, ***p<0.001. Values represent mean ± SEM (n=6). Data shown is a 
combination of 2 individual experiments.  
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Figure 6.4. NK cells and innate like lymphocyte subsets from the spleens of DR3wt and 
DR3ko mice injected with Alum and OVA. Mice were injected on day 0 via the peritoneal 
cavity and sacrificed on day 7. Splenocytes were isolated and subsets determined using 
antibody cell markers. NK cells (Interaction=0.981, Genotype=0.058, Alum=*0.032), 
NKT cells (Interaction=0.736, Genotype=***p<0.0001, Alum=***0.0008), γδ T cells 
(Interaction=0.612, Genotype=**0.003, Alum=*0.041). Significance determined using 2 
way ANOVA; *p<0.05, **p<0.01, ***p<0.001. Values represent mean ± SEM (n=6). Data 
shown is a combination of 2 individual experiments.  
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6.3.2 DR3 expression in the spleen  
 
6.3.2.1 DR3 expression on splenic lymphocytes 
Using Flow cytometry, relative (RF) DR3 cell surface expression was determined on 
particular lymphocyte populations within the spleen. The highest levels of DR3 cell 
surface expression were seen on NKT cells. However, the concentration of Alum 
determined the degree of NKT cell surface DR3 expression (p=0.021), with higher 
Alum doses resulting in lower signal detection (Alum 50mg RF 8.6±1.1, Alum 1mg RF 
20.1±2.9). As seen previously (Chapter 4), activated CD4+ T cells were found to 
express more DR3 signal than CD44- naive CD4+ T cells. In contrast to previous 
findings, DR3 expression did not differ between naive and activated CD8+ T cells, 
although both exhibited less DR3 signal than CD4+ T cell populations. (Figure 6.5) 
(Table 6.1). Alum was not required to induce DR3 expression, as comparable levels 
were seen on lymphocytes from OVA injected mice. Importantly, all DR3wt populations 
analysed displayed higher signals than control DR3ko cell types indicating the 
specificity of the reagents (p<0.0001) (Figure 6.5) (Table 6.1).   
 
 
 
  
Figure 6.5. Ratio of DR3 MFI’s on T cell populations in the spleens of DR3wt and DR3ko 
mice injected with Alum and OVA. Mice were injected on day 0 via the peritoneal cavity 
and sacrificed on day 7. Spleens were harvested and cells were stained with DR3 antibody.  
CD4+ T cells (Interaction=0.512, Genotype=***p<0.0001, Alum=0.112), CD8+ T cells 
(Interaction=0.393, Genotype=***p<0.0001, Alum=0.488), Activated CD4+ T cells 
(Interaction=0.075, Genotype=***p<0.0001, Alum=0.115), Activated CD8+ T cells 
(Interaction=0.220, Genotype=***p<0.0001, Alum=0.380) and NKT cells 
(Interaction=**0.008, Genotype=***p<0.0001, Alum=*0.021). Ratio DR3 was 
calculated by the MFI fold increase compared to control IgG antibody. Results determined 
using 2 way ANOVA; *p<0.05, **p<0.01, ***p<0.001. Bars represent mean ± SEM 
(n=3).  
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Table 6.1. DR3 expression on T cell populations in the spleen following injection with OVA and varying concentrations of Alum 
DR3wt DR3ko 
Alum 
concentration* 
CD4+ T 
cells 
 
Act.CD4+ 
T cells 
CD8+ T 
cells 
Act.CD8+ 
T cells 
NKT 
cells 
CD4+ T 
cells 
Act.CD4+ 
T cells 
CD8+ T 
cells 
Act.CD8+ 
T cells 
NKT 
cells 
Significance$ 
OVA 8.1±0.4 10.5±0.5 4.7±0.1 4.3±0.1 13.0±0.8 2.0±0.1 1.9±0.1 2.3±0.1 2.2±0.1 1.6±0.1 ***p<0.0001 
0.1mg 10.3±1.2 13.8±2.0 5.3±0.3 5.3±0.3 19.5±2.3 2.1±0.1 2.0±0.1 2.2±0.1 2.3±0.2 1.0±0.04 ***p<0.0001 
0.4mg 9.5±0.6 10.6±0.7 4.9±0.4 4.2±0.3 13.0±1.3 2.0±0.1 2.0±0.2 2.1±0.2 2.3±0.2 2.4±1.3 ***p<0.0001 
1mg 11.1±0.3 1501±0.4 5.9±0.1 5.7±0.1 20.1±2.9 3.0±1.1 1.9±0.1 2.5±0.3 2.1±0.2 1.2±0.1 ***p<0.0001 
2mg 10.0±0.5 11.7±0.5 5.4±0.4 5.0±0.2 16.3±1.5 2.2±0.1 2.2±0.1 2.4±0.1 2.4±0.1 1.7±0.04 ***p<0.0001 
10mg 8.2±1.4 10.2±0.1 4.8±0.9 4.7±0.4 13.7±2.7 2.2±0.1 2.4±0.2 2.5±0.1 2.3±0.1 1.5±0.3 ***p<0.0001 
50mg 7.0±1.8 9.9±1.7 4.3±0.5 4.6±0.7 8.6±1.1 1.8±0.4 2.2±0.2 2.5±0.2 2.4±0.3 1.4±0.2 ***p<0.0001 
* Corresponds to the concentration of Alum injected into mice (mg/ml) 
$ Significance of genotype measured by 2 way ANOVA.   
Median fluorescence intensity (MFI) ratio calculated by dividing the test median by the isotype following gating on the specified population ± SEM following 
flow cytometry.  
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6.3.3 Antigen specific responses following adjuvant and OVA injection  
 
6.3.3.1 Antigen specific antibody production  
Alum was found to significantly affect OVA specific IgG production (p<0.0001). Mice 
treated with higher concentrations of the adjuvant showed higher levels of OVA specific 
IgG in their serum, with a dose response between 0.1mg Alum (DR3wt 0.1±0.02, DR3ko 
0.1±0.04) and 50mg (Alum 50mg DR3wt 0.5±0.1, DR3ko 0.6±0.03). Very little OVA 
specific IgG was produced in mice injected solely with OVA (DR3wt 0.05±0.02, DR3ko 
0.1±0.1) (Figure 6.6) (Table 6.2). Importantly, no significant differences were observed 
in antibody production between DR3wt and DR3ko mice, suggesting DR3 does not 
regulate antibody responses quantitatively, despite the differences noted in B cell 
number, T cell activation and DC numbers.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Antigen specific antibody response of DR3wt and DR3ko mice injected with 
Alum and OVA. Mice were injected on day 0 via the peritoneal cavity and sacrificed on 
day 7. Serum was isolated from blood obtained from cardiac puncture and tested for 
concentrations of  OVA specific IgG (Interaction=0.415, Genotype=0.511, 
Alum=***p<0.0001). Significance determined using 2 way ANOVA and Bonferroni post 
test; *p<0.05, **p<0.01, ***p<0.001. Values represent mean ± SEM (n=3). Data shown 
is representative of 2 experiments. 
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Table 6.2. Serum levels of OVA specific IgG following injection with OVA and 
varying concentrations of Alum  
                                                     DR3wt                                          DR3ko 
Alum 
Concentration* 
OVA IgG Significance$ 
OVA 0.05±0.02 0.1±0.1 N.S.D 
0.1mg 0.1±0.02 0.1±0.05 N.S.D 
0.4mg 0.3±0.1 0.2±0.1 N.S.D 
1mg 0.4±0.1 0.3±0.5 N.S.D 
2mg 0.5±0.03 0.5±0.01 N.S.D 
10mg 0.5±0.1 0.6±0.01 N.S.D 
50mg 0.5±0.1 0.6±0.03 N.S.D 
* Corresponds to the concentration of Alum injected into mice 
$ Significance between DR3wt and DR3ko mice measured by 2 way ANOVA. N.S.D= no 
significant difference.  
Values represent the mean±SEM of the optical density reading from the OVA specific IgG 
ELISA using serum from DR3wt and DR3ko mice from 2 different experiments (n=6).  
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6.3.3.2 DR3wt and DR3ko splenocytes displayed comparable proliferative responses 
 
 
Whole splenocyte populations from DR3wt and DR3ko mice were stimulated in vitro 
with 2 different concentrations of OVA, 10μg/ml and 50μg/ml. Cells were then pulsed 
with 3H-thymidine to assess the proliferative response. Results confirmed that DR3wt 
and DR3ko mice had comparable proliferative responses when challenged with OVA, 
suggesting that the defects noted were not due to a lack of antigen-specific T cell 
expansion. At no concentration of Alum were significant differences seen between the 2 
genotypes, although 3H-thymidine incorporation did increase in response to higher 
doses of OVA. Cells treated with 50μg/ml of OVA proliferated more than those treated 
with 10μg/ml, with this difference being significant in all experimental dosage groups 
(Figure 6.7) (Table 6.3). Furthermore, proliferation was greater in cells from mice 
treated with 50mg Alum than the lower concentrations of Alum, particularly 0.1mg. 
 
 
 
 
 
 
 
  
Figure 6.7. Proliferation of DR3wt and DR3ko splenocytes in response to OVA following 
injection with Alum and OVA. Mice were injected on day 0 via the peritoneal cavity and 
sacrificed on day 7. Splenocytes were extracted via mashing of the spleen and stimulated 
in vitro with 2 concentrations of OVA; 10μg/ml, 50μg/ml. Alum 50mg (Interaction=0.947, 
Genotype=0.592, Stimulation=***0.0004), Alum 10mg (Interaction=0.211, 
Genotype=0.067, Stimulation=***p<0.0001), Alum 2mg (Interaction=0.807, 
Genotype=0.259, Stimulation=***p<0.0001), Alum 1mg n.s.d, Alum 0.4mg 
(Interaction=0.591, Genotype=0.08, Stimulation=**0.007), Alum 0.1mg 
(Interaction=0.603, Genotype=0.135, Stimulation=*0.040), OVA (Interaction=0.335, 
Genotype=0.904, Stimulation=***0.0002). Significance determined using 2 way 
ANOVA; *p<0.05, **p<0.01, ***p<0.001. Values represent mean ± SEM (n=3). Data 
shown is representative of 2 experiments. 
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Table 6.3. Proliferative response of DR3wt and DR3ko mice injected with OVA and 
varying concentrations of Alum 
  DR3wt                                                 DR3ko 
Alum 
Concentration* 
OVA 
10ug/ml^ 
OVA 
50ug/ml€ 
OVA 
10ug/ml^ 
OVA 
50ug/ml€ 
Significance$ 
OVA 750±112 1051±106 634±165 1285±210 N.S.D 
0.1mg 537±286 905±297 258±113 491±127 N.S.D 
0.4mg 1612±452 2165±450 752±439 1341±541 N.S.D 
1mg 1673±814 2104±818 751±147 1129±362 N.S.D 
2mg 1604±52 2716±236 1338±409 2235±520 N.S.D 
10mg 1337±79 2570±162 1029±147 2049±298 N.S.D 
50mg 1869±592 2972±1018 2156±215 3332±346 N.S.D 
* Corresponds to the concentration of Alum injected into mice 
^ Corresponds to cells stimulated with 10ug/ml of OVA 
€ Corresponds to cells stimulated with 50ug/ml of OVA 
$ Significance between DR3wt and DR3ko mice measured by 2 way ANOVA. N.S.D= no 
significant difference.  
Values represent mean±SEM of the cpm readings from 3h-thymidine pulsed DR3wt and DR3ko 
splenocytes from 2 different experiments (n=6).  
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6.3.4 Investigating the mechanisms for DR3wt cellular accumulation in the spleen 
6.3.4.1 Spleens from DR3wt mice contained higher levels of CXCL10 than DR3ko mice 
Reduced cellular accumulation in the spleens of DR3ko mice was not found to be 
dependent on antigen-specific proliferation, therefore chemokine levels were measured 
from spleen lysates to determine whether a defect in recruitment was potentially 
contributing to reduced cellular accumulation. Results showed that DR3ko mice had 
lower levels of CXCL10, as 2-way ANOVA analysis showed genotype to be a 
significant factor (p=0.001). This difference was particularly apparent in mice injected 
with 50mg of Alum (DR3wt 2127±264 pg/ml, DR3ko 1438.±120 pg/ml) (p<0.05). No 
other chemoattractants measured were found to significantly differ between DR3wt and 
DR3ko mice, although Alum concentration did affect the levels of many. CCL3, CXCL2 
and CXCL1 concentrations were found to be higher in mice treated with 50mg of Alum, 
which correlated with an increase in neutrophils, the known responder of CXCL1 
(p=0.004). In contrast CCL5 levels decreased with the higher doses of Alum (p=0.013). 
No significant differences were seen in CXCL13 release, a typical B cell 
chemoattractant, although levels did correlate with B cell number (Figure 6.8) (Table 
6.4).  
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Figure 6.8. Chemokine levels in the spleens of DR3wt and DR3ko mice injected with 
Alum and OVA. Mice were injected on day 0 via the peritoneal cavity and sacrificed on 
day 7. Spleens were harvested to form a lysate, from which chemokine levels were 
measured using ELISA. CCL3 (Interaction=0.743, Genotype=0.571, Alum=*0.019), 
CCL4 n.s.d, CCL5 (Interaction=0.257, Genotype=0.948, Alum=*0.013), CXCL1 
(Interaction=0.802, Genotype=0.553, Alum=**0.004),  CXCL2 n.s.d, CXCL10 
(Interaction=0.596, Genotype=**0.002, Alum=0.146)and CXCL13 n.s.d. Significance 
determined using 2 way ANOVA and Bonferroni post test; *p<0.05, **p<0.01, 
***p<0.001. Symbols represent mean ± SEM (n=3).  
 
 
 
 
 
 
Table 6.4. Chemokine levels in the spleens of DR3wt and DR3ko mice challenged with varying concentrations of Alum with OVA 
DR3wt DR3ko 
 Alum 
conc.* 
50mg 10mg 2mg 0.4mg OVA 50mg 10mg 2mg 0.4mg OVA  
Chemokine 
(ng/ml) 
 
           Significance$ 
CCL3  0.4±0.2 0.2±0.05 0.2±0.02 0.1±0.02 0.08±0 0.4±0.01 0.1±0.05 0.2±0.08 0.2±0.04 0.2±0 N.S.D 
CCL4  0.4±0.1 0.3±0.1 0.3±0.01 0.3±0.02 0.2±0 0.4±0.09 0.2±0.06 0.5±0.2 0.4±0.06 0.4±0 N.S.D 
CCL5  15±11.1 30.1±7.4 25.6±4.5 26.5±2.5 20.2±0 9.4±0.9 21.2±6.6 27.7±4.7 38.3±9.2 16.8±0 N.S.D 
CXCL1  0.7±0.2 0.2±0.02 0.4±0.1 0.3±0.4 0.3±0 0.8±0.3 0.1±0.02 0.2±0.4 0.2±0.06 0.3±0 N.S.D 
CXCL2  0.3±0.06 0.2±0.01 0.2±0.03 0.2±0.02 0.2±0 0.2±0.03 0.1±0.01 0.2±0.01 0.2±0.02 0.2±0 N.S.D 
CXCL10  2.1±0.3 1.8±0.1 2.0±0.2 2.1±0.2 1.8±0 1.4±0.1 1.3±0.1 1.8±0.1 1.8±0.2 1.7±0 **p=0.0084 
CXCL13  85.6±15.9 93.2±34.4 85.7±19.8 61.4±6.7 55.7±0 51.2±6.1 62.5±22.8 87.4±1.7 59.9±16.7 30.7±0 N.S.D 
*Corresponds to the concentration of Alum injected into mice (mg/ml) 
$ Significance of genotype measured by 2 way ANOVA. N.S.D= no significant difference, *p<0.05, **p<0.01.  
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6.4 Discussion 
To examine the splenic response observed in Chapter’s 4 and 5, whereby a reduction in 
splenocyte accumulation was noted in DR3ko mice exposed to multiple OVA/Alum 
challenges during acute and chronic inflammatory models of allergic lung 
inflammation, a more basic model was utilised to explore this phenotype. Mice were 
injected once in the peritoneal cavity with an OVA/Alum mix followed by a detailed 
analysis of splenic myeloid and lymphocyte populations at day 7. Results showed that 1 
sensitisation injection was sufficient to initiate alterations in the cellular content of 
DR3wt spleens, and this was significantly different in DR3ko mice.  
 
This novel phenotype was made even more so by the defect in multiple myeloid cell 
subset numbers. Little research exists regarding DR3 and the regulation of myeloid cell 
numbers, despite numerous reports citing DR3 as a co-stimulator of T cell expansion 
(Meylan, Davidson et al. 2008; Jones, Stumhofer et al. 2011; Slebioda, Rowley et al. 
2011; Buchan, Taraban et al. 2012; Twohig, Marsden et al. 2012). In the model of 
antigen induced arthritis (AIA), mice were sub-cutaneously immunised twice 1 week 
apart, with methylated BSA (mBSA) and complete freunds adjuvant (CFA). AIA was 
then induced in the joint via an intra-articular injection of mBSA 21 days after the initial 
immunisation. No impairment was found in F4/80+ (a marker for macrophages) cell 
number between DR3wt and DR3ko mice at either 3 or 21 days post arthritis induction, 
suggesting DR3 did not control myeloid cell recruitment to the joint (Bull, Williams et 
al. 2008). F4/80+ macrophages act as the precursor for the bone resorbing cells, 
osteoclasts, identified using TRAP staining. Within the same model, DR3 was found to 
affect osteoclast generation at sites of bone pathology, particularly the pannus area, as 
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reduced numbers were noted in DR3ko mice. As well as this, in vitro, it was found that 
TL1A could promote osteoclast differentiation from bone marrow derived macrophages 
in the presence of RANK-L and M-CSF, as well as human peripheral blood monocytes 
(Bull, Williams et al. 2008).  
 
In contrast, in this thesis DR3 was found to affect the numbers of multiple myeloid cell 
subsets in the spleen following immunisation, including F4/80+ macrophages at higher 
adjuvant concentrations. This increase occurred after only 1 peritoneal sensitisation 
injection, as opposed to the 2 priming events and inflammatory hit used in the AIA 
model. This may be due to the use of different adjuvants, as Alum was used in this 
study compared to CFA, as well as the use of the i.p route of sensitisation in this 
Chapter as opposed to subcutaneous and intra-articular injections utilised by Bull et al 
(Bull, Williams et al. 2008).  
 
DR3 expression has itself been reported on the human macrophage cell line THP-1 in 
the basal state (Kang, Kim et al. 2005; Su, Chang et al. 2006), as well as foam cells in 
carotid endarterectomy tissue (Kim, Lee et al. 2001; Kang, Kim et al. 2005; Kim, Kang 
et al. 2008). Foam cells are essential in the development of atherosclerotic plaques via 
the ingestion of low-density lipoprotein (LDL) (Lusis, Mar et al. 2004). DR3 has been 
reported to directly stimulate human macrophage foam cell formation (McLaren, Calder 
et al. 2010). THP-1 cells and human monocyte derived macrophages stimulated with 
TL1A for 24hrs, demonstrated a significantly increased uptake of acetylated and 
oxidised LDL compared to untreated controls. This uptake was ablated upon 
administration of a soluble DR3-Fc fusion protein. As well as LDL uptake, caused by 
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TL1A driven up-regulation of scavenger receptors, cholesterol efflux was also reduced, 
via a decrease in the levels of apoE and ABCG-1 gene expression. To ensure that TL1A 
was acting though DR3, DR3 expression was reduced using a recombinant adenovirus 
expressing DR3 shRNA. These DR3 knock down macrophages failed to uptake LDL or 
effect cholesterol efflux in response to TL1A, confirming increased foam cell formation 
was DR3 dependent. The results were mirrored using murine bone marrow derived 
macrophages where DR3ko cells displayed impaired LDL uptake, correlating with a 
reduction in scavenger receptor mRNA (McLaren, Calder et al. 2010). This role for 
DR3 in myeloid cell function and differentiation implies that, like in this Chapter, DR3 
is important beyond T cells in the immune response.  
 
As well as macrophages, DR3ko mice also displayed reduced numbers of myeloid DCs 
following OVA/Alum injection. Some studies report Alum to act directly on myeloid 
DCs, increasing antigen uptake and internalisation and enhancing the expression of co-
stimulatory molecules (Sun, Pollock et al. 2003; Morefield, Sokolovska et al. 2005). 
More recently however, Flach et al used atomic force microscopy to hypothesise that as 
opposed to internalisation, Alum actually binds to DCs via lipid moieties, particularly 
sphingomyelin and cholesterol, delivering antigen via endocytosis. Binding promoted 
lipid sorting in the DC plasma membrane, including clustering of immunoreceptor 
tyrosine based activation motif (ITAM) containing receptors, which in turn activated the 
spleen tyrosine kinase (Syk) and PI3K pathways through a phosphorylation cascade.  
This led to the initiation of the immune response via an up-regulation of the co-
stimulatory molecules CD86, CD80 and ICAM-1, promoting tight interactions with 
CD4+ T cells (Flach, Ng et al. 2011). As DR3 has been shown to regulate cholesterol 
levels upon macrophages (McLaren, Calder et al. 2010), it may be acting in a similar 
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manner on myeloid DCs. It is tempting to speculate that the Alum-triggered reduction 
of myeloid DC numbers in DR3ko spleen is related to DR3’s capacity to regulate 
cholesterol uptake, but further studies would be required to confirm this.  
 
Myeloid DC differentiation and proliferation is driven by, amongst other proteins, GM-
CSF. GM-CSF has been shown to enhance conventional DC expansion both in vitro 
(Inaba, Steinman et al. 1992), and in vivo when over-expressed (Vremec, Lieschke et al. 
1997). Proliferation relies on the PI3K pathway, and more particularly, the downstream 
effector mammalian target of rapamycin (mTOR), inhibition of which prevents GM-
CSF human monocyte derived DC development due to reduced proliferation and 
survival (Kim, Kang et al. 2010). GM-CSF levels increase during inflammation, with 
some reporting the cytokine promotes monocyte conversion to murine spleen myeloid 
DCs (Naik, Metcalf et al. 2006), as well as DC generation in disease models, including 
acute inflammatory arthritis and antigen induced peritonitis (Campbell, van 
Nieuwenhuijze et al. 2011).  TL1A has previously been found to augment GM-CSF 
release from the splenocytes of a model of acute graft versus host response ex vivo, as 
well as suboptimally stimulated peripheral blood T cells (Migone, Zhang et al. 2002), 
suggesting TL1A is able to influence GM-CSF production and so potentially myeloid 
DC proliferation.  
 
Splenic CD11c+ DCs have been shown to rapidly release TL1A in response to multiple 
stimuli, including STAg, via the TLR pathway (Scanga, Aliberti et al. 2002) and cross 
linked IgG (Meylan, Davidson et al. 2008), although no expression was seen following 
Salmonella enterica Typhimurium infection (Buchan, Taraban et al. 2012). In a mouse 
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model of chronic ileitis, TL1A and CD11c+ cells were found to co-localise using lamina 
propria mononuclear cells from inflamed SAMP1/YitFc and TNF∆ARE mice, with flow 
cytometry results suggesting cells were DCs due to their CD11c+ MHCII+ phenotype 
(Bamias, Mishina et al. 2006). Despite this, little has been published specifically 
relating to DR3 function in plasmacytoid DCs.  
 
Plasmacytoid DCs are characterised by their ability to release high levels of type I 
interferons (Cella, Jarrossay et al. 1999), hence they are predominantly known for their 
functions in anti-viral immunity. Plasmacytoid DC development is thought to be 
dependent on Flt3-L, as Flt3-L deficient mice were found to have fewer plasmacytoid 
DCs compared to control animals (Brawand, Fitzpatrick et al. 2002), while GM-CSF 
has also been shown to support the survival of plasmacytoid DC precursors (Ghirelli, 
Zollinger et al. 2010). Flt3-L treatment was also shown to greatly enhance the number 
of plasmacytoid DCs in the lungs of allergen challenged mice, leading to reduced Th2 
associated eosinophilia. They were also shown to suppress the ongoing immune 
response, as their depletion, using the antibody 120G8, abrogated inflammation (Kool, 
van Nimwegen et al. 2009). Similar results were presented by De Heer et al, as 
depletion of plasmacytoid DCs led to IgE sensitisation, airway eosinophilia, goblet cell 
hyperplasia and Th2 cytokine release, in response to normally inert antigen, suggesting 
plasmacytoid DCs could be tolerogenic as opposed to immunogenicity exhibited by 
myeloid DCs. They were also found to suppress the generation of effector T cells (de 
Heer, Hammad et al. 2004). In the spleen, antigen pulsed plasmacytoid DCs induced 
minimal proliferation and cytokine polarisation in antigen-specific T cell receptor-
transgenic T cells, even in the presence of IL-2. They instead gained a regulatory 
phenotype and suppressed antigen-specific T cell proliferation (Martín, Del Hoyo et al. 
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2002; Takagi, Fukaya et al. 2011). However, others have suggested plasmacytoid DCs 
hold T cell stimulatory and expansion abilities once activated, although to a lesser 
extent than conventional myeloid DCs (Salio, Palmowski et al. 2004; Schlecht, Garcia 
et al. 2004; Villadangos and Young 2008). When virus activated they have been shown 
to elicit Th1 responses (Liu, Kanzler et al. 2001), although Ito et al observed 
plasmacytoid DCs to prime Th2 cells when activated by IL-3 and CD40-L in an OX40-
L dependent manner (Ito, Amakawa et al. 2004).  
 
DR3ko spleens contained significantly fewer plasmacytoid DCs than DR3wt mice 
following immunisation with Alum and OVA or OVA alone. Unlike myeloid DCs, the 
results of this Chapter show that plasmacytoid DC accumulation is enhanced by, but not 
dependent upon adjuvant, but rather just antigenic stimulation, suggesting DR3ko 
plasmacytoid DC deficiencies are due to a lack of expansion. It would therefore be 
interesting to examine the effects of TL1A on Flt3-L levels, to determine if the 
DR3/TL1A pathway regulates production and consequently plasmacytoid DC 
proliferation and survival. Alternatively, TL1A, like OX40-L, may induce plasmacytoid 
DCs to prime Th2 cells, or increase the levels of IFNγ, thereby enhancing the immune 
response. Whilst, no cytokine measurements were made in this study, it is clear that the 
role of DR3 in plasmacytoid DC accumulation and function requires further 
investigation.  
 
Both myeloid and plasmacytoid DCs arise from a common DC precursor (Naik, Sathe 
et al. 2007), expanding through stimulation of the previously mentioned tyrosine kinase, 
Flt3 and cytokine GM-CSF, as well as M-CSF and IL-3 amongst others (Karsunky, 
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Merad et al. 2003; Liu, Victora et al. 2009). However, unlike DR3 effects on 
osteoclastogenesis (Bull, Williams et al. 2008), the Receptor is unlikely to have a role in 
myeloid or plasmacytoid DC differentiation and homeostasis as comparable numbers 
were recorded between DR3wt and DR3ko mice in the basal state (Chapter 3). 
Furthermore, Tian et al found TL1A to have no effect on murine bone marrow derived 
DC maturation, compared to its shorter variant VEGI, which was found to induce early 
DC activation. This included up-regulation of the maturation markers CD83, CCR7, 
CD40, CD80 and CD86 as well as early activation of the maturation signalling 
molecules NF-κB, STAT3, p38, JNK, leading to cytoskeleton reorganisation and 
premature dendrite formation (Tian, Grimaldo et al. 2007). TNFα too, has been shown 
to aid umbilical cord derived CD34+ haematopoietic cells to develop into DCs when 
cultured with stem cell factors and GM-CSF. DCs were apparent by day 14, except 
when treated with an anti-TNFR1 antibody, so verifying that TNFα was acting through 
TNFR1 (Morrison Iii, Cruse et al. 2003). Similarly in the mouse, using bone marrow 
precursors from TNFαko C57BL/6 mice, DCs displayed an inability to mature, instead 
retaining the phenotype of immature DCs (Ritter, Meissner et al. 2003). It would 
therefore be interesting to measure the levels of DC co-stimulatory molecules, as 
although DR3 does not appear to be important in DC differentiation, like TNFα, it may 
affect myeloid and plasmacytoid DC activation and maturation upon antigenic 
challenge. 
 
DCs are essential for T cell priming and sensitisation, leading to the clonal expansion of 
antigen-specific T cells, for which Alum assists, acting as an additional co-stimulatory 
signal. Whilst it has been suggested that Alum does not activate DCs in vitro (Sun, 
Pollock et al. 2003), in vivo, Alum has been shown to initiate DC induced adaptive 
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immunity via NLRP10. NLRP10-/- mice were unable to migrate to the draining lymph 
nodes, despite antigen capture, resulting in absolute loss of CD4+ T cell priming 
(Eisenbarth, Williams et al. 2012). The results obtained within this Chapter however, 
suggest T cell priming is unaffected by the loss of DR3, as despite reduced T cell 
accumulation in the spleens of DR3ko mice, proliferation in response to OVA was 
comparable between the 2 genotypes.  
 
The DR3/TL1A pathway has previously been shown to have a role in the proliferation 
of murine T cells including, Th17 cells in the presence of low anti-CD3 stimulation 
(Pappu, Borodovsky et al. 2008; Jones, Stumhofer et al. 2011), CD4+ memory cells 
when stimulated with IL-12 and TL1A (Bamias, Mishina et al. 2006) and whole CD4+ T 
cell populations when stimulated with high concentrations of TL1A in the absence of 
CD28 co-stimulation (Meylan, Davidson et al. 2008). Furthermore, reduced peptide-
specific proliferation of DR3ko splenocytes was observed in a model of EAU (Calder 
and Wang 2012). Splenocytes were removed 21 days after subcutaneous injection of 
interphotoreceptor retinoid binding protein (IRBP) emulsified with CFA and 
Mycobacterium tuberculosis, stimulated with IRBP and pulsed with 3H-thymidine. 
Whilst the assay revealed no proliferative differences at 10 days post injection, at day 
21, DR3ko splenocytes displayed a significant reduction in proliferation compared to 
DR3wt cells, suggesting DR3 was required for sustained splenic T cell responses rather 
than priming (Calder and Wang 2012). DR3 altogether failed to enhance Treg 
proliferation in vitro under suboptimal signalling conditions (Schreiber, Wolf et al. 
2010). Adding to this, DR3 was reported to inhibit the expansion of human B cells, 
though survival was unaffected (Cavallini, Lovato et al. 2013). The experiments 
performed within this Chapter imply DR3 has a redundant role in the generation of 
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antigen-specific T cells, as comparable 3H-thymidine uptake was recorded from both 
DR3wt and DR3ko in vitro cell stimulations. Having said that, only 1 timepoint was 
measured and no attempt was made to assess proliferation in vivo, using for example, a 
Ki67 stain. In contrast to the methods employed in this Chapter, the majority of the 
above studies investigated the expansion of T cells that had been activated via their 
TCR and co-stimulated with TL1A. Like Calder et al (Calder and Wang 2012), the data 
presented here implies DR3 has no significant effect on T cell priming, despite the 
difference in DC numbers.  
 
Although T cell priming was not impaired in DR3ko mice, the numbers of activated T 
cells were, as a lack of expansion was observed following antigenic stimulation. 
Memory T cells have previously been reported to demonstrate a higher rate of 
proliferation in response to TL1A than naive lymphocytes (Bamias, Mishina et al. 
2006), whilst Meylan et al showed TL1A to have a role in expanding effector T cells at 
the site of inflammation in vivo. The same group also observed DR3 to be dispensable 
for the differentiation of naive T cells (Meylan, Davidson et al. 2008), suggesting the 
Receptor is required for expansion rather than activation. Furthermore, DR3/TL1A 
interactions were found to be required for activated T cell function against viral 
proteins, experiments of which were not performed in this Chapter, despite reduced 
numbers.  
 
Recruitment was also examined as a possible means by which DR3wt splenocytes 
increased in comparison to DR3ko mice. The spleen lysates from mice injected with 
OVA and Alum were analysed for a range of chemokines, with results showing that 
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DR3wt and DR3ko mice had significant differences in the levels of CXCL10, also known 
as IP-10. CXCL10 is thought to act as a chemoattractant for a range of cells, including 
CD4+ and CD8+ T cells, NKT cells, NK cells, monocytes (Campanella, Tager et al. 
2008) and plasmacytoid DCs (Sozzani, Vermi et al. 2010) via the receptor CXCR3. It is 
also secreted by various immune subsets, including DCs, as well as structural cells, such 
as endothelia (Luster and Ravetch 1987), in response to IFNγ stimulation (Dufour, 
Dziejman et al. 2002). 
 
TL1A has previously been reported to synergise with the IL-12/IL-18 pathway to 
induce IFNγ expression from human NK cells (Papadakis, Prehn et al. 2004) as well as 
CD4+ T cells (Prehn, Mehdizadeh et al. 2004; Cassatella, da Silva et al. 2007). Shih et al 
further treated CD4+ T cells with bacteria treated DCs (Shih, Kwan et al. 2009), whilst 
Migone et al stimulated T cells with anti-CD3 and anti-CD28 (Migone, Zhang et al. 
2002). Biener et al took a different approach, using HEK-293 cells expressing 
membrane bound TL1A and co-culturing them with IL-12/IL-18 primed CD4+ T cells 
(Biener-Ramanujan, Gonsky et al. 2010). However, the results were consistent; TL1A 
was able to stimulate IFNγ release. Similar reports have been published using murine 
cells, as IL-12/IL-18 primed CD4+ T cells up-regulated IFNγ in response to TL1A 
(Kamada, Hisamatsu et al. 2010). Bamias et al also stimulated murine CD4+ 
lymphocytes with anti-CD3 and anti-CD28 along with recombinant mouse TL1A, 
which was shown to induce IFNγ release in a dose dependent manner. Suboptimal anti-
CD3 concentrations revealed an additive effect of TL1A, enhancing IFNγ release 
(Bamias, Mishina et al. 2006). Using DR3ko cells from a model of EAU, Calder et al 
recorded reduced IFNγ production from splenocytes stimulated ex vivo with IRBP 
compared to DR3wt mice (Calder and Wang 2012). A TL1A-driven induction of IFNγ 
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could therefore explain the significant increases noted in CXCL10 levels in DR3wt mice, 
that further impacts on the recruitment of cell types thought to produce IFNγ, including 
plasmacytoid DCs and CD4+ T cells (Vremec, O'Keeffe et al. 2007).  However, Alum is 
typically thought to induce a Th2 response. Further studies would be needed to 
determine the polarisation of the T cell response following OVA and Alum challenge in 
the absence of DR3.   
 
CXCL10 has an already established role during inflammation and has been found to be 
elevated in several disease models, including EAE, whereby anti-CXCL10 treatment 
blocked the recruitment of antigen-specific effector T cells into the CNS (Fife, Kennedy 
et al. 2001) and CIA, where treatment with anti-CXCL10 significantly inhibited the 
infiltration of CD4+ T cells and F4/80+ cells into the synovium and attenuated bone 
destruction, as well as inhibiting RANK-L and TNFα levels (Kwak, Ha et al. 2008). 
CXCL10ko mice have also been shown to have impaired T cell responses, including 
proliferation to allogeneic and antigenic stimulation and IFNγ secretion in response to 
antigen challenge (Dufour, Dziejman et al. 2002). Unlike the data presented by Dufour 
et al, proliferation was found to be intact in DR3ko mice, despite CXCL10 levels being 
decreased. This suggests CXCL10 works downstream of DR3, perhaps affecting 
cellular accumulation due to a lack of TL1A signalling, which may directly stimulate 
chemokine release, or function by inducing IFNγ, creating a positive feedback loop 
regulated by the DR3/TL1A pathway. In order to test this theory, immunisations could 
be performed using CXCL10ko mice. Alternatively, CXCL10 levels could be silenced in 
DR3wt mice using antibody inhibition prior to Alum/OVA injection. Spleens could then 
be examined to see whether they present a similar phenotype to DR3ko mice. However, 
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due to the pleiotrophic nature of chemokine, as well as ensuring absolute depletion, 
experiments such as these are difficult to execute.  
 
DR3 has previously been shown to influence the release of other chemokines, albeit 
using human cells. Following the IFNγ priming of THP-1 cells, TL1A was found to 
induce IL-8, the murine ortholog being CXCL1 (Kang, Kim et al. 2005). IL-8 was also 
shown to be released from monocyte derived macrophages in a dose dependent manner 
upon TL1A stimulation, as well as on HEK-293 cells via DR3 over expression (Su, 
Chang et al. 2006). As well as IL-8, DR3 has previously been shown to induce CCL2 
release from THP-1 cells. Levels were further increased after LPS stimulation (Kang, 
Kim et al. 2005). In this Chapter, CXCL1 levels did not differ between DR3wt and 
DR3ko mice, whilst CCL2 measurements were not taken.   
 
Despite the analysis of multiple chemokines, significant differences were only observed 
between DR3wt and DR3ko mice in CXCL10 levels. No differences were noted in 
typical myeloid cell chemoattractants including CCL3, CCL4 or CCL5, despite 
differences in the numbers of some of these subsets. However, data within the 
laboratory has shown DR3 to elicit an extremely early effect in an un-sensitised model 
of peritoneal inflammation. Mice were peritoneally injected with an inactivated 
bacterial suspension (Hurst, Wilkinson et al. 2001), followed by assessments of 
leukocyte subsets in the peritoneal cavity. Chemokine analysis showed DR3ko mice had 
multiple defects, including CXCL1, CCL3 and CCL4 (Perks, 2013 PhD). This suggests 
that DR3 acts up-stream of several chemoattractants, including those directed at 
myeloid cell recruitment, exerting its effects as early as 6hrs post injection. Therefore, it 
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may be that the timepoint chosen to assess chemokine levels in this model were too late 
for some of those tested. Considering the results recently obtained within the laboratory, 
it would be interesting to examine chemokine levels over a time-course following 
OVA/Alum injection, to determine how early DR3 acts in this model regarding 
chemokine regulation.   
 
Alum itself is thought to affect the cellular recruitment of innate immune cells to the 
injection site (Goto and Akama 1982; Goto, Kato et al. 1997), via the regulation of 
chemokines. Mosca et al used genome wide microarray to demonstrate the ability of 
Alum to modulate chemokine expression following intra-muscular injection (Mosca, 
Tritto et al. 2008), whilst intra-peritoneal injection of Alum has been shown to induce 
the local production of the chemoattractants CCL2 and CXCL1. This led to neutrophil, 
eosinophil and monocyte recruitment, the latter of which were shown to migrate to the 
draining lymph node and differentiate into inflammatory DCs (Kool, Soullie et al. 
2008). Moreover, Alum has also been to shown to induce IL-8 and CCL2 release from 
macrophages and monocytes (Seubert, Monaci et al. 2008), as well as recruit CD11b+ 
myeloid cells following intra-muscular injection. These recruited cell types were found 
to take up adjuvant and antigen and transport to the draining lymph nodes, with the 
authors proposing Alum injection leads to chemokine driven immune amplification, 
increasing the numbers of antigen presenting cells contributing to the onset of immunity 
(Calabro, Tortoli et al. 2011). Adding to this, innate cell depletion post Alum injection 
had little effect in the generation of an adaptive immune response (McKee, Munks et al. 
2009). As multiple DR3ko innate cell subsets are depleted between 2mg and 50mg, 
including macrophages, eosinophils, monocytes, NK cells, NKT cells and γδ T cells, as 
well as the chemokine CXCL10, it is possible Alum is influencing cellular recruitment 
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via DR3. However, the data suggests a certain threshold for this effect, as the biggest 
differences are observed at the higher adjuvant concentrations.  
 
Splenic differences have also been published between DR3wt and DR3ko mice in a 
model of MCMV infection (Twohig, Marsden et al. 2012). The spleen is a site of robust 
viral specific T cell and NK cell responses during MCMV infection. Whilst NK cell 
expansion was found not to differ, a significant reduction was noted in DR3ko CD4+ T 
cell numbers at day 6 post-infection, and CD8+ T cells throughout the studied time-
course. These T cell decreases were also observed using recombinant Vaccinia virus. 
Priming was found to be intact, indicated by similar levels of cytokine-producing and 
degranulating T cells, assessed using a CD107 assay. However, DR3ko mice were found 
to have fewer virus-specific IFNγ expressing T cells in the early response, but not the 
late response, suggesting the memory response was unaffected. This impairment in T 
cell expansion was shown to be DR3 specific, using adoptive transfer of congenic 
DR3wt and DR3ko T cells differing at the Thy1 locus, demonstrated that only DR3wt but 
not DR3ko CD4+ and CD8+ T cells expanded. This expansion was found to be due to 
increased proliferation rather than reduced cell death. 
 
Though similar results were obtained in this Chapter, in that T cell splenic differences 
were observed by day 7, the means by which this was achieved were quite different. An 
MCMV viral model is a chronic model of pathogen infection, as once mice have been 
infected they are constantly exposed to the virus and therefore suffer constant immune 
activation. The model employed in this Chapter involved only 1 injection of non-
infectious OVA/Alum. Furthermore, Twohig et al considered a lack of proliferation to 
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be responsible for reduced DR3ko T cell numbers (Twohig, Marsden et al. 2012), whilst 
the results of this Chapter suggest antigen-specific proliferation is unaffected by the 
absence of DR3. Therefore, the mechanism by which T cell numbers increase in the 
spleen is likely to differ between the MCMV model and that described in this study, 
with the results presented here implying a contribution from defects in recruitment.  
 
Despite significant differences in B cell number between DR3wt and DR3ko mice, no 
differences were found in OVA specific IgG production, again signifying priming was 
unimpaired. However, little antibody was produced in the absence of Alum. Alum has 
been shown to directly modulate B cells to produce IgG1 (Jin, Kim et al. 2013), by 
inducing uric acid and activating inflammatory DCs (Kool, Soullie et al. 2008). DCs 
were found to influence the humoral response as DC depleted mice injected with 
OVA/Alum, displayed significant reductions in the levels of OVA-specific IgG1 10 
days after injection (Kool, Soullie et al. 2008). Alum, even without antigen, was found 
to influence the in vivo priming activity of splenic B cell responses via an increase in 
calcium following B cell surface MHCII aggregation, so leading to antigen specific B 
cell expansion. This was reported to be mediated by a population of Gr1+/CD11b+ IL-4 
producing cells (Jordan, Mills et al. 2004), which were later identified as eosinophils 
(Wang and Weller 2008). NKT cells have also been reported to be involved in Alum 
stimulated antibody enhancement (Shah, Devera et al. 2012).  
 
Limited research has been published regarding the role of DR3 on B cells. Naive murine 
splenic and human peripheral blood derived B cells have been reported as DR3 negative 
(Fang, Adkins et al. 2008; Cavallini, Lovato et al. 2013), however, activation through 
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the B cell receptor (BCR) induced its expression in vitro and it has been detected in vivo 
in tonsil germinal centres (Cavallini, Lovato et al. 2013).  Cavallini et al also stated that 
DR3 reduced B cell proliferation, but had no effects on survival. However, no 
functional experiments were performed to decipher the role of DR3 in somatic hyper-
mutation or affinity maturation.  
 
Affinity maturation occurs in germinal centres and precedes B cell differentiation into 
either memory B cells or plasma cells. It is the process by which rare mutants 
expressing BCRs with high affinity for antigen are expanded through cycles of mutation 
and cell death. The TNFSF have an established role in the B cell response, such as 
CD40/CD40-L, which is required for a sustained immune response and isotype 
switching (Grewal and Flavell 1998), BAFF which can provide the necessary signals in 
the absence of CD40-L (Mackay and Browning 2002) and TACI, which is thought to 
maintain B cell homeostasis (Yan, Wang et al. 2001). B cells are able to assess the 
affinity of antigen using BCR-intrinsic mechanisms during the early phase of the B cell 
response, leading to activation. High affinity BCRs form oligomers which in turn grow 
into microclusters. This leads to enhanced recruitment of Syk kinases and calcium 
fluxes, so triggering signalling cascades and activation (Liu, Meckel et al. 2010). 
Affinity discrimination is key in the initiation of BCR responses. Those with low 
affinity undergo apoptosis, whilst those with high affinity receive survival signals rather 
than a proliferative advantage (Anderson, Khalil et al. 2009). Therefore, although it 
appears class switching is not altered by the absence of DR3, shown by the comparable 
antigen specific IgG levels, no studies have examined the effects of DR3 on B cells with 
high affinity for antigen.  
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6.5 Summary 
The results of this Chapter show accumulation of multiple populations of splenocytes to 
be reduced in DR3ko mice after one intra-peritoneal injection of non-pathogenic antigen 
and the adjuvant Alum. As well as confirming its previously described role in 
influencing T cell numbers, this thesis also shows DR3 to regulate the numbers of B 
cells, DC subsets, macrophages and eosinophils. The functional consequences of this 
remain unknown as antigen-specific T cell proliferation and antibody production were 
unchanged in this model. Results suggest that recruitment may be an important factor, 
as one chemokine, CXCL10, was significantly reduced in DR3ko compared to DR3wt 
spleens, although further experiments need to be conducted to determine whether other 
chemokines may also be involved at earlier timepoints. Furthermore, while most 
splenocyte subsets demonstrated an impaired capacity to increase numbers in DR3ko 
mice, myeloid DCs showed a decrease relative to baseline levels, suggesting 
involvement of other mechanisms separate to recruitment. These are novel descriptions 
of a previously undiscovered immune phenotype in DR3ko mice and indicate there may 
be more basic impairments in their immunity than initially reported.  
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Chapter 7: 
General Discussion 
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7.1 Summary 
The results of this thesis indicate that whilst DR3 is not required for the homeostatic 
maintenance of leukocytes in the lung, spleen and peripheral blood upon the induction 
of allergic lung inflammation, it induces a multitude of effects. Following acute allergic 
lung inflammation, DR3ko mice displayed reduced cellular inflammation into the lung 
characterised by decreased 7/4- monocytes, NK cells and NKT cells, as well as into the 
BAL fluid, whereby numbers of 7/4- monocytes, myeloid DCs, CD4+ T cells, CD8+ T 
cells and NKT cells were reduced. In a more clinically relevant model of chronic 
allergic lung inflammation, DR3ko mice exhibited lower mucin levels and inflammation 
in the lung parenchyma compared to DR3wt mice. Interestingly, both acute and chronic 
models induced DR3 dependent changes in the spleen, as DR3ko mice displayed reduced 
accumulation of multiple myeloid and lymphocyte subsets compared to DR3wt mice. 
This phenotype was further explored, with results showing that one intra-peritoneal 
immunisation was sufficient to induce these altered splenocyte numbers, although as 
comparable antigen-specific T and B cell responses were observed, the functional 
biological consequences of this remain unclear. 
 
7.2 DR3 is not required for leukocyte homeostasis  
Despite the presence of DR3 on naive T cell populations, lung, spleen and peripheral 
blood leukocyte numbers did not differ between DR3wt and DR3ko mice, suggesting 
DR3 is not involved in the immunological maintenance of these organs. However, 
DR3’s constant presence and the lack of an inflammatory response suggest that either 
soluble DR3 or TL1A may be regulated to prevent constant bouts of inflammation and 
an unintended effector response.  
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7.3 DR3 in allergic lung inflammation  
Data within this thesis implicates the DR3/TL1A pathway during specific phases of 
allergic lung inflammation. Reduced cellular accumulation was observed in the lungs 
and BALF of DR3ko mice following acute allergic lung inflammation, raising the 
possibility that DR3 could be a potential therapeutic target during acute exacerbations of 
the disease. As previously reported, reduced effector T cell numbers correlated with 
reduced mucin levels in mice lacking functional DR3. Meylan et al suggested DR3 is 
required for effector T cell expansion at the site of inflammation, as well as the 
production of the pathogenic cytokines IL-5 and IL-13 after re-challenge with antigen 
(Meylan, Davidson et al. 2008). DN DR3 transgenic mice exhibited similar resistance to 
OVA induced acute allergic lung inflammation, whilst blockade with an anti-TL1A 
antibody as late as 1 day before challenge also inhibited disease. Adding to this, Fang et 
al showed DR3+ NKT cells to be central in disease development.  Jα18-deficient mice, 
which lack invariant NKT cells and are resistant to OVA induced airway inflammation, 
were transferred with DN DR3 NKT cells, which unlike WT NKT cells, failed to restore 
airway inflammation. The authors therefore proposed that NKT cells secrete IL-13 in 
response to TL1A, which acts on mucus producing cells and promotes the asthma 
phenotype (Fang, Adkins et al. 2008). Both of these hypotheses are supported by the 
data of this thesis, where reduced CD4+ T cell and NKT cell numbers were recorded in 
the DR3ko BALF, which corresponded to reduced mucin levels. Together this data 
implies that in acute inflammation, DR3 is required for disease progression as its 
absence hinders the development of both cellular infiltration and a resulting remodelling 
effect.  
 
315 
 
During chronic disease, DR3 appears to be essential for architectural changes in the 
lung, as DR3ko mice exhibited reduced peribronchial and perivascular cuffing as well as 
lower mucin levels, a causative of mucus plugging and bronchoconstriction. Though the 
mechanisms behind these structural changes were not examined, data in this thesis 
implicates DR3 as a driver of mucin production during lung inflammation. Mucus 
overproduction is commonly associated with Th2 derived cytokines, although the data 
of Chapter 5 shows T cell numbers to be comparable between DR3wt and DR3ko mice. 
There are a number of plausible explanations for this mucin hyperplasia, despite the 
absence of T cell increases.  
 
Firstly, cellular accumulation in the chronic treated DR3wt lung may have been 
transient. T cells may have been present in increased numbers before the point of 
harvest, releasing the necessary cytokines to induce airway remodelling before 
migrating from the lung. However, as neither cytokine levels nor multiple timepoints 
were examined in this thesis, this hypothesis requires further experiments to confirm.  
 
A second potential explanation for the observed mucin increases is the involvement of 
alternative cells types besides CD4+ T cells. Asthma, and consequently allergic lung 
inflammation is increasingly being considered a heterogeneous disease involving more 
than just Th2 cells. While multiple T cell and myeloid cell subsets were examined, no 
account was taken of mast cells during this study, irrespective of their central role in 
allergic inflammation and more specifically airway alterations. Increased mast cell 
numbers have been reported in the airway smooth muscle of asthmatic patients, 
corresponding with disease severity (Brightling, Bradding et al. 2002). In vitro, human 
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mast cells have been shown to adhere to airway smooth muscle through smooth muscle 
membrane bound SCF, soluble IL-6 and cell adhesion molecule 1 (CADM1), which is 
also required for mast cell adhesion to fibroblasts (Moiseeva, Roach et al. 2013). This 
smooth muscle and mast cell interaction was shown to support mast cell survival, 
proliferation, as well as de-granulation in co-culture (Hollins, Kaur et al. 2008). 
Through the release of inflammatory mediators, including, β-tryptase (Berger, Girodet 
et al. 2003), chymase (Lazaar, Plotnick et al. 2002), leukotriene D4 (Espinosa, Bosse et 
al. 2003), histamine (Panettieri, Yadvish et al. 1990) and TGFβ (Woodman, Siddiqui et 
al. 2008),  mast cells have been reported to influence smooth muscle proliferation, 
although this has been disputed by some (Kaur, Hollins et al. 2010). Mast cell 
importance in allergic lung inflammation has been further confirmed using mice lacking 
FcRγ chain, a signalling adaptor used by FcεRI. FcRγ deficiency results in the 
inhibition of mast cell activation by antigen and IgE dependent FcεRI aggregation, and 
thereby resistance to airway remodelling (Yu, Tsai et al. 2006). Human mast cells have 
also been shown to release amphiregulin, an epidermal growth factor ligand, causing an 
up-regulation in mucin gene expression in epithelial cells, leading to goblet cell 
differentiation (Okayama, Okumura et al. 2009). The same study reported intracellularly 
stored TSLP release by mast cells in asthmatic subjects following FcεRI aggregation 
and IL-4 stimulation (Okayama, Okumura et al. 2009), leading to smooth muscle actin 
and collagen up-regulation in a STAT3 dependent manner (Wu, Liu et al. 2013). IL-9, 
produced by a newly described subset known as Th9 cells (Veldhoen, Uyttenhove et al. 
2008), as well as mast cells themselves (Hültner, Kölsch et al. 2000), has been shown to 
enhance mast cell growth, differentiation and protease expression. In both OVA and 
house dust mite induced chronic models of allergic lung inflammation, IL-9 
neutralisation was reported to attenuate structural changes including mucus secretion, 
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sub-epithelial collagen deposition and release of pro-fibrotic factors (Kearley, Erjefalt et 
al. 2011). This overwhelming evidence of mast cell involvement in airway remodelling 
combined with the structural changes observed in this study in the absence of T cell 
differences, suggests mast cells as a good candidate for inducing DR3-dependent mucin 
release. 
 
γδ T cells have also been reported to enhance Th2 cytokine production following 
allergen challenge (Krug, Erpenbeck et al. 2001), with some observing an increase in 
intracellular IL-4 in γδ T cells isolated from the airways of asthmatic patients 
(Pawankar, Okuda et al. 1996; Spinozzi, Agea et al. 1996), suggesting γδ T cells have a 
pro-inflammatory role in allergic asthma. The absence of γδ T cells in mice was 
reported to prevent the development of airway hyper-reactivity and eosinophil and T 
cell infiltration in an OVA induced model of acute allergic lung inflammation, although 
timing of depletion was found to be important (Lahn, Kanehiro et al. 1999). Depletion 
just before challenge resulted in airway hyper-responsiveness, whilst before 
sensitisation, hypo-responsiveness was observed in response to Methacholine (Hahn, 
Taube et al. 2004). Mice lacking γδ T cells also displayed reduced IgE and IgG release 
following acute allergic lung inflammation (Zuany-Amorim, Ruffie et al. 1998), similar 
to an OVA chronic model of allergic lung inflammation whereby mice demonstrated 
reduced airway hyper-reactivity, inflammation and allergen specific IgE (Tamura-
Yamashita, Endo et al. 2008). Jaffar et al observed an increase in intra-epithelial 
associated IL-17 producing γδ T cells following allergic lung inflammation, up-
regulated through prostaglandin I2 and IL-6 (Jaffar, Ferrini et al. 2011). IL-17 has 
previously been shown to have a role in allergic lung inflammation (Nakae, Komiyama 
et al. 2002; Song, Luo et al. 2008) and is increased in the airways and sputum of 
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asthmatic patients, correlating with airway hyper-responsiveness (Molet, Hamid et al. 
2001; Barczyk, Pierzchala et al. 2003).  Furthermore, IL-17 was also shown to stimulate 
the mucin genes MUC5B and MUC5AC from both human and mouse tracheo-bronchial 
epithelial (TBE) cells in combination with IL-6 (Chen, Thai et al. 2003), suggesting γδ 
T cell derived IL-17 could possibly be initiating mucus hyperplasia.  In contrast, 
Murdoch et al proposed these IL-17 γδ T cells, which were more prevalent than IL-17 
αβ T cells, to promote resolution in an acute OVA model of allergic lung inflammation 
(Murdoch and Lloyd 2010). γδ T cells were transferred intra-tracheally at day 13, the 
peak of acute allergic lung inflammation, ameliorating asthmatic features as opposed to 
γδ T cell blockade, which led to disease exacerbation. Transfer of Th17 cells was found 
to have no effect on disease outcome, whilst IL-17 deficient γδ T cells were unable to 
promote resolution, suggesting γδ T cell derived IL-17 as important in controlling 
allergic lung inflammation (Murdoch and Lloyd 2010) Others also suggest γδ T cells to 
have a regulatory role, inhibiting airway responses through the release of IFN-γ (Isogai, 
Athiviraham et al. 2007). Though conflicting results exist regarding the role of γδ T 
cells in asthma pathogenesis, this evidence of cytokine release suggests they could be a 
contributing factor to the mucus increase observed in repeatedly challenged DR3wt 
mice. It would therefore be interesting to analyse DR3 expression and compare numbers 
between DR3wt and DR3ko mice to determine any differences and thereby potential 
contribution to the mucin over-production noted in the chronic allergic lung 
inflammation model described here.  
 
Alternatively, TL1A may be acting directly on goblet cells, bypassing the requirement 
for Th2 derived cytokines and therefore effector T cell increases in DR3wt mice. DR3wt 
mice did display a significant increase in myeloid DCs which have previously been 
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shown to release TL1A in inflammatory circumstances, suggesting they could be a 
direct source of TL1A and therefore goblet cell induced mucus release. TSLP, released 
by mast cells (Okayama, Okumura et al. 2009), has previously been shown to initiate 
DC maturation via the release of the TNFSF member OX40-L (Ito, Wang et al. 2005). 
Due to the DR3wt myeloid DC increases observed in the lung during the chronic model, 
it is tempting to speculate that TSLP may be stimulating DC activation via TL1A. TSLP 
storage by mast cells suggests early release in the innate response, whereby it may 
directly activate DCs. This in turn may initiate TL1A release and thereby potentially 
activate goblet cells to release mucin in the absence of T cells. In support of this theory, 
DR3 expression also appeared to correlate with goblet cell location, though 
experimental attempts to prove this association proved unsuccessful. Definitive 
conclusions regarding this theory are difficult to draw as no account was taken of either 
mast cells or TSLP. Adding to this, due to a lack of murine reagents at the time of 
experimentation, TL1A levels were not examined in this model. Despite these 
drawbacks, this is the first report of DR3 in chronic allergic lung inflammation and its 
potential as a therapeutic target for antagonism of goblet cell hyperplasia and associated 
mucus over-production as a result of allergic disease.  
 
Mast cells, as mentioned previously, are known to produce inflammatory mediators 
during inflammation. However, whilst the main mediator in humans is histamine, it is 
serotonin release which dominates in rodents (Canning 2003). Serotonin is a chemo-
transmitter which is predominantly sourced from platelets in humans, though it is also 
found in neuroendocrine cells of the respiratory tract (Mao, Morimoto et al. 1996). It’s 
role in human asthma remains unclear, although Lechin et al reported a positive 
correlation between serotonin concentration and asthma symptoms (Lechin, van der 
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Dijs et al. 1996). Treatment with tianeptine, which acts to reduce free plasma serotonin, 
also decreased clinical asthma features (Lechin, van der Dijs et al. 1996; Lechin, van 
der Dijs et al. 1998; Lechin, van der Dijs et al. 1998), whilst corticosteroids, the 
mainstream asthma treatment, have also been reported to reduce serotonin levels 
(Pretorius 2004). Menard et al found serotonin to inhibit the production of the Th1 
cytokines TNF, IL-12 and IL-10 whilst enhancing the production of nitrous oxide and 
prostaglandin E2 from alveolar macrophages (Menard, Turmel et al. 2007). In rodents, 
serotonin is thought to work by potentiating acetylcholine release, inducing contraction 
of bronchial muscle via activation of 5-HT2 and 5-HT3 receptors (Cazzola, Matera et al. 
1995; Takahashi, Ward et al. 1995; Lechin, van der Dijs et al. 2004). This contraction 
requires an intact parasympathetic system, as ablation of the sensory neurons 
compromised the cholinergic pathways, thereby inhibiting bronchoconstriction after 
antigen challenge in a mouse model of asthma (Cyphert, Kovarova et al. 2009). In 
immunised BP2 mice, which produce high titres of antibody, serotonin was shown to 
provoke bronchoconstriction upon challenge via acetylcholine release (Eum, Norel et al. 
1999), whilst the chemo-transmitter has also been shown to induce microvascular 
leakage in rodents (Michel and Kendall 1997).  This emphasises the importance of 
serotonin in rodent allergic disease in initiating bronchoconstriction, for which mast 
cells have frequently been implicated (Margulis, Nocka et al. 2009). As serotonin is 
known to be released by mast cells, it may explain their proximity to the airway nerves 
(Myers, Undem et al. 1991).  
 
Interestingly, aging DR3ko mice were observed to have abnormal neurochemistry, in 
that dopamine levels increased by 60% in the striatum of the brain whilst serotonin 
levels decreased 4 fold. This differential neurotransmitter expression was accompanied 
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by progressive behavioural defects in the absence of inflammation and neuropathology 
(Twohig, Roberts et al. 2010). The consequences of this unexpected finding were not 
examined beyond the brain by Twohig et al, though it is tempting to speculate that 
DR3ko resistance to allergic lung inflammation may stem from a defect in serotonin 
production. This in turn may lead to reduced bronchoconstriction and inflammation if 
DR3ko mast cells are impaired in their ability to produce serotonin and thus lack 
acetylcholine-induced constriction. It may then have been worthwhile to examine 
plasma serotonin levels to determine if a link exists between DR3 neurological function 
and immunity.   
 
Though modelled on the protocols employed by Fernandez Rodriguez et al, the results 
of this thesis differ somewhat from those noted by the former. These discrepancies may 
be a result of using C57BL/6 mice as opposed to the BALB/c strain. Variation is known 
to occur in the development of allergic lung inflammation between different mouse 
strains. Shinagawa et al found A/J mice to exhibit the features of allergic lung 
inflammation to a greater degree than BALB/c and C57BL/6 following repeated 
intranasal challenge (Shinagawa and Kojima 2003), agreeing with Zu et al who also 
reported decreased eosinophils, IgE, IL-5 and IL-13 in the BALF of C57BL/6 mice 
compared to FVB/NJ and BALB/c mice (Zhu and Gilmour 2009). Using an inhalation 
model of allergic lung inflammation, Brewer et al reported marked variability amongst 
strains in the development of pulmonary responsiveness, eosinophilia and IgE levels, 
suggesting, like Whitehead et al, disease progression is genetically determined (Brewer, 
Kisselgof et al. 1999; Whitehead, Walker et al. 2003). Interestingly, Kumar et al could 
not elicit any airway lesions or airway hyper-reactivity in sensitised C57BL/6 mice 
chronically exposed to aerosolised antigen (Kumar and Foster 2002). Adding to this, 
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conflicting data has been published regarding the importance of eosinophils in disease 
progression, as ablation on a C57BL/6 background showed eosinophils to be integral to 
airway inflammation and hyper-reactivity (Lee, Dimina et al. 2004; Walsh, Sahu et al. 
2008), whilst on a BALB/c background, mice were not protected from AHR, but rather 
airway remodelling (Humbles, Lloyd et al. 2004).  
 
BALB/c mice are generally considered better Th2 responders than C57BL/6 mice, 
judged by their increased pulmonary eosinophilia and cytokine production (Zhu and 
Gilmour 2009; De Vooght, Vanoirbeek et al. 2010). Though many of the expected 
asthma-like features materialised in the acute model, chronically challenged mice failed 
to display increased accumulation of some subsets within the lung and the BAL. 
Potential reasons for this have previously been discussed (Chapter 5, section 5.4.1), 
though another contributing factor may have been the use of C57BL/6 mice. An 
alternative would have been to generate DR3ko mice on a BALB/c background, though 
this was beyond the scope of this thesis in terms of time and resources. The above 
examples illustrate the need to standardise murine models as well as assess multiple 
endpoints to decipher associations between the immune response and allergic lung 
disease.   
 
7.4 DR3 and splenic accumulation  
In addition to the lung, a novel phenotype was also noted in the spleen following acute 
and chronic allergic lung inflammation. Further investigation found DR3ko mice to 
exhibit a global reduction in splenocytes after just one i.p immunisation with non-
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pathogenic substances, associated with a reduction in the chemokine CXCL10. 
However, this deficit appeared to have little effect on spleen function or immunity, as 
neither antigen-specific T cell proliferation nor antibody production were impaired. This 
is in contrast to previous studies following infection with either viral (Twohig, Marsden 
et al. 2012) or bacterial (Buchan, Taraban et al. 2012) organisms, as reductions were 
noted in the expansion of T cell populations. Buchan et al reported reduced numbers of 
activated/memory CD4+ T cells in the DR3ko spleen following Salmonella infection 
(Buchan, Taraban et al. 2012). Twohig et al too, observed reduced numbers of splenic 
CD4+ and CD8+ T cells in response to MCMV infection using Ki67. This reduction was 
shown to be due to decreased DR3ko proliferation. Peptide specific CD8+ T cells were 
also Ki67+, suggesting that impaired anti-viral T cell generation in DR3ko mice was 
caused by intrinsic defects in the capacity of CD4+ and CD8+ T cells to expand in 
response to antigen (Twohig, Marsden et al. 2012). In a model of HSV-1 infection, an 
anti-DR3 antibody was found to expand TregS in the spleen, peripheral blood and 
draining lymph node of C57BL/6 mice when administered either 2 days pre infection or 
day 0 (J Reddy, Schreiber et al. 2012). This led to decreased numbers of neutrophils as 
well as IFNγ producing CD4+ T cells, leading to reduced lesions. However, in order to 
function as a therapeutic as well as prophylactic treatment, the anti-DR3 antibody 
required galectin-9. Anti-DR3 enhanced the proliferation of TregS, whilst galectin-9 
increased effector T cell apoptosis, resulting in reduced mRNA levels of IFNγ, IL-6 and 
CXCL1, and increased levels of IL-10 and TGFβ (J Reddy, Schreiber et al. 2012). The 
former mentioned viral and bacterial models involved the use of infectious organisms, 
with both alluding to faulty pathogen clearance in DR3ko mice, resulting in constant 
immune stimulation and a sustained immune response due to constant pathogen 
presence. Meanwhile, Reddy et al demonstrated the therapeutic potential of an agonist 
324 
 
DR3 antibody, ablating the development of disease in a pathogenic viral model of 
infection. The results described in this thesis suggest the DR3/TL1A pathway as a 
booster of the immune response, including both myeloid and lymphocyte populations. 
This could be particularly beneficial in chronic conditions, such as those presented by 
MCMV and HSV-1, whereby DR3 is required to clear infection and protect from 
pathogen induced disease.  
 
Whilst it is clear that DR3ko mice suffer defective leukocyte accumulation in the spleen 
following intra-peritoneal sensitisation, the biological and functional impact of this is 
unclear. Readouts tested, including antigen-specific proliferation and antibody release, 
were unaffected by the loss of DR3 suggesting further research is required into the 
functional consequences of this decreased cellular accumulation, such as affinity 
maturation and splenic organisation. Attempts were made to examine T and B cell 
interactions in the spleen following OVA/Alum injection using IHC to examine whether 
broad splenic structure was DR3 dependent following challenge, as well as measure 
germinal centre size using peanut agglutinin lectin (PNA) (Appendix figure 1.3). 
However, problems arose concerning staining and due to time constraints, meant this 
line of investigation could not be concluded.  
 
Other TNFSF members have been shown to influence splenic architecture, including 
TNF, lymphotoxin (LT)α and LTβ. TNF was found to be essential for the formation of 
primary B cell follicles, follicular DC networks and germinal centres (Pasparakis, 
Alexopoulou et al. 1996; Pasparakis, Alexopoulou et al. 1997), whilst LTαko mice 
display severe disorganisation of the splenic architecture, including lack of marginal 
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zones, follicular DC networks and germinal centres as well as un-segregated B and T 
cell areas (De Togni, Goellner et al. 1994; Matsumoto, Fu et al. 1997). However, TNFko 
mice maintain the capacity to Ig class switch (Pasparakis, Alexopoulou et al. 1996), 
whilst splenic T cells of LTαko mice exhibit normal lytic function (De Togni, Goellner 
et al. 1994), thus implying that despite defective organisation and development, 
particular functions remained unaltered. With this in mind, it would be interesting to 
optimise splenic T and B cell staining to determine whether structure and organisation 
were compromised in DR3ko mice following challenge.  
 
As well as reduced leukocyte numbers, spleen lysates of DR3ko mice also displayed 
decreased levels of CXCL10, which could have aided a potential loss of architecture. 
Leukocytes are positioned in distinct locations by chemoattractants in the spleen, 
allowing interactions between cells as well as antigen and thereby an effective immune 
response. The observed deficiencies in CXCL10, could have altered splenocyte 
positioning and as a result splenic architecture, altering DR3ko response to antigen. In a 
model of MCMV infection, the virus was found to preferentially infect the endothelial 
cells of the stroma, suppressing the release of CCL21. This chemokine loss resulted in 
the failure of T cells to locate to the T cell zone in the spleen, which was partially 
restored via the activation of the LTβ signalling pathway (Benedict, De Trez et al. 
2006). Although using a virus, Benedict et al showed splenic remodelling to impede 
efficient contact between cells by altering the migration of T cells. A similar situation 
could be occurring in DR3ko mice, in that CXCL10 decrease may impair leukocyte 
accumulation into the spleen as well as arrangement without affecting select functional 
responses.  
ACUTE allergic lung inflammation 
 
           Cell infiltration 
 
 
CHRONIC  allergic lung inflammation 
 
           Goblet cell hyperplasia 
 
 
IL-13 ? 
Direct TL1A? 
         CXCL10 
Increase in splenocytes 
IFNγ ? 
DR3 
+ve feedback 
TL1A ? 
IFNγ ? 
 
 
Figure 7.1. Proposed summary of DR3 action in acute allergic lung inflammation, chronic allergic lung inflammation and splenic 
responses. Results of this thesis show DR3 to have differential roles in different phases of allergic lung inflammation. DR3wt mice 
displayed increased numbers of leukocytes in the lung and BAL compared to DR3ko mice in acute disease, whilst chronically challenged 
mice exhibited goblet cell hyperplasia. This may be due to increased IL-13 levels or direct TL1A action on goblet cells. In the spleen, 
DR3wt mice showed increased levels of CXCL10, promoting splenocyte accumulation, which may lead to further release of TL1A and 
IFNγ, thereby acting as a positive feedback loop.  
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7.5 Future Directions  
Although, a broad assessment of the DR3/TL1A pathway in allergic lung inflammation 
was examined in this thesis, further experiments could be performed to strengthen data 
and improve analysis: 
 
• A lack of reagents to identify both TL1A and DR3 have hindered profiling of 
their expression during this project. Upon continuation of these experiments, 
specific TL1A primers will be used to measure levels of the cytokine using 
qPCR. It would also be beneficial to develop a soluble murine DR3 ELISA to 
quantify membrane bound isoforms in comparison to soluble DR3, as well as 
produce antibodies capable of differentiating between the different isoforms. 
RT-PCR could also be used to examine these, though post-translational DR3 
gene expression could not be accounted for. Using these techniques, the 
expression of DR3 and TL1A can be further elucidated allowing a 
comprehensive assessment of their levels in both naive and inflammatory 
situations.  
 
• Mast cells and γδ T cells could also be investigated. Mast cells can be identified 
using flow cytometry and the markers CD117 and FcεRI (Chen, Grimbaldeston 
et al. 2005), whilst DR3 expression on γδ T cells can be studied to explore 
whether these cells may respond to TL1A signalling. 
 
• Key cytokines, such as IL-5, IL-13 and TGFβ, could also be measured, due to 
their known importance in mucin production and structural remodelling. These 
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cytokines could be measured in the BALF and the spleens. Adding to this, it 
would be interesting to examine the serum concentration of serotonin in DR3ko 
and DR3wt mice, to determine whether levels are reduced in DR3ko mice beyond 
the brain, as well as in an inflammatory setting.  
 
• As impaired myeloid cell numbers were observed in the spleens of DR3ko mice 
following immunisation, myeloid cell analysis could be extended using IHC to 
identify rare cell types. CD35 would allow the identification of follicular DCs 
whilst SIGN-R1 could be used to examine marginal zone macrophages. 
SIGLEC-1 and MOMA-1 are also known markers of metallophilic macrophages 
(Mebius and Kraal 2005).  
 
• Alternative routes of antigen administration (intra-nasal, subcutaneous) could 
also be studied, to determine if the observed splenic phenotype is specific to 
intra-peritoneal immunisation. I.P injections are commonly used in murine 
models as a means of antigen sensitisation and enhancement, including DR3ko 
models of allergic lung inflammation (Meylan, Davidson et al. 2008) and EAU 
(Calder and Wang 2012). However, the results of this thesis suggest that DR3ko 
splenic accumulation is reduced following I.P injection compared to DR3wt 
mice. Though the biological impact of this is unknown, it cannot be said for 
certain that splenic defects did not affect previously published data using DR3ko 
mice.  
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• Conditional knockouts could be used to confirm the role of DR3 in the 
generation of the splenic immune response and define Receptor function in 
individual cell subsets. This could be achieved by using Cre-lox recombination 
driven by tissue-specific promoters to remove the DR3 gene, which in order to 
study DC function, could be CD11c.  
 
• Murine TL1A injections could be utilised in addition to OVA, to examine if 
effects are TL1A dose dependent or even independent of allergen once priming 
has occurred. Injections of anti-TL1A antibody in DR3wt mice following 
sensitisation in both allergic lung inflammation and the splenic model described 
in this thesis, could be interesting, to observe whether effects were ameliorated 
and align with the phenotype of DR3ko mice.  
 
• Human BAL samples from healthy controls, mild and severe asthma patients 
could be tested for TL1A, DcR3 and potentially, soluble DR3 levels to 
determine just how translatable and clinically relevant the data within this 
project is.  This would also allow an arbitrary assessment of how TL1A levels 
fluctuate with disease severity and for what stages of asthma development it 
may be important. 
 
• To examine the effects of TL1A on DC proliferation, DCs could be isolated 
from the spleens of DR3wt and DR3ko mice following injection using the marker 
CD11c and FACS. Cells could be stimulated in vitro with TL1A, and 
proliferation measured using BrdU. The supernatants from cell cultures could 
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also be used to study the effects of TL1A on GM-CSF and Flt3-L levels in 
comparison to un-stimulated cells.  
 
• The data of Chapter 6 suggests Alum reduces splenic DR3ko myeloid DC 
numbers, whilst reduced macrophage and eosinophil numbers are only observed 
upon injection of higher Alum concentrations. It would therefore be interesting 
to use alternative adjuvants, such as LPS or CpG, to determine whether the 
noted effects are Alum specific. Adding to this, in contrast to Alum, both LPS 
and CpG are known to be dependent on the TLR pathway.  
 
• As reduced numbers of activated T cells were observed in the DR3ko spleen, it 
would be interesting to examine whether the function of these cells is also 
impaired. Cytokine release in response to OVA could be examined, including 
the Th1 cytokine IFNγ, as well as the Th2 cytokine IL-4. Additionally, the 
proportion of T cells releasing TNFα or de-granulating could be measured using 
a CD107 assay.  
 
• To assess whether affinity maturation is affected by the loss of DR3, the BCR 
repertoires of DR3wt and DR3ko mice could be analysed using high throughout 
sequencing following immunisation. The BCR could be amplified using specific 
primers and analysed using a sequencer to identify clones. Bioinformatics could 
be used to identify gene segments and correct for sequencing errors. Any 
differences between the 2 genotypes could then be analysed and used as an 
indicator to assess whether affinity maturation is impaired in DR3ko mice.  
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7.6 Final conclusions 
The research described in this thesis has, for the first time, shown an important role for 
the DR3/TL1A axis in chronic allergic lung inflammation. Blockade of this pathway 
through gene knockout reduced cellular accumulation in acute inflammation and 
severity of histopathological changes in chronic models of allergic lung inflammation, 
in particular mucin production. These experiments in turn led to the discovery of a 
novel splenic phenotype, as DR3ko mice displayed impaired T cell and DC 
accumulation after a single peritoneal injection of non-pathogenic substances, These 
results suggest that DR3 exerts effects beyond just effector T cell expansion and 
myeloid differentiation, around which publications in the field have previously been 
orientated. Though further investigation is required to fully elucidate the effects of DR3 
absence on spleen function, this data suggests chemokine levels and recruitment to be 
affected.   
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 Appendix 
               DR3wt                                                             DR3ko 
Chemokine PBS* OVA^ PBS* OVA^ Significance$ 
24hrsε  CCL3 36±10 31±5 38±4 27±3 N.S.D 
CCL4 N/A† N/A† N/A† N/A† N/A† 
CCL5 145±40 125±22 138±21 96±11 N.S.D 
CXCL1 74±16 45±6 63±5 48±8 N.S.D 
CXCL2 254±54 216±20 272±18 185±25 N.S.D 
CXCL10 799±144 955±246 941±90 666±64 N.S.D 
CXCL13 551±99 556±46 716±32 483±65 N.S.D 
72hrs ¥ CCL3 28±3 30±4 22±2 22±3 N.S.D 
CCL4 N/A† N/A† N/A† N/A† N/A† 
CCL5 152±15 154±18 88±6 102±23 *p=0.0266 
CXCL1 72±7 76±16 38±6 143±9 ***p=<0.0001 
CXCL2 237±16 228±48 136±17 149±13 *p=0.0256 
CXCL10 943±59 940±178 582±57 679±53 *p=0.0354 
CXCL13 1110±64 1197±178 759±94 809±63 *p=0.0223 
* PBS corresponds to mice challenged via inhalation with PBS 
^ OVA corresponds to mice challenged via inhalation with OVA 
ε 24hrs corresponds to mice harvested 24hrs after the final inhalation challenge 
¥ 72hrs corresponds to mice harvested 72hrs after the final inhalation challenge 
† N/A corresponds to chemokines either not being present or too low to be tested 
$ Significance between groups using 1 way ANOVA, N.S.D = no significant difference  
Appendix Table 1.1. Chemoattractant levels in BAL fluid at 24 and 72hrs post 
inhalation following chronic allergic lung inflammation 
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Appendix figure 1.1. Chemokine levels within the BAL of DR3wt and DR3ko mice 
following chronic allergic lung inflammation (24hrs). Mice were sacrificed 24hr post 
final inhalation challenge with either OVA or PBS (n=5). BAL fluid was isolated and 
the supernatant used to determine chemokine levels using ELISA. CCL3 n.s.d, CCL5 
n.s.d, CXCL1, n.s.d, CXCL2 n.s.d, CXCL10 n.s.d and CXCL13 n.s.d. No significant 
differences seen. Significance determined using 1 way ANOVA and Bonferroni post test 
Bars represent mean ± SEM. 
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Appendix figure 1.2. Chemokine levels within the BAL of DR3wt and DR3ko mice 
following chronic allergic lung inflammation (72hrs). Mice were sacrificed 72hr post 
final inhalation challenge with either OVA or PBS (n=7). BAL fluid was isolated and 
the supernatant used to determine chemokine levels using ELISA. CCL3 n.s.d, CCL5 
(*p=0.0266), CXCL1 (***p=,<0.0001), CXCL2 (*p=0.0256), CXCL10 (*p=0.0354) 
and CXCL13 (*p=0.0223). Significance determined using 1 way ANOVA and 
Bonferroni post test. Bars represent mean ± SEM.  
(A) 
 
 
 
 
 
 
 
 
 
 
 
(B) 
Appendix figure 1.3. Examples of T cell (blue) and B cell (brown) splenic interactions 
in DR3ko mice following OVA/Alum injection. IHC was used to examine T and B cell 
interactions in frozen spleen sections using CD3 and B220 staining. (A) is an example 
of a relatively successful stain compared to (B) where the section is lifting from the 
slide resulting in ‘patchy’ staining. Scale bar=100μM.  
